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Abstract
The clinical effectiveness and cost-effectiveness of 
cetuximab (mono- or combination chemotherapy), 
bevacizumab (combination with non-oxaliplatin 
chemotherapy) and panitumumab (monotherapy) for the 
treatment of metastatic colorectal cancer after first-line 
chemotherapy (review of technology appraisal No. 150 and 
part review of technology appraisal No. 118):  
a systematic review and economic model
M Hoyle,1* L Crathorne,1 J Peters,1 T Jones-Hughes,1 C Cooper,1 
M Napier,2 P Tappenden3 and C Hyde1
1Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK
2Royal Devon & Exeter Foundation Trust Hospital, Exeter, UK
3School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
*Corresponding author
Background: Colorectal cancer is the third most commonly diagnosed cancer in the UK 
after breast and lung cancer. People with metastatic disease who are sufficiently fit are 
usually treated with active chemotherapy as first- or second-line therapy. Recently, targeted 
agents have become available including anti-epidermal growth factor receptor (EGFR) 
agents, for example cetuximab and panitumumab, and anti-vascular endothelial growth 
factor (VEGF) receptor agents, for example bevacizumab.
Objective: To investigate the clinical effectiveness and cost-effectiveness of panitumumab 
monotherapy and cetuximab (mono- or combination chemotherapy) for Kirsten rat sarcoma 
(KRAS) wild-type (WT) patients, and bevacizumab in combination with non-oxaliplatin 
chemotherapy, for the treatment of metastatic colorectal cancer after 
first-line chemotherapy.
Data sources: The assessment comprises a systematic review of clinical effectiveness and 
cost-effectiveness studies, a review and critique of manufacturer submissions and a de 
novo cohort-based economic analysis. For the assessment of effectiveness, a literature 
search was conducted in a range of electronic databases, including MEDLINE, EMBASE 
and The Cochrane Library, from 2005 to November 2010. 
Review methods: Studies were included if they were randomised controlled trials (RCTs) 
or systematic reviews of RCTs of cetuximab, bevacizumab or panitumumab in participants 
with EGFR-expressing metastatic colorectal cancer with KRAS WT status that has 
progressed after first-line chemotherapy (for cetuximab and panitumumab) or participants 
with metastatic colorectal cancer that has progressed after first-line chemotherapy 
(bevacizumab). All steps in the review were performed by one reviewer and checked 
independently by a second. Synthesis was mainly narrative. An economic model was 
developed focusing on third-line and subsequent lines of treatment. Costs and benefits 
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were discounted at 3.5% per annum. Probabilistic and univariate deterministic sensitivity 
analyses were performed.
Results: The searches identified 7745 titles and abstracts. Two clinical trials (reported in 12 
papers) were included. No data were available for bevacizumab in combination with non-
oxaliplatin-based chemotherapy in previously treated patients. Neither of the included 
studies had KRAS status performed prospectively, but the studies did report retrospective 
analyses of the results for the KRAS WT subgroups. Third-line treatment with cetuximab 
plus best supportive care or panitumumab plus best supportive care appears to have 
statistically significant advantages over treatment with best supportive care alone in 
patients with KRAS WT status. For the economic evaluation, five studies met the inclusion 
criteria. The base-case incremental cost-effectiveness ratio (ICER) for KRAS WT patients 
for cetuximab compared with best supportive care is £98,000 per quality-adjusted life-year 
(QALY), for panitumumab compared with best supportive care is £150,000 per QALY and 
for cetuximab plus irinotecan compared with best supportive care is £88,000 per QALY. All 
ICERs are sensitive to treatment duration.
Limitations: In the specific populations of interest, there is a lack of evidence on 
bevacizumab, cetuximab and cetuximab plus irinotecan used second line and on 
bevacizumab and cetuximab plus irinotecan used third line. For cetuximab plus irinotecan 
treatment for KRAS WT people, there is no direct evidence on progression-free survival, 
overall survival and duration of treatment.
Conclusions: Although cetuximab and panitumumab appear to be clinically beneficial for 
KRAS WT patients compared with best supportive care, they are likely to represent poor 
value for money when judged by cost-effectiveness criteria currently used in the UK. It 
would be useful to conduct a RCT for patients with KRAS WT status receiving cetuximab 
plus irinotecan.
Funding: The National Institute for Health Research Health Technology 
Assessment programme.
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Note
This monograph is based on the Technology Assessment Report produced for NICE. The full 
report contained a considerable number of data that were deemed commercial-in-confidence. 
The full report was used by the Appraisal Committee at NICE in their deliberations. The 
full report with each piece of commercial-in-confidence removed and replaced by the 
statement ‘commercial-in-confidence information removed’ is available on the NICE 
website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining 
readability, but some sections, sentences, tables and figures have been removed. Readers should 
bear in mind that the discussion, conclusions and implications for practice and research are 
based on all the data considered in the original full NICE report.
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Executive summary
Background
Colorectal cancer is a malignant neoplasm arising from the lining of the large intestine (colon 
and rectum). It is the third most commonly diagnosed cancer in the UK after breast and lung 
cancer. In 2008 there were 39,991 new cases of large bowel cancer registered in the UK, around 
two-thirds (25,551) in the colon and one-third (14,440) in the rectum. Colorectal cancer was 
the second most common cause of cancer death (10%) after lung cancer in the UK in 2006 
[Cancer Research UK. Bowel (colorectal) cancer – UK incidence statistics; 2011. URL: http://info.
cancerresearchuk.org/cancerstats/types/bowel/incidence (accessed 10 March 2011)]. In total, 
there were 16,259 deaths from colorectal cancer: 10,164 from colon cancer and 6095 from rectal 
cancer [Cancer Research UK. Bowel (colorectal) cancer – mortality statistics; 2011. URL: http://
info.cancerresearchuk.org/cancerstats/types/bowel/mortality/ (accessed 10 March 2011)].
In metastatic colorectal cancer the tumour has spread beyond the confines of the locoregional 
lymph nodes to other parts of the body. This is described as stage IV of the American Joint 
Committee on Cancer (AJCC) tumour node metastases (TNM) system or stage D of the 
modified Dukes’ classification. The 5-year survival of patients with advanced disease (modified 
Dukes’ D) is < 7% [Cancer Research UK. Bowel (colorectal) cancer – survival statistics; 2011. URL: 
http://info.cancerresearchuk.org/cancerstats/types/bowel/survival/ (accessed 10 March 2011)].
Individuals with metastatic disease who are sufficiently fit (normally those with World Health 
Organization performance status ≤ 2) are usually treated with active chemotherapy as first- or 
second-line therapy. First-line active chemotherapy options include:
 ■ infusional 5-fluorouracil plus folinic acid (5-FU/FA)
 ■ oxaliplatin plus infusional 5-FU/FA (FOLFOX)
 ■ irinotecan plus infusional 5-FU/FA (FOLFIRI)
 ■ oral analogues of 5-FU (capecitabine and tegafur with uracil) may also be used instead of 
infusional 5-FU.
More recently, targeted agents have become available including anti-epidermal growth factor 
receptor (EGFR) agents, for example cetuximab and panitumumab, and anti-vascular endothelial 
growth factor (VEGF) receptor agents, for example bevacizumab. The EGFR signalling pathway 
has been the focus of new drug development for colorectal cancer because it is overexpressed in 
approximately 80% of colorectal carcinomas. Kirsten rat sarcoma (KRAS) mutation status – wild 
type (WT) or mutant – can explain resistance to anti-EGFR therapy. 
A treatment algorithm for colorectal cancer in England and Wales developed by Tappenden 
and colleagues (technology appraisal No. 118) estimated that up to 85% of patients with 
advanced metastatic colorectal cancer not amenable to resection receive active first-line therapy 
[Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of 
bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol 
Assess 2007;11(12)]. Of these, approximately 50% go on to receive second-line therapy with 5% 
of those estimated to go on to receive third-line therapy. This treatment algorithm showed that 
roughly 300 patients receive a third-line chemotherapy in England and Wales. 
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The National Institute for Health and Clinical Excellence (NICE) currently recommends 
FOLFOX and FOLFIRI as first-line treatment options for advanced colorectal cancer. FOLFOX 
or irinotecan alone are recommended as subsequent therapy options. The oral analogues of 5-FU, 
capecitabine and tegafur, in combination with uracil (and FA) are also recommended as first-line 
treatment options for metastatic colorectal cancer. Cetuximab in combination with FOLFOX, 
or in combination with FOLFIRI, is recommended as an option for the first-line treatment of 
metastatic colorectal cancer when the metastatic disease is confined to the liver and the aim of 
treatment is to make the metastases resectable. In technology appraisal No. 118, bevacizumab in 
combination with 5-FU/FA, with or without irinotecan, as a first-line treatment and cetuximab in 
combination with irinotecan as a second- or subsequent-line treatment were not recommended 
for metastatic colorectal cancer. Technology appraisal No. 150 on cetuximab for the treatment 
of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy in 2008 
was terminated because the manufacturer submitted a ‘no evidence’ response to NICE [National 
Institute for Health and Clinical Excellence. Cetuximab for the treatment of metastatic colorectal 
cancer following failure of oxaliplatin-containing chemotherapy. TA150 (terminated appraisal). 
London: NICE; 2008].
This technology assessment report considered three pharmaceutical interventions: bevacizumab 
(Avastin, Roche), cetuximab (Erbitux, Merck Serono) and panitumumab (Vectibix, Amgen). 
All three have UK marketing authorisation:
 ■ bevacizumab is licensed in combination with fluoropyrimidine-based chemotherapy for the 
treatment of patients with metastatic colorectal cancer
 ■ cetuximab is licensed for the treatment of patients with EGFR-expressing metastatic 
colorectal cancer with KRAS WT status either in combination with chemotherapy or as a 
single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who 
are intolerant to irinotecan
 ■ panitumumab is licensed for the treatment of EGFR-expressing metastatic colorectal 
cancer with KRAS WT status after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-
containing chemotherapy regimens.
The following question was addressed by this report: ‘What is the clinical effectiveness and cost-
effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination 
with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of 
metastatic colorectal cancer after first-line chemotherapy’.
The main comparators of interest are irinotecan- or oxaliplatin-based chemotherapy regimens 
and best supportive care. The populations of interest were limited to metastatic colorectal cancer 
patients with KRAS WT status in the case of cetuximab and panitumumab.
Methods
The assessment comprises a systematic review of clinical effectiveness and cost-effectiveness 
studies, a review and critique of manufacturer submissions and a de novo economic analysis.
Clinical effectiveness systematic review
For the assessment of effectiveness, a literature search was conducted in a range of electronic 
databases including MEDLINE, EMBASE and The Cochrane Library (2005–17 November 2010).
Studies were included if they were:
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 ■ RCTs or systematic reviews of RCTs of cetuximab, bevacizumab or panitumumab
 – in participants with EGFR-expressing metastatic colorectal cancer with KRAS WT status 
that has progressed after first-line chemotherapy (for cetuximab and panitumumab)
 – in participants with metastatic colorectal cancer that has progressed after first-line 
chemotherapy (for bevacizumab).
All steps in the review were performed by one main reviewer and checked independently 
by a second. Quality was assessed using criteria specified by the Centre for Reviews and 
Dissemination (CRD). Synthesis was mainly narrative.
Cost-effectiveness systematic review
For the cost-effectiveness review, the inclusion and exclusion criteria were the same as for 
the clinical effectiveness review except for study design, with non-randomised studies, full 
cost-effectiveness analyses, cost–utility analyses, cost–benefit analyses and cost–consequence 
analyses included.
Review of manufacturers’ submissions
The cost-effectiveness analyses reported in the manufacturers’ submissions to NICE were 
critically appraised using established frameworks, including the NICE reference case.
Three manufacturers’ submissions were potentially available for this appraisal; however, only 
one full economic model was submitted, by Merck Serono (the manufacturer of cetuximab), 
for cetuximab plus irinotecan and panitumumab plus best supportive care compared with 
best supportive care. Roche (the manufacturer of bevacizumab) submitted some basic cost 
calculations in its report for a comparison between bevacizumab plus FOLFIRI and cetuximab 
plus FOLFIRI. Amgen did not provide any details of a cost-effectiveness model, nor make any 
comment on the likely cost-effectiveness of panitumumab, its product.
Peninsula Technology Assessment Group cost-effectiveness analysis
A decision-analytic model was developed following the NICE reference case, from the 
perspective of the NHS and Personal Social Services (PSS).
The model focused on third- and subsequent-line treatment as agreed with NICE. The use of 
drugs of interest second line was theoretically covered by the scope, but there were no clinical 
effectiveness data, no case for such a comparison was made by the manufacturers and there 
was no obvious clinical case for such use. We did not model bevacizumab in combination with 
non-oxaliplatin-based chemotherapy because of the absence of clinical effectiveness data for 
this treatment.
The structure of the model is widely used for metastatic cancers. It uses an ‘area under the curve’ 
method to determine state probabilities at each cycle of the model. The model has three health 
states: progression-free survival, progressive disease and dead. We performed an indirect four-
way comparison of the cost-effectiveness of best supportive care, cetuximab, panitumumab and 
cetuximab plus irinotecan.
The clinical effectiveness of best supportive care and cetuximab is taken from a RCT of cetuximab 
plus best supportive care compared with best supportive care, and of panitumumab is taken from 
a RCT of panitumumab plus best supportive care compared with best supportive care. Both of 
these RCTs were those identified in the systematic review (see Results). The clinical effectiveness 
of cetuximab plus irinotecan was derived from a RCT of cetuximab plus irinotecan compared 
with cetuximab in which information on KRAS status was not available.
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Results
Number and quality of clinical effectiveness studies
The searches identified 7745 titles and abstracts. Two clinical trials (reported in 12 papers) were 
included. No data were available for bevacizumab in combination with non-oxaliplatin-based 
chemotherapy in previously treated patients. Neither of the included studies had KRAS status 
performed prospectively, but the studies did report retrospective analyses of the results for the 
KRAS WT subgroups. Taken as a whole, the quality of the included studies was considered good.
Summary of benefits and risks
Third-line treatment with cetuximab plus best supportive care or panitumumab plus best 
supportive care appears to have clinically relevant and statistically significant advantages over 
treatment with best supportive care alone in patients with KRAS WT status. In both trials, 
median progression-free survival almost doubles. For cetuximab plus best supportive care, 
median progression-free survival increases from approximately 2 months to approximately 
4 months [hazard ratio 0.40, 95% confidence interval (CI) 0.30 to 0.54]. For panitumumab 
plus best supportive care, median progression-free survival increases from approximately 
2 months to approximately 3 months (hazard ratio 0.45, 95% CI 0.34 to 0.59) (Karapetis 
CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations 
and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65; 
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D, et al. Wild-type KRAS is 
required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 
2008;26:1626–34).
For the KRAS WT population, median overall survival in the cetuximab arm is 9.5 months 
compared with 4.8 months for best supportive care (hazard ratio 0.55, 95% CI 0.41 to 0.75). The 
effect of panitumumab on overall survival is less convincing and not statistically significant. The 
median overall survival for panitumumab was 8.1 months compared with 7.6 months for best 
supportive care (hazard ratio 0.99, 95% CI 0.75 to 1.29). The rapid crossover of 76% of patients 
originally allocated to best supportive care to treatment with panitumumab (median time to 
crossover 7.1 weeks) is likely to have had an extensive confounding effect (Amado et al. 2008; Van 
Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial 
of panitumumab plus best supportive care compared with best supportive care alone in patients 
with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–64).
For both progression-free survival and overall survival the effects in patients with KRAS WT 
status are greater than those in the whole trial populations.
Number and quality of cost-effectiveness studies
Summary of economic evaluations
Our literature search identified five published full economic evaluations meeting the inclusion 
criteria. Three abstracts were also identified but these did not provide sufficient detail for a full 
critical appraisal.
All of the included studies assessed the cost-effectiveness of cetuximab used as third-line therapy 
(Annemans L, Van Cutsem E, Humblet Y, Van Laethem JL, Bleiberg H. Cost-effectiveness of 
cetuximab in combination with irinotecan compared with current care in metastatic colorectal 
cancer after failure on irinotecan – a Belgian analysis. Acta Clin Belg 2007;62:419–25; Mittmann 
N, Au HJ, Tu D, O’Callaghan CJ, Isogai PK, Karapetis CS, et al. Prospective cost-effectiveness 
analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute 
of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009;101:1182–92; Norum J. 
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Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness 
analysis. J Chemother 2006;18:532–7; Starling N, Tilden D, White J, Cunningham D. Cost-
effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment 
of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J 
Cancer 2007;96:206–12; Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. 
Cost implications of new treatments for advanced colorectal cancer. Cancer 2009;115:2081–91). 
However, only one of these, by Mittmann and colleagues, directly addressed a comparison 
of interest, cetuximab plus best supportive care compared with best supportive care, in the 
population of direct interest, metastatic colorectal cancer patients with KRAS WT status. The 
trial-based cost-effectiveness analysis (2007) calculated a cost per quality-adjusted life-year 
(QALY) of C$186,761 (95% CI C$130,326 to C$334,940). Updating this to 2011, converting 
to pounds sterling and using the current UK price of cetuximab we estimated this to be 
approximately equivalent to £101,000 per QALY.
Industry submissions
Merck Serono (the manufacturer of cetuximab) focused its submission on third- and subsequent-
line use and presented base-case incremental cost-effectiveness ratios (ICERs) of £47,000 per 
QALY gained for cetuximab plus best supportive care compared with best supportive care and 
£44,000 per QALY gained for cetuximab plus irinotecan combination therapy compared with 
best supportive care.
Our main critique of Merck Serono’s model is that it underestimates the mean treatment 
duration leading to ICERs that are too low. Assuming that patients are treated for as long as 
they remain progression free (which we believe is a more realistic assumption) leads to much 
larger ICERs: £75,000 and £67,000 per QALY gained for cetuximab monotherapy compared with 
best supportive care and for cetuximab plus irinotecan combined therapy compared with best 
supportive care respectively.
We also believe that Merck Serono has underestimated the costs of best supportive care drug 
administration, leading us to the conclusion that more realistic ICERs from Merck Serono’s 
model are around £82,000 and £75,000 per QALY gained for cetuximab plus best supportive 
care compared with best supportive care and for cetuximab plus irinotecan combined therapy 
compared with best supportive care respectively.
Roche (the manufacturer of bevacizumab) did not estimate cost-effectiveness but did present a 
case that, used second line, bevacizumab plus FOLFIRI would be less expensive than cetuximab 
plus FOLFIRI.
Amgen presented reasonable analyses to adjust for crossover in the study by Amado and 
colleagues (2008), leading to an adjusted estimate of overall survival advantage of 2.74 or 
3.13 months, depending on the method of adjustment used, for panitumumab compared with 
best supportive care. Amgen did not present any estimates of cost-effectiveness.
De novo economic model results
Based on our degree of certainty of clinical effectiveness and mean treatment duration, we 
estimate that the cost-effectiveness of:
 ■ cetuximab compared with best supportive care is £98,000 per QALY gained and is 
reasonably accurate
 ■ panitumumab compared with best supportive care is £150,000 per QALY gained and is 
reasonably accurate
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 ■ cetuximab plus irinotecan compared with best supportive care is £88,000 per QALY gained 
but is highly uncertain.
The incremental costs and QALYs for cetuximab and panitumumab compared with best 
supportive care are similar (approximately £25,000 and 0.20 QALYs per person), whereas these 
quantities are both far greater for cetuximab plus irinotecan compared with best supportive care 
(approximately £53,000 and 0.60 QALYs per person).
The probability that the three treatment regimens are cost-effective compared with best 
supportive care, up to a willingness-to-pay threshold of £60,000 per QALY, is zero.
The deterministic sensitivity analysis suggests that progression-free survival, overall survival, 
time on drug treatment, drug acquisition costs and drug administration costs strongly influence 
cost-effectiveness estimates.
Discussion
Strengths and limitations of the systematic review of effectiveness studies
The strengths of this systematic review are that it was conducted by an independent research 
team using the latest evidence to a prespecified protocol. The main limitation was lack of 
evidence on bevacizumab, cetuximab and cetuximab plus irinotecan used second line in the 
populations of interest and lack of evidence on bevacizumab and cetuximab plus irinotecan used 
third line.
Strengths and limitations of the systematic review of 
cost-effectiveness studies
The strengths of this systematic review are that it was conducted by an independent research 
team using the latest evidence to a prespecified protocol. The main limitation was the incomplete 
reporting of the cost-effectiveness of panitumumab and the absence of cost-effectiveness 
estimates for bevacizumab.
Strengths and limitations of the critique of industry submissions
This was conducted by an independent research team using a number of established frameworks 
to identify strengths and weaknesses. The scope of the submissions on bevacizumab and 
panitumumab, which did not directly estimate cost-effectiveness, was the main limitation.
Strengths and limitations of the economic modelling by the Peninsula 
Technology Assessment Group
Strengths
Our assessment of the cost-effectiveness of drugs for metastatic colorectal cancer is independent. 
Our analysis is the second independent fully published cost-effectiveness analysis of cetuximab 
compared with best supportive care for patients with KRAS WT status, the first being that of 
Mittmann and colleagues (2009), and the first specifically for the UK. Our analysis is the first 
independent fully published cost-effectiveness analysis of panitumumab compared with best 
supportive care for patients with KRAS WT status and of cetuximab plus irinotecan compared 
with best supportive care for patients with KRAS WT status. We have carefully compared our 
model and the results of our analysis with those of Mittmann and colleagues and Merck Serono, 
and in doing so we have highlighted areas in common and those where there is disagreement.
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Our certainty about the accuracy of our cost-effectiveness results for cetuximab compared with 
best supportive care and panitumumab compared with best supportive care is increased given 
that the effectiveness evidence that underpins these analyses is taken from high-quality RCTs 
whose data are mature. There is much greater uncertainty concerning the analysis for cetuximab 
plus irinotecan compared with best supportive care given the lack of effectiveness evidence, 
particularly for patients with KRAS WT status.
We have confidence in the accuracy of our utility estimates for the best supportive care, 
panitumumab and cetuximab treatment arms. Indeed their accuracy is greater than is typically 
available for cost-effectiveness analysis, being derived from direct observation of patients in trials. 
This is not true for the utilities for cetuximab plus irinotecan.
Limitations
Some factors limit the accuracy of our analysis. For example, the mean duration of drug 
treatment for patients with KRAS WT status, a vital parameter, is available in published form only 
for panitumumab, although we have been told the mean duration of cetuximab monotherapy by 
personal communication. These are important limitations in the evidence for our analysis given 
that cost-effectiveness is very sensitive to these parameters.
The external validity of the results is uncertain given that we use efficacy data from RCTs 
in which patients are relatively young (median age approximately 63 years) and fit [Eastern 
Cooperative Oncology Group (ECOG) score 0–2], compared with people in actual clinical 
practice who are typically older and less fit (some with ECOG score 3–4).
Progression-free survival and overall survival for cetuximab plus irinotecan are available only for 
all patients combined: KRAS WT and KRAS mutant status. Like Merck Serono we have therefore 
been forced to adjust these estimates using other data sources to obtain estimates of progression-
free survival and overall survival in patients with KRAS WT status. However, we have provided 
several possible methods of adjustment and the ICER for cetuximab plus irinotecan compared 
with best supportive care remains high regardless of which estimates for progression-free survival 
and overall survival are used.
In common with Merck Serono we do not stratify our analysis according to the line of treatment 
as the necessary individual patient data were not available.
We estimate the cost of medical management in progressive disease for all treatment groups 
based on a study of medical management in progressive disease for women with breast cancer 
(Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the 
United Kingdom. Br J Cancer 2004;91:77–83). Like Merck Serono we believe that this is 
methodologically acceptable given the absence of suitable alternatives, but do caution that the 
data from this publication are now rather old, relating to practices from 2000.
Main findings in the light of strengths and limitations
Clinical effectiveness
There is no consensus about the evidence on the effectiveness of cetuximab and panitumumab for 
patients with KRAS WT status. Based on RCTs, both cetuximab and panitumumab are effective 
used third line, particularly with respect to progression-free survival. We broadly agree with 
Merck Serono’s estimates of the effectiveness of cetuximab plus irinotecan for patients with KRAS 
WT status even though it has not been directly measured in a RCT. There is an absence of RCT 
evidence of bevacizumab combined with non-oxaliplatin chemotherapy in second and further 
lines of therapy.
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Cost-effectiveness of cetuximab plus best supportive care
There are many similarities between Merck Serono’s cost-effectiveness model for cetuximab 
compared with best supportive care and the Peninsula Technology Assessment Group’s (PenTAG) 
de novo model. Importantly, we assume the same mean times as Merck Serono for progression-
free survival and overall survival for cetuximab and for best supportive care. Nonetheless, Merck 
Serono estimates a far lower ICER than us for cetuximab compared with best supportive care: 
£47,000 compared with £98,000 per QALY gained. This is explained almost entirely by Merck 
Serono’s estimates of the total mean costs of cetuximab acquisition and administration, which 
are far lower than our estimates. These differences in turn are due almost entirely to Merck 
Serono’s far lower estimate of the mean time on cetuximab treatment: 2.6 months compared with 
4.8 months. Merck Serono’s derivation of its estimate is based on its imposition of an artificial 
maximum time on cetuximab treatment. When we use Merck Serono’s model, and lift its cap on 
the time on cetuximab treatment, the ICER increases from £47,000 to £75,000 per QALY gained.
We are aware of only one other fully published cost-effectiveness analysis of any of the treatments 
in this appraisal for patients with KRAS WT status, that of Mittmann and colleagues (2009). They 
perform a trial-based economic analysis to consider cost-effectiveness from the health-care payer 
perspective in Canada. After we adjust their result for the cost per mg of cetuximab appropriate 
in the UK in 2011, and other costs for inflation to the year 2011, we estimate that their ICER 
is approximately equivalent to £101,000 per QALY gained. This is very close to our estimate of 
£98,000 per QALY gained and much higher than Merck Serono’s £47,000 per QALY gained.
Cost-effectiveness of cetuximab plus irinotecan compared with best 
supportive care
Again, there are many similarities between Merck Serono’s model for cetuximab plus irinotecan 
compared with best supportive care and the PenTAG de novo model. Importantly, we assume 
similar mean times as Merck Serono for progression-free survival and overall survival for 
cetuximab plus irinotecan and for best supportive care. Merck Serono estimates a far lower ICER 
than us for cetuximab plus irinotecan compared with best supportive care: £44,000 compared 
with £88,000 per QALY gained. Similar to the case of cetuximab compared with best supportive 
care, this is explained almost entirely by Merck Serono’s estimates of the total mean costs of 
cetuximab plus irinotecan acquisition and administration, which are far lower than our estimates. 
These differences, in turn, are due almost entirely to Merck Serono’s far lower estimate of the 
mean time on cetuximab plus irinotecan treatment: 4.4 months compared with 8.8 months. 
Merck Serono’s derivation of its estimate is based on its imposition of an artificial maximum time 
on cetuximab plus irinotecan treatment. When we use Merck Serono’s model and lift its cap on 
the time on treatment, the ICER increases from £44,000 to £67,000 per QALY.
Cost-effectiveness of panitumumab compared with best 
supportive care
The estimate of cost-effectiveness from the PenTAG de novo model is £150,000 per QALY gained, 
with no alternative estimate being offered by the manufacturer.
Conclusions
On balance we conclude that, used for third- and subsequent-line treatment relative to best 
supportive care, cetuximab plus best supportive care, cetuximab plus irinotecan plus best 
supportive care and panitumumab plus best supportive care are effective but not cost-effective if a 
decision threshold of £20,000 per QALY or £30,000 per QALY is used.
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There is no additional evidence on the effectiveness and cost-effectiveness of cetuximab used in 
second-line treatment to that informing the guidance on second-line use provided by technology 
appraisal No. 118.
In common with the manufacturer, we were not able to estimate the cost-effectiveness of 
bevacizumab in combination with non-oxaliplatin chemotherapy second or subsequent line 
because of the absence of RCT evidence.
Suggested research priorities
 ■ Given the lack of clinical data for patients with KRAS WT status receiving cetuximab plus 
irinotecan, it would be useful to conduct a RCT for these patients comparing cetuximab plus 
irinotecan with cetuximab plus best supportive care or panitumumab plus best supportive 
care. It would be helpful to collect health-related quality of life data in such a trial.
 ■ There is a need to have data documenting the proportions of patients on the various 
pathways of disease once metastatic colorectal cancer has occurred to better inform the 
clinical costs and overall costs.
 ■ We cannot model the cost-effectiveness of bevacizumab in combination with non-oxaliplatin 
chemotherapy because of the absence of relevant clinical evidence. Ideally a RCT should be 
conducted, but only if this was thought to be a potentially important use of the agent by the 
wider clinical community.
 ■ Given that the mean duration of cetuximab plus irinotecan treatment strongly influences 
its cost-effectiveness, and that it is not known with certainty, further data on this parameter 
from the BOND RCT (Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro 
A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory 
metastatic colorectal cancer. N Eng J Med 2004;351:337–45) of cetuximab plus irinotecan 
compared with cetuximab would be helpful.
 ■ Given that the medical management cost data come from a study of women with breast 
cancer from over 10 years ago, collecting data on the medical management of metastatic 
colorectal cancer would be useful.
Ongoing trials identified in the course of this appraisal indicate that some of the gaps in 
knowledge may already be being addressed.
Funding
The National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 
Background
Description of health problem
Colorectal cancer is a malignant neoplasm arising from the lining of the large intestine (colon 
and rectum). Over 95% of colon and rectal cancers are adenocarcinomas, cancers that start in the 
cells that line the inside of the colon and rectum. Cancer cells eventually spread to nearby lymph 
nodes (local metastases) and subsequently to more remote lymph nodes and other organs in the 
body. The liver and the lungs are common metastatic sites of colorectal cancer.
Vascular endothelial growth factor and epidermal growth factor receptor
Two key elements in the growth and dissemination of tumours are the vascular endothelial 
growth factor (VEGF) and the epidermal growth factor receptor (EGFR); both pathways are 
closely related, sharing common downstream signalling pathways.1 VEGF and EGFR play 
important roles in tumour growth and progression through the exertion of both indirect and 
direct effects on tumour cells.1 Biological agents targeting the VEGF and EGFR pathways 
have shown clinical benefit in several human cancers, either alone or in combination with 
standard cytotoxic therapies. Inhibition of VEGF-related pathways is thought to contribute to 
the mechanism of action of agents targeting the EGFR.2 Conversely, (over)activation of VEGF 
expression independent of EGFR signalling is thought to be one way that tumours become 
resistant to anti-EGFR therapy.3 Specific ongoing point mutations in the EGFR gene are also 
thought to convey resistance to anti-EGFR tyrosine kinase inhibitors.4 The possibility that 
combined VEGF and EGFR pathway blockade could further enhance antitumour efficacy and 
help prevent resistance to therapy is currently being evaluated in clinical trials.1
Kirsten rat sarcoma
Kirsten rat sarcoma (KRAS) is a gene that codes for a protein that plays an important role in the 
EGFR pathway, a complex signalling cascade that is involved in the development and progression 
of cancer.
The KRAS protein regulates other proteins, downstream in the EGFR signalling pathway, that are 
associated with tumour survival, angiogenesis, proliferation and metastasis.5 There are different 
types of the KRAS gene found in tumours that either code for a ‘normal’, non-mutated KRAS 
protein known as KRAS wild type (WT), or an abnormal, mutated protein known as mutant 
KRAS. The KRAS ‘status’ (KRAS WT vs KRAS mutant) may be indicative of prognosis and 
predictive of response to certain drugs including those under consideration in this review. In 
tumours with KRAS WT status, the protein is only temporarily activated in response to certain 
stimuli such as EGFR signalling. This tight regulation warrants a close control of downstream 
effects. In tumours with the mutated version of the KRAS gene, the KRAS protein is permanently 
‘turned on’ even without being activated by the upstream EGFR-mediated signalling. As a result 
the downstream effects that lead to tumour growth and spread continue unregulated.
The KRAS test is performed on a sample of tumour tissue that is sent to a laboratory for analysis 
of the KRAS mutation status – WT or mutant. The process helps to enable the most effective 
treatment to be selected for the individual patient. There are multiple methods for determining 
the KRAS mutation status of a tumour (Table 1);6 all appear to have adequate clinical sensitivity to 
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detect patients unlikely to respond to cetuximab or panitumumab. The limitation of sequencing 
technologies is the requirement of > 5–10% mutant alleles for pyrosequencing and > 20% for 
Sanger sequencing, although newer approaches are being developed to increase the sensitivity of 
sequencing methods.6
In colorectal cancer, up to 65% of patients are KRAS WT status; the remaining 35% are 
KRAS mutant.7
Epidemiology
Incidence and prevalence
Colorectal cancer is a common form of malignancy in developed countries but occurs much less 
frequently in the developing world. It is the third most commonly diagnosed cancer in the UK, 
with around 39,991 new cases registered in the UK in 2008 (32,644 cases registered in England 
and Wales).8 The number of cases of colorectal cancer and the incidence rates in England and 
Wales are shown in Table 2.
The occurrence of colorectal cancer is strongly related to age, with 86% of cases arising in people 
aged 60+ years.8 Until age 50, men and women have similar rates for colorectal cancer, but in later 
life the incidence rate for men is higher. In numerical terms there are more cases of colorectal 
cancer in men among almost all age groups up to the age of 84, after which cases of colorectal 
cancer in women are in the majority, even though their rates are lower, as women make up a 
larger proportion of the elderly population.8 Overall, the male-to-female ratio is 11 : 10.8 The 
lifetime risk of being diagnosed with colorectal cancer in the UK is estimated to be 1 in 16 for 
men and 1 in 20 for women.8
TABLE 1 Methods used for KRAS mutation testing6
Method
Sensitivity of 
mutant alleles (%) Strengths Weaknesses
Sanger sequencing 20  ■ Gold standard
 ■ Detects all possible mutations
 ■ Inexpensive
 ■ Time-consuming
 ■ Open PCR system requires strict control for 
contamination
Pyrosequencing 5–10  ■ Ability to sequence short PCR products 
(advantageous for DNA from fixed 
tissue)
 ■ Detects all possible mutations
 ■ Inexpensive
 ■ Faster than Sanger sequencing
 ■ Short reading length for sequences used
 ■ Open PCR system requires strict control for 
contamination
Allele-specific real-time 
PCR
1  ■ Rapid, closed PCR system (eliminates 
risk of contamination with previously 
generated amplicons)
 ■ Available as a commercial kit
 ■ Detects only the seven most common 
mutations
 ■ Requires more tissue for analysis than other 
methods
 ■ Cost
Post-PCR fluorescent 
melting curve analysis 
with specific probes
5–10  ■ Rapid, closed PCR system
 ■ Detects all possible mutations 
(heterozygous and homozygous)
 ■ Occasionally difficult to distinguish between 
mutation types
 ■ More expensive than Sanger sequencing
PCR clamping method 1  ■ Rapid, closed PCR system
 ■ Available as a commercial kit
 ■ Does not allow control of quality of DNA and 
efficiency of PCR amplification
DNA, deoxyribonucleic acid; PCR, polymerase chain reaction.
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Data for colorectal cancer patients diagnosed in England in 2000–4 did show a deprivation 
gradient for male patients with incidence rates 11% higher in the most deprived groups than in 
the affluent groups.8
Pathology
Colorectal cancer includes malignant growths from the mucosa of the colon and rectum. 
Cancer cells eventually spread to nearby lymph nodes (local metastases) and subsequently to 
more remote lymph nodes and other organs in the body. The liver and the lungs are common 
metastatic sites of colorectal cancer.
The pathology of the tumour is usually determined by analysis of tissue taken from a biopsy 
or surgery. Colorectal cancer stage can be described using the modified Dukes’ staging system 
(based on postoperative findings – a pathological staging based on resection of the tumour and 
measuring the depth of invasion through the mucosa and bowel wall) or the more precise TNM 
staging system, which is based on the depth of tumour invasion (T), nodal involvement (N) and 
metastatic spread (M) assessed preoperatively by radiological examination (Table 3).9
Knowing the stage of colon cancer is important for several reasons, including helping the 
physician to define an appropriate treatment plan and in predicting prognosis. In the UK, 
approximately 11% of patients are diagnosed at TNM stage I, 32% at stage II, 26% at stage III 
(lymph node involvement) and 30% at stage IV (metastatic disease). It is estimated that around 
30% of patients present with metastatic disease and a further 20% may eventually develop 
metastatic disease.10 Metastatic disease often develops first in the liver but metastases may also 
occur at other sites, including the lungs.10
Prognosis
The treatment, prognosis and survival rate depend on the stage of disease at diagnosis.
The 5-year relative survival rates for both men and women with colorectal cancer have doubled 
between the early 1970s and the mid-2000s.11 Five-year survival rates for men with colorectal 
cancer rose from 25% in the early 1970s to 51% in the mid-2000s and from 27% to 55% for men 
TABLE 2 Number of new cases of colorectal cancer [International Classification of Disease (ICD) codes C18–C21] and 
European age-standardised incidence rates: England and Wales (2008)8
England Wales
Men Cases 18,040 1311
Crude rate per 100,000 
population
71.2 89.8
ASR per 100,000 population 
(95% CI)
57.0 (56.2 to 57.8) 64.4 (60.9 to 67.9)
Women Cases 14,604 989
Crude rate per 100,000 
population
55.9 64.6
ASR per 100,000 population 
(95% CI)
36.9 (36.3 to 37.5) 39.3 (36.9 to 41.8)
Total Cases 32,644 2300
Crude rate per 100,000 
population
63.4 76.9
ASR per 100,000 population 
(95% CI)
46.1 (45.6 to 46.6) 50.7 (48.6 to 52.8)
ASR, age-standardised incidence rate; CI, confidence interval.
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with colon cancer.11 These improvements are a result of earlier diagnosis and better treatment but 
there is still much scope for further progress.11 Ten-year survival rates are only a little lower than 
those at 5 years indicating that most patients who survive for 5 years are cured from this disease.11
Patients who are diagnosed at an early stage have a much better prognosis than those who present 
with more extensive disease.11 Over 93% of patients diagnosed with stage A on the modified 
Dukes’ classification system (the earliest stage of the disease) survived for 5 years compared with 
< 7% of patients with advanced disease (stage D) (Table 4).11
Treatment of colorectal cancer may be curative or palliative depending on the location of the 
tumour and the degree to which the tumour has penetrated the bowel and spread to other organs 
in the body. Treatment options differ considerably for colon and rectal tumours. Recurrence 
of colorectal cancer may be local or metastatic; however, local recurrence is less commonly 
reported in patients with colon cancer. Treatments of metastatic recurrence of colorectal cancer 
are typically palliative; however, hepatic resection and pulmonary resection may offer a chance of 
cure in a small proportion of patients. The mainstay of treatment for metastatic colorectal cancer 
involves chemotherapy; cytotoxic agents include 5-fluorouracil (5-FU), capecitabine, oxaliplatin, 
irinotecan, tegafur with uracil, and mitomycin. Again, these may be given according to a variety 
of regimens across different lines of therapy.
Impact of the health problem
Significance for patients in terms of ill-health (burden of disease)
Colorectal cancer is a significant cause of morbidity and mortality. When treating patients with 
metastatic colorectal cancer, the main aims of treatment are to relieve symptoms and to improve 
health-related quality of life (HRQoL) and survival.12 In 2008 there were 14,233 deaths from 
colorectal cancer in England and Wales. The majority of deaths occurred in older people: around 
80% in people aged 65+ years and almost 40% in those aged 80+ years (Table 5).12
Quality of life
Assessment of HRQoL has become an important feature of cancer trials, enabling evaluation of 
treatment effectiveness from the perspective of the person with the condition and facilitating 
improved clinical decision-making.
TABLE 3 Staging of colorectal cancer9
Staging group TNM staging and sites involved Modified Dukes’ stage
Stage 0 Carcinoma in situ (Tis, N0, M0) 
Stage I No nodal involvement, no distant metastases
Tumour invades submucosa (T1, N0, M0)
Tumour invades muscularis propria (T2, N0, M0)
A
Stage II No nodal involvement, no distant metastases
Tumour invades muscularis propria into pericolorectal tissues (T3, N0, M0)
Tumour penetrates surface of visceral peritoneum or directly invades or is adherent to other 
organs or structures (T4a/b, N0, M0)
B
Stage III Nodal involvement, no distant metastases (any T, any N, M0) C
Stage IV Distant metastases (any T, any N, M1a/M1b) D
T0, no evidence of tumour; Tis, tumour in situ (abnormal cells present but may spread to neighbouring tissue, sometimes referred to as 
preinvasive cancer); T1, T2, T3, T4, stage of cancer; N0, no regional lymph node involvement; M0, no distant metastasis; M1, distant metastasis 
is present.
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There are several general HRQoL instruments for people with cancer that can be used to assess 
quality of life (QoL) both in research studies and in clinical practice, for example the National 
Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Cancer 
Symptom Index (NCCN FCSI) and the European Organisation for Research and Treatment of 
Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30).
Significance for the NHS
Current service provision
National guidelines
The National Institute for Health and Clinical Excellence (NICE) has issued the 
following guidance:
 ■ Technology appraisal (TA) No. 93 – Irinotecan, oxaliplatin and raltitrexed for the treatment 
of advanced colorectal cancer: review of technology appraisal No. 3314
 ■ TA61– Guidance on the use of capecitabine and tegafur with uracil for metastatic 
colorectal cancer15
 ■ TA118 – Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer16
TABLE 4 Percentage of cases and 5-year relative survival by modified Dukes’ stage at diagnosis in colorectal cancer 
patients diagnosed from 1996 to 2002 in England11
Modified Dukes’ stage at diagnosis Percentage of cases 5-year relative survival (%)a
A 9 93
B 24 77
C 24 48
D 9 7
Unknown 34 35
a Defined as the ratio of the proportion of observed survivors in a cohort of cancer patients to the proportion of expected survivors in a 
comparable set of cancer-free individuals.
TABLE 5 Number of deaths and mortality rates from colorectal cancer: England and Wales (2008)12
England Wales
Deaths 
Men 7178 499
Women 6138 418
Total 13,316 917
Crude rate per 100,000 population
Men 28.4 34.1
Women 23.5 27.3
Total 25.9 30.6
ASR (European) per 100,000 population (95% CI)
Men 21.8 (21.3 to 22.3) 23.6 (21.5 to 25.6)
Women 13.6 (13.3 to 14.0) 14.6 (13.2 to 16.0)
Total 17.3 (17.0 to 17.6) 18.6 (17.4 to 19.8)
ASR, age-standardised mortality rate; CI, confidence interval.
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 ■ TA176 – Cetuximab for the first-line treatment of metastatic colorectal cancer17
 ■ TA105 – Laparoscopic surgery for colorectal cancer: review of NICE technology 
appraisal No. 11718
 ■ TA212 – Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid 
or capecitabine for the treatment of metastatic colorectal cancer19
 ■ Guidance for Commissioning Cancer Services: Improving Outcomes in Colorectal Cancers: 
Research Evidence for the Manual Update13
 ■ Clinical Guideline 131– Colorectal cancer: The diagnosis and management of 
colorectal cancer20
In addition, the Association of Coloproctology of Great Britain and Ireland (ACPGBI) has 
published guidelines for the management of colorectal cancer.21
Current management
The treatment and prognosis for colorectal cancer depend on the stage of the cancer. For early 
cancer, treatment may consist of surgery alone.10 Surgery to remove the primary tumour is the 
principal first-line treatment for approximately 80% of patients, after which about 40% will 
remain disease free in the long term.20 In 20–30% of cases the disease is too far advanced at 
initial presentation for any attempt at curative intervention; many of these patients die within a 
few months.20
The most frequent site of metastases is the liver. In as many as 50% of patients with advanced 
disease the liver may be the only site of spread, and for these patients surgical resection may be 
the only chance of a cure.10,20 Reported 5-year survival rates for resection of liver metastases range 
from 16% to 48%, which is considerably better than those for systemic chemotherapy.10
Individuals with metastatic disease who are sufficiently fit (normally those with World Health 
Organization performance status ≤ 2) are usually treated with active chemotherapy as first- or 
second-line therapy.20 The backbone to treatment across all lines of therapy is composed of 
fluoropyrimidine, irinotecan or oxaliplatin. More recently, targeted agents have become available, 
including anti-EGFR agents, for example cetuximab and panitumumab, and anti-VEGF agents, 
for example bevacizumab (see National guidelines).
Based on a literature review and elicitation of expert opinion, Shabaruddin and colleagues22 
identified predominant treatment pathways within NHS colorectal cancer specialties as first-
line treatment with oxaliplatin-based regimens, second-line treatment with irinotecan-based 
regimens and third-line treatment with mitomycin-based regimens. Current evidence indicates 
that the use of 5-FU, oxaliplatin and irinotecan at any sequence within a patient’s care pathway 
has survival advantages.23
A treatment algorithm for colorectal cancer in England and Wales developed by Tappenden and 
colleagues10 (TA11816) estimates that up to 85% of patients with advanced metastatic colorectal 
cancer not amenable to resection receive active first-line therapy. Of these, approximately 50% 
go on to receive second-line therapy with 5% of those estimated to go on to receive third-
line therapy. This treatment algorithm showed that roughly 300 patients receive a third-line 
chemotherapy in England and Wales. However, there is a paucity of data based on modern 
clinical oncology practice documenting the proportions of patients on the various pathways of 
disease once metastatic colorectal cancer has occurred, and this is often estimated via expert 
advisory groups.
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First-line treatment
First-line active chemotherapy options include oxaliplatin plus infusional 5-FU/folinic acid (FA) 
(FOLFOX) and irinotecan plus infusional 5-FU/FA (FOLFIRI) (TA93).14 Additionally, TA93 did 
not recommend raltitrexed for those with advanced colorectal cancer unless they were taking 
part in a clinical trial. Oral analogues of 5-FU (capecitabine and tegafur with uracil) may also be 
used instead of infusional 5-FU (TA61).15
Cetuximab in combination with FOLFOX or in combination with FOLFIRI is also recommended 
by NICE as an option for the first-line treatment of metastatic colorectal cancer when the 
metastatic disease is confined to the liver and the aim of treatment is to render the metastases 
resectable (TA176).17
In 2009 NICE did not recommend bevacizumab in combination with oxaliplatin and either 
5-FU/FA or capecitabine for those with metastatic colorectal cancer.16
Second-line treatment
For those patients first receiving FOLFOX, irinotecan may be a second-line treatment option, 
whereas for patients first receiving FOLFIRI, oxaliplatin may be a second-line treatment option 
(TA93).14 Patients receiving 5-FU/FA or an oral analogue as first-line treatment may be offered 
FOLFOX or FOLFIRI as second-line and subsequent therapies.
Technology appraisal No. 118 did not recommend cetuximab in combination with irinotecan for 
the treatment of those with metastatic colorectal cancer previously treated with irinotecan.16
Third-line treatment
In the third-line setting the majority of patients will receive best supportive care.
Description of technologies under assessment
Bevacizumab (Avastin®, Roche)
Bevacizumab is a recombinant humanised monoclonal antibody that acts as an angiogenesis 
inhibitor. It targets the biological activity of human VEGF, which stimulates new blood vessel 
formation in the tumour.24 Depriving tumours of VEGF has several effects that are relevant to 
the therapeutic use of bevacizumab. These include preventing the development of new tumour 
blood vessels, causing the regression of existing vasculature and normalising the function of the 
remaining tumour blood vessels resulting in enhanced delivery of concomitantly administered 
cytotoxic drugs.25
Bevacizumab is licensed in combination with 5-fluoropyrimidine-based chemotherapy and is 
indicated for treatment of patients with metastatic colorectal cancer.24 The original European 
Medicines Agency (EMA) marketing authorisation for bevacizumab in metastatic colorectal 
cancer restricted it to use in the first-line setting in combination with 5-FU-based chemotherapy 
with or without irinotecan, based on the Phase III trial data then available. The EMA granted 
a broader marketing authorisation in 2010 licensing bevacizumab in combination with 
fluoropyrimidine-based chemotherapy for treatment of patients with metastatic cancer of the 
colon and rectum. The extension to the marketing authorisation followed publication of further 
studies showing that bevacizumab added to combinations of 5-FU or capecitabine in the first- or 
second-line setting also improved treatment outcomes.26,27
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Bevacizumab is contraindicated in patients who are pregnant or who have hypersensitivity 
to products derived from Chinese hamster ovary cell cultures or other recombinant 
human or humanised antibodies. Special warnings and precautions for use include 
gastrointestinal perforations, wound healing complications, hypertension, proteinuria, arterial 
thromboembolism, haemorrhage and congestive heart failure/cardiomyopathy.24
The most common adverse events with bevacizumab (incidence > 10% and at least twice the 
control arm rate) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry 
skin, rectal haemorrhage, lacrimation disorder and exfoliative dermatitis.
Bevacizumab must be administered under the supervision of a clinician experienced in the use 
of antineoplastic medicinal products.24 It is administered over 90 minutes as an intravenous 
infusion at a dose of 5 mg/kg body weight once every 14 days, and is recommended until there is 
underlying disease progression.24
Cetuximab (Erbitux®, Merck Serono Pharmaceuticals)
Cetuximab is a recombinant monoclonal antibody that blocks the human EGFR. EGFR is found 
on the surface of some cells and plays a role in regulating cell growth. Cetuximab is believed 
to interfere with the growth of cancer cells by binding to EGFR so that the normal epidermal 
growth factors cannot bind and stimulate the cells to grow.
Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-
expressing KRAS WT metastatic colorectal cancer either in combination with chemotherapy 
or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and 
who are intolerant to irinotecan.28 The Summary of Product Characteristics recommends that 
cetuximab must be administered under the supervision of a physician experienced in the use 
of antineoplastic medicinal products. Close monitoring is required during the infusion and 
for at least 1 hour after the end of the infusion in a setting with resuscitation equipment and 
other agents necessary to treat anaphylaxis. Patients requiring treatment should be monitored 
for longer.28
Special warnings and precautions for use include hypersensitivity reactions, dyspnoea and skin 
reactions. Only patients with adequate renal and hepatic function have been investigated to date 
(serum creatinine ≤ 1.5-fold, transaminases ≤ 5-fold and bilirubin ≤ 1.5-fold the upper limit 
of normal).28 Cetuximab has not been studied in patients presenting with one or more of the 
following laboratory parameters:28
 ■ haemoglobin < 9 g/dl
 ■ leucocyte count < 3000/mm3
 ■ absolute neutrophil count < 1500/mm3
 ■ platelet count < 100,000/mm3.
The most common adverse events with cetuximab (incidence ≥ 25%) are cutaneous adverse 
reactions (including rash pruritus and nail changes), headache, diarrhoea and infection.
The recommended initial dose, either as monotherapy or in combination with irinotecan, is 
400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/
minute). The recommended subsequent weekly dose, either as monotherapy or in combination 
with irinotecan, is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/minute) 
until disease progression or unacceptable toxicity.
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There is limited experience in the use of cetuximab in combination with radiation therapy in 
colorectal cancer.28
Panitumumab (Vectibix®, Amgen)
Panitumumab is a recombinant monoclonal antibody that targets the EGFR receptor, thereby 
inhibiting the growth of EGFR-expressing tumours. Panitumumab is licensed as monotherapy 
for treating patients with EGFR-expressing metastatic colorectal cancer with KRAS WT status 
after failure of previous chemotherapy regimens containing fluoropyrimidine, irinotecan 
and oxaliplatin.
Panitumumab treatment should be supervised by a physician experienced in the use of anticancer 
therapy.29 The recommended dose of panitumumab is 6 mg/kg of body weight given once every 
2 weeks.29 Before infusion, panitumumab should be diluted in 0.9% sodium chloride injection to 
a final concentration not to exceed 10 mg/ml.29
Panitumumab is contraindicated in patients with a history of severe or life-threatening 
hypersensitivity reactions to the active substance or to any of the excipients.29 The most common 
adverse events (incidence ≥ 20%) are skin toxicities (i.e. erythema, dermatitis acneiform, pruritus, 
exfoliation, rash and fissures), paronychia, hypomagnesaemia, fatigue, abdominal pain, nausea, 
diarrhoea and constipation.
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Chapter 2 
Definition of the decision problem
Decision problem
The purpose of this report is to assess the clinical effectiveness and cost-effectiveness of 
cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-
oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic 
colorectal cancer after first-line chemotherapy.30
Population including subgroups
The population for this assessment is adults with metastatic colorectal cancer who have failed 
first-line chemotherapy. This is further restricted to patients with EGFR-expressing metastatic 
colorectal cancer with KRAS WT status for cetuximab and panitumumab in line with the 
marketing authorisations for these treatments.
Interventions
This technology assessment report will consider three pharmaceutical interventions:
 ■ bevacizumab in combination with non-oxaliplatin-based chemotherapy
 ■ cetuximab monotherapy and in combination with chemotherapy
 ■ panitumumab monotherapy.
Each should be being used in accordance with the marketing authorisation and in the 
populations indicated in Population including subgroups.
Relevant comparators
Any clinically relevant alternative treatment for the population in question, but 
particularly including:
 ■ irinotecan- or oxaliplatin-based chemotherapy regimens (in the case of 
second-line treatment)
 ■ best supportive care (in the case of third-line or later treatment) consisting of pain control, 
antiemetics, appetite stimulants (steroids) and, in some cases, radiotherapy
 ■ one of the other interventions under consideration.
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Chapter 3 
Assessment of clinical effectiveness
Methods for reviewing effectiveness
The clinical effectiveness of bevacizumab, cetuximab and panitumumab for metastatic colorectal 
cancer was assessed by a systematic review of research evidence. The review was undertaken 
following the principles published by the NHS Centre for Reviews and Dissemination (CRD).31
Identification of studies
Electronic databases were searched using terms related to the population and the interventions 
only, without recourse to methodological or outcome filters. The sensitivity here allowed for the 
multiple requirements of the review.
Appendix 1 shows the search strategies undertaken databases searched; these included 
MEDLINE, EMBASE (both via Ovid), The Cochrane Library, Web of Science (ISI) (including 
Conference Proceedings Citation Index) and EconLit (EBSCOhost). ClinicalTrials.gov, Current 
Controlled Trials, the US Food and Drug Administration (FDA) website and the EMA website 
were also searched. The search initially used as its basis a previous multiple technology 
assessment (MTA) by Tappenden and colleagues10 to construct the population aspect of the 
search. Searches were not limited by language but were limited by date (2005–17 November 
2010), as stated in the protocol (see Appendix 2).
Included studies and industry submissions were analysed to ensure the saturation of 
relevant studies.
All references were exported into EndNote X4 (Thomson Reuters CA, USA) for conversion 
to RIS format before being uploaded into EPPI Reviewer (version 4, EPPI-Centre, Institute of 
Education, London, UK) where manual deduplication was performed.
Relevant studies were then identified in two stages. Titles and abstracts returned by the search 
strategy were examined independently by two researchers (LC and TJH) and screened for 
possible inclusion. Disagreements were resolved by discussion. Full texts of the identified studies 
were obtained. Two researchers (LC and TJH) examined these independently for inclusion or 
exclusion, and disagreements were again resolved by discussion.
Inclusion and exclusion criteria
Study design
Inclusion criteria
For the review of clinical effectiveness, only randomised controlled trials (RCTs) and systematic 
reviews of RCTs were considered. The review protocol made provision for broadening the 
search criteria to include some observational evidence if insufficient systematic reviews or RCTs 
were identified.
Systematic reviews were used as a source for finding further RCTs and to compare with our 
systematic review. For the purpose of this review, a systematic review was defined as one that has:
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 ■ a focused research question
 ■ explicit search criteria that are available to review, either in the document or on application
 ■ explicit inclusion/exclusion criteria, defining the population(s), intervention(s), 
comparator(s) and outcome(s) of interest
 ■ a critical appraisal of included studies, including consideration of the internal and external 
validity of the research 
 ■ a synthesis of the included evidence, whether narrative or quantitative.
The preliminary screening of titles and abstracts did not discriminate according to KRAS status, 
to ensure that trials were not excluded in error. However, during the full-text screening process it 
became apparent that no clinical trials existed with prospective analysis of KRAS status. Because 
this relatively recent understanding of KRAS WT status and intervention efficacy is key to this 
review, trials that retrospectively analysed outcomes according to this subgroup were included.
Exclusion criteria
Studies were excluded if they did not match the inclusion criteria and in particular were:
 ■ non-randomised studies (except for adverse events)
 ■ animal models
 ■ preclinical and biological studies
 ■ narrative reviews, editorials, opinions
 ■ non-English-language papers
 ■ reports published as meeting abstracts only, in which insufficient methodological details 
were reported to allow critical appraisal of study quality.
Population
Randomised controlled trials were included for panitumumab and cetuximab if they reported 
clinical outcomes for an adult population with EGFR-expressing metastatic colorectal cancer 
with KRAS status assessed that has progressed after first-line chemotherapy. The justification 
for including only studies in which the population had their KRAS status assessed revolves 
around recent evidence indicating that anti-EGFR-targeted antibodies, such as cetuximab 
and panitumumab, are effective only in patients with KRAS WT as opposed to KRAS 
mutant oncogenes.32
For bevacizumab, studies were included if the population with metastatic colorectal cancer had 
progressed after first-line chemotherapy. No stipulation for EGFR expression or KRAS status was 
required as this has been shown to have no influence on bevacizumab activity.33
Interventions and comparators
Studies were included if the technologies they assessed fulfilled the following criteria:
 ■ after first-line therapy with cetuximab as monotherapy or in combination with chemotherapy
 ■ after first-line therapy with bevacizumab in combination with non-
oxaliplatin-based chemotherapy
 ■ after first-line therapy with panitumumab as monotherapy.
Alternative treatments for the population in question (clinically relevant comparators) were:
 ■ irinotecan- or oxaliplatin-based chemotherapy regimens
 ■ one of the interventions under consideration
 ■ best supportive care.
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We have also considered the validity of indirect comparisons between interventions 
when appropriate.
Outcomes
Studies were included if they reported data on one or more of the following outcomes:
 ■ overall survival
 ■ progression-free survival
 ■ tumour response rate
 ■ adverse effects of treatment
 ■ HRQoL
 ■ liver resection rates.
Data extraction strategy
Data were extracted by one reviewer (TJH) using a standardised data extraction form in 
Microsoft Access 2007 (Microsoft Corporation, Redmond, WA, USA) and checked by a second 
reviewer (LC). Disagreements were resolved by discussion, with involvement of a third reviewer 
if necessary. Data extraction forms for each included study can be found in Appendix 3.
Critical appraisal strategy
The methodological quality of the studies was assessed according to criteria specified by the 
CRD.31 Quality was assessed by one reviewer and judgements were checked by a second. Any 
disagreement was resolved by discussion, with involvement of a third reviewer as necessary. The 
instrument is summarised below. Results were tabulated and the relevant aspects described in the 
data extraction forms.
Internal validity
The instrument sought to assess the following:
 ■ Was the assignment to the treatment groups really random?
 ■ Was the treatment allocation concealed?
 ■ Were the groups similar at baseline in terms of prognostic factors?
 ■ Were the eligibility criteria specified?
 ■ Were outcome assessors blinded to the treatment allocation?
 ■ Was the care provider blinded?
 ■ Was the patient blinded?
 ■ Were point estimates and a measure of variability presented for the primary 
outcome measure?
 ■ Did the analyses include an intention-to-treat (ITT) analysis?
 ■ Were withdrawals and dropouts completely described?
In addition, methodological notes were made for each included study, with the reviewer’s 
observations on sample size and power calculations, participant attrition, methods of data 
analysis, and conflicts of interest.
External validity
External validity was judged according to the ability of a reader to consider the applicability of 
findings to a patient group and service setting. Study findings can be generalisable only if they 
provide enough information to consider whether or not a cohort is representative of the affected 
population at large. Therefore, studies that appeared to be typical of the UK metastatic colorectal 
cancer population with regard to these considerations were judged to be externally valid.
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Methods of data synthesis
Details of the extracted data and quality assessment for each individual study are presented 
in structured tables and as a narrative description. Any possible effects of study quality on the 
effectiveness data are discussed. Survival data (overall survival and progression-free survival) are 
presented as hazard ratios where available.
When data on head-to-head comparisons between interventions were not available, we 
performed adjusted indirect comparisons using an adaption of the method described by 
Bucher and colleagues.34 This method aims to overcome the potential problems of a simple 
direct comparison (i.e. comparison of simple arms of different trials), in which the benefit of 
randomisation is lost leaving the data subject to the biases associated with observational studies. 
The method is valid only when the characteristics of patients are similar between the different 
studies being compared. Further details of the methods used can be found in Appendix 4.
Use of manufacturers’ submissions to the National Institute for Health and 
Clinical Excellence
A description of the search strategy employed in each of the manufacturers’ submissions and 
a comment on whether or not it was appropriate is detailed in Appendix 5. All of the clinical 
effectiveness data included in the manufacturers’ submissions were assessed. When these met 
the inclusion criteria and had not already been identified from published sources, they were 
included in the systematic review of clinical effectiveness. However, it became apparent that 
the manufacturers’ submissions were dependent on evidence that did not include KRAS status 
and would not fulfil the inclusion criteria for this part of the report. Therefore, to maintain 
consistency, the papers reported in the manufacturers’ submissions are briefly critiqued here, 
with a more detailed discussion in Chapter 5.
Interpreting the results from the clinical trials
Effectiveness
Most of the clinical trials in which the efficacy of these interventions has been evaluated report 
results in terms of hazard ratios – the ratio of hazard rates in two groups, such as a treatment 
group and a control group. The hazard rate describes the number of events per unit time per 
number of people exposed (i.e. the slope of the survival curve, or the instantaneous rate of events 
in the group). A hazard ratio of ≥ 1 indicates that the event  of interest is happening faster in the 
treatment group, whereas a hazard ratio of ≤ 1 indicates that the event of interest is happening 
more slowly in the treatment group. A hazard ratio of 1 suggests that there is no difference 
between the groups.
Adverse drug effects
The National Cancer Institute Common Terminology Criteria (NCI-CTC) (Table 6) are 
frequently used by trials to report drug toxicities.35 For each adverse event, grades are assigned 
using a scale from 0 to 5. Grade 0 is defined as absence of an adverse event or within normal 
limits for values. Grade 5 is defined as death associated with an adverse event.
TABLE 6 National Cancer Institute Common Terminology Criteria for adverse events35 
Grade Description
0 No adverse event or within normal limits
1 Mild adverse event
2 Moderate adverse event
3 Severe or medically significant adverse event but not immediately life-threatening
4 Life-threatening or disabling adverse event
5 Death related to an adverse event
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Results of the clinical effectiveness review
The results of the assessment of clinical effectiveness are presented as follows:
 ■ An overview of the quantity and quality of available evidence together with a table 
summarising all included trials (see Table 7) and a summary table of key quality indicators 
(see Table 9).
 ■ A critical review of the available evidence for each of the stated research questions (see Study 
characteristics), covering:
 – the quantity and quality of available evidence
 – a summary table of the study characteristics
 – a summary table of the baseline population characteristics
 – comparison of the baseline populations in the included trials
 – study results presented in narrative and tabular form
 – comparison of the results in terms of effectiveness and safety.
 ■ A summary of evidence for clinical effectiveness used in the manufacturers’ submissions. 
This is included to address the trials used by the manufacturers, none of which meet the 
inclusion criteria for this systematic review (see Study characteristics).
Quantity and quality of research available
Number of studies identified
The electronic searches retrieved a total of 7745 titles and abstracts. No additional papers were 
found by searching the bibliographies of included studies. A total of 7690 papers were excluded 
based on screening the title and abstract. The full text of the remaining 55 papers was requested 
for more in-depth screening, resulting in a total of 13 papers being included in the review. The 
process of study selection is shown in Figure 1.
FIGURE 1 Summary of study selection.
Titles and abstracts identified: n = 7745
Full-text paper retrieved: n = 57
Included: n = 13 (2 studies, 1 systematic review)
Not a clinical trial or does not fulfil
inclusion criteria: n = 7690
Not a RCT, CCT or relevant systematic
review: n = 5
Results mixed for different populations or
interventions: n = 8
No relevant intervention: n = 9
No relevant comparison: n = 0
No relevant population: n = 16
No relevant intervention or population: n = 4
Not in English: n = 2
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Number of studies excluded
Papers were excluded for at least one of the following reasons: duplicate publication, narrative 
review, uncontrolled study (when evidence from controlled trials was available for the research 
question) and publication (systematic reviews and individual studies) not considering the 
relevant interventions, population, comparisons or outcomes. The bibliographic details of studies 
retrieved as full papers and subsequently excluded, along with the reasons for their exclusion, are 
detailed in Appendix 6.
Number and description of included studies
Two main clinical trials and one single-arm extension reported in 12 papers were included in the 
review for cetuximab plus best supportive care and panitumumab plus best supportive care. One 
systematic review was also included.36 Both trials had retrospective KRAS status determination 
after the study had been completed. All included clinical effectiveness studies are detailed 
in Table 7. It should be noted that no studies used in the earlier NICE report10 that reviewed 
bevacizumab and cetuximab for the treatment of metastatic colorectal cancer met the inclusion 
criteria in this instance, as the included trials for bevacizumab were first line and KRAS status 
was not established for cetuximab.
We were unable to identify any suitable data on the clinical effectiveness of bevacizumab with 
non-oxaliplatin-based chemotherapy; however, a clinical trial is currently under way comparing 
bevacizumab with FOLFIRI against panitumumab with FOLFIRI after first-line treatment 
(Appendix 7).39 No data have yet been published.
Study characteristics
Bevacizumab
There is currently no clinical evidence for the effectiveness of bevacizumab with non-oxaliplatin 
therapy after first-line treatment in metastatic colorectal cancer, although the EMA has granted 
marketing authorisation for its use in this clinical setting (see Description of technologies under 
assessment, Bevacizumab). However, Roche reports three trials that it considers relevant to the 
consideration of bevacizumab for first-line use in patients with metastatic colorectal cancer, 
which were not included in the review. These are the ‘966 Study’ by Saltz and colleagues40 on 
oxaliplatin-combined therapy, the study by Hurwitz and colleagues on irinotecan-combined 
therapy26 and the study by Kabbinavar and colleagues27 on 5-FU/FA combined therapy. For 
second-line combined treatment, Roche refers to the ‘E3200 Study’ by Giantonio and colleagues41 
TABLE 7 Summary information of all included clinical effectiveness studies
Study Year Study type n Intervention Comparator Supplementary publications
CET + BSC vs BSC after first-line therapy
Jonker et al.37 2007 R, O, C, BR, Phase III, 
international, multicentre
572 CET + BSC BSC 8, 13, 49–51
PAN + BSC vs BSC after first-line therapy
Van Cutsem et al.7 2007 R, O, C, BR, Phase III, 
international, multicentre
463 PAN + BSC BSC 9, 11, 52, 54
PAN after first-line therapy – supplement to main trial (above)
Van Cutsem et al.38 2008 ES, O, single-arm 
supplement
176 PAN NA –
BR, independent (blind) central review of radiological images used to assess primary outcome; BSC, best supportive care; C, controlled; CET, 
cetuximab; ES, extension study; NA, not applicable; O, open label; PAN, panitumumab; R, randomised.
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on bevacizumab with oxaliplatin therapy. Further details can be found in Chapter 5; however, the 
outcomes will be briefly discussed in this chapter for consistency.
Cetuximab plus best supportive care compared with best 
supportive care
Jonker and colleagues37 report the results of the CO.17 trial, an open-label RCT in which 572 
patients across Canada and Australia with advanced colorectal cancer expressing EGFR were 
randomised to receive either cetuximab plus best supportive care or best supportive care alone. 
Note that this primary paper does not analyse results according to KRAS status. The trial has 
been reported in one publication37 and four supplementary papers,42–45 one of which addresses 
the retrospective analysis of tissue samples for KRAS mutations with the others looking at cost-
effectiveness, QoL and subgroup analysis.
The aim of the study was to demonstrate the effectiveness of cetuximab for survival and QoL 
in patients with advanced colorectal cancer. To that end, the primary end point was overall 
survival, defined as time from randomisation until death from any cause. Secondary outcomes 
investigated were progression-free survival, QoL and response rates. Objective tumour response 
was evaluated using the modified Response Evaluation Criteria in Solid Tumours (RECIST)46 and 
QoL was assessed using the EORTC QLQ-C30.
To be eligible for entry into the trial participants had to have advanced colorectal cancer 
expressing EGFR that was detectable by immunohistochemical methods in a central reference 
laboratory. The participants must have experienced tumour progression, unacceptable adverse 
events or contraindications to treatment with fluoropyrimidine, irinotecan or oxaliplatin.
Randomisation was performed centrally in a 1 : 1 ratio to cetuximab plus best supportive care 
or best supportive care alone, with participants stratified according to Eastern Cooperative 
Oncology Group (ECOG) performance status (0 or 1 vs 2) and centre. Patients in the treatment 
arm received intravenously administered cetuximab over 120 minutes with an initial dose of 
400 mg/m2 of body surface area, followed by a weekly maintenance infusion of 250 mg/m2 over 
60 minutes. An antihistamine was given 30–60 minutes before each dose of cetuximab. Treatment 
was continued until death in the absence of unacceptable adverse events, tumour progression, 
worsening symptoms of the cancer or request by the patient.
The median duration of follow-up was reported as 14.6 months, although no range is given and 
it is not clear if this is for both arms. The median duration of cetuximab treatment was only 
8.1 weeks (range 1–60 weeks), largely because of disease progression. The median dose intensity 
after the initial dose was 247 mg/m2/week and the relative dose intensity, that is, the ratio of the 
dose administered to the planned dose, was ≥ 90% in 75% of patients.
The first supplementary paper by Karapetis and colleagues47 considers the association between 
KRAS status and clinical benefit from cetuximab. The rationale for this investigation revolved 
around evidence suggesting that KRAS mutation rendered EGFR inhibitors, in this case 
cetuximab, ineffective.36,48 The retrospective analysis was performed on 394 tumour samples 
obtained from the 572 participants of the CO.17 trial, with KRAS status then correlated with 
overall survival, progression-free survival and QoL.
The examination of tissue samples was performed by blinded assessors, with all statistical 
analysis performed in accordance with a protocol written before the assessment of KRAS status 
was performed.47 The primary and secondary outcomes were consistent with those of the main 
trial report.37
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Au and colleagues44 focused on HRQoL in patients participating in the CO.17 trial to assess the 
influence of KRAS status in predicting benefit of cetuximab. The primary HRQoL analyses were 
defined prospectively as a comparison of the change of scores on the EORTC QLQ-C30 from 
baseline to 8 and 16 weeks for the physical function and global health status scales. Secondary 
HRQoL analyses included comparisons of the proportions of patients with worsened physical 
function and global health status at 8 and 16 weeks. A 10-unit change in score was predefined as 
clinically important.
The paper by Asmis and colleagues43 considered the relationships between comorbidity, age and 
performance status as predictors of outcome. The Charlson Comorbidity Index (CCI) was used 
to measure comorbidity, with the score determined by two physician reviewers. Variables of 
participant age and CCI score were dichotomised: age < 65 years compared with ≥ 65 years and 
CCI score 0 compared with ≥ 1, with higher scores indicating greater comorbidity. Univariate 
analysis was also performed for the association between age group and baseline characteristics.
Finally, the study by Mittmann and colleagues42 evaluated the cost-effectiveness of cetuximab 
with some preference-based health utility values, using the Health Utility Index (HUI) Mark 3 
(HUI3).
In addition to the CO.17 trial, Merck Serono provided details of the BOND trial49 through De 
Roock and colleagues.48 This is a retrospective analysis of cetuximab plus best supportive care 
compared with cetuximab plus irinotecan according to KRAS status. Data are used from the 
following four trials: BOND,49 EVEREST,50 SALVAGE51 and BABEL. Because De Roock and 
colleagues are not reporting a trial, or a systematic review, this study is not formally included in 
this review of clinical effectiveness. However, the de novo model relies heavily on this evidence; 
therefore, relevant information will be included throughout this chapter. Further details with a 
more substantial critique may be found in Chapter 5.
Panitumumab plus best supportive care compared with best 
supportive care
Van Cutsem and colleagues7 present the results of an open-label, Phase III, international 
(Western Europe, Central Europe, Eastern Europe, Canada, Australia, New Zealand) multicentre 
RCT in which 463 patients with metastatic colorectal cancer were randomised to receive either 
panitumumab and best supportive care or best supportive care alone. The trial has been reported 
in one main publication7 and four supplementary publications,32,38,52,53 which are summarised 
in Table 8.
Eligibility criteria included pathological diagnosis of metastatic colorectal adenocarcinoma 
and radiological documentation of disease progression during treatment or within 6 months 
following the last administration of fluoropyrimidine, irinotecan and oxaliplatin.
TABLE 8 Summary of primary and supplementary studies for panitumumab
Study Description Median (range) follow-up (months)
Van Cutsem et al.7 Main trial of PAN + BSC vs BSC 8.8 (3.8–19)
Siena et al.53 Analysis of association of progression-free survival with colorectal 
cancer symptoms, HRQoL and overall survival
18 (13–28.3)
Van Cutsem et al.38 Crossover extension study 15.3 (4.5–25.8)
Amado et al.32 Retrospective KRAS analysis of main trial 14.1 (for 36 patients remaining at time of analysis)
Peeters et al.52 Analysis of association of skin toxicity severity with efficacy of PAN 18 (13–28.3)
BSC, best supportive care; PAN, panitumumab.
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The aim of the study was to evaluate the effect of panitumumab monotherapy in patients with 
chemorefactory metastatic colorectal cancer. The primary outcome was progression-free survival 
assessed by blinded central radiology. Secondary outcomes were best objective response, overall 
survival, time to response and duration of response.
The study was designed to have 90% power for a two-sided 1% significance level test given a 
hazard ratio of 0.67 (panitumumab relative to best supportive care).
Patients were randomly assigned in the ratio 1 : 1 to receive panitumumab plus best supportive 
care or best supportive care alone; however, details of the randomisation procedure are not 
given. Random assignment was stratified by ECOG performance status (0 or 1 vs 2) and region 
(Western Europe vs Central and Eastern Europe vs the rest of the world). Patients allocated to the 
intervention arm received panitumumab via a 60-minute intravenous infusion of 6 mg/kg once 
every 2 weeks until progression or unacceptable toxicity developed.
All patients were followed for survival every 3 months for up to 2 years after randomisation; 
however, median follow-up reported in this paper was approximately 35 weeks (range 
15–76 weeks) in the panitumumab arm.
In the best supportive care group, 176 (76%) patients received panitumumab in a crossover 
protocol, which is reported in a supplementary paper.38 The median time to crossover was 
7 weeks (range 6.6–7.3 weeks) and the median follow-up after crossover was 61 weeks (range 
18–103 weeks). The median duration of treatment and dose intensity were not reported.
Siena and colleagues53 examine the association of progression-free survival with colorectal cancer 
symptoms, HRQoL and overall survival for the panitumumab trial. Patient-reported outcomes 
were measured using the NCCN FCSI for colorectal cancer symptoms and HRQoL was measured 
using the European Quality of Life-5 Dimensions (EQ-5D) Health Index Scale, the EQ-5D visual 
analogue scale (VAS) and the EORTC QLQ-C30 global health status/QoL scale. In this paper 
median follow-up time for survival (enrolment to data cut-off for analysis) for all patients was 
reported as 72 weeks (range 52–113 weeks).
The efficacy and safety findings for panitumumab from the extension study of the main trial, 
that is, the crossover from best supportive care to panitumumab, are presented by Van Cutsem 
and colleagues;7,38 hence, this was a multicentre, open-label, single-arm trial. To be eligible, 
participants must have documented disease progression and were required to have completed 
the last assessment on the Phase III study not more than 3 months before enrolment in the 
extension study. During the interim participants could not have received systemic chemotherapy, 
radiotherapy, investigational agents or antitumour therapies.
Patients were followed for survival approximately every 3 months for up to 2 years from the 
randomisation date into the Phase III study.7 The primary end point was safety and, although 
not prespecified in the protocol, progression-free survival, objective response rate, time to and 
duration of response, duration of stable disease and survival were explored.
The sample size was limited to the patients enrolled in the best supportive care arm of the Phase 
III study who met the eligibility criteria. Assuming a true event rate of 1%, the probability of at 
least one patient experiencing a given adverse event was 87% for a sample size of 200. Median 
follow-up time was reported as 61 weeks (range 18–103 weeks).
Amado and colleagues32 reported on a retrospective study assessing the predictive role of KRAS 
status in the main panitumumab trial. Of the 463 patients originally enrolled, 427 were included 
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in the KRAS analysis, although the assessable sample size was 380 because of unavailable or 
poor-quality samples. The primary objective was to determine whether or not the effect of 
panitumumab plus best supportive care on progression-free survival differed between patients 
with KRAS mutant status and those with KRAS WT status. Secondary outcomes included 
whether or not panitumumab improved progression-free survival, overall survival and response 
rate in the KRAS WT group compared with the best supportive care group.
Estimating a 60% KRAS WT status prevalence, power was calculated at more than 99% if the 
hazard ratio was 1.0 in the KRAS mutant group and at 87% if the hazard ratio was 0.80 in the 
KRAS mutant group, assuming an overall hazard ratio of 0.54 among all patients.
The final supplementary paper by Peeters and colleagues52 uses data from the main trial to 
investigate the association of skin toxicity severity and patient-reported skin toxicity with 
progression-free survival, overall survival, disease-related symptoms and HRQoL. Associations 
by KRAS status were also evaluated.
Assessment of study quality
A summary of the quality assessment of studies included in this review is shown in Table 9; study 
characteristics are summarised in the narrative below and in Appendix 3.
TABLE 9 Summary of quality assessment: studies included in the clinical effectiveness review
Jonker et al.37 Van Cutsem et al.7 Van Cutsem et al.38
Study design RCT RCT Single arm/crossover
Is a power calculation provided? Yes Yes N/A
Is the sample size adequate? Yes Yes N/A
Was ethical approval obtained? ? Yes Yes
Were the study eligibility criteria specified? Yes Yes N/A
Were the eligibility criteria appropriate? Yes Yes N/A
Were patients recruited prospectively? Yes Yes N/A
Was assignment to the treatment groups really random? Yes ? N/A
Was the treatment allocation concealed? No No No
Were adequate baseline details presented? Yes Yes Yes
Were the participants representative of the population in question? Yes Yes Yes
Were the groups similar at baseline? Yes Yes N/A
Were baseline differences adequately adjusted for in the analysis? N/A N/A N/A
Were the outcome assessors blind? ? Yes N/A
Was the care provider blind? No No N/A
Are the outcome measures relevant to the research question? Yes Yes Yes
Is compliance with treatment adequate? Yes ? ?
Are withdrawals/dropouts adequately described? Yes Yes Yes
Are all patients accounted for? Yes Yes Yes
Is the number randomised reported? Yes Yes N/A
Are protocol violations specified? No No No
Are data analyses appropriate? Yes Yes Yes
Is analysis conducted on an ITT basis? Yes Yes N/A
Are missing data appropriately accounted for? Partial No Yes
Were any subgroup analyses justified? Yes Yes No
Are the conclusions supported by the results? Yes Yes Yes
?, unclear or unknown; N/A, not applicable.
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Cetuximab plus best supportive care compared with best 
supportive care
The CO.17 trial reported by Jonker and colleagues37 is a good-quality, open-label, randomised 
Phase III trial. The evaluation of the trial in relation to study quality is shown in Table 9.
Randomisation methods and withdrawal were adequately reported. As previously mentioned, 
dose intensity was also noted to be adequate at 90%. However, blinding of assessors was not 
reported. A reason for the open-label nature of the study was also not given, although this may 
be due to the anticipated skin toxicity of anti-EGFR agents. The assessment of tissue samples for 
KRAS status was confirmed as performed in a blinded manner.47
The De Roock study,48 not formally included in this review but cited by Merck Serono for clinical 
effectiveness, analyses KRAS status from several cetuximab-based studies. The data reveal several 
key issues:
 ■ of the relatively small sample size (n = 113), a total of 67 patients had KRAS WT status: 40% 
of the patients (n = 27) from the BOND trial,49 42% (n = 28) from the EVEREST trial,50 15% 
(n = 10) from SALVAGE51 and 3% (n = 2) from BABEL
 ■ in the BOND trial, 50% of patients from the cetuximab plus best supportive care arm 
received irinotecan after disease progression, indicating potential crossover and subsequent 
underestimation of overall survival in those treated with cetuximab plus irinotecan49
 ■ the EVEREST trial is described as a RCT comparing cetuximab plus irinotecan, escalating 
doses of cetuximab plus irinotecan and cetuximab plus best supportive care; however, it is 
unclear why only data from cetuximab plus irinotecan patients are included in De Roock and 
colleagues48,50,54,55
 ■ the SALVAGE study is a non-comparative study of patients receiving cetuximab plus best 
supportive care only who have received at least two previous lines of therapy51
 ■ the BABEL study appears to be investigating the effect of tetracycline to alleviate a rash in 
cetuximab therapy, although further details on this study have been difficult to identify
 ■ patients were included on the basis of availability of formalin-fixed paraffin-embedded 
tumour tissue; however, there are no details on what this percentage was for each of the four 
studies contributing patient data.
As such, there are concerns regarding the disease progression and effectiveness estimates 
calculated using De Roock and colleagues.48 The estimates are likely to be subject to high levels of 
bias and confounding, although it is unclear what impact this will have.
Panitumumab plus best supportive care compared with best 
supportive care
The trial by Van Cutsem and colleagues7 is a large, good-quality, open-label, international, 
multicentre, randomised Phase III study. The lack of participant and clinician/investigator 
blinding due to expected skin toxicity is discussed; however, to mitigate this, tumour assessments 
were performed by blinded central review. Unfortunately, it is unclear whether or not 
randomisation was performed centrally. Further details of the quality assessment can be found in 
Table 9.
Population baseline characteristics
Cetuximab plus best supportive care compared with best supportive care For the main trial37 
the demographic characteristics and disease status were well matched (Table 10). The baseline 
characteristics were re-examined by Karapetis and colleagues47 according to KRAS status, which 
is also included in Table 10. Of the original 572 samples, 394 were available for analysis. Fifty-
eight per cent were revealed to be WT, with 51% assigned to cetuximab plus best supportive care 
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and 49% to best supportive care. The relative proportions of each characteristic remained similar 
between arms.
Panitumumab plus best supportive care compared with best supportive care At baseline, the two 
groups were well matched in the original trial.7 A slight difference was noted with disease status, 
with the best supportive care arm having 34% of participants with an ECOG performance status 
of 0 and 50% with an ECOG performance status of 1, and the treatment arm having 46% of 
participants with an ECOG performance status of 0 and 41% with an ECOG performance status 
of 1 (see Table 10). The supplementary study32 ascertained KRAS status in 92% of the original 
participants, showing the distribution of KRAS WT and KRAS mutant status between arms and 
ECOG performance status to be broadly similar.
Comparability of baseline population characteristics Participants in the two main trials of 
cetuximab plus best supportive care compared with best supportive care were similar in terms of 
age, gender distribution and site of primary cancer.45 However, as is usually the case with cancer 
trials, the study populations were significantly younger than the general population presenting 
with colorectal cancer, with the peak in number of cases in the UK, for example, between 70 and 
79 years for men and 75–85+ years for women as opposed to a median of 62–64 years shown in 
Table 10.
Reporting of disease status in the panitumumab trial was limited to only ECOG performance 
status rather than providing details of primary or metastatic sites. A higher proportion of 
participants was noted to have an ECOG performance status of 0 in the treatment arm than in 
the best supportive care arm (46% vs 25%), which equates to ‘fully active, able to carry on all 
pre-disease performance without restriction’; therefore, this suggests a fitter population in the 
intervention arm.
Assessment of clinical effectiveness
Overall survival (Table 11)
Bevacizumab There is currently no clinical evidence for the effectiveness of bevacizumab with 
non-oxaliplatin therapy after first-line treatment in metastatic colorectal cancer. However, the 
trials reported by Roche, which are not included in this review, will be briefly mentioned here.
First line Saltz and colleagues40 conducted a RCT for first-line bevacizumab combined with 
oxaliplatin in 1401 patients, 75% of whom had not previously received chemotherapy. Treatment 
TABLE 11 Summary of overall survival: cetuximab plus best supportive care and panitumumab plus best supportive 
care vs best supportive care after first-line therapy
Study Interventiona n Median OS (months) HR 95% CI p-value
Jonker et al.37 All: CET + BSC 287 6.1 0.77 0.64 to 0.92 0.005
All: BSC 285 4.6
Karapetis et al.47 WT: CET + BSC 117 9.5 0.55b 0.41 to 0.74 < 0.001
WT: BSC 113 4.8 − − −
Van Cutsem et al.7 All: PAN + BSC 231 NR 1.00 0.82 to 1.22 0.81
All: BSC 232 NR − − −
Amado et al.32 WT: PAN + BSC 124 8.1 0.99 0.75 to 1.29 NR
WT: BSC 119 7.6 − − −
BSC, best supportive care; CET, cetuximab; HR, hazard ratio; NR, not reported; OS, overall survival; PAN, panitumumab.
a All, mutant and WT patients. 
b These results are before adjustment for potential prognostic factors. The difference remained significant following adjustment.
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arms were capecitabine plus oxaliplatin (XELOX) plus bevacizumab, XELOX plus placebo, 
5-FU, FA and oxaliplatin (FOLFOX-4) plus bevacizumab or FOLFOX-4 plus placebo. The 
hazard ratio for overall survival for bevacizumab compared with placebo was not statistically 
significant (hazard ratio 0.89, 97.5% CI 0.76 to 1.03, p = 0.077), with a median overall survival of 
21.3 months for bevacizumab and 19.9 months in the placebo arm.
Hurwitz and colleagues26 randomised 813 people to receive either irinotecan, bolus fluorouracil 
and leucovorin (IFL) plus bevacizumab or IFL alone for first-line treatment (28% of IFL patients 
and 24% of IFL plus bevacizumab patients had received previous adjuvant chemotherapy). 
ITT analyses showed that median survival was 20.3 months for those treated with IFL plus 
bevacizumab and 15.6 months for those receiving IFL alone (hazard ratio 0.6, p < 0.001).
Subsequent treatment Kabbinavar and colleagues27 randomised 209 patients to receive 
fluorouracil and leucovorin (FU/LV) plus bevacizumab or FU/LV only. Twenty-one per cent 
of the FU/LV plus bevacizumab patients and 19% of the FU/LV patients had prior adjuvant 
chemotherapy. The primary end point of overall survival produced a non-statistically significant 
hazard ratio of 0.76 (95% CI 0.56 to 1.10) for FU/LV plus bevacizumab compared with FU/LV, 
with a median overall survival of 16.6 months in the FU/LV plus bevacizumab arm and 
12.9 months in the FU/LV arm. The authors argue that the large number of patients receiving 
postprogression treatment could partly explain the lack of statistical significance in the primary 
end point of overall survival. A similar percentage of patients from both treatment arms received 
irinotecan, oxaliplatin or both post progression (39% of the FU/LV plus bevacizumab patients 
and 46% of the FU/LV patients).
Giantonio and colleagues41 report a RCT with 820 patients previously treated with a 
fluoropyrimidine and irinotecan randomised to one of three arms: FOLFOX-4 plus bevacizumab, 
FOLFOX-4 or bevacizumab alone. Median overall survival was greater in the FOLFOX-4 plus 
bevacizumab arm: 12.9 months compared with 10.8 months for FOLFOX-4 and 10.2 months 
for bevacizumab alone. The hazard ratio for overall survival associated with FOLFOX-4 plus 
bevacizumab compared with FOLFOX-4 was 0.75 (p = 0.01).
Cetuximab plus best supportive care compared with best supportive care Overall survival, defined 
as the time between date of randomisation and death from any cause, was the primary end 
point in the CO.17 trial.37 The analysis was performed on an ITT basis, with the final analysis 
conducted after at least 445 patients were known to have died.
The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the best 
supportive care group, with a hazard ratio of 0.77 (95% CI 0.64 to 0.92, p = 0.005). Seven percent 
of patients receiving best supportive care were administered cetuximab after crossover; however, 
this would be unlikely to bias the results against treatment.37
No significant differences were seen for the benefit of cetuximab on the basis of ECOG 
performance status at baseline, age or sex in subgroup analysis. However, unplanned analysis 
indicated that grade of rash in patients receiving cetuximab was correlated with overall survival, 
with median survival of 2.6 months in patients with no rash, 4.8 months in patients with grade 1 
rash and 8.4 months is patients with grade 2 rash (p < 0.001).37
For patients with KRAS mutant status, analysis by Karapetis and colleagues47 showed a median 
overall survival of 4.5 months for cetuximab and 4.6 months for best supportive care, with a 
hazard ratio of 0.98 (95% CI 0.70 to 1.37, p = 0.89). Among patients with WT status, the median 
overall survival was 9.5 months in the cetuximab group compared with 4.8 months in the best 
supportive care group, with an hazard ratio of 0.55 (95% CI 0.41 to 0.74, p < 0.001). Subsequent to 
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adjustment for potential prognostic factors, which are reported to be as specified in the protocol 
but are not described in the paper, the hazard ratio increases to 0.62 (95% CI 0.44 to 0.87, 
p = 0.006); however, these results remain favourable towards cetuximab plus best supportive care.
Panitumumab plus best supportive care compared with best supportive care At the time of 
analysis, the study had achieved the event rate required for 90% power.7 Overall survival was 
calculated from the day of random assignment until death, censoring patients at the last day 
known to be alive. Median overall survival values were not given; however, it was reported that 
no significant difference was found between arms (hazard ratio of 1.00, 95% CI 0.82 to 1.22, 
p = 0.81). The authors cite confounding because of the rapid crossover of 76% of patients from the 
best supportive care arm to receive active treatment for the lack of significant difference between 
arms,32 which would bias the results against treatment.
Exploratory analysis of skin toxicity demonstrated a longer overall survival in patients with a skin 
toxicity of grade 2–4 than in those with a skin toxicity of grade 1, resulting in an hazard ratio of 
0.59 (95% CI 0.42 to 0.85).
The retrospective investigation of panitumumab efficacy and KRAS status revealed no statistically 
significant overall survival difference between treatment arms in either of the KRAS groups.32 The 
hazard ratios for overall survival were 1.02 (95% CI 0.75 to 1.39) and 0.99 (95% CI 0.75 to 1.29) 
for the KRAS mutant and WT groups, respectively, which is in contrast to the analysis for skin 
toxicity, which apparently favours overall survival and only occurs in WT patients.52
Median overall survival is also unclear. Patients with KRAS WT status treated with panitumumab 
show a median survival of 8.1 months compared with 7.6 months for those treated with best 
supportive care; and patients with KRAS mutant status treated with panitumumab show a 
median overall survival of 4.9 months compared with 4.4 months for those treated with best 
supportive care.32
Progression-free survival (Table 12)
Bevacizumab Roche mentions a number of papers that did not fulfil the inclusion criteria for this 
review, but their results will be briefly summarised here for completeness. Further details can be 
found in Chapter 5.
Saltz and colleagues40 report a hazard ratio for progression-free survival for bevacizumab 
compared with placebo of 0.83 (97.5% CI 0.72 to 0.95), with median progression-free survival of 
9.4 months for bevacizumab and 8 months for placebo.
The hazard ratio for progression-free survival determined by Hurwitz and colleagues26 was 0.54 
(p < 0.001), with patients treated with IFL plus bevacizumab having a progression-free survival of 
10.6 months and those in the IFL arm having a progression-free survival of 6.2.
Kabbinavar and colleagues27 showed a statistically significantly longer progression-free survival 
in the FU/LV plus bevacizumab arm (9.2 months) than in the FU/LV alone arm (5.5 months) 
(hazard ratio 0.5, 95% CI 0.34 to 0.73).
Finally, Giantonio and colleagues41 showed median progression-free survival of 7.3 months 
for FOLFOX-4 plus bevacizumab, 4.7 months for FOLFOX-4 and just 2.7 months for 
bevacizumab alone.
Cetuximab plus best supportive care compared with best supportive care Progression-free 
survival was defined in the CO.17 study37 as the time from randomisation until the first objective 
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observation of disease progression or death from any cause. It should be noted that it was 
not reported whether or not assessors were blinded. Treatment with cetuximab significantly 
improved progression-free survival, with a hazard ratio of 0.68 (CI 0.57 to 0.80, p < 0.001). No 
median progression-free survival is reported for either arm; however, the estimated proportions 
of patients who were alive without documented objective progression of the disease at 3 and 
6 months were 41% and 15%, respectively, in the cetuximab group and 24% and 3%, respectively, 
in the best supportive care group.
For patients with KRAS mutant status, median progression-free survival was 1.8 months in 
both the cetuximab and the best supportive care groups (hazard ratio 0.99, 95% CI 0.73 to 1.35, 
p = 0.96).47 For patients with KRAS WT status, median progression-free survival was 3.7 months 
in the cetuximab group and 1.9 months in the best supportive care group, with a hazard ratio of 
0.40 (95% CI 0.30 to 0.54, p < 0.001).
Panitumumab plus best supportive care compared with best supportive care Progression-free 
survival (primary end point) for this trial was calculated from the day of random assignment 
until determination by blinded assessors of radiological progression or death.7 A statistically 
significant improvement was observed in patients receiving panitumumab, giving a hazard 
ratio of 0.54 (95% CI 0.44 to 0.66). The difference in median progression-free survival time 
was statistically significant at 2 months (95% CI 7.9 to 8.4) for panitumumab and 1.8 months 
(95% CI 7.1 to 7.7) for best supportive care; however, the difference in mean progression-free 
survival time was more substantial at 3.5 months [standard error (SE) 0.2] for panitumumab and 
2.1 months (SE 0.1) for best supportive care.
The supplementary KRAS analysis revealed a beneficial effect of panitumumab for patients with 
KRAS WT status (hazard ratio 0.45, 95% CI 0.3 to 0.59), with a median progression-free survival 
of 12.3 weeks in contrast to 7.3 weeks for best supportive care.32
Tumour response (Table 13)
Cetuximab plus best supportive care compared with best supportive care In the cetuximab RCT,37 
response rates (defined according to RECIST criteria) were assessed; however, it is unknown 
whether or not the assessors were blinded. All patients were assessed every 4 weeks. Chest 
radiographs and cross-sectional imaging were performed at baseline and every 8 weeks in both 
study groups until tumour progression occurred. In the cetuximab group, 23 patients (8%) had 
partial responses, with none in the best supportive care group (p < 0.001). Stable disease occurred 
TABLE 12 Summary of progression-free survival: cetuximab plus best supportive care and panitumumab plus best 
supportive care vs best supportive care after first-line therapy
Study Interventiona n Median PFS (months) HR 95% CI p-value
Jonker et al.37 All: CET + BSC 287 NR 0.68 0.57 to 0.80 < 0.001
All: BSC 285 NR − − −
Karapetis et al.47 WT: CET + BSC 117 3.7 0.40b 0.30 to 0.54 < 0.001
WT: BSC 113 1.9 − − −
Van Cutsem et al.7 PAN + BSC 231 2 0.54 0.44 to 0.66 −
BSC 232 1.8 − − −
Amado et al.32 PAN + BSC 124 3.1 0.45 0.34 to 0.59 −
BSCd 119 1.8 − − −
BSC, best supportive care; CET, cetuximab; HR, hazard ratio; NR, not reported; PAN, panitumumab; PFS, progression-free survival.
a All, mutant and WT patients.
b These results are before adjustment for potential prognostic factors. The difference remained significant following adjustment.
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in 90 patients in the cetuximab group (31.4%) and 31 patients in the best supportive care group 
(10.9%, p < 0.001). No data were provided on time to response and duration.
Subsequent KRAS assessment revealed that, for patients with KRAS WT status in the cetuximab 
group, the response rate was 12.8%, whereas only 1.2% with KRAS mutant status displayed 
a response.47
Panitumumab plus best supportive care compared with best supportive care Objective response 
was evaluated by blinded central review using modified RECIST at weeks 8, 12, 16, 24, 32, 40 and 
48 and every 3 months thereafter until disease progression.7 At the discretion of the investigator, 
patients could be evaluated for radiographic tumour assessment after developing symptoms 
consistent with disease progression.
Objective response rates were greater in those treated with panitumumab than in those treated 
with best supportive care. After a 12-month minimum follow-up, 10% of patients in the 
panitumumab arm had an objective response, whereas no patients in the best supportive care 
group had an objective response (p < 0.0001). Median time to response was 7.9 weeks (range 
6.7–15.6 weeks) and median duration of response was 17.0 weeks (range 7.9–76.7 weeks). 
Twenty-seven per cent of patients in the panitumumab group and 10% of patients in the best 
supportive care group had a best response of stable disease.7
According to Amado and colleagues,32 best overall response data were unassessable or missing 
for 15% of patients receiving panitumumab and 23% of best supportive care patients, although 
this was not reported in the main trial report. For the KRAS-assessable patients receiving 
panitumumab, response was 10%, stable disease was 25% and disease progression was 50%; in 
the best supportive care arm, 0% had a response and 10% had stable disease. In the panitumumab 
group with KRAS WT status, 21 patients (17%, 95% CI 11% to 25%) had a partial response and 
34% had stable disease; no responders were identified in the panitumumab group with KRAS 
mutant status. Median time to response was 7.9 weeks (range 7.0–15.6 weeks) and median 
duration of response was 19.7 weeks (range 7.9–88.7 weeks).32
Health-related quality of life
A summary of the HRQoL results for cetuximab plus best supportive care compared with best 
supportive care is shown in Table 14.
TABLE 13 Summary of tumour response: cetuximab plus best supportive care and panitumumab plus best supportive 
care vs best supportive care after first-line therapy
Study Interventiona n
Objective response rate, % (n)
p-value for OROR CR PR SD
Jonker et al.37 All: CET + BSC 287 8.0 (23) 0 8.0 (23) 31.4 (90) < 0.001
All: BSC 285 0 0 0 10.9 (31) −
Karapetis et al.47 WT: CET + BSC 117 − 0 12.8 (15) NR < 0.001
WT: BSC 113 − 0 0 NR −
Van Cutsem et al.7b All: PAN + BSC 231 10 (22) 0 10 (22) 27 (62) < 0.0001
All: BSC 232 0 0 0 10 (23) −
Amado et al.32 WT: PAN + BSC 124 17 (21) 0 17 (21) 34 (42) NR
WT: BSC 119 − 0 0 12 (14) −
BSC, best supportive care; CET, cetuximab; CR, complete response; NR, not reported; OR, overall response; PAN, panitumumab PR, partial 
response; SD, stable disease.
a All, mutant and WT patients.
b Results from independent central view of radiological images.
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TABLE 14 Summary of HRQoL: cetuximab plus best supportive care and panitumumab plus best supportive care vs 
best supportive care after first-line therapy
Study Interventiona n
Mean change from 
baseline SD 95% CI p-valueb
Jonker et al.37 All: CET + BSC Week 8 PF NR –3.9 − − < 0.05
Week 16 PF –5.9 − − 0.03
Week 8 GHS –0.5 − − 0.008
Week 16 GHS –3.6 − − < 0.001
All: BSC Week 8 PF –8.6 − − −
Week 16 PF –12.5 − − −
Week 8 GHS –7.1 − − −
Week 16 GHS –15.2 − − −
Karapetis et al.45 WT: CET + BSC Week 8 GHS NR 3.2 − 4.2 to 17.6 0.002
Week 16 GHS –0.2 − 7.6 to 28.2 < 0.001
WT: BSC Week 8 GHS –7.7 − − −
Week 16 GHS –18.1 − − −
Au et al.44 CET + BSC Week 8 PF
All 185 –3.9 15.6 − 0.046
WT 90 –0.69 13.59 − 0.11
Week 8 GHS
All 185 –0.5 20.4 − 0.008
WT 88 3.22 19.63 − 0.0016
Week 16 PF
All 125 –5.9 17.7 − 0.027
WT 69 –3.43 17.93 − 0.0078
Week 16 GHS
All 128 –3.6 –3.6 − < 0.001
WT 70 –0.24 –0.24 − < 0.001
BSC Week 8 PF
All 147 –8.6 20.4 − −
WT 62 –7.15 20.26 − −
Week 8 GHS
All 149 –7.1 22.4 − −
WT 63 –7.67 21.34 − −
Week 16 PF
All 76 –12.5 21.6 − −
WT 36 –13.8 21.47 − −
Week 16 GHS
All 75 –15.2 25.8 − −
WT 36 –18.1 27.64 − −
Mittmann et al.42 All: CET + BSC Baseline 263 0.72 0.23 − −
Week 4 HUI 220 0.73 0.26 − −
Week 8 HUI 190 0.73 0.24 − −
Week 16 HUI 119 0.73 0.24 − −
Week 24 HUI 82 0.77 0.33 − −
All: BSC Baseline 260 0.71 0.24 − −
Week 4 HUI 184 0.68 0.26 − −
Week 8 HUI 149 0.66 0.28 − −
Week 16 HUI 72 0.63 0.30 − −
Week 24 HUI 36 0.70 0.24 − −
continued
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Study Interventiona n
Mean change from 
baseline SD 95% CI p-valueb
Odom et al.56 All: PAN + BSC NCCN FCSI 188 3.60 – 0.90 to 6.30 ≤ 0.05
EQ-5D 0.17 – 0.09 to 0.25 –
WT: PAN + BSC NCCN FSCI 112 5.62 – 2.38 to 8.86 ≤ 0.05
EQ-5D 0.22 – 0.12 to 0.32 ≤ 0.05
BSC, best supportive care; CET, cetuximab; GHS, global health status; NR, not reported; PF, physical function; SD, standard deviation.
a All, mutant and WT patients.
b p-value between cetuximab and BSC.
TABLE 14 Summary of HRQoL: cetuximab plus best supportive care and panitumumab plus best supportive care vs 
best supportive care after first-line therapy (continued)
Cetuximab plus best supportive care compared with best supportive care HRQoL for the CO.17 
trial37 was reported in several papers; however, because this study was not blinded there is the 
potential for bias in the QoL measures.
Quality of life reported in the main trial paper was assessed by the EORTC QLQ-C30 at baseline 
and at 4, 8, 16 and 24 weeks after randomisation.37 Compliance with the questionnaire reduced 
from 94% at baseline in both groups to 67% at 16 weeks in the cetuximab group and 43% at 
16 weeks in the best supportive care group. It is acknowledged that there was a systematic 
difference in compliance between the treatment groups and HRQoL data were not missing 
at random. Au and colleagues44 suggest that patients in the best supportive care arm were 
subject to worse progression-free survival and overall survival and therefore were less able to 
complete questionnaires. Lack of blinding was also recognised as a potential bias, because of the 
placebo effect.
In comparison with best supportive care, the reported results indicate that cetuximab was 
associated with reduced deterioration in physical function at 8 weeks (mean change score –3.9 
vs –8.6, p = 0.05) and 16 weeks (mean change score –5.9 vs –12.5, p = 0.03). The cetuximab arm 
also demonstrated less deterioration in global health status at 8 weeks (mean change score –0.5 vs 
–7.1, p = 0.008) and 16 weeks (mean change score –3.6 vs –15.2, p < 0.001).37 The data for HRQoL 
at 24 weeks are not reported.
According to Karapetis and colleagues,47 patients with KRAS WT status in the cetuximab arm 
had an improvement in global health status at 8 weeks, whereas those in the best supportive care 
group deteriorated (mean change score 3.2 vs –7.7, 95% CI 4.2 to 17.6, p = 0.002). Patients with 
KRAS WT status in the cetuximab group also had less deterioration at 16 weeks than those in the 
best supportive care group (mean change score –0.2 vs –18.1, 95% CI 7.6 to 28.2, p < 0.001).
Mittmann and colleagues42 report on HUI3 data collected during the CO.17 trial, in which 
patients assess their own health attributes: vision, hearing, speech, ambulation, dexterity, 
emotion, cognition and pain. The assessments were performed at 4, 8, 16 and 24 weeks after 
randomisation, and the results show that the scores were relatively unchanged for the cetuximab 
arm, but declined for best supportive care. However, these results are not displayed according 
to KRAS status; in addition, bias is likely as patients in the best supportive care arm may 
deteriorate more quickly than those in the cetuximab arm, and therefore be less able to complete 
the questionnaire.
Panitumumab plus best supportive care compared with best supportive care Patient-reported 
outcomes were analysed using the EQ-5D VAS, the NCCN FCSI, EORTC QoL subscales and 
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a dermatology question. Results in the main trial report by Van Cutsem and colleagues7 were 
included in an online appendix. No data were given, just a summary concluding that patients 
were more concerned by their skin condition in the cetuximab group than in the best supportive 
care group. It was reported that no clinically meaningful differences in overall QoL were observed 
between the groups.
A subsequent study by Odom and colleagues56 reported more information on this study. 
They report on data collected using the NCCN FCSI and the EQ-5D. The results were 
analysed according to KRAS status, which was ascertained in 92% of participants. The authors 
acknowledged the large amount of missing patient-reported data and attributed this to declining 
health, as approximately 50% of patients in the best supportive care arm, and patients with 
KRAS mutant status in the panitumumab plus best supportive care arm, had progressed by 
week 8. Sensitivity analysis was performed to evaluate the effect of attrition on QoL between 
treatment arms.
Overall, information on KRAS status together with post-baseline patient-reported outcome 
data were available for 78% of the study population. Baseline characteristics were broadly 
similar across groups, other than the panitumumab plus best supportive care group which had a 
slightly higher percentage of people with an ECOG performance status of 0. Less deterioration 
was observed in the FCSI score and EQ-5D index in the panitumumab plus best supportive 
care group than in the best supportive care group alone, both overall and for those with KRAS 
WT status.
For the FCSI score, an average least squares mean difference between treatment groups across all 
weeks favoured panitumumab by 3.60 (95% CI 0.90 to 6.30) overall and by 5.62 (95% CI 2.38 to 
8.86) for patients with KRAS WT status. The EQ-5D index results also favoured panitumumab, 
with an average least squares mean difference between treatment groups across all weeks of 0.17 
(95% CI 0.09 to 0.25) overall and 0.22 (95% CI 0.12 to 0.32) for those with KRAS WT status. 
Analysis of the KRAS mutant group did not show any significant differences in QoL between 
those treated with panitumumab plus best supportive care and those treated with best supportive 
care. Odom and colleagues56 suggest a limitation of the study concerning skin toxicity, which 
was associated with higher HRQoL, as the rash may be seen as a predictor of benefit by patients. 
However, the majority of KRAS mutant patients on panitumumab who also experienced a rash 
did not report this benefit.
Indirect comparison of cetuximab and panitumumab
There are no RCTs directly comparing the effectiveness of cetuximab with that of panitumumab. 
However, an indirect comparison between the two treatments can be made if it is assumed that 
the best supportive care arms of Karapetis and colleagues45 and Amado and colleagues32 are 
equivalent in terms of the care and treatment received. Based on this assumption the hazard 
ratios for overall survival and progression-free survival can be calculated for an indirect 
comparison of cetuximab and panitumumab.34 Details of the method used can be found in 
Appendix 4.
Two sets of results are given in Table 15, those using the unadjusted overall survival and 
progression-free survival hazard ratios from Karapetis and colleagues and those using the KRAS-
adjusted overall survival and progression-free survival hazard ratios. Given that KRAS status is 
assessed retrospectively in Karapetis and colleagues and that KRAS status was not determined for 
all participants, there may be some selection bias in the study (even though the authors report 
that there were similarities between patient characteristics for those with KRAS WT status and 
those with KRAS mutant status); therefore, it would seem reasonable to attach more importance 
to the hazard ratios adjusted for patient characteristics than those not adjusted. Note that 
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Amado and colleagues32 do not report hazard ratios adjusted for patient characteristics, only the 
unadjusted hazard ratios. It is therefore possible that the unadjusted hazard ratios from Amado 
and colleagues are subject to selection bias as well, but the magnitude of this bias is difficult 
to quantify.
The indirect comparisons indicate that there is no statistically significant difference in the hazard 
for progression-free survival between those receiving cetuximab plus best supportive care and 
those receiving panitumumab plus best supportive care, regardless of whether the adjusted or 
unadjusted hazard ratio from Karapetis and colleagues45 is used. On the other hand, the results 
suggest that there is a statistically significant difference in hazard for overall survival between 
cetuximab plus best supportive care and panitumumab plus best supportive care, with patients 
receiving cetuximab plus best supportive care having longer overall survival. However, the study 
by Amado and colleagues32 is subject to a large number of patients randomised to receive best 
supportive care actually receiving panitumumab plus best supportive care during the progressed 
disease stage, potentially biasing the results against panitumumab. Thus, the hazard ratio for 
overall survival from this study is subject to confounding. No published analyses have addressed 
this issue of crossover in the study by Amado and colleagues. In Amgen’s submission, analyses 
were undertaken to address the crossover (see Chapter 5), but the results are not presented in 
terms of hazard ratios and so are not included in the indirect comparisons described here.
Adverse events (Table 16)
Adverse events were graded in the cetuximab plus best supportive care and panitumumab 
plus best supportive care studies using the NCI-CTC version 2.0, other than for selected 
dermatological/skin toxic effects, which, for panitumumab plus best supportive care, were graded 
using the NCI-CTC version 3.0 with modifications.
Comparison between the cetuximab and the panitumumab trials indicates a disparity in fatigue. 
For example, although the population characteristics between the studies are similar, Merck 
Serono (cetuximab) reports that 30% of patients suffered grade 3 or higher fatigue in the best 
supportive care arm, whereas Amgen (panitumumab) reports that only 3% of patients in the best 
supportive care arm experienced the same level of fatigue.
Although different criteria were used for skin toxicity, for example the cetuximab trial combined 
all skin-related adverse events as a rash whereas the panitumumab trial employed a variety of 
conditions, such as erythema and pruritus, the numbers were similar.
Bevacizumab For consistency, the following is a brief overview of papers cited by Roche, which 
were not applicable for inclusion in the review. Further details are available in Chapter 5.
TABLE 15 Direct and indirect hazard ratios (and 95% CIs) for overall survival and progression-free survival
Outcome
HR from 
Karapetis et al.45 CET + BSC vs BSC45 PAN + BSC vs BSC32
CET + BSC vs PAN + BSC 
(calculated by PenTAG34)
Progression-
free survival
Unadjusted 0.40 (0.30 to 0.54) 0.45 (0.34 to 0.59) 0.89 (0.59 to 1.33)
Adjusted 0.42 (0.30 to 0.58) 0.93 (0.61 to 1.43)
Overall 
survival
Unadjusted 0.55 (0.41 to 0.74) 0.99 (0.75 to 1.29) 0.56 (0.37 to 0.83)
Adjusted 0.62 (0.44 to 0.87) 0.63 (0.41 to 0.97)
BSC, best supportive care; CET, cetuximab; HR, hazard ratio; PAN, panitumumab.
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Saltz and colleagues40 report that 30% of patients in the bevacizumab arm discontinued treatment 
because of adverse events compared with 21% in the placebo arm. Hurwitz and colleagues26 
report statistically significantly more grade 3 or 4 adverse events in the IFL plus bevacizumab 
arm than in the IFL arm (p < 0.01), because of hypertension. Kabbinavar and colleagues27 also 
experienced an increase in grade 3 or 4 adverse events with bevacizumab (87% for FU/LV plus 
bevacizumab vs 71% for FU/LV), as did Giantonio and colleagues41 (75% for FOLFOX-4 plus 
bevacizumab vs 61% for FOLFOX-4).
Cetuximab plus best supportive care compared with best supportive care Safety analysis for the 
CO.17 trial37 was conducted on an on-treatment basis, contrasting patients who had at least 
one dose of cetuximab (including those who crossed over) with patients assigned to supportive 
TABLE 16 Adverse events (grades 3 and 4): cetuximab plus best supportive care vs best supportive care and 
panitumumab plus best supportive care vs best supportive care after first-line therapy
Jonker et al.37 Van Cutsem et al.7 Van Cutsem et al.38
CET + BSC BSC PAN + BSC BSC PAN + BSC
n 288 274 229 234 176
Grade 3/4 adverse events (%)
Erythema − − 5 0 6
Dermatitis acneiform − − 7 0 6
Pruritus − 2 0 1
Skin exfoliation − − 2 0 1
Fatigue 33 30 4 3 −
Paronychia − − 1 0 2
Abdominal pain 13 16 7 4 −
Anorexia 8 6 3 2 −
Nausea 6 6 1 0 −
Diarrhoea − − 1 0 1
Rash 12 0 1 0 5
Skin fissures − − 1 0 −
Constipation 3 5 3 1 −
Vomiting 6 6 2 1 −
Dyspnoea 16 12 5 3 −
Pyrexia − − 0 2 −
Asthenia − − 3 2 −
Cough − − 0 0 −
Back pain − − 2 0 −
Oedema 5 6 1 0 −
Conjunctivitis − − − − 1
General physical health deterioration − − 7 2 −
Other paina 15 7 − − −
Non-neutropenic infection 13 6 − − −
Confusion 6 2 − − −
Hypomagnesaemia 6 0 3 − 4
Infusion reactions 5 0 − − −
BSC, best supportive care; CET, cetuximab; PAN, panitumumab.
a Excludes arthralgia, myalgia, earache, headache and abdominal, bone, chest, hepatic, neuropathic, pelvic, pleuritic, rectal, perirectal and 
tumour pain
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care alone, and omitting patients who withdrew consent before any intervention. Grades were 
determined according to the NCI-CTC version 2.0.
It should be noted that the data are presented with the patient as the unit of measurement. No 
information is given as to whether or not patients experienced more than one adverse event.
No statistically significant differences were apparent between the cetuximab group and the best 
supportive care group in the incidence of grade 3 or higher adverse events, with the exception 
of rash (11.8% for cetuximab vs 0.4% for best supportive care, p < 0.001), infection without 
neutropenia (12.8% vs 5.5%, p = 0.003), confusion (5.6% vs 2.2%, p = 0.05) and pain defined 
as other according to the NCI-CTC (14.9% vs 7.3%, p = 0.005). Hypomagnesaemia was also 
more common in the cetuximab group than in the best supportive care group (5.8% vs 0.0%, 
p < 0.001).37
Grade 3 or 4 infusion reactions occurred in 4.5% of patients assigned to cetuximab. A total of 11 
patients had an adverse event leading to discontinuation of cetuximab, most frequently because 
of an infusion reaction. Patients in the cetuximab group also had a higher incidence of rash of 
any grade than patients in the best supportive care group (88.6% vs 16.1%, p < 0.001).37
In total, 59 patients died within 30 days after the last date of the cetuximab infusion. All died of 
colorectal cancer except for one patient who had a pulmonary embolus.
Unfortunately, safety data were not retrospectively analysed for cetuximab in relation to 
KRAS status.
Panitumumab plus best supportive care compared with best supportive care It should be noted 
that the safety data are presented with the patient as the unit of measurement, as opposed to the 
number of adverse events in each arm. No information is given as to whether or not patients 
experienced more than one adverse event.
Skin-related toxicities occurred in 90% of patients in the panitumumab group and in 9% of the 
best supportive care group. One patient in the panitumumab group discontinued treatment 
because of grade 2 dermatitis acneiform and another due to a grade 2 hypersensitivity reaction.7 
Grade 3 or 4 hypomagnesaemia occurred in 3% of patients in the panitumumab group.
Eighty-one per cent of patients in the panitumumab group and 84% in the best supportive care 
group died during the study, none of which was treatment related. Nearly all deaths were related 
to disease progression.
Specific adverse events according to KRAS status in each arm were not reported. However, in 
the group with KRAS WT status, 100% of patients receiving panitumumab and 90% of patients 
receiving best supportive care had an adverse event, although no level of statistical significance is 
given.32 Consistent with previous reports,7 patients with the worst grade skin toxicity in the KRAS 
WT group appeared to experience better progression-free survival and overall survival. The other 
main adverse event in the panitumumab arm was a higher incidence of diarrhoea of any grade 
(KRAS WT 24%, KRAS mutant 19%). Amado and colleagues32 report the incidence of adverse 
events leading to withdrawal in the panitumumab arm to be 7% for the group with KRAS WT 
status, with 2% withdrawing for panitumumab-related events.
With regard to the single-arm extension study, 92% of patients experienced adverse events 
considered related to panitumumab, 16% had a grade 3 treatment-related adverse event and 
2% had a grade 4 treatment-related adverse event (acute renal failure, pulmonary embolism, 
erythema and pustular acne).38 There were no fatal adverse events related to panitumumab.
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Fifty-three per cent of patients had at least one serious adverse event, most of which were typical 
of metastatic colorectal cancer disease progression, with 6% experiencing serious adverse events 
considered at least possibly related to panitumumab. Adverse events leading to discontinuation 
of the treatment phase occurred in 11% of patients, with 4% discontinuing treatment because of 
skin and subcutaneous tissue disorders that were possibly related to panitumumab.38
All deaths were attributed to disease progression, with 10% of patients dying during the 
treatment period, 20% within 30 days of treatment discontinuation and 52% after 30 days of 
receiving the last panitumumab infusion.
Summary of safety data
Skin toxicity is the most common adverse event associated with EGFR inhibitors, although it 
has been shown that skin toxicity severity may be associated with efficacy.52 With panitumumab 
treatment this association was seen only for patients with KRAS WT status; however, the trial 
authors advise caution on the apparent correlation because the analysis was not a randomised 
comparison and patients remaining for longer on the study because of benefit of treatment are 
more likely to develop skin toxicity.52
Overall conclusion
From the limited clinical data available, treatment with both interventions (cetuximab plus best 
supportive care and panitumumab plus best supportive care) appears to have clinically relevant 
and statistically significant advantages over treatment with best supportive care alone (Table 17). 
In both trials, median progression-free survival in patients with KRAS WT status appears to 
almost double as a result of active treatment. For cetuximab, median progression-free survival 
increases from approximately 2 months to approximately 4 months and for panitumumab, 
median progression-free survival increases from approximately 2 months to approximately 
3 months (hazard ratio for cetuximab vs best supportive care 0.40, 95% CI 0.30 to 0.54; hazard 
ratio for panitumumab vs best supportive care 0.45, 95% CI 0.34 to 0.59).32,47
For median overall survival in the clinically relevant KRAS WT population, the cetuximab arm 
exhibits a statistically significant improvement of 9.5 months compared with 4.8 months for 
best supportive care (hazard ratio 0.55, 95% CI 0.41 to 0.75). The evidence for panitumumab is 
less convincing. Although a median overall survival of 8.1 months compared with 7.6 months 
for best supportive care is presented, the hazard ratio of 0.99 (95% CI 0.75 to 1.29) indicates a 
lack of significant difference. The rapid crossover of 76% of patients (median time to crossover 
7.1 weeks) is likely to have had an extensive confounding effect.7,32
Tumour response indicated that stable disease occurred in 31.4% of patients in the cetuximab 
group and 10.9% of patients in the best supportive care group (p < 0.001); however, it is unclear 
TABLE 17 Summary of clinical effectiveness results
CET + BSC vs BSC Significantly greater progression-free survival for cetuximab
Significantly greater overall survival for cetuximab
PAN + BSC vs BSC Significantly greater progression-free survival for panitumumab
No significant difference in overall survivala
CET + BSC vs PAN + BSCb No significant difference in progression-free survival
Significantly greater overall survival for cetuximaba
BSC, best supportive care; CET, cetuximab; PAN, panitumumab.
a At risk of confounding.
b Calculated by PenTAG.
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whether or not the assessors were blinded.37 Partial response was seen in 8% of patients in the 
cetuximab group, with no partial response seen in the best supportive care group. Subsequent 
KRAS analysis revealed that, for patients with KRAS WT status in the cetuximab group, the 
partial response rate was 12.8%, whereas only 1.2% with KRAS mutant status had a response.47 
Stable disease was not reported.
Objective response for the panitumumab study was evaluated by blinded central review and was 
shown to favour panitumumab over best supportive care. After a 12-month minimum follow-up, 
10% of patients in the panitumumab group had a partial response, whereas no patients in the best 
supportive care group had an objective response (p < 0.0001). In the panitumumab group with 
KRAS WT status, 17% had a partial response and 34% had stable disease, whereas no responders 
were identified in the panitumumab group with KRAS mutant status.
Data on adverse events are difficult to compare between the interventions. The panitumumab 
trial does not confirm the adverse event scale used; therefore, it is unclear if these adverse event 
data are analogous with those on cetuximab.
Skin toxicity was clearly an issue for both treatments, although, again, it was reported differently. 
Patients in the cetuximab group had an 88% incidence of rash of any grade compared with 
skin toxicity of 90% for panitumumab. There appears to be a correlation between extent of skin 
toxicity and treatment efficacy, although one paper suggests exercising caution with these results 
as a patient remaining longer on a treatment because of its benefit is more likely to develop skin 
toxicity at some point.52
Health-related quality of life was at risk of bias in both trials because of lack of blinding and the 
knowledge that skin toxicity may also have been a predictor of benefit. There may also have been 
systematic differences in compliance between treatment groups, for example patients in the best 
supportive care arm were subject to worse progression-free survival and overall survival and 
therefore were less able to complete questionnaires. For patients receiving cetuximab plus best 
supportive care, a slower deterioration in global health status and physical function was noted 
in comparison with best supportive care alone. According to Karapetis and colleagues,45 patients 
with KRAS WT status in the cetuximab plus best supportive care arm had an improvement in 
global health status at 8 weeks, whereas those in the best supportive care group deteriorated.
For patients receiving panitumumab plus best supportive care, it was initially reported that no 
clinically meaningful differences in overall QoL were observed between the groups;7 however, 
subsequent analysis revealed less deterioration in the FCSI score and EQ-5D index in the 
panitumumab plus best supportive care group than in the best supportive care alone group, both 
overall and for those with KRAS WT status.56
As there are no head-to-head comparison data available for cetuximab compared with 
panitumumab, we carried out an indirect comparison to consider which intervention might be 
the most clinically effective. The results indicate that there is no statistically significant difference 
in the hazard for progression-free survival between those receiving cetuximab plus best 
supportive care and those receiving panitumumab plus best supportive care. In contrast, there 
is a statistically significant difference in hazard for overall survival between cetuximab plus best 
supportive care and panitumumab plus best supportive care, with patients receiving cetuximab 
plus best supportive care having longer overall survival. However, the study by Amado and 
colleagues32 is subject to a large number of patients randomised to receive best supportive care 
actually receiving panitumumab plus best supportive care during the progressive disease stage; 
thus, the hazard ratio for overall survival from this study is subject to confounding.
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Chapter 4 
Assessment of cost-effectiveness: 
systematic review
The cost-effectiveness of bevacizumab, cetuximab and panitumumab compared with relevant comparators within their licensed indications for the treatment of metastatic colorectal 
cancer after first-line chemotherapy was assessed in a systematic review of the literature. An 
outline discussion is presented on the literature searching undertaken in the general literature 
on metastatic colorectal cancer, covering the costs associated with the treatment of metastatic 
colorectal cancer, HRQoL associated with metastatic colorectal cancer states, and the modelling 
of disease progression in metastatic colorectal cancer.
Systematic review of existing cost-effectiveness evidence
Cost-effectiveness evidence that supported existing guidance
A review by Tappenden and colleagues10 evaluated the clinical effectiveness and cost-effectiveness 
of bevacizumab and cetuximab for the treatment of individuals with metastatic colorectal cancer; 
this informed NICE guidance TA118.16 Both were identified in the literature searches and are 
summarised in Table 18 and Considerations for cetuximab from technology appraisal No. 118. 
The assessment of bevacizumab in the Tappenden review falls beyond the scope of this current 
appraisal as it considered evidence of the use of bevacizumab in untreated metastatic colorectal 
cancer patients (i.e. first-line treatment). The review of cetuximab is relevant to this appraisal 
as it considered patients with EGFR-expressing metastatic colorectal cancer who had failed 
irinotecan-including therapy. It was not, however, restricted to patients with KRAS WT status as 
this was not part of the cetuximab licence at the time that TA118 was developed.
Considerations for cetuximab from technology appraisal No. 11816
Main guidance
Cetuximab in combination with irinotecan is not recommended for the second-line 
or subsequent treatment of mCRC after the failure of an irinotecan-containing 
chemotherapy regimen. People currently receiving . . . cetuximab should have the option 
to continue therapy until they and their consultants consider it appropriate to stop.16
Key economic considerations
Effectiveness data representative of third-line not second-line usage:
The Committee considered the cost-effectiveness for cetuximab. It noted that the 
economic modelling from both the manufacturer and the assessment group had been 
completed using effectiveness data from the RCT of cetuximab where approximately 
80% of patients received cetuximab plus irinotecan as a third-line or subsequent therapy. 
It [the Appraisal Committee] was also aware that the comparator used in both models 
was ASC/BSC, which meant the modelled scenario and corresponding estimates of cost-
effectiveness more closely resembled third-line or subsequent use of cetuximab rather 
than second-line use.16
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TABLE 18 Summary of systematic review and economic evaluation of cetuximab plus irinotecan for the treatment of 
metastatic colorectal cancer: Tappenden and colleagues10 and TA 11816
Study purpose To assess the clinical effectiveness and cost-effectiveness of bevacizumaba and cetuximab in the treatment of 
individuals with mCRC
Country setting UK
Base-year prices Not stated explicitly but manufacturer’s submissions are 2005
Intervention/comparator CET + IRIN vs ASC/BSC
Line of treatment Second or subsequent line (CET)
Study type Threshold analysis; based on Merck Serono’s submission to NICE in 2005
Model duration/cycle 
length
Unclear
Number of health states Unclear. Description of utilities suggests two alive health states: stable disease and progressive disease
Study group Patients with EGFR-expressing mCRC after failure of irinotecan-including cytotoxic therapy
Perspective NHS/PSS perspective
Discount rate per annum Not included; distribution of costs incurred over time is not included in the model although given the short time horizon 
this omission is unlikely to have a substantial impact on the cost-effectiveness or cost–utility estimates
Source of funding Funding for this review was provided by the NIHR
Base-case findings Mean overall survival durations for ASC/BSC treatment groups range from 0.60 LYs to 0.77 LYs. Based on these 
estimates of overall survival the cost per LYG for CET + IRIN, given according to the proposed continuation rule, may be 
as low as £58,048 or as high as £462,889. When health outcomes are measured in terms of QALYs, the equivalent 
range is likely to be £77,210–335,358 per QALY gained. When the proposed continuation rule is not applied the cost 
per LYG may be as low as £77,345 or as high as £375,487, or between £104,747 and £370,044 per QALY gained 
(again, depending on calculation of mean overall survival duration for ASC/BSC groups). Minimum overall survival 
advantage required by CET + IRIN over ASC/BSC is 0.65 years assuming the continuation rule
Scenario
Min. overall survival (years) advantage for CET + IRIN over 
comparator to have a cost per QALY gained of £30,000
Sensitivity analyses Base case (with continuation rule) 0.65
Base case (without continuation rule) Not possible for the incremental cost–utility of CET + IRIN vs ASC/BSC 
to be < £30,000 per QALY gained
Alternative HRQoL data source (MABEL) 0.6
Comparator is oxaliplatin + 5-FU/FA Approx. 0.8
Comparator is BSC alone Not possible for CET + IRIN to have a cost per QALY that is < £30,000
Including indirect effectiveness evidence 0.14
ASC, active supportive care; BEV, bevacizumab; BSC, best supportive care; CET, cetuximab; ICER, incremental cost-effectiveness ratio; IRIN, 
irinotecan; LY, life-year; LYG, life-year gained; mCRC, metastatic colorectal cancer; NIHR, National Institute for Health Research; PSS, Personal Social 
Services; QALY, quality-adjusted life-year.
a Bevacizumab was considered in combination with 5-FU-containing/-releasing regimens in previously untreated mCRC patients, which falls 
outside the scope of the current review.
Uncertainties surrounding the utility estimates were discussed:
The Committee discussed the uncertainties around the estimates of utility for patients 
with mCRC. The manufacturer had provided estimates between 0.95 and 0.71, both 
constant over the lifetime of the patient. The Committee considered that the utility for a 
patient with mCRC was likely to reflect the lower end of this range, based on additional 
data submitted by the manufacturer from the MABEL study. The Committee concluded 
that, using the most realistic utility estimates, the cost effectiveness estimates provided by 
both the manufacturer and the assessment group were not compatible with the best use 
of NHS resources. The Committee also noted that these estimates were associated with a 
high level of uncertainty because they were based on indirect comparisons.16
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Results from the threshold analysis were considered:
The Committee therefore considered threshold analyses completed by the assessment 
group, where the survival in the comparator arm was held as unknown. The base-case 
threshold analysis suggested that, with the application of the continuation rule, a cost 
per quality-adjusted life-year (QALY) gained of £30,000 could only be achieved if 
survival with ASC/BSC is less than two months. A sensitivity analysis adjusting the 
assumptions to reflect utility values from the MABEL study did not materially alter the 
results. The Committee noted that the manufacturer had provided an estimate of mean 
survival of 5.6 months for patients receiving ASC/BSC in their economic model, while 
studies of ASC/BSC identified in their assessment report provided estimates of median 
survival ranging from six to nine months. The Committee therefore considered that 
an estimate of mean survival while receiving ASC/BSC of approximately two months 
was an unrealistic underestimate. Considering all the available evidence on clinical 
and cost effectiveness, the Committee therefore concluded that cetuximab, either as a 
second-line or a subsequent line treatment for mCRC would not be a cost-effective use 
of NHS resources.16
Methods
Electronic databases were searched using population and intervention sets only, without 
restricting to methodological or outcome filters; see Chapter 3, Identification of studies and 
Appendix 1.
Study selection criteria and procedures
The inclusion and exclusion criteria for the systematic review of economic evaluations are similar 
to those for the systematic review of clinical effectiveness (see Chapter 3, Inclusion and exclusion 
criteria), subject to the following exceptions:
 ■ non-randomised studies were included (e.g. decision model-based analyses, or analyses of 
patient-level cost and effectiveness data alongside observational studies)
 ■ full cost-effectiveness, cost–utility, cost–benefit and cost–consequence analyses were 
included (economic evaluations that report only average cost-effectiveness ratios were 
included if the incremental ratios could be easily calculated from the published data)
 ■ standalone cost analyses based in the UK NHS were also sought and appraised.
Relevant studies to the cost-effectiveness analysis were identified in two stages based on the 
above inclusion/exclusion criteria. Titles and abstracts returned by the search strategy were 
examined independently by two researchers (CH and LC) and screened for possible inclusion. 
Disagreements were resolved by discussion. Full texts of the identified studies were obtained. 
Two researchers (CH and LC) examined these independently for inclusion or exclusion, and 
disagreements were again resolved by discussion.
Study quality assessment
The methodological quality of included economic evaluations was assessed according to 
internationally accepted criteria such as the Consensus on Health Economic Criteria (CHEC) 
questions developed by Evers and colleagues57 and the critical appraisal checklist developed by 
Drummond and colleagues.58 The studies were assessed by one reviewer (LC) and checked by a 
second reviewer (CH).
Data extraction strategy
For those studies that were of relevance to the current decision problem, data were extracted 
by one researcher (LC) into a summary table describing the study design and main results. The 
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table includes author and year; model type or trial based; study design (e.g. cost-effectiveness 
analysis or cost–utility analysis); service setting/country; study population; comparators; 
research question; perspective; time horizon and discounting; main costs included; base-case 
findings; sensitivity analyses conducted; and other notable design features. Finally, the reviewer’s 
comments on study quality and generalisability (in relation to the final scope) of the results were 
recorded (see Tables 21 and 22 and Appendix 9).
Synthesis of extracted evidence
Narrative synthesis supported by abridged data extraction tables (see Appendix 3) was used to 
summarise the available evidence base.
Results
The systematic search of electronic databases produced 7745 titles and abstracts, of which 
7670 items did not meet the specified inclusion criteria. Of 77 full papers screened, five were 
included in the review (further details and references for these excluded papers are available in 
Appendix 10).42,59–62 A flow chart of the study selection process is shown in Figure 2.
One published systematic review10 was identified in the literature search, which informed 
previous guidance (TA118,16 also identified in the review). These were not included in the 
main review but are summarised in Table 18 and Cost-effectiveness evidence that supported 
existing guidance.
Five abstracts63–67 were identified that met the specified inclusion criteria. Additional information 
was requested from the corresponding authors of each of the abstracts, but at the time of writing 
no responses had been received. Three of the abstracts63–65 are referred to in the discussion in 
this section.
FIGURE 2 Flow diagram for the study selection process for the review of the cost-effectiveness of bevacizumab, 
cetuximab and panitumumab for the treatment of metastatic colorectal cancer.
Titles and abstracts identified: n = 7745
Full-text paper retrieved: n = 77
Included: n = 5
Excluded on title and abstract: n = 7668
Not relevant intervention: n = 10
Not relevant population: n = 21
Not relevant study design: n = 20
Not English language: n = 3
Paper not retrievable: n = 4
Abstract only: n = 5 (further information not
available)  
Background only: n = 9
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Five published full economic evaluations meeting the inclusion criteria were included.42,59–62
Summary of cost-effectiveness studies
Table 19 gives a summary of the included cost-effectiveness studies.
Cetuximab plus best supportive care compared with best 
supportive care
One study addressed the cost-effectiveness of cetuximab plus best supportive care compared with 
best supportive care (Table 20).42 The study is quality assessed in Tables 21 and 22. This quality 
assessment suggests that the study was generally well conducted.
This study by Mittmann and colleagues was a trial-based cost-effectiveness analysis based on 
the CO.17 study,37 a Phase III, multicentre, open-label, randomised study37 in which resource 
utilisation and utility values were collected prospectively for 572 patients with advanced 
colorectal cancer expressing EGFR who received cetuximab plus best supportive care or best 
supportive care alone. The CO.17 study is also included in the clinical effectiveness review 
(see Chapter 3, Study characteristics, Cetuximab plus best supportive care compared with best 
supportive care). 
Mean improvement in overall survival for the entire study population was 0.12 years and mean 
improvement in quality-adjusted survival was 0.08 QALYs. The incremental cost of cetuximab 
(all patients) compared with best supportive care was C$23,969. The incremental cost-
effectiveness ratio (ICER) for cetuximab plus best supportive care compared with best supportive 
care alone was C$199,742 per life-year gained (LYG) (95% CI C$125,973 to C$652,492 per LYG) 
and the incremental cost–utility ratio was C$299,613 per QALY gained (95% CI C $187,440 to 
C$898,201 per QALY gained).
For patients with KRAS WT status, the incremental cost of cetuximab was C$33,617 and mean 
gains in overall and quality-adjusted survival were 0.28 years and 0.18 QALYs respectively. The 
ICER was C$120,061 per LYG (95% CI C$88,679 to C$207,075 per LYG) and the incremental 
cost–utility ratio was C$186,761 per QALY gained (95% CI C$130,326 to C$334,940 per QALY 
gained). Updating this to 2011, converting to pounds sterling and using the current UK price 
of cetuximab we estimate the cost–utility ratio to be approximately equivalent to £101,000 
per QALY.
Cetuximab plus irinotecan compared with best supportive care
Three studies addressed the cost-effectiveness of cetuximab plus irinotecan compared with best 
supportive care (Table 23).
TABLE 19 Summary of cost-effectiveness studies
Author Intervention Comparator Location Notes
Mittmann et al.42 CET + BSC BSC Canada Based on CO.17 study37
Annemans et al.59 CET + IRIN BSC Belgium Based on BOND study49
Norum60 CET + IRIN BSC Norway –
Starling et al.61 CET + IRIN BSC UK –
Wong et al.62 Treatment sequences to measure the cost implications of 
treatments that include chemotherapy for the treatment of 
metastatic colorectal cancer; five sequences consider either 
CET + BSC or CET + IRIN use as a third-line treatment option
USA –
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
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TABLE 20 Summary of cost-effectiveness analysis: cetuximab plus best supportive care vs best supportive care
Mittmann et al.42
Study purpose To investigate the cost-effectiveness of CET in metastatic colorectal cancer
Country setting Canada
Base-year prices 2007
Intervention/comparator CET vs BSC
Line of treatment Third line
Study type Trial-based cost-effectiveness analysis; CO.17 study
Model duration/cycle length 18–19 months
Number of health states Not applicable
Study group Participants in the CO.17 study: 572 patients with chemorefractory colorectal cancer
Perspective Payer perspective: Canadian government
Discount rate per annum Not used
Source of funding Funding for the CO.17 study was provided by NCIC CTG, AGIGT, B-MS and ImClone Systems
Base-case findings For all patients the incremental cost of CET compared with BSC was C$23,969. The ICER was C$199,742 per LYG 
(95% CI C$125,973 to C$652,492 per LYG) and the incremental cost–utility ratio was C$299,613 per QALY gained 
(95% CI C$187,440 to C$898,201 per QALY gained).
For patients with KRAS WT tumours, the incremental cost of CET compared with BSC was $33,617 and the 
ICER was C$120,061 per LYG (95% CI C$88,679 to C$207,075 per LYG), The incremental cost–utility ratio was 
C$186,761 per QALY gained (95% CI C$130,326 to C$334,940 per QALY gained).
Sensitivity analyses A sensitivity analysis was performed on every cost, resource and effectiveness variable. The ICERs were most 
sensitive to changes in the cost of CET and patient survival
Variable Range ICER over range (C$/LYG)
Entire study population
Cost of CET (C$) (base case 3.24/
kg)
2.94–6.73/kg 188,734–384,823
Overall survival with CET [base case 
7.7 months (0.64 years)]
6.2 months (0.52 years)– 
9.2 months (0.77 years)
166,451–249,677
KRAS WT patients
Cost of CET (C$) (base case 3.24/
kg)
2.94–6.73/kg 112,939–228,591
Overall survival with CET [base case 
9.5 months (0.79 years)]
7.6 months (0.63 years)– 
11.4 months (0.95 years)
100,051–150,076
AGIGT, Australasian Gastrointestinal Trials Group; B-MS, Bristol-Myers Squibb; BSC, best supportive care; ICER, incremental cost-effectiveness 
ratio; LYG, life-year gained; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; QALY, quality-adjusted life-year.
Of the three included studies evaluating cetuximab plus irinotecan compared with best 
supportive care, one was a model-based cost-effectiveness analysis and the other two were trial-
based cost-effectiveness analyses. Unfortunately, none of the studies considered patients with 
KRAS WT status, reducing their relevance to this assessment.
An analysis by Annemans and colleagues59 compared the cost-effectiveness of cetuximab plus 
irinotecan with that of current care in the treatment of EGFR-expressing metastatic colorectal 
cancer that has failed irinotecan-containing therapy. Treatment outcomes and medical resource 
use data for patients receiving cetuximab plus irinotecan from the BOND study49 (Phase III, 
multicentre, open-label, randomised study) were compared with those from a matched group of 
patients (current care). Current care was based on a retrospective review of treatment received 
by patients in the three largest BOND study centres (Belgium, France, Italy) who met the 
eligibility for inclusion in the BOND study but who fell outside the recruitment period for the 
study. Fifteen per cent had received one prior line of chemotherapy and 77% at least two prior 
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TABLE 21 Summary of quality assessment of Mittmann and colleagues42 using critical appraisal checklist from Evers 
and colleagues57 
Item Yes/no 
1 Is the study population clearly described? Yes. The results of all study patients from the CO.17 study were used in this analysis: a total 
of 572 patients with chemorefractory colorectal cancer all had received prior chemotherapy 
with a fluoropyrimidine, 98% of patients had received prior treatment with oxaliplatin and 
96% had received prior treatment with irinotecan
2 Are competing alternatives clearly 
described?
Yes. The study prospectively evaluated the cost-effectiveness of cetuximab when given in 
addition to best supportive care
3 Is a well-defined research question posed 
in answerable form?
Yes. Cetuximab plus best supportive care vs best supportive care for patients with 
chemorefractory colorectal cancer
4 Is the economic study design appropriate 
to the stated objective?
Yes. A trial-based cost-effectiveness analysis
5 Is the chosen time horizon appropriate to 
include relevant costs and consequences?
Yes. The time horizon of the analysis was the duration of the clinical trial (i.e. 18–19 months) 
because > 77% of the patients on cetuximab and 82% of those on best supportive care 
alone had died by the end of the collection period
6 Is the actual perspective chosen 
appropriate?
Yes. The study was calculated from a payer perspective – Canadian government
7 Are all important and relevant costs for 
each alternative identified?
Yes. Most main categories of cost were captured (drug, outpatient visits, hospitalisation and 
surgical procedures, serious adverse events, laboratory tests and diagnostic procedures). 
KRAS testing was not, however, included
8 Are all costs measured appropriately in 
physical units?
Yes. For instance, the total dosage of cetuximab used by each patient in the trial was the 
basis for drug cost calculations
9 Are costs valued appropriately? Yes. For instance, cetuximab drug cost/mg was the median value in the countries that were 
reviewed by the Patented Medicines Prices Review Board
10 Are all important and relevant outcomes 
for each alternative identified?
Yes
11 Are all outcomes measured appropriately? Yes. Treatment benefit was defined in terms of mean survival gain after random assignment. 
Self-reported HUI3 was prospectively collected to assess preference-based measures 
of health status throughout the study (baseline and weeks 4, 8, 16 and 24 after random 
assignment)
12 Are outcomes valued appropriately? Yes – quality-adjusted life-years
13 Is an incremental analysis of costs and 
outcomes of alternatives performed?
Yes, and subjected to sensitivity analysis
14 Are all future costs and outcomes 
discounted appropriately?
No. No discounting appears to have been carried out
15 Are all important variables whose values 
are uncertain appropriately subjected to 
sensitivity analysis?
Yes. One-way deterministic sensitivity analyses to test the robustness of the incremental 
ratios were performed on every cost, resource and effectiveness variable. Uncertainty 
surrounding the estimates of cost-effectiveness was illustrated by means of cost-
effectiveness acceptability curves
16 Do the conclusions follow from the data 
reported?
Yes. The ICERs were acknowledged to be ‘high’, which is consistent with the ICERs reported
17 Does the study discuss the generalisability 
of the results to other settings and patient/
client groups?
Yes. The authors state that the results may not be generalisable to all patients under routine 
care for advanced colorectal cancer
18 Does the article indicate that there is 
no potential conflict of interest of study 
researcher(s) and funder(s)?
Funding for the CO.17 study was provided by the National Cancer Institute of Canada 
Clinical Trials Group, the Australasian Gastrointestinal Trials Group, Bristol-Myers Squibb and 
ImClone Systems
19 Are ethical and distributional issues 
discussed appropriately?
Yes. Fully explored in discussion section
lines of chemotherapy for metastatic disease. Approximately 80% of these patients went on to 
receive chemotherapy, including capecitabine, 5-FU, raltitrexed and rechallenge with irinotecan 
or oxaliplatin. Annemans and colleagues considered two scenarios in which cetuximab was 
discontinued at 6 weeks or at 12 weeks if there was no tumour response at those time points. 
The ICERs were €17,000 per LYG and €40,000 per LYG for the 6- and 12-week rule respectively 
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TABLE 22 Summary of quality assessment of Mittmann and colleagues42 using critical appraisal checklist from 
Drummond and colleagues58 
Item
Critical 
appraisal Reviewer comment
Is there a well-defined question? ü Cetuximab plus best supportive care vs best supportive care for patients with 
chemorefractory colorectal cancer. Whole population and KRAS WT population analysed
Is there a clear description of 
alternatives (i.e. who did what to whom, 
where and how often)?
ü Patients in the CO.17 study; cetuximab vs best supportive care in patients with 
chemorefractory colorectal cancer
Has the correct patient group/population 
of interest been clearly stated?
ü Yes. The study prospectively evaluated the cost-effectiveness of cetuximab when given in 
addition to best supportive care
Is the correct comparator used? ü Best supportive care, reflective of current standard of care 
Is the study type reasonable? ü Trial-based economic evaluation
Is the perspective of the analysis clearly 
stated?
ü Health-care payer perspective – Canadian government
Is the perspective employed appropriate? ü Costs and benefits are appropriate to the perspective
Is the effectiveness of the intervention 
established?
ü The CO.17 study population demonstrated a clinically and statistically significant overall 
survival advantage for cetuximab vs best supportive care in chemorefractory colorectal 
cancer patients (median survival 6.1 months vs 4.6 months, hazard ratio for death 0.77, 
p = 0.005). The survival advantage was even greater in the subset of patients with KRAS 
WT status (median overall survival for cetuximab vs best supportive care 9.5 months vs 
4.8 months, hazard ratio for death 0.55, p < 0.001)
Has a lifetime horizon been used for 
analysis or if not has a shorter time 
horizon been justified?
ü The time horizon of the study was the duration of the clinical trial (i.e. 18–19 months) 
because > 77% of the patients on cetuximab and 82% of those on best supportive care 
alone had died by the end of the data collection period. Median survival time in the study 
was < 1 year
Are the costs and consequences 
consistent with the perspective 
employed?
ü The main categories of cost were drugs, outpatient visits, hospitalisation and surgical 
procedures, serious adverse events, laboratory tests and diagnostic procedures. This is 
consistent with the health-care payer perspective
Is differential timing considered? û No. No discounting appears to have been carried out
Is incremental analysis performed? ü Yes
Is sensitivity analysis undertaken and 
presented clearly? 
ü One-way deterministic sensitivity analyses were performed and presented in table 20
compared with current care. Sensitivity analyses showed an acceptable robustness of the 
results, with generally acceptable ICERs for the 6-week rule, even in the worst-case scenario for 
cetuximab (defined as higher end survival and lower end cost for the control group). The study 
concluded that cetuximab plus irinotecan was cost-effective compared with current care when 
treatment was stopped in the case of non-response after 6 weeks.
Norum60 explored the cost-effectiveness of including cetuximab plus irinotecan in the treatment 
of metastatic colorectal cancer in Norway using a model-based cost-effectiveness analysis. 
Based on randomised trial data the increased lifetime gain was between 1.7 and 2.0 months, in 
addition to the 18–21 months of expected lifetime with standard chemotherapy. The median 
cost per patient treated was calculated as €34,256–45,764, yielding a cost per LYG in the range 
€205,536–323,040. Sensitivity analysis documented the price of cetuximab and survival gain 
to be the major factors influencing the ICER. The efficacy data for this analysis were based on 
one RCT and single-arm Phase II or III studies; the randomised study did not measure overall 
survival as its primary end point and had a crossover following progressive disease, with 50% of 
the patients crossing over from cetuximab alone to cetuximab plus irinotecan. The study, funded 
by the Norwegian Cancer Union, concluded that cetuximab plus irinotecan was a promising but 
expensive treatment.
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TABLE 23 Summary of cost-effectiveness analysis: cetuximab plus irinotecan vs best supportive care 
Annemans et al.59 Norum60 Starling et al.61
Study purpose To investigate the cost-
effectiveness of CET + IRIN with 
current approaches to treatment
To compare the cost-effectiveness 
of including CET in the treatment 
of metastatic colorectal cancer in 
Norway
To investigate the cost-
effectiveness of CET + IRIN vs BSC
Country setting Belgium Norway UK
Base-year prices Not reported, but study that 
analysis is based on was carried 
out in 2007
2005 Not reported but study carried out 
in 2004
Intervention/comparator CET + IRIN vs current carea CET + IRIN vs BSC CET + IRIN vs BSC
Line of treatment Third line Third line Third line
Study type Trial-based cost-effectiveness 
analysis; BOND study49
Model-based cost-effectiveness 
analysis
Trial-based cost-effectiveness 
analysis49,68
Model duration/cycle length 6-week and 12-week ruleb Unclear Lifetime
Number of health states Not applicable Unclear but likely two states Not applicable
Study group Belgian participants from the 
BOND trial (n = 218) vs eligible 
participants in the three largest 
study centres (Belgium, France 
and Italy) who fell outside the 
recruitment period (retrospective; 
n = 66)
Patients with metastatic colorectal 
cancer
Metastatic colorectal cancer 
patients with disease progression 
following IRIN failure; patients in 
the BOND trial49
Perspective Health-care perspective Third-party payer NHS perspective
Starling and colleagues61 compared the cost-effectiveness of cetuximab plus irinotecan with 
that of best supportive care from an NHS perspective for the treatment of metastatic colorectal 
cancer patients who have failed previous chemotherapy treatment. Effectiveness estimates for 
the treatment groups were modelled from key clinical trials: Cunningham and colleagues49 
compared cetuximab plus irinotecan with cetuximab plus best supportive care, and Cunningham 
and colleagues68 compared irinotecan monotherapy in a second-line setting with supportive 
care. The discounted life expectancy was 0.91 years for patients treated with cetuximab plus 
irinotecan compared with 0.47 years for patients receiving best supportive care. Patients treated 
with cetuximab plus irinotecan accumulated mean additional costs of £18,901 per patient 
relative to best supportive care, with £11,802 attributable to drug costs of cetuximab. The 
incremental cost per LYG of cetuximab plus irinotecan compared with best supportive care 
was £42,975. The incremental cost per QALY gained was £57,608. The study concluded that the 
incremental cost per LYG for cetuximab plus irinotecan is relatively high compared with that for 
other interventions.
Cetuximab compared with best supportive care and cetuximab plus 
irinotecan compared with best supportive care
One included study62 evaluated the cost implications of treatment with sequential regimens that 
include chemotherapy and/or monoclonal antibodies. Nine possible treatment sequences were 
selected to reflect the sequential advances in colorectal cancer treatment. Of these, five treatment 
sequences involving cetuximab third line were considered relevant to this review. The general 
characteristics of this study are given in Table 24.
Wong and colleagues62 used a Markov model to evaluate a hypothetical cohort of 1000 patients 
with newly diagnosed metastatic colorectal cancer. Patients received up to three lines of 
treatment before supportive care and subsequent death. Data were obtained from published, 
multicentre, Phase III clinical trials. The study considered nine possible treatment sequences; of 
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these, five were considered relevant to this review (i.e. drug of interest in the third-line setting: 
three sequences of cetuximab plus best supportive care and two sequences of cetuximab plus 
irinotecan). Based on drug costs alone, treatment that included the new chemotherapeutic 
agents increased survival at an ICER of US$100,000 per discounted life-year. The addition of 
monoclonal antibodies improved survival at an ICER of > US$170,000 per discounted life-
year. The results were most sensitive to changes in the initial regimen. Even with significant 
improvements in clinical characteristics (efficacy and toxicity), treatments with the most effective 
regimens have very high ICERs. The authors concluded that treatment of metastatic colorectal 
cancer with the most effective regimens came at very high incremental costs.
Of the three abstracts identified in the review, one65 examined the cost-effectiveness of cetuximab 
use among metastatic colorectal cancer patients. Despite further information being requested 
from the authors none was received. It should be noted that the title of the abstract suggests that 
the analysis was undertaken in an elderly patient population. In the patients with metastatic 
colorectal cancer, the incremental cost per QALY was $336,218 for cetuximab and $318,609 
TABLE 24 Summary of cost-effectiveness analyses: cetuximab plus best supportive care and cetuximab plus irinotecan
Wong et al.62
Publication type Full paper
Study purpose To measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal 
antibodies
Country setting USA
Base-year prices 2008
Intervention/comparator Nine possible treatment strategies selected to reflect the sequential advances in colorectal cancer treatment. Of these, 
five treatment sequences involving CET third line were considered relevant to this reviewa
Line of treatment Sequences of relevance to the review consider third-line treatment
Study type Model-based cost-effectiveness analysis
Model duration/cycle 
length
Unclear
Number of health states Unclear but likely four states
Study group A hypothetical cohort of 1000 patients with newly diagnosed metastatic colorectal cancer. Patients supposedly received 
up to three lines of treatment before supportive care and death (as stated above, only the five treatment sequences that 
considered CET third line were considered relevant to this review)
Perspective Third-party payer
Discount rate per annum Life expectancyb and costs at 3% per year 
Source of funding Three authors had acted as consultants for industry (Amgen, Sanofi-Aventis, B-MS, Pfizer and Genentech) and one 
author had received a research grant from B-MS and was supported during the research by funding from the ASCO 
Young Investigator Award
Base case findings The ICER per discounted LYG for adding the modern chemotherapy agents is approximately US$100,000. The benefits 
of adding monoclonal antibodies come at a higher cost (US$170,000 per discounted LYG). The modest additional 
benefits of the most effective regimen (using both CET and IRIN in the third-line setting) come at an even higher cost 
(US$240,00 per discounted LYG)
Sensitivity analyses One-way sensitivity analyses on progression, toxicity, drug cost and second progression demonstrated that the ICERs 
for sequences containing monoclonal antibodies are very high. The most significant changes in the ICERs occurred 
when the parameters for first-line treatment were changed
ASCO, American Society of Clinical Oncology; B-MS, Bristol-Myers Squibb; CET, cetuximab; IRIN, irinotecan.
a Sequence E: FOLFOX (first line), irinotecan (second line), cetuximab (third line), BSC (fourth line); sequence F: FOLFOX and bevacizumab (first 
line), irinotecan (second line), cetuximab (third line), BSC (fourth line); sequence G: FOLFIRI and bevacizumab (first line), FOLFOX (second line), 
cetuximab (third line), BSC (fourth line); sequence H: FOLFIRI and bevacizumab (first line), FOLFOX (second line), cetuximab + irinotecan (third 
line), BSC (fourth line); sequence I: FOLFOX and bevacizumab (first line), irinotecan (second line), cetuximab + irinotecan (third line), BSC (fourth 
line). Sequences G and I were two of the four sequences used to calculate ICERs and perform sensitivity analysis.
b Life expectancy was used rather than quality-adjusted life expectancy because patients with life-threatening diseases may choose treatments 
associated with a high risk of toxicity but low potential benefit. In addition, using life expectancy rather than utilities results in a conservative 
(lower) estimate for ICERs, because preference weights for patients with advanced cancer generally are < 1.
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for cetuximab plus irinotecan in comparison with best supportive care. Probabilistic sensitivity 
analysis demonstrated that best supportive care is more cost-effective than cetuximab treatments 
until the willingness-to-pay threshold is raised to $240,000. The authors conclude that cetuximab 
is not cost-effective, either in monotherapy or in combination with irinotecan, as the cost-
effectiveness ratios are far beyond the accepted threshold of $50,000 per QALY gained.
Kirsten rat sarcoma testing and cetuximab treatment
Mittmann and colleagues42 concluded that restricting cetuximab to patients with KRAS WT 
status reduced the ICER, resulting in a more efficient use of health-care resources. However, 
Mittmann and colleagues also note that, as the KRAS WT patient group had a greater survival 
gain with cetuximab compared with best supportive care (3–4 months or 0.25–0.33 years) 
than the overall group (1.5 months or 0.13 years), the drug cost was also greater in the group 
with KRAS WT status because cetuximab was used for a longer time. The ICER was still high 
for the group with KRAS WT status (C$120,061 per LYG and C$189,761 per QALY gained) 
and would generally be considered unfavourable. The authors hypothesise that, to achieve a 
generally accepted level of cost-effectiveness, the survival gain would need to be in the order of 
6–8 months.
One of the abstracts identified63 examined the cost–utility of using KRAS mutation testing 
before initiating monotherapy for patients with metastatic colorectal cancer from a US payer 
perspective. Although further information was requested none was received and more detailed 
assessment was not possible. It is worth noting, however, that the results suggest that the use 
of KRAS testing to select patients for cetuximab treatment in metastatic colorectal cancer can 
reduce costs (US$10,037) with a negligible impact on QALYs compared with using cetuximab for 
all patients.
Panitumumab plus best supportive care compared with best 
supportive care
Graham and colleagues64 assessed the cost-effectiveness of panitumumab plus best supportive 
care compared with best supportive care alone in chemorefractory metastatic colorectal cancer 
patients with KRAS WT status in the Netherlands. In the base-case analysis, the ICERs for 
metastatic colorectal cancer patients with KRAS WT status receiving panitumumab plus best 
supportive care compared with best supportive care alone were €51,314 per LYG and €59,440 per 
QALY gained. Univariate sensitivity analyses and probabilistic sensitivity analyses showed the 
results to be robust to assumptions around input parameters. We requested more information on 
this abstract from the authors but none was received to allow a more detailed assessment of the 
study for inclusion. Interestingly, despite a number of Amgen-linked authors, no mention was 
made of this abstract in Amgen’s submission.
No other studies looking at the cost-effectiveness of panitumumab in the relevant patient 
population were found in the literature review.
Bevacizumab plus non-oxaliplatin-containing regimens
No studies looking at the cost-effectiveness of bevacizumab in the relevant patient population 
were found in the literature review.
Conclusions
There were five studies included in the review that considered cetuximab or cetuximab plus 
irinotecan in third-line therapy. In addition, three abstracts were identified for which we received 
no further information; of these, one considered the cost-effectiveness of KRAS testing prior to 
cetuximab treatment,63 one considered the cost-effectiveness of cetuximab (monotherapy and 
combination therapy)65 and one considered panitumumab in third-line therapy.64
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Of the full papers, Annemans and colleagues59 concluded that, in comparison with best 
supportive care, cetuximab was a cost-effective treatment option in one of the scenarios tested 
(6-week rule, i.e. cetuximab was discontinued at 6 weeks if there was no tumour response at that 
time point). The other studies42,43,60–63 concluded that, although clinically effective, cetuximab 
is an expensive intervention. The study by Wong and colleagues,62 which evaluated treatment 
strategies that included one, two, three or four therapies, concluded that, in general, the 
treatment of metastatic colorectal cancer with the most effective regimens comes at very high 
incremental costs.
Of the studies identified in the review, the study by Mittmann and colleagues42 was the only full 
paper to consider metastatic colorectal cancer patients with KRAS WT status. They concluded 
that, although the ICER for cetuximab compared with best supportive care in metastatic 
colorectal cancer patients was high and sensitive to drug cost, it was lower when analysis was 
limited to patients with KRAS WT tumours. We consider this in greater detail and in comparison 
with the PenTAG cost-effectiveness model in Chapter 6. In addition, results from a study by 
Carlson and colleagues63 also suggest that the use of KRAS testing to select patients for cetuximab 
treatment in metastatic colorectal cancer can reduce costs compared with using cetuximab for all 
patients, with a negligible impact on QALYs.
One abstract64 identified in the review found panitumumab to be a cost-effective treatment 
option in metastatic colorectal cancer patients with KRAS WT status; however, no further 
information was made available for analysis.
Most of the available studies were supported by grants from industry. In some cases, the cost-
effectiveness studies received independent funding, for example that by Norum,60 yet many of the 
RCTs on which they were based had received funding, either in full or in part, from industry.
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Chapter 5 
Assessment of industry submissions 
to the National Institute for Health and 
Clinical Excellence
Introduction
Three manufacturer submissions were potentially available for this MTA; however, only one full 
economic model was submitted, which was by Merck Serono for cetuximab.69 Roche submitted 
some basic cost calculations in its report of a comparison between bevacizumab plus FOLFIRI 
and cetuximab plus FOLFIRI,70 whereas Amgen did not provide any details of a cost-effectiveness 
model, nor make any comment on the likely cost-effectiveness of panitumumab.71 In this section 
the full economic model submitted by Merck Serono, the cost calculations presented by Roche 
and the trial analysis submitted by Amgen are critiqued. The material in this chapter which has 
been reproduced from these manufacturers’ submissions in text, tables and figures has been done 
so with the permission of Merck Serono, Roche and Amgen.
Industry submission critique 1: Merck Serono, cetuximab
The decision problem: cetuximab
Merck Serono restricts the evaluation of cetuximab to third and subsequent lines of treatment. 
Bevacizumab is disregarded by Merck Serono as an inappropriate treatment comparator for 
cetuximab because of the lack of published clinical data on the effectiveness of bevacizumab for 
metastatic colorectal cancer patients with KRAS WT status in third-line treatment. In summary, 
Merck Serono reports estimates of cost-effectiveness for the following four comparisons:
 ■ cetuximab plus best supportive care compared with best supportive care
 ■ cetuximab plus irinotecan compared with best supportive care
 ■ cetuximab plus best supportive care compared with panitumumab plus best supportive care
 ■ cetuximab plus irinotecan compared with panitumumab plus best supportive care.
There are three points of interest relating to these comparisons. First, the pairwise cost-
effectiveness comparisons are selective in the sense that several relevant comparisons, although 
possible, are not presented. Figure 3 shows the data available to Merck Serono (the bold lines) 
and the cost-effectiveness comparisons that it has undertaken (the dashed lines). It has not 
compared cetuximab plus irinotecan with cetuximab plus best supportive care despite the data 
being available.
Second, depending on the active comparator arm, the best supportive care arm is modelled 
slightly differently (hence, post hoc incremental analysis could not be undertaken by the 
assessment group). This difference in the modelling of the best supportive care arms appears to 
depend on data availability and flexibility in modelling and is discussed in Modelling progression-
free survival and overall survival: cetuximab. Third, Merck Serono assesses cost-effectiveness only 
in third-line treatment and does not consider the second-line scenario, which the scope of this 
guidance also covers (see Line of treatment: cetuximab).
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Overview of model design: cetuximab
A three-state Markov model, with health states defined as progression free, progressive disease 
and death, is used by Merck Serono to compare best supportive care with cetuximab plus best 
supportive care and cetuximab plus irinotecan in third-line treatment for metastatic colorectal 
cancer patients with KRAS WT status (Figure 4). Treatment-specific utilities are assigned to the 
progression-free and progressive disease states (discussed further in Utilities: cetuximab). The 
costs associated with KRAS testing, drug acquisition and administration, best supportive care and 
adverse events are accounted for in the model (discussed further in Utilities: cetuximab). Merck 
Serono states that all patients in the progression-free state are assumed to receive active treatment 
whereas those in the progressive disease state receive best supportive care only (see p. 94 of 
Merck Serono’s submission69). As will be discussed in Drug acquisition costs and dose intensity: 
cetuximab, this is not how the base-case analysis is modelled and so the reported base-case ICERs 
are misleading.
Summary of results: cetuximab
The base-case results are reproduced from the Merck Serono submission in Tables 25 and 26 
for cetuximab plus best supportive care compared with best supportive care and cetuximab 
plus irinotecan compared with best supportive care respectively. Merck Serono shows that the 
biggest cost component for the cetuximab plus best supportive care and the cetuximab plus 
irinotecan arms is the drug acquisition costs, followed by the best supportive care and drug 
administration costs. The QALYs gained for cetuximab plus best supportive care are similar 
between the progression-free and the progressive disease health states, as is also the case for 
cetuximab plus irinotecan. Merck Serono conducted a probabilistic sensitivity analysis of its 
base-case assumptions. It reports that the probability that cetuximab plus best supportive care 
is cost-effective compared with best supportive care is 0.1% at a willingness to pay of £30,000 
per QALY gained and 65% at a willingness to pay of £50,000 per QALY gained. It also reports a 
16% probability that cetuximab plus irinotecan is cost-effective compared with best supportive 
care at a willingness to pay of £30,000 per QALY gained, with a probability of 68% of cetuximab 
plus irinotecan being cost-effective compared with best supportive care at a willingness to pay of 
£50,000 per QALY gained. Merck Serono argues that the end of life (EoL) criteria are appropriate 
for both cetuximab plus best supportive care and cetuximab plus irinotecan.
Merck Serono has followed NICE’s reference case as far as is possible given the evidence 
limitations. A NHS and Personal Social Services (PSS) perspective has been taken, with costs and 
outcomes discounted at an annual rate of 3.5% (Table 27). The only exception is for the health-
related utility values for which HUI3 rather than EQ-5D data were used. The impact of this on 
the results is unknown.
FIGURE 3 Diagram of the available data and the cost-effectiveness comparisons modelled by Merck Serono. Bold lines 
represent published effectiveness data, dashed lines represent the cost-effectiveness comparisons made by Merck 
Serono. BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PAN, panitumumab.
CET + BSC
CET + IRINBSC
PAN + BSC
De Roock et al.
(2008)17
Karapetis et al.
(2008)8
Amado et al. (2008)9
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FIGURE 4 Three-state Markov model used by Merck Serono.
TABLE 25 Base-case results from Merck Serono for cetuximab plus best supportive care vs best supportive carea 
Comparators
Total costs 
(£)
Total 
LYG
Total 
QALYs
Incremental costs 
(£)
Incremental 
LYG
Incremental 
QALYs ICER (£/QALY)
BSC 7580 0.512 0.359
CET + BSC 21,836 0.829 0.662 14,256 0.317 0.303 47,095
BSC, best supportive care; CET, cetuximab.
a Taken from Merck Serono’s Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) spreadsheet.69
TABLE 26 Base-case results from Merck Serono for cetuximab plus irinotecan vs best supportive carea
Comparators
Total costs 
(£)
Total 
LYG
Total 
QALYs
Incremental costs 
(£)
Incremental 
LYG
Incremental 
QALYs ICER (£/QALY)
BSC 7947 0.547 0.391
CET + IRIN 37,248 1.325 1.059 29,301 0.779 0.668 43,887
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
a Taken from Merck Serono’s Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) spreadsheet.69
TABLE 27 NICE reference case and the Merck Serono model
Element NICE reference case72 Merck Serono’s model
Perspective on costs NHS and PSS ü
Perspective on outcomes All health effects on individuals ü
Type of economic 
evaluation
Cost-effectiveness ü Cost–utility
Synthesis of evidence on 
outcomes
Based on systematic review ü Except that data relating to cetuximab plus irinotecan 
vs cetuximab plus best supportive care48 are not from a 
RCT and are of questionable quality
Measure of health effects QALYs; EQ-5D preferred measure of HRQoL ü QALYs used, but utilities based on HUI3
Source of data for 
measurement of HRQoL
Reported directly by patients and/or carers ü Reported directly by patients. Valuation based on 
Canadian public preferences42
Discount rate Annual rate of 3.5% for costs and health effects ü
Equity weighting Same QALY weight regardless of other characteristics 
of the individuals receiving the health benefit
ü
Death
Progression-free Progressive
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Sensitivity analyses suggest that the important drivers for the cost-effectiveness analysis are 
the cetuximab acquisition and administration costs, the utility values assigned to progression-
free and progressive disease and the cost of best supportive care. In Critique of Merck Serono’s 
model for cetuximab a number of uncertainties regarding the cetuximab administration and 
best supportive care costs and the utilities used in the Merck Serono model are discussed. 
Furthermore, Merck Serono did not assess the sensitivity of the model to the effectiveness data.
Line of treatment: cetuximab
Merck Serono argues that it considers only third-line use of cetuximab in its submission because 
this is ‘based on clinical need, the strength of the evidence, expert opinion and current usage’ (p. 21, 
Merck Serono’s submission69). Accordingly, the studies informing estimates of effectiveness in 
the model mainly involve patients who have previously received two or more lines of treatment. 
The EPIC study73–75 is available to model second-line treatment comparing cetuximab plus 
irinotecan with irinotecan. Merck Serono argues that irinotecan is an appropriate second-line 
treatment comparator, and our clinical expert agrees that it is part of current practice in second-
line treatment. There are, however, a number of issues related to the EPIC study: first, 46.9% of 
patients randomised to irinotecan crossed over to receive cetuximab at some stage and, second, 
KRAS status is not known for the participants. It is understood that the manufacturer did not 
have access to the individual patient data and could not address this accurately; however, it would 
have been possible for some assumptions to have been made to find some indication of the likely 
cost-effectiveness of cetuximab plus irinotecan compared with irinotecan in second-line therapy.
Peninsula Technology Assessment Group corrections for errors: cetuximab
In this section all ICERs reported from the Merck Serono model have been corrected for 
the following three logical errors identified in Merck Serono’s Excel (Microsoft Corporation, 
Redmond, WA, USA) spreadsheet:
 ■ cetuximab plus irinotecan cost of administration: a cost of £180 is modelled when Merck 
Serono reports in its submission that this value should be £196
 ■ incorrect proportion in progression-free state at cycle 0 for best supportive care arm in 
comparison with cetuximab plus best supportive care
 ■ cost of non-serious adverse events in best supportive care arm: cost of £200 is modelled when 
Merck Serono reports in its submission that this value should be £174.
Note that correction for these errors leads to slightly increased base-case ICERs compared with 
those reported by Merck Serono – from £47,095 to £48,238 per QALY for cetuximab plus best 
supportive care compared with best supportive care and from £43,887 to £44,429 per QALY for 
cetuximab plus irinotecan compared with best supportive care.
Critique of Merck Serono’s model for cetuximab
In this section we detail our main concerns over the assumptions made in the model submitted 
by Merck Serono. Where possible we present the impact on the ICERs of alternative assumptions. 
In Impact on the ICERs: cetuximab the cumulative effect of different assumptions on Merck’s 
base-case results are presented.
Drug acquisition costs and dose intensity: cetuximab
Merck Serono assumes a guaranteed NHS price of £136.50 for a 20-ml (100-mg) vial of 
cetuximab. We believe that this price is that which would be available nationally. Merck assumes 
a cost for generic irinotecan of £120.30 for a 5-ml (100-mg) vial from the British National 
Formulary (BNF) 61.76
The manufacturer states that dose intensity is included in the model and presents details in 
table 81 of its submission69 for dose intensity of cetuximab plus best supportive care, cetuximab 
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plus irinotecan, and irinotecan (Table 28). However, examination of the Microsoft Excel 
model indicates that only the calculations for the cost of cetuximab include consideration of 
dose intensity. The value used in the Excel model is 94% but the value reportedly used in the 
submission is 98% (‘based on CO.17 study’; see p. 110, Merck Serono’s submission69). Thus, 
for cetuximab plus best supportive care, a lower dose intensity is assumed in the model than 
is specified in the report. For irinotecan, 100% dose intensity is modelled even though the 
report indicates that a dose intensity of 90% is modelled. Adjusting the drug costs for these 
discrepancies has negligible impact on the PenTAG corrected base-case ICERs.
Merck Serono assumes vial wastage for cetuximab in its base-case analysis but does not assume 
wastage for treatment with irinotecan, instead assuming vial sharing. Although inconsistent, this 
is unlikely to have much of an impact on the ICERs as the cost of irinotecan is very small relative 
to the cost of cetuximab; however, vial sharing of irinotecan does not happen in the UK.
Administration costs: cetuximab
Merck Serono assumes that administration takes place in the day-care setting, with a cost of 
£180 for cetuximab plus best supportive care for ‘deliver simple parenteral chemotherapy at first 
attendance’ from the NHS reference costs for 2008–2009,77 and £196 for cetuximab plus irinotecan 
(the average of £180 for delivery of cetuximab plus best supportive care and £213 for ‘deliver 
more complex chemotherapy at first attendance’).
The costs of administration of cetuximab used by Merck Serono could be too low as they refer 
to drugs at first delivery, whereas ‘delivery of subsequent elements of chemo cycle’ is likely to 
be more relevant. This would incur costs of £227 per administration at 2008–9 prices. Note that 
this is the cost of drug administration assumed by Roche in its cost calculations for bevacizumab 
(see Costs: bevacizumab). Merck Serono does not account for pharmacy preparation costs in 
its model. In the PenTAG model we assume a pharmacy preparation cost of £15 per infusion 
informed by data from a pharmacist at the Royal Devon and Exeter Hospital (Kate Copland, 
Chief Technician Aseptic Services in Pharmacy, Royal Devon & Exeter Hospital, personal 
communication, 2011; see Chapter 6). Although these pharmacy preparation costs are small, 
they are incurred for every administration. Thus, assuming an administration cost of £242 
(£227 + £15) for cetuximab plus best supportive care at 2008–9 costs (consistent with Merck’s 
model) increases the ICER slightly (Table 29).
TABLE 28 Reported and modelled dose intensities in Merck Serono’s submission
Treatment Reported (%) Modelled (%) Impact
CET (in CET + BSC) 98 94 Negligible
CET (in CET + IRIN) 94 94 Negligible
IRIN 90 100 Negligible
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
TABLE 29 Assumptions about administration costs (including pharmacy preparation) per infusion
Treatment Cost used by Merck Alternative cost value Impact
CET (in CET + BSC) £180 £242 Alternative cost value increases ICER from 
£43,238 to £50,624 per QALY gained
CET (in CET + IRIN) £196 £242 per CET infusion; £128.50 
per IRIN infusion
Alternative cost value increases ICER from 
£44,429 to £47,624 per QALY gained
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
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It is difficult to assess the administration costs of irinotecan in addition to those of cetuximab. In 
the PenTAG model a best estimate of the average cost of no additional administration time being 
required (£0) and the same administration time as that for cetuximab being required (£227) is 
assumed (see Chapter 6, Pharmacy drug preparation costs). This leads to an administration cost 
for irinotecan, including pharmacy preparation time, of £128.50 per infusion (£113.50 + £15). 
Using this cost estimate, the ICER for cetuximab plus irinotecan compared with best supportive 
care increases slightly (see Table 29).
In the sensitivity analyses Merck Serono examines the impact of assuming different dosing 
regimens for irinotecan for the cetuximab plus irinotecan compared with best supportive care 
comparison. It is reported that the ICER increases when assuming 350 mg/m2 administration 
every 3 weeks, and decreases when assuming 125 mg/m2 every 3 weeks. However, the base-case 
analysis assuming that administration of irinotecan is every 2 weeks at a dose of 180 mg/m2 
nationally is reasonable.
Treatment duration: cetuximab
In the Excel model, for the base-case analyses, drug acquisition and administration costs are 
modelled for all patients in the progression-free state until week 13 for cetuximab plus best 
supportive care and week 24 for cetuximab plus irinotecan. At these times approximately 60% of 
patients are still in the progression-free state for all active treatments. After these times, no drug 
acquisition or administration costs are assumed for patients but they remain in the progression-
free health state. In the Excel model the 13- and 24-week cut-offs imply an estimated mean time 
on drug treatment of 11.4 weeks and 19.4 weeks for cetuximab plus best supportive care and 
cetuximab plus irinotecan respectively. This is our main concern with Merck Serono’s model.
In its report, Merck Serono gives no explanation for the value of these cut-offs for cetuximab 
(plus best supportive care or irinotecan). Instead, it states in the list of model assumptions (see 
table 59, Merck Serono’s submission69) that ‘the model is adjusted with clinical data related to 
the mean number of weeks on chemotherapy’. However, Merck Serono does not report the 
mean number of weeks on treatment for cetuximab plus best supportive care or cetuximab 
plus irinotecan in its submission nor does it provide sufficient detail concerning the proper 
justification for these very important assumptions. The rationale for this assumption cited in 
the report is ‘The model offers the option to adjust the number of chemotherapy cycles in order 
to (1) generate the mean number of cycles corresponding to the estimated mean number of 
doses in clinical studies, (2) ensure that the chemotherapy costs stay within plausible ranges 
in the probabilistic sensitivity analysis when the parameters of the progression-free survival 
can be sampled from a distribution and generate an unrealistic amount of time spent on active 
treatment’ (p. 97, Merck Serono’s submission69).
We asked Merck Serono to clarify its assumptions regarding mean time on treatment as it was 
not sufficiently reported in the submission. In its response it states that only the median time on 
treatment for the total cetuximab plus best supportive care population (KRAS WT and KRAS 
mutant status) is available, and this is 8.1 weeks.37 It is reported in the panitumumab plus best 
supportive care compared with best supportive care study by Amado and colleagues32 that a 
mean of 10 panitumumab infusions was received by patients with KRAS WT status. For all 
patients (KRAS WT and KRAS mutant status combined) the mean number of panitumumab 
infusions is reported to be seven. Using these data from the panitumumab plus best supportive 
care compared with best supportive care study, Merck Serono multiplies the median 8.1 weeks 
on cetuximab for all patients by 10/7 to estimate the mean number of infusions of cetuximab 
for patients with KRAS WT status. This gives a value of 11.57 infusions for patients with KRAS 
WT status. Merck Serono then adjusts the mean number of weeks on treatment in the model to 
11.4, which corresponds ‘as close as possible to 11.57’, assuming one infusion per week.69 This 
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approach assumes that the relative difference between the mean number of infusions for patients 
with KRAS WT status and the mean number of infusions for all patients in panitumumab plus 
best supportive care is the same as the difference between the ‘median weeks on treatment’ for 
patients with KRAS WT status and the ‘median weeks on treatment’ for all patients. First, there 
is no evidence to suggest that the relative difference between the mean number of infusions for 
patients with KRAS WT status and for all patients in the panitumumab plus best supportive 
care arm can be assumed for cetuximab plus best supportive care. Second, there is no evidence 
to suggest that the relative difference in means is the same as the relative difference in medians. 
Furthermore, the median 8.1 weeks on cetuximab treatment from Jonker and colleagues37 is very 
similar to the median progression-free survival in this study (8.2 weeks). This suggests but does 
not prove that treatment is received throughout the progression-free state, which our clinical 
expert believes is reasonable. For more information on this see Chapter 6, Time on cetuximab plus 
irinotecan treatment.
For cetuximab plus irinotecan, Merck Serono states in its response to our request that in the 
cetuximab plus irinotecan compared with cetuximab plus best supportive care study (BOND49) 
the mean number of infusions for all patients (KRAS WT and KRAS mutant status combined) 
receiving cetuximab plus best supportive care and cetuximab plus irinotecan was 7 and 18 
respectively. In fact, these figures refer to the median not mean number of infusions.49 Second, 
it is not clear how this mean of 18 infusions was then translated by Merck Serono into its 
assumed mean of 19.4 weeks of treatment for cetuximab plus irinotecan. Note again that, as for 
cetuximab plus best supportive care, the trial data suggest that treatment duration is very similar 
to progression-free survival. It is reported in BOND that median progression-free survival for 
all patients on cetuximab plus best supportive care is 6.5 weeks whereas the median number of 
infusions of cetuximab was seven, corresponding to 7 weeks of treatment.49 For more information 
on this see Chapter 6, Time on cetuximab plus irinotecan treatment.
Merck Serono’s assumption that drug treatment ceases at the cut-off times (of 13 and 24 weeks) 
even if patients have not progressed has a large impact on the base-case ICERs, as the costs 
associated with drug treatment are reduced yet there is no impact on time to progression or death 
and therefore on QALYs. This contradicts another of Merck Serono’s assumptions, that ‘Patients 
in the progression free state are assumed to be on therapy whereas patients in the progressive 
disease health state are assumed to receive no active treatment’ (see p. 94, Merck Serono’s 
submission69). Assuming that all patients continue to receive active treatment as long as they 
remain in the progression-free state increases the ICERs substantially, as shown in Table 30.
These ICERs are much larger than those reported by Merck Serono (£47,000 vs £75,417 per 
QALY gained for cetuximab plus best supportive care vs best supportive care and £44,000 vs 
£67,429 per QALY gained for cetuximab plus irinotecan vs best supportive care). The estimates 
in Table 30 are likely to be slight overestimates as some patients in the progression-free state may 
discontinue active treatment for reasons other than disease progression. However, the trial data 
indicate that very few patients discontinue treatment because of adverse events [e.g. Jonker and 
colleagues37 report that 11 patients (4%) receiving cetuximab plus best supportive care withdrew 
because of adverse events]. Merck Serono argues that ‘patient[s] dropping out of treatment are 
not doing so due to an injection site reaction but more probably due to non efficacious treatment. 
At this point patients are in PD’ (see table 59, Merck Serono’s submission69). Therefore, the ICERs 
in Table 30 are more likely to be closer to reality than those presented in Merck Serono’s base 
case, in which it is assumed that treatment ceases for all patients at 13 or 24 weeks.
In Merck Serono’s submission it is stated that ‘patients dropping out of active treatment are 
allocated to the progressive disease state’ (table 59, Merck Serono’s submission69). However, in 
Merck Serono’s model patients remaining in the progression-free state after stopping active 
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treatment continue to receive the utilities for being progression free, not those associated with 
progressive disease as this assumption would indicate.
Best supportive care costs: cetuximab
Merck Serono uses a monthly value of £785 for best supportive care costs in its model. It cites 
Remak and Brazil78 for the source of this cost but does not provide the actual value extracted 
from Remak and Brazil. It is therefore assumed that the cost of best supportive care of £675 
is extracted (from table 578). We believe that Merck Serono has made two errors in its use of 
the Remak and Brazil data: first, by the methods of inflating this value and, second, by its use 
of this value in both the progression-free and progressive disease health states. Inflating £675 
from 2004 to 2008–9 costs using the Retail Price Index,79 as reported by Merck Serono, gives 
the value used by the manufacturer of £785. However, the manufacturer’s inflating of the best 
supportive care costs are incorrect as it assumes that the costs reported by Remak and Brazil are 
at 2004 prices when in fact they are at 2000 prices.78 Using Merck’s method of inflating using 
the Retail Price Index from 2000 leads to a monthly cost of best supportive care of £856 (rather 
than £785). In addition to this, Merck Serono has used the incorrect index to inflate this value. 
It uses the Retail Price Index as opposed to the Hospital and Community Health Service Index 
from Curtis,79 which is widely used in health technology assessment (HTA) economic analyses 
as it refers specifically to hospital and health service costs. Using the Hospital and Community 
Health Service Index and inflating the Remak and Brazil value of £675 from 2000 to 2008–9 gives 
a cost of £917 a month, a 17% increase on the value used by Merck Serono. This increase in the 
cost of best supportive care leads to slight increases in the ICERs: £49,938 per QALY gained for 
cetuximab plus best supportive care compared with best supportive care, and £46,276 per QALY 
gained for cetuximab plus irinotecan compared with best supportive care (assuming PenTAG’s 
corrections to Merck Serono’s base-case ICERs as reported in Peninsula Technology Assessment 
Group correction for errors: cetuximab).
This value is not appropriate to use for both the progression-free and the progressed disease 
health states as Merck Serono does. Remak and Brazil78 present costs for four periods of stage 
IV breast cancer treatment: (1) active drug treatment, (2) follow-up after active treatment until 
disease progression, (3) active supportive care after disease progression and (4) EoL care. The 
value assumed to have been extracted by Merck Serono, £675, relates to active supportive care 
after disease progression; however, Merck Serono applies this value to all patients in all treatment 
arms regardless of whether they are in the progression-free or progressive disease health state. 
Remak and Brazil report the combined monthly cost for the progression-free state [covering 
TABLE 30 Results from PenTAG’s calculations using the model assuming that treatment continues for all patients for 
the entire time in the progression-free state
CET + BSC vs 
BSC
CET + IRIN vs 
BSC
ICER (£/QALY) 75,417 67,429
Incremental costs (£) 22,289 45,018
Incremental QALYs 0.296 0.668
Total costs (CET + BSC/IRIN) (£) 29,868 52,927
Total costs (BSC) (£) 7580 7909
Total QALYs (CET + BSC/IRIN) 0.662 1.059
Total QALYs (BSC) 0.367 0.391
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
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periods (1) and (2) above]. This cost is £679, which is very similar to the cost of active supportive 
care that Merck Serono uses from Remak and Brazil for the progression-free state. However, the 
progression-free state costs from Remak and Brazil included active treatment (including drugs 
specifically for breast cancer) and so are likely to be an overestimate of the best supportive care 
costs appropriate to the progression-free state in the Merck Serono model, because this should 
reflect non-drug-related costs. This will lead to the total costs of the best supportive care arms 
being overestimated with the consequence that the ICERs for cetuximab plus best supportive 
care compared with best supportive care and cetuximab plus irinotecan compared with best 
supportive care are underestimated. Given these issues related to the best supportive care costs 
that Merck Serono has used from Remak and Brazil, we believe that the best supportive care 
cost assumed by Merck Serono is an underestimate for the progressive disease state and an 
overestimate for the progression-free state.
Kirsten rat sarcoma testing costs: cetuximab
Merck Serono accounts only for the KRAS costs associated with those patients who subsequently 
receive cetuximab, that is, those who are KRAS WT. In practice, all patients considered for 
cetuximab will have a KRAS test and therefore it is appropriate that the cost of the KRAS test 
should also include those patients who are tested but who are KRAS mutant. Previous cost–utility 
models for cetuximab have assumed a KRAS testing cost of £300;17 however, data from the All 
Wales Medical Genetics Service suggest that the cost of a KRAS test is £160.80 The real cost of 
KRAS testing (including the cost of those identified to be KRAS mutant) is likely to be £296 
(£160/0.54) (see Chapter 6, Costs of epidermal growth factor receptor and Kirsten rat sarcoma 
testing). Updating Merck’s model with this assumption increases the ICER very slightly.
Utilities: cetuximab
Merck Serono uses utilities from the cost-effectiveness analysis of CO.17 by Mittmann and 
colleagues,42 who report the analysis of HUI3 scores according to values taken from the CO.17 
study and valued by the general Canadian population. As Merck Serono states, the utility analysis 
by Mittmann and colleagues is presented at baseline and 2, 8, 16 and 24 weeks after random 
assignment and is therefore not useful for the Merck Serono model in which the health states are 
defined as progression free and progressed disease. Thus, Merck Serono has reanalysed the utility 
data from the CO.17 study according to these health states. The reanalysis produces mean HUI 
values that are generally greater than those reported by Mittmann and colleagues (Table 31).
TABLE 31 Health Utility Index values in the literature for metastatic colorectal cancer
Study Stage of disease Treatment arm No. of patients Utility values
Ramsey et al.81 Stage IV N/A 13 0.76−0.95
Mittmann et al.42 Study baseline CET + BSC 263 0.72
BSC 260 0.71
24 weeks from baseline CET + BSC 82 0.77
BSC 36 0.70
Merck Serono69 Progression-free state CET + BSC 294 0.81
BSC 170 0.75
Progressive disease state CET + BSC 83 0.79
BSC 85 0.69
BSC, best supportive care; CET, cetuximab; N/A, not applicable.
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Assessment of the CO.17 study indicates that at baseline all patients were progression free.37,47 
Therefore, we can assume that the baseline mean HUI values reported by Mittmann and 
colleagues could give some idea of the likely progression-free utility values that the manufacturer 
may obtain in its analysis (utility cetuximab plus best supportive care utility = 0.72, best 
supportive care = 0.71). However, the utility values that the manufacturer reports are considerably 
greater for the progression-free state (utility cetuximab plus best supportive care = 0.81, best 
supportive care = 0.75).
The numbers of patients included in the calculations of the utility values differ between the 
analysis by Mittmann and colleagues42 and the manufacturer’s reanalysis (see Table 31). There is 
no explanation as to why this has occurred. We asked Merck to clarify the population base on 
which its utility estimates are based. It reported that the utility estimates are restricted to patients 
with KRAS WT status (see Appendix 11). However, given the numbers of patients contributing 
to the utility estimates, it is unlikely that this is the case. For example, 294 patients receiving 
best supportive care and 170 patients receiving cetuximab contribute to Merck’s reanalysis of 
utilities in the progression-free health state (see table 80, Merck Serono’s submission69); however, 
in Karapetis and colleagues45 it is reported that the total numbers of patients with KRAS WT 
status receiving best supportive care and cetuximab plus best supportive care are 113 and 117 
respectively. By considering all patients (KRAS WT and KRAS mutant status combined), the 
mean utility for those receiving cetuximab could have been underestimated by Merck Serono, as 
patients with KRAS mutant status would not experience a treatment effect. It would be difficult to 
quantify this underestimation without access to the individual patient data. Moreover, it is highly 
unlikely that the utility values used by Merck Serono are larger than would be expected in the 
absence of all sources of bias, as is now discussed.
The progressive disease utility estimates from the analysis by Mittmann and colleagues42 and the 
Merck Serono reanalysis are based on a much lower number of patients than the number used 
for the progression-free state (see Table 31). Furthermore, there is likely to be unequal dropout 
between the treatment arms, with those in the best supportive care arm more likely to drop out 
because of a lack of treatment effect, meaning that they progress more quickly and are perhaps 
less able to complete the questionnaire. In addition, the CO.17 study37 is not blinded and so there 
is the potential for bias in the QoL measures. The unequal dropout and lack of blinding in the 
CO.17 study could lead to overestimates of the utilities in both treatment arms. Placing these 
utility values in context, the HUI values from Ramsey and colleagues81 are of a similar magnitude 
to, or even greater than, those reported by Merck Serono: 0.76–0.95 for stage IV depending on 
time since diagnosis compared with 0.69–0.81 (see Table 31). However, Ramsey and colleagues 
note that the study design is likely to have excluded more severely ill patients and the utility 
values are based on just 13 patients; therefore, these values are likely to be overestimates. This 
seems probable when the UK EQ-5D norm is 0.73 for those aged ≥ 75 years.82 EQ-5D values 
collected alongside the MABEL study61 for metastatic colorectal cancer patients receiving 
cetuximab plus irinotecan also suggest such high values: mean utility of 0.746.
In the Merck Serono cost–utility model, although the utility data are from the cetuximab plus 
best supportive care compared with best supportive care study (CO.1737), all active treatments 
are assumed to have utilities as reported for cetuximab plus best supportive care. There is a 
concern here that irinotecan is a particularly toxic chemotherapy and therefore it would seem 
unreasonable to assume that the utility for cetuximab plus best supportive care is equivalent to 
that for cetuximab plus irinotecan. In fact, our clinical expert agrees that QoL is unlikely to be 
equivalent for cetuximab plus best supportive care and cetuximab plus irinotecan; therefore, the 
utilities associated with cetuximab plus irinotecan in the Merck Serono model are likely to be 
overestimates. Merck Serono’s assumption of equivalent utilities leads to a more favourable ICER 
for cetuximab plus irinotecan over any comparator but, in the absence of data, it is difficult to 
quantify the extent to which this is an overestimate.
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As can be seen in Table 31, the utility values calculated by Merck Serono associated with 
cetuximab plus best supportive care are greater than those for best supportive care, regardless 
of the health state. Au and colleagues44 found a similar pattern in their analysis of the EORTC 
QLQ-C30 data from CO.17: higher QoL for cetuximab than for best supportive care. For the 
progression-free state this finding appears reasonable given that patients are more likely to be 
responding with cetuximab plus best supportive care than with best supportive care and therefore 
more likely to have a greater QoL, even though they are more likely to experience treatment-
related adverse events (see Chapter 3, Indirect comparison of cetuximab and panitumumab, 
Adverse events).
The progressive disease utilities are also different between treatment arms, with cetuximab plus 
best supportive care utilities higher than best supportive care utilities. This is difficult to explain 
as it is assumed in Merck Serono’s model that all progressed patients cease cetuximab plus best 
supportive care and therefore they will no longer be responding to treatment. The magnitude 
of this difference in utility is difficult to explain. The mean utility value in the progression-free 
state for those on cetuximab plus best supportive care is 0.063 greater than that for those on 
best supportive care alone. In the progressive disease state this difference is even greater: 0.097. 
This is inconsistent as patients are receiving the same care once in progressive disease regardless 
of whether they received cetuximab plus best supportive care or best supportive care alone in 
the progression-free state. Given the possibilities for bias in the analysis of these data (lack of 
blinding, unequal dropout and healthier patients more likely to complete the QoL survey), it does 
not seem reasonable that QoL in progressive disease should differ between the treatment arms. 
By assuming higher utilities in the progressive disease state for those receiving cetuximab plus 
best supportive care in the progression-free state, greater total QALYs will be associated with 
cetuximab plus best supportive care than with best supportive care.
As a sensitivity analysis, if the utility of 0.693 is assumed for both treatment arms in the 
progressive disease state and leaving unchanged Merck Serono’s utility assumptions in 
the progression-free state, the following ICERs are obtained by PenTAG rerunning Merck 
Serono’s model:
 ■ cetuximab plus best supportive care compared with best supportive care: £56,132 per QALY 
gained (vs £48,238 per QALY gained)
 ■ cetuximab plus irinotecan compared with best supportive care: £49,233 per QALY gained (vs 
£44,439 per QALY gained).
It is worth noting that Merck Serono is aware that ‘there are uncertainties around whether the 
utilities are truly representative of likely quality of life when in progression free and PD states’ 
(scenarios 3a and b, p. 136, Merck Serono’s submission69), and that the utilities used in both 
health states were found to be important drivers in its model. The trial contributing evidence to 
the utility estimates is open label, which introduces the possibility of bias in favour of cetuximab 
plus best supportive care for the QoL estimates but which is difficult to avoid.
Impact on the incremental cost-effectiveness ratios: cetuximab
In the above sections the impact of individual issues on the PenTAG corrected base-case ICERs 
has been discussed. In this section the simultaneous impacts on the ICER of a number of the 
important assumptions are presented. As can be seen in Tables 32 and 33, the simultaneous 
adjustment of a number of the assumptions regarding the costs associated with treatment and 
care for patients with metastatic colorectal cancer has quite a large impact on the PenTAG 
corrected base-case ICERs: from £48,238 per QALY gained to £95,238 per QALY gained for 
cetuximab plus best supportive care compared with best supportive care and from £44,429 per 
QALY gained to £83,215 per QALY gained for cetuximab plus irinotecan compared with best 
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supportive care. However, removing Merck’s cap on the mean duration of treatment and instead 
assuming that patients are treated throughout the progression-free state has the greatest impact 
on the ICERs (see Treatment duration: cetuximab).
Effectiveness evidence: cetuximab
Karapetis and colleagues (CO.17)47
Merck Serono uses the individual patient data from the CO.17 study to inform time to disease 
progression and death for patients receiving cetuximab plus best supportive care compared 
with best supportive care. The data used are from the retrospective analysis of the CO.17 
study by Karapetis and colleagues,47 which stratifies by KRAS status (see also Chapter 3, Study 
characteristics, Cetuximab plus best supportive care compared with best supportive care). Karapetis 
and colleagues present both hazard ratios adjusted for patient characteristics for progression-
free survival and overall survival and unadjusted hazard ratios (Table 34). In the Merck Serono 
model, the unadjusted hazard ratios are used. However, given that KRAS status is assessed 
retrospectively in Karapetis and colleagues and that KRAS status was not determined for all 
participants, there may be some selection bias in the study (even though the authors report that 
TABLE 32 Impact on the base-case ICER reported by Merck Serono of changes in assumptions: cetuximab plus best 
supportive care vs best supportive care 
ICER (£/
QALY)
Incremental 
cost (£)
Incremental 
QALYs
Total cost (£) Total QALYs
CET + BSC BSC CET + BSC BSC
Merck Serono base case 47,095 14,256 0.303 21,836 7580 0.662 0.359
PenTAG corrected base casea 48,238 14,256 0.296 21,836 7580 0.662 0.367
Drug administration costs £242; BSC 
costs £917; KRAS test cost £296; 
treated throughout progression-free state
81,922 24,211 0.296 32,601 8390 0.662 0.367
Drug administration costs £242; BSC 
costs £917; KRAS test cost £296; 
treated throughout progression-free 
state; PD utilities 0.693
95,328 24,211 0.254 32,601 8390 0.621 0.367
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PD, progressive disease; PF, progression free.
a See Peninsula Technology Assessment Group corrections for errors: cetuximab.
TABLE 33 Impact of changes in assumption on the base case ICERs reported by Merck Serono: cetuximab plus 
irinotecan vs best supportive care 
ICER (£/
QALY)
Incremental 
cost (£)
Incremental 
QALYs
Total cost (£) Total QALYs
CET + IRIN BSC CET + IRIN BSC
Merck Serono base case 43,887 29,301 0.668 37,248 7947 1.059 0.391
PenTAG corrected base casea 44,429 29,663 0.668 37,571 7909 1.059 0.391
Drug administration costs £306; BSC 
costs £917; KRAS test cost £296; 
treated throughout progression-free 
state
75,015 50,083 0.668 58,857 8774 1.059 0.391
Drug administration costs £306; BSC 
costs £917; KRAS test cost £296; 
treated throughout progression-free 
state; PD utilities 0.693
83,125 50,083 0.603 58,857 8774 0.994 0.391
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PD, progressive disease.
a See Peninsula Technology Assessment Group corrections for errors: cetuximab.
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there were similarities between patient characteristics for those identified to be KRAS WT and 
those KRAS mutant). Therefore, it would seem more reasonable for Merck Serono to have used 
the adjusted hazard ratios rather than the unadjusted hazard ratios. The adjusted hazard ratios 
from Karapetis and colleagues47 are less favourable to the effectiveness of cetuximab plus best 
supportive care compared with best supportive care (i.e. the adjusted hazard ratio is closer than 
the unadjusted hazard ratio to 1) than Merck Serono suggests in its submission (table 52, Merck 
Serono’s submission69).
De Roock and colleagues48
Although details of the BOND trial49 are presented throughout the submission by Merck Serono, 
the BOND trial only impacts on its submission through De Roock and colleagues.48 De Roock 
and colleagues48 is a retrospective analysis of cetuximab plus best supportive care compared with 
cetuximab plus irinotecan using data from four studies (BOND,49 EVEREST,50,54,55 SALVAGE51 
and BABEL) based at four centres in Belgium, in which KRAS status has been retrospectively 
determined for a selection of patients. Note that the four studies included in De Roock and 
colleagues48 did not distinguish KRAS status; therefore, these studies are not covered in the 
clinical effectiveness systematic review (see Chapter 3) but are briefly described below.
Restricting the De Roock and colleagues48 data to only those patients with KRAS WT status (as 
done by the manufacturer) leads to a rather small sample of 67 patients. A total of 40% of the 
patients (n = 27) in De Roock and colleagues are from the BOND trial (whereas the total number 
of patients in BOND is 329), 42% (n = 28) are from the EVEREST trial, 15% (n = 10) are from the 
SALVAGE trial and 3% (n = 2) are from the from BABEL trial (Table 35).
The BOND trial49 consists of 329 patients randomly assigned to cetuximab plus best supportive 
care (n = 111) or cetuximab plus irinotecan (n = 218), with 80% of those randomised having 
received at least two previous lines of therapy. Importantly, 50% (n = 56) of patients from the 
cetuximab plus best supportive care arm received irinotecan after disease progression; thus, 
there is a great deal of crossover in the BOND trial, which does not appear to have been dealt 
with, or even discussed, by De Roock and colleagues48 or Merck Serono. Ignoring this crossover 
underestimates the overall survival effectiveness of cetuximab plus irinotecan compared with 
cetuximab plus best supportive care.
TABLE 34 Unadjusted and adjusted hazard ratios (95% CIs) from Karapetis and colleagues47
Unadjusted Adjusted for potential prognostic factors
Overall survival 0.55 (0.41 to 0.74) 0.62 (0.44 to 0.87)
Progression-free survival 0.40 (0.30 to 0.54) 0.42 (0.30 to 0.58)
TABLE 35 Kirsten rat sarcoma WT data contributing to De Roock and colleagues48a 
Original study
Treatment arms in 
original study
Total no. (%) of patients 
contributing to De Roock et al.48
No. (%) of patients 
receiving CET + BSC
No. (%) of patients 
receiving CET + IRIN
BOND49 CET + IRIN vs CET + BSC 27 8 19
EVEREST50,54,55 CET + IRIN vs CET + BSC 28 0 28
SALVAGE51 CET + BSC 10 10 0
BABEL Unclear 2 0 2
Total − 67 (100) 18 (27) 49 (73)
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
a Calculated from table 2 in the appendices of De Roock and colleagues.48
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In its submission, Merck Serono categorises the EVEREST trial50,54,55 as relating to second-line 
treatment yet comments that the study is ‘not fully published. It is unclear what proportion of 
patients received the experimental treatment in the second-line compared with the third-line’ 
(p. 42, Merck Serono’s submission69). Although EVEREST is described as a RCT comparing 
cetuximab plus irinotecan, escalating doses of cetuximab plus irinotecan and cetuximab plus 
best supportive care, it is surprising that only data from cetuximab plus irinotecan patients are 
included in De Roock and colleagues (see Table 35).
The SALVAGE study,51 although representing only 15% of patients in De Roock and colleagues,48 
is not mentioned in the manufacturer’s submission. Our investigations indicate that this is a 
non-comparative study of patients receiving cetuximab plus best supportive care only who have 
received at least two previous lines of therapy. The BABEL study also appears to be a single-arm 
study, although further details have been difficult to find.
More generally, De Roock and colleagues comment that patients were included on the basis of 
availability of formalin-fixed paraffin-embedded tumour tissue; however, there are no details 
on what this percentage was for each of the four studies contributing patient data. In addition 
to this, there are uncertainties as to the inclusion of some patients and the exclusion of others. 
For instance, EVEREST is a three-arm trial [cetuximab plus irinotecan, cetuximab (escalating) 
plus irinotecan and cetuximab plus best supportive care] but only data from patients receiving 
cetuximab plus irinotecan have been included and it is unclear if this is from the escalating or 
non-escalating cetuximab plus irinotecan arm. Given these issues, there are concerns that the 
disease progression and effectiveness estimates calculated using De Roock and colleagues are 
likely to be subject to high levels of bias and confounding. This is in addition to the possibility 
of chance findings given that only 18 patients with KRAS WT status contribute to the cetuximab 
plus best supportive care arm of De Roock and colleagues.48
The manufacturer used data from the Kaplan–Meier curves reported in De Roock and 
colleagues48 to calculate hazard ratios for progression-free survival and overall survival for 
cetuximab plus irinotecan compared with cetuximab plus best supportive care. As described in 
the next section, Merck Serono used data from De Roock and colleagues83 in the calculation of 
the indirect hazard ratios. This study is a non-comparative data set consisting of 773 cetuximab 
plus irinotecan-treated patients from 11 European centres. In total, 87% of patients had two or 
more previous lines of therapy, with 58% of patients (n = 448) found to have KRAS WT status. 
Note that De Roock and colleagues83 point out that progression-free survival and overall survival 
are not appropriate outcomes given the differences in the studies.
Indirect comparison: cetuximab
Merck Serono uses the Bucher method34 to calculate indirect comparisons for progression-free 
survival and overall survival hazard ratios (see Figure 3 for comparison network). There are a 
number of concerns with the method employed by Merck Serono to calculate the indirect hazard 
ratios: (1) randomised and non-randomised evidence is combined, (2) no assessment is made of 
the similarities/appropriateness for comparison between the patient populations of the studies, 
(3) the indirect hazard ratio for overall survival is adjusted using De Roock and colleagues,83 
(4) unadjusted hazard ratios from CO.1747 are used and (5) there is no accounting for crossover 
in De Roock and colleagues48 (i.e. BOND49).
With respect to the first concern, in the indirect comparisons, because of limitations in the 
available evidence, data from a RCT47 and a non-RCT48 have been combined without considering 
the fact that different study designs are being used. These different study designs are subject to 
different sources of bias and confounding; in particular, we have serious concerns over the use 
of De Roock and colleagues.48 It is difficult to ascertain what impact the synthesis of randomised 
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and non-randomised data may have on the subsequent hazard ratio estimates. Related to this 
is the second point, that Merck Serono makes no assessment of the patient populations from 
the different studies involved in the indirect comparison. In any form of evidence synthesis, 
there should be some consideration of whether or not the populations and interventions are 
comparable across studies. Although Merck Serono reports the baseline characteristics for 
CO.1747 and for De Roock and colleagues,48 it does not explicitly evaluate the appropriateness of 
combining these studies. A quick assessment of the baseline characteristics suggests that patients 
in De Roock and colleagues are slightly younger and more likely to have had fewer lines of 
therapy than those in the CO.17 study (Table 36).47 It is unclear what impact this may have on the 
results of the indirect comparison.
The third concern with the indirect comparison is specific to the calculation of the overall 
survival hazard ratio for cetuximab plus irinotecan compared with best supportive care. The 
manufacturer uses data from De Roock and colleagues48 and CO.1747 for this comparison (see 
table 46, Merck Serono’s submission69). After calculating the hazard ratio using the Bucher 
approach, plots of the observed Kaplan–Meier curves and fitted parametric curves for this 
comparison are shown (see figure 29, Merck Serono’s submission69), but Merck Serono states 
that advice from clinical experts indicated that the modelled curves were not a good fit. As a 
consequence, the manufacturer uses data from the non-comparative study by De Roock and 
colleagues83 to adjust the hazard ratio obtained from the indirect comparison from 0.29 (95% CI 
0.14 to 0.59) to 0.32 (95% CI 0.14 to 0.59). It is unclear why model fit was determined by clinical 
experts as the submission suggests rather than by statistical methods. There is no explanation 
from Merck Serono as to how exactly this adjustment was made, regardless of the fact that De 
Roock and colleagues83 is a non-comparative study. Given that, as stated in the previous section, 
De Roock and colleagues83 themselves state that progression-free survival and overall survival 
are not the best outcomes to assess given the differences in the studies, there are further issues of 
bias and confounding associated with the indirect estimates obtained by the manufacturer for the 
overall survival hazard ratio for cetuximab plus irinotecan compared with best supportive care.
The adjustment made to the indirect hazard ratio using data from De Roock and colleagues83 is 
less favourable to cetuximab plus irinotecan than the initial indirect comparison results (from 
a hazard ratio of 0.29 to 0.32). {Interestingly, a similar estimate of hazard ratio to that using the 
TABLE 36 Baseline characteristics of patients with KRAS WT status in the studies used by Merck Serono
Characteristic
CET + BSC vs 
BSC47
CET + IRIN vs 
CET + BSC48
Male (%) 67.8 58.1
Age (years),  
median (range)
63.5 (28.6–85.9) 61 (22–86)
ECOG status (%)
0 24.3 −
1 55.2 −
2 20.4 −
Number of lines of previous therapy (%)
≤ 2 20.0 62.2
3 37.4 24.0
4 27.4 9.2
≥ 5 15.2 3.6
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
NIHR Journals Library
66 Assessment of industry submissions to the National Institute for Health and Clinical Excellence
data from De Roock and colleagues83 is obtained if the adjusted hazard ratio from CO.1747 is 
used in this indirect comparison instead of the unadjusted hazard ratio [0.33, 95% CI 0.16 to 
0.68] [as discussed in Effectiveness evidence: cetuximab, Karapetis and colleagues (CO.17)47].} 
After adjustment of the hazard ratio using data from De Roock and colleagues,83 Merck Serono 
assumes the same 95% CI for the hazard ratio adjusted by the data from De Roock and colleagues 
as that from the initial indirect comparison. This will lead to more favourable estimates for 
cetuximab in the probabilistic sensitivity analysis even though the mean value is slightly different. 
It is very unusual to externally adjust an indirect comparison as Merck Serono has reported for 
the overall survival of cetuximab plus irinotecan compared with best supportive care. Within 
the other indirect comparisons reported by Merck Serono there is no indication that such 
an assessment of the Kaplan–Meier curves using clinical experts was undertaken. Although 
this adjustment leads to a less favourable estimate for cetuximab plus irinotecan, it is unclear 
whether or not the manufacturers went through a similar process including experts for the other 
calculations and outcomes.
The fourth concern is that already expressed in Effectiveness evidence: cetuximab, Karapetis and 
colleagues (CO.17)47, that unadjusted hazard ratios from CO.1747 were used by the manufacturer 
in the indirect comparison when adjusted hazard ratios would have been more appropriate. 
Consequently, this means that the effectiveness of cetuximab in all comparisons is likely to be 
overestimated, particularly for overall survival for which the difference between the adjusted 
hazard ratio and the unadjusted hazard ratio is most pronounced.
The fifth point for concern is that there appears to be no accounting for the crossover in the 
BOND data used in De Roock and colleagues.48 Such crossover during progressive disease will 
underestimate the effectiveness of cetuximab plus irinotecan in terms of overall survival.
Note further that Merck Serono did not investigate uncertainty surrounding the effectiveness 
within its sensitivity analyses.
Modelling progression-free survival and overall survival: cetuximab
Cetuximab plus best supportive care compared with best 
supportive care
Merck Serono uses the individual patient data from Karapetis and colleagues45 to model disease 
progression for cetuximab plus best supportive care and best supportive care: ‘[individual patient 
data] allows the progression-free health state (over time) for cetuximab monotherapy and BSC 
arms (from CO.17 study) to be determined by two processes based on death before progression 
and ‘real progression’ (p. 98, Merck Serono’s submission69). Merck Serono fits four parametric 
functions to the individual patient data: exponential, Weibull, lognormal and log-logistic. The 
Akaike information criterion (AIC) was used to identify the best fitting function. For both time 
to ‘real progression’ and time to ‘death before progression’, a log-logistic function was the best 
fit (although the AIC results for ‘real progression’ are illegible in their report). The parametric 
log-logistic curves have a reasonable fit to the Kaplan–Meier curves (see figure 35, Merck 
Serono’s submission69).
For overall survival, the same four parametric functions are fitted to the cetuximab plus best 
supportive care and best supportive care individual patient data. The Weibull function was found 
to give the best fit according to the AIC and appears to give a reasonable fit to the Kaplan–Meier 
data. Note, however, that 20% and 10% of patients receiving cetuximab plus best supportive care 
and best supportive care, respectively, have not died before the end of the study; therefore, the 
appropriateness of the Weibull function to extrapolate beyond the data cannot be assessed.
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Cetuximab plus irinotecan compared with best supportive care
Merck Serono fits a Weibull curve to the progression-free survival and overall survival individual 
patient data for the best supportive care arm of the study by Karapetis and colleagues.47 Using the 
indirect progression-free survival and overall survival hazard ratios for cetuximab plus irinotecan 
compared with best supportive care calculated as described and critiqued in Indirect comparison: 
cetuximab, Merck Serono assumes proportional hazards and uses the following equation to 
calculate the corresponding Weibull function for progression-free survival and overall survival 
in the cetuximab plus irinotecan arm: S(t) = exp(–(λHR)tγ), where S(t) is the survival function 
at time t, HR is the indirect hazard ratio for cetuximab plus irinotecan compared with best 
supportive care, and λ and γ are the parameters of the Weibull distribution.
Merck Serono presents the Kaplan–Meier curves of the best supportive care arm from Karapetis 
and colleagues45 and the cetuximab plus irinotecan arm from De Roock and colleagues48 
alongside the Weibull fitted curves. Because the indirect hazard ratio has been used for the 
cetuximab plus irinotecan Weibull fit, one would not necessarily expect a good fit to the 
Kaplan–Meier curve from De Roock and colleagues.48 Nevertheless, the parametric curve 
seems to fit reasonably well to the Kaplan–Meier curve for both progression-free survival and 
overall survival. There is no explanation as to why a Weibull curve was used to model the best 
supportive care progression-free survival and overall survival data and no statistical assessment 
of the goodness of fit of this curve (e.g. using the AIC). Presumably, a Weibull model was used 
for simplicity to allow calculation of the cetuximab plus irinotecan curve using the indirect 
hazard ratio. Given the lack of direct evidence for cetuximab plus irinotecan compared with best 
supportive care, Merck Serono has taken a reasonable approach to calculate the fitted curves for 
progression-free survival and overall survival in the cetuximab plus irinotecan arm, but we still 
have concerns regarding the use of data from De Roock and colleagues48 and the ‘adjustment’ to 
the indirect overall survival hazard ratio using data from De Roock and colleagues83 (see Indirect 
comparison: cetuximab). Note that the Weibull curve does not appear to be a particularly good fit 
to the best supportive care progression-free survival Kaplan–Meier data; however, this is likely to 
lead to an underestimate of the progression-free survival in the best supportive care arm and can 
therefore be considered conservative. The Weibull fit to the best supportive care overall survival 
data, however, appears to be reasonable.
Finally, note that Merck’s log-logistic modelling of ‘real progression’ and ‘death before 
progression’ in the best supportive care arm for the cetuximab plus best supportive care 
compared with best supportive care comparison and Weibull parametric modelling of 
progression-free survival in the best supportive care arm for cetuximab plus irinotecan compared 
with best supportive care are the source of the difference in the best supportive care arm 
depending on the comparator (see The decision problem: cetuximab)
Adverse events: cetuximab
Merck Serono includes in the model the costs associated with treatment for grade 3 or 4 adverse 
events (Table 37). The manufacturer assumes that the utilities used in the model reflect the 
impact of any adverse events experienced, and so does not calculate disutilities for adverse 
events. As Merck Serono’s results suggest, the cost of the adverse events has very little impact 
on the ICERs. Yet for completeness, we report the assessment of the costing and inclusion of 
adverse events in the Merck model having identified a number of points worth highlighting. 
The adverse event data used by Merck Serono are taken from the subset of patients with KRAS 
WT status and an ECOG performance status of 0 or 1 from the CO.17 study.47 Merck Serono 
assumes that all grade 1 or 2 adverse events are minor and do not require treatment; therefore, 
they are not associated with any costs. Grade 3/4 adverse events reported in CO.17 are divided 
into three categories: non-serious (requiring outpatient treatment only), serious but not leading 
to hospitalisation, and serious leading to, or prolonging, hospitalisation.
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Merck Serono has calculated the cost of adverse events by assigning each type of adverse event 
experience in CO.17 (non-serious, serious but not requiring hospitalisation, serious requiring 
hospitalisation) to a body type/system. For the non-serious and serious but not requiring 
hospitalisation adverse events, the corresponding body type/system is matched to appropriate 
Healthcare Resource Group (HRG) codes and a mean cost (from the NHS reference costs 
2008–200977) is assigned to the body type/system adverse event. The average cost per body 
type/system ranges from £106 for ocular adverse events to £259 for infection and influenza-
like symptom adverse events. Note that the adverse events from the best supportive care and 
cetuximab plus best supportive care arms are combined to obtain a cost per non-serious or 
serious but not requiring hospitalisation adverse event across treatment arms. For serious adverse 
events requiring hospitalisation, the adverse events were also assigned to a body type/system but 
were allocated inpatient procedure costs based on the HRG codes. Note that the adverse events 
are assigned to body type/system not reported by the actual adverse event experienced.
Based on the CO.17 data analysed by Merck Serono, the cost of a non-serious adverse event is 
slightly higher than that of a serious adverse event not requiring hospitalisation (£175 compared 
with £165). There is a greater percentage of serious adverse events requiring hospitalisation 
(the adverse event associated with the most costs) in the best supportive care arm than in the 
cetuximab plus best supportive care arm: 32% of adverse events in the cetuximab plus best 
supportive care arm require hospitalisation compared with 40% in the best supportive care arm. 
Both of these findings appear unintuitive.
Merck Serono assumes the same proportion of different types of adverse events for cetuximab 
plus irinotecan as its analysis suggests for cetuximab plus best supportive care; however, given 
that irinotecan is known to have significant toxicities, the assumption made by Merck Serono 
is likely to underestimate the costs of adverse events associated with cetuximab plus irinotecan. 
Given the lack of available evidence it is difficult to quantify what the level of adverse events 
should be for cetuximab plus irinotecan. Nevertheless, we have no better evidence for the adverse 
events associated with best supportive care, cetuximab plus best supportive care or cetuximab 
plus irinotecan.
Summary of cost-effectiveness
Cetuximab monotherapy
We have major concerns over a number of Merck Serono’s important assumptions including 
the adjustment for modelling mean time on cetuximab plus best supportive care, the utilities 
used and the costs associated with best supportive care. Simultaneously modelling alternative 
TABLE 37 The number and costs of adverse events used in the Merck Serono submission
CET + BSC CET + IRIN BSC (in CET + BSC) BSC (in CET + IRIN)
No. (%) of non-serious adverse events 245 (63) 245 (63) 129 (58) 129 (58)
No. (%) of serious (no hospitalisation) adverse events 21 (5) 21 (5) 7 (3) 7 (3)
No. (%) of serious (hospitalised) adverse events 126 (32) 126 (32) 88 (40) 88 (40)
Total no. (%) of adverse events 392 (100) 392 (100) 224 (100) 224 (100)
Total no. of patients 97 97 87 87
Cost of non-serious adverse event (£) 174 174 174 200a
Cost of serious (no hospitalisation) adverse event (£) 165 165 165 165
Cost of serious (hospitalised) adverse event (£) 2460 2460 2460 2460
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan.
a Reported to be £174 in Merck’s report (this has been corrected for in PenTAG’s reanalysis of the base-case ICERs (see PenTAG corrections for 
errors: cetuximab).
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assumptions for these concerns leads to an ICER of £82,000–95,000 per QALY gained for 
cetuximab plus best supportive care compared with best supportive care.
Cetuximab combined therapy
We have major concerns over a number of important assumptions including the adjustment 
that Merck Serono makes for modelling mean time on treatment, the utilities used, the costs 
associated with best supportive care and the effectiveness data for cetuximab plus irinotecan. 
Simultaneously modelling alternative assumptions for these concerns leads to an ICER of 
£75,000–83,000 per QALY gained for cetuximab plus irinotecan compared with best supportive 
care. However, there is a great deal of uncertainty regarding the impact of the questionable 
effectiveness data from De Roock and colleagues48 on which the cetuximab plus irinotecan arm is 
modelled; thus, we have very little confidence in the ICER estimated by Merck for cetuximab plus 
irinotecan compared with best supportive care.
Industry submission critique 2: Roche, bevacizumab
Roche did not submit a decision model for the cost-effectiveness of bevacizumab in combination 
with non-oxaliplatin chemotherapy for the treatment of metastatic colorectal cancer after first-
line therapy. Instead, it presents some cost calculations for bevacizumab plus FOLFIRI compared 
with cetuximab plus FOLFIRI. Below we critique the effectiveness evidence submitted by Roche 
and its basic cost calculations.
Effectiveness evidence: bevacizumab
Although there is no clinical evidence for the effectiveness of bevacizumab with non-oxaliplatin 
therapy after first-line treatment in metastatic colorectal cancer, the main focus of Roche’s 
argument for the effectiveness of bevacizumab in this setting is that there is evidence for 
the effectiveness of bevacizumab in first-line treatment and for second-line treatment in 
combination with oxaliplatin. From this, Roche argues that the benefits of bevacizumab in 
addition to chemotherapy are therefore not dependent on regimen or line of therapy, suggesting 
that there is no reason to expect that bevacizumab plus non-oxaliplatin therapy after first-line 
treatment would not provide added benefits. This argument was adequate for the EMA to grant 
marketing authorisation for bevacizumab with non-oxaliplatin therapy after first-line treatment 
in metastatic colorectal cancer; however, this does not make a case for the cost-effectiveness of 
bevacizumab in the scope of this review.
Roche reports three trials relevant to the consideration of bevacizumab for first-line use in 
patients with metastatic colorectal cancer: the 966 study by Saltz and colleagues40 for oxaliplatin 
combined therapy, Hurwitz and colleagues26 for irinotecan combined therapy and Kabbinavar 
and colleagues27 for 5-FU/FA combined therapy. For second-line combined treatment, Roche 
refers to the E3200 study by Giantonio and colleagues41 for bevacizumab with oxaliplatin therapy.
Saltz and colleagues40 conducted a 2 × 2 factorial design RCT and randomised 1401 patients, 
75% of whom had not previously received chemotherapy. Treatment arms were XELOX plus 
bevacizumab, XELOX plus placebo, FOLFOX-4 plus bevacizumab or FOLFOX-4 plus placebo. 
In ITT analyses, patients receiving XELOX plus bevacizumab or FOLFOX-4 plus bevacizumab 
were pooled, as were those receiving XELOX plus placebo or FOFLOX-4 plus placebo, as no 
statistically significant treatment difference was identified between XELOX and FOLFOX-4. 
The hazard ratio for progression-free survival for bevacizumab compared with placebo was 0.83 
(97.5% CI 0.72 to 0.95), with median progression-free survival of 9.4 months for bevacizumab 
and 8 months for placebo. The hazard ratio for overall survival for bevacizumab compared with 
placebo was not statistically significant (hazard ratio 0.89, 97.5% CI 0.76 to 1.03), with a median 
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overall survival for bevacizumab of 21.3 months compared with 19.9 months in the placebo arm. 
Saltz and colleagues40 report that 30% of patients in the bevacizumab arm discontinued treatment 
because of adverse events compared with 21% in the placebo arm. Furthermore, they note that 
the percentage of patients receiving treatment until progression (as defined in the protocol) was 
particularly low: 29% of the bevacizumab arm and 47% of the placebo arm.
Hurwitz and colleagues26 randomised 813 patients from the USA, Australia and New Zealand 
to either irinotecan with FU/LV plus bevacizumab or irinotecan with FU/LV alone for first-line 
treatment (28% of irinotecan with FU/LV patients and 24% of irinotecan with FU/LV plus 
bevacizumab patients had previously received adjuvant chemotherapy). ITT analyses showed that 
median survival was 20.3 months for those treated with irinotecan with FU/LV plus bevacizumab 
and 15.6 months for those receiving irinotecan with FU/LV alone (hazard ratio 0.6, p < 0.001). 
The hazard ratio for progression-free survival was 0.54 (p < 0.001), with patients treated with 
irinotecan with FU/LV plus bevacizumab having a progression-free survival of 10.6 months 
compared with 6.2 months for patients in the irinotecan with FU/LV arm. The authors report 
statistically significantly more grade 3 or 4 adverse events in the irinotecan with FU/LV plus 
bevacizumab arm than in the irinotecan with FU/LV arm (p < 0.01), mainly explained by 
differences in hypertension rates between the arms.
Kabbinavar and colleagues27 randomised 209 patients to FU/LV plus bevacizumab or FU/LV only. 
Twenty-one percent of the FU/LV plus bevacizumab patients and 19% of the FU/LV patients 
had previous adjuvant chemotherapy. The primary end point of overall survival was associated 
with a hazard ratio of 0.76 (95% CI 0.56 to 1.10) for FU/LV plus bevacizumab compared with 
FU/LV, with a median overall survival of 16.6 months in the FU/LV plus bevacizumab arm and 
12.9 months in the FU/LV arm. Progression-free survival, however, was statistically significantly 
longer in the FU/LV plus bevacizumab arm (9.2 months) than in the FU/LV arm (5.5 months) 
(hazard ratio 0.5, 95% CI 0.34 to 0.73). Treatment with FU/LV plus bevacizumab was associated 
with a greater incidence of grade 3 or 4 adverse events than treatment with FU/LV (87% for FU/
LV plus bevacizumab vs 71% for FU/LV). The authors argue that the large number of patients 
receiving postprogression treatment could partly explain the lack of statistical significance in the 
primary end point of overall survival. A similar percentage of patients from both treatment arms 
received irinotecan, oxaliplatin or both post progression (39% of the FU/LV plus bevacizumab 
patients and 46% of the FU/LV patients).
Giantonio and colleagues41 report the ITT analyses of a RCT with 820 patients previously 
treated with fluoropyrimidine and irinotecan randomised to one of three arms: FOLFOX-4 plus 
bevacizumab, FOLFOX-4 or bevacizumab alone. Median overall survival was greater in the 
FOLFOX-4 plus bevacizumab arm: 12.9 months compared with 10.8 months for FOLFOX-4 
and 10.2 months for bevacizumab alone. The hazard ratio for overall survival associated 
with FOLFOX-4 plus bevacizumab compared with FOLFOX-4 was 0.75 (p = 0.01). Median 
progression-free survival was also greater in the FOLFOX-4 plus bevacizumab arm: 7.3 months 
compared with 4.7 months for FOLFOX-4 and just 2.7 months for bevacizumab alone. A greater 
number of grade 3/4 adverse events were reported in the FOLFOX-4 plus bevacizumab arm 
(75%) than in the FOLFOX-4 arm (61%).
As Roche points out in its submission, these four trials suggest that bevacizumab in combination 
with therapies is associated with benefit for progression-free survival and overall survival, which 
is statistically significant for progression-free survival in all four trials. None of these trials is 
included in our systematic review of clinical effectiveness in Chapter 3 as they do not meet the 
inclusion criteria for this review.
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The decision problem: bevacizumab
The manufacturer argues that, because of the lack of clinical evidence on the effectiveness of 
bevacizumab after first-line therapy, a decision model comparing bevacizumab plus FOLFIRI 
with FOLFIRI ‘would be subject to sizeable uncertainty’ (p. 8, Roche’s submission70). Therefore, 
no economic evaluation or cost calculations for bevacizumab plus FOLFIRI compared with 
FOLFIRI are presented by the manufacturer. In comparison with cetuximab, Roche argues 
that bevacizumab is likely to be less expensive given the purchase prices of each drug. 
The manufacturer does, however, provide very basic cost calculations for a comparison of 
bevacizumab plus FOLFIRI with cetuximab plus FOLFIRI in patients who have failed one 
previous line of therapy, and these are critiqued in the sections below. Note that even though 
Roche states that there is considerable uncertainty over the bevacizumab plus FOLFIRI compared 
with cetuximab plus FOLFIRI comparison, cost calculations are still presented; it is reasonable to 
query why such basic cost calculations were not performed for the bevacizumab plus FOLFIRI 
compared with FOLFIRI comparisons with the same caveat of ‘sizeable uncertainty’.
Costs: bevacizumab
Roche focuses on the incremental cost differences between bevacizumab plus FOLFIRI and 
cetuximab plus FOLFIRI over a seven-cycle (14-week) treatment regime. Roche accounts for 
differences in KRAS testing and drug acquisition and administration costs between bevacizumab 
plus FOLFIRI and cetuximab plus FOLFIRI. Roche uses the ‘guaranteed NHS cost’ for cetuximab 
as reported in the submission from Merck Serono.69 Roche assumes a cost of £462 for KRAS 
testing associated with each KRAS WT patient as in TA176.17 This cost is defined to account for 
the costs of all KRAS testing including patients who are KRAS mutant (who would not go on 
to receive cetuximab treatment). However, Roche’s assumption for KRAS test costs may be too 
high as it is based on a KRAS test cost of £300. Data indicate that the test cost is £160;80 thus, the 
cost for testing for KRAS, accounting for those identified as KRAS mutant (54%), is likely to be 
around £296 (as discussed in KRAS testing costs: cetuximab).
The drug preparation and administration costs assumed by Roche include an additional hospital 
visit for cetuximab plus FOLFIRI per cycle for administration at £218 per visit (from NHS 
reference costs 2008–9, SB15Z77). However, this value is actually reported as £227 in NHS reference 
costs 2008–2009.77 This is based on the assumption that bevacizumab plus FOLFIRI requires one 
administration per 2-week cycle, whereas cetuximab plus FOLFIRI requires two administrations 
per 2-week cycle. Similarly, an additional pharmacy preparation cost of £9 (12 minutes of 
pharmacy time) per cycle is assumed for cetuximab plus FOLFIRI. Thus, Roche assumes an 
incremental cost per cycle for drug preparation and administration associated with cetuximab 
plus FOLFIRI of £227 when in fact this value should be £236 if the £9 pharmacy cost is assumed. 
Data given to PenTAG on pharmacy preparations suggest that pharmacy costs are £15 (see 
Appendix 12). The impact of changing the preparation and administration costs from £227 to 
£242 (£227 + £15) is assessed below.
To calculate the dose of bevacizumab required per administration Roche assumes a mean weight 
of 75 kg, referencing TA118,16 and to calculate the of dose of cetuximab required it assumes a 
mean body surface area of 1.75 m2 (although this estimate of body surface area is not referenced). 
Using the body surface area-to-weight calculations used by Merck Serono in its submission 
(p. 112, Merck Serono’s submission69), it is assumed that a weight of 75 kg is equivalent to 
a body surface area of 1.91 m2. Therefore, Roche’s estimate of cetuximab dose required per 
administration could be an underestimate if we are to accept the equations used by Merck. The 
impact of this is assessed below.
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The total incremental cost of cetuximab plus FOLFIRI over bevacizumab plus FOLFIRI 
calculated and reported by Roche is therefore £5408 (KRAS testing costs of £462 plus drug costs 
of £3357 plus administration costs of £1589).
Threshold analysis assumptions and results: bevacizumab
To undertake threshold analyses on the incremental costs for bevacizumab plus FOLFIRI 
compared with cetuximab plus FOLFIRI, Roche assumes a utility of 0.6 for progressive disease. 
This is taken from TA11816 and does not appear to be based on any evidence. The threshold 
analyses reported by Roche using this utility value indicate that cetuximab plus FOLFIRI would 
have to provide a survival advantage of 3.6 months over bevacizumab plus FOLFIRI to be 
considered cost-effective at a willingness to pay of £30,000 per QALY gained.
Adjusting the drug preparation, administration and KRAS test costs and body surface area 
estimates for cetuximab plus FOLFIRI has no impact on the estimated survival advantage of 
3.6 months required by cetuximab plus FOLFIRI to be considered cost-effective compared 
with bevacizumab plus FOLFIRI at a willingness to pay of £30,000 per QALY gained. Note that 
the progressive disease utility of 0.6 is lower than that used by Merck Serono for either best 
supportive care or active treatment. If a utility of 0.693 is assumed in addition to the updated 
KRAS testing and administration costs and body surface area, a survival advantage of 3.2 months 
would be required.
Summary of cost calculations: bevacizumab
As Roche states, these are very basic cost calculations and, given the lack of effectiveness evidence 
for bevacizumab plus FOLFIRI, they do not really help with the decision-making. Only KRAS 
test, drug acquisition and administration costs associated with a seven-cycle treatment regimen 
are accounted for. Roche assumes that no patients (either those receiving cetuximab plus 
FOLFIRI or those receiving bevacizumab plus FOLFIRI) progress or die within that 14-week 
(seven-cycle) period. Furthermore, by assuming a utility for progressive disease in the threshold 
analysis, Roche is implicitly assuming that time progression free is the same for bevacizumab plus 
FOLFIRI as for cetuximab plus FOLFIRI. The differential cost of treating adverse events between 
cetuximab plus FOLFIRI and bevacizumab plus FOLFIRI is not considered. Given the lack of 
evidence for adverse events associated with bevacizumab plus FOLFIRI, it is difficult to state what 
impact they may have on the cost calculations, but it is likely to be slight.
Roche conducted a comparison only of bevacizumab plus FOLFIRI with cetuximab plus 
FOLFIRI, but another appropriate comparison would be between bevacizumab plus FOLFIRI 
and cetuximab plus best supportive care. This can be crudely estimated by subtracting the 
costs of irinotecan from the cetuximab plus FOLFIRI costs calculated by Roche. We assume, 
as assumed by Merck, that irinotecan is administered every 2 weeks at a dose of 180 mg/m2, 
and that the mean body surface area is 1.75 m2 as Roche assumes. At a cost of £1.23 per mg of 
irinotecan (from Merck Serono) and assuming wastage, the cost of one cycle of irinotecan is 
£385. Over seven cycles this gives a cost of £2695. Thus, the incremental cost of cetuximab plus 
FOLFIRI is adjusted by subtracting £2695 from £5408 to roughly estimate the incremental cost 
of cetuximab monotherapy compared with bevacizumab plus FOLFIRI (£2713). Assuming this 
incremental cost and a willingness-to-pay threshold of £30,000 per QALY leads to the estimation 
of incremental QALYs of 0.09. Assuming a progressive disease utility of 0.6 leads to cetuximab 
monotherapy requiring an additional 1.8 months of survival over bevacizumab plus FOLFIRI. As 
with the threshold analysis undertaken by Roche, this is a very basic calculation that considers 
only the costs of the first 14 weeks of treatment, and it is difficult to evaluate the likelihood of the 
finding that cetuximab would need 1.8 months of survival over bevacizumab plus FOLFIRI to be 
considered cost-effective at a willingness to pay of £30,000 per QALY gained.
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Industry submission critique 3: Amgen, panitumumab
Amgen did not submit an economic model for this appraisal and does not argue that 
panitumumab could be a cost-effective treatment option for patients with KRAS WT status after 
first-line treatment in metastatic colorectal cancer. Its submission consists of an analysis of the 
only RCT of panitumumab after first-line treatment in which KRAS status is known, that by 
Amado and colleagues.32 Here, we critique Amgen’s analysis of this trial data, in particular its 
adjustment for the large proportion of patients who crossed over from best supportive care to 
panitumumab plus best supportive care at disease progression.
Effectiveness evidence: panitumumab
An important feature in Amado and colleagues32 is that 76% of patients randomised to best 
supportive care received panitumumab plus best supportive care once they had progressed. Thus, 
estimates of overall survival are confounded by this crossover, and no effect of panitumumab 
plus best supportive care over best supportive care was found. The manufacturer has made 
adjustments to the calculation of overall survival to account for this crossover. As it notes, there 
are a number of techniques available for adjusting for crossover, but, given the specific nature of 
the relationship between the effectiveness of panitumumab plus best supportive care and KRAS 
status, Amgen uses a simple method for adjustment.
Amgen estimates overall survival for patients with KRAS WT status in the best supportive care 
treatment arm adjusted for crossover as equal to that for patients with KRAS mutant status in 
the best supportive care treatment arm, regardless of whether or not patients crossed over at 
progression (Table 38).
In coming to this approach, Amgen argues that including all patients as they were randomised 
(i.e. ignoring the fact that many best supportive care patients crossed over to panitumumab 
plus best supportive care at progression) will underestimate the effectiveness of panitumumab 
plus best supportive care relative to best supportive care in terms of overall survival. Similarly, it 
argues that censoring all patients who crossed over from best supportive care to panitumumab 
plus best supportive care at progression would overestimate the effectiveness of panitumumab 
plus best supportive care, because patients who crossed over were generally fitter with a better 
prognosis than those patients who did not cross over. It further argues that just censoring those 
who crossed over and achieved stable disease or a complete or partial response would also 
lead to an overestimate of the effectiveness of panitumumab plus best supportive care, for the 
same reason.
The approach used by Amgen depends on two main assumptions. First, to be able to include 
KRAS mutant patients randomised to the best supportive care arm as a substitute for KRAS 
WT patients in the best supportive care arm, even though they may have crossed over to 
panitumumab plus best supportive care at progression, it must be assumed that panitumumab 
plus best supportive care is not effective for patients with KRAS mutant status. Second, to use 
only patients with KRAS mutant status randomised to best supportive care (see Table 38), it must 
be assumed that survival in patients with KRAS mutant status assigned to best supportive care is 
TABLE 38 Patient populations used by Amgen to adjust for crossover in calculations of overall survival
BSC Panitumumab arm
KRAS mutant patients randomised to receive BSC (n = 100) KRAS WT patients randomised to receive panitumumab (n = 124)
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similar to survival in patients with KRAS WT status assigned to best supportive care (had these 
patients with KRAS WT status not crossed over to receive panitumumab).
The first assumption is based on the retrospective analysis of effectiveness by KRAS status by 
Amado and colleagues.32 As reviewed in Chapter 3, Panitumumab plus best supportive care 
compared with best supportive care, the evidence indicates that this is a fair assumption, that is, 
that panitumumab plus best supportive care is not effective for patients with KRAS mutant status.
The second assumption is also based on data from Amado and colleagues32 and involves an 
additional important assumption that similarities in progression-free survival between patients 
with KRAS mutant and KRAS WT status randomised to best supportive care can predict 
similarities in overall survival between these two groups of patients. Amgen states that there are 
few differences between the Kaplan–Meier curves for progression-free survival for patients with 
KRAS mutant and those with KRAS WT status randomised to best supportive care.
We agree that there is very little difference between the two curves; in fact, Amgen reports 
that mean progression-free survival is 71 days for patients who are KRAS mutant and 64 days 
for those who are KRAS WT. Thus, if anything, its assumption for the survival benefit of 
panitumumab plus best supportive care may be biased against panitumumab plus best supportive 
care. In further analyses, Amgen compares baseline characteristics across the four groups 
(treatment × KRAS status) to identify any statistically significant differences between the groups. 
Amgen then carries out Cox regression on three groups of patients [(1) all patients, (2) patients 
with KRAS mutant status and (3) patients with KRAS mutant status receiving best supportive 
care and patients with KRAS WT status receiving panitumumab plus best supportive care] to 
determine whether or not any of the baseline variables are statistically significant predictors 
of survival. In doing this, Amgen is evaluating whether or not any differences in the survival 
between the KRAS mutant best supportive care arm and the KRAS WT panitumumab plus best 
supportive care arm can be attributed to factors other than treatment.
Amgen appears to have taken a reasonable approach to this evaluation of characteristics; 
however, its focus on the 5% level of statistical significance does not help to fully assess whether 
or not any variables important to predicting time to death are different across the groups. For 
instance, there may be important factors that Amgen has not included because they were found 
to have a p-value above the p = 0.05 cut-off used (i.e. p = 0.051).
The additional point that the similarity in progression-free survival in patients with KRAS 
mutant status receiving best supportive care and in patients with KRAS WT status receiving best 
supportive care translates to a similarity in overall survival is difficult to assess given the limited 
data available. However, there is evidence that could shed some light on this. In an evaluation of 
the impact of KRAS status on response to bevacizumab for metastatic colorectal cancer, Ince and 
colleagues84 and Hurwitz and colleagues33 reported a greater median overall survival for patients 
with KRAS WT status treated with placebo than for patients with KRAS mutant status (17.6 vs 
13.6 months). Hurwitz and colleagues do not report whether or not any patients randomised 
to best supportive care received bevacizumab; however, as KRAS status has no impact on the 
effectiveness of bevacizumab, these data suggest that in this trial overall survival was not similar 
between KRAS WT and mutant patients. However, neither was progression-free survival similar 
between the KRAS subgroups (7.4 months for patients with KRAS WT status vs 5.5 months for 
patients with KRAS mutant status), plus the sample sizes are small (67 patients with KRAS WT 
status and 34 patients with KRAS mutant status).
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Quality of life data: panitumumab
Amgen summarises the analyses of QoL data from the Van Cutsem and colleagues7 and Amado 
and colleagues32 studies published by Odom and colleagues.56 It is reported that HRQoL, as 
measured by the EQ-5D and NCCN FCSI, was greater for patients receiving panitumumab plus 
best supportive care than for patients receiving best supportive care alone (a mean difference 
of 0.22 on the EQ-5D scale). Furthermore, average estimates from both measures were greater 
than the minimum clinically important differences reported in the published literature. Note that 
Odom and colleagues report that HRQoL was reported only for patients in the progression-free 
survival health state, and that there was a great deal of patient dropout. Amgen reports that the 
analysis suggested that dropout was treatment related, being much higher in patients in the best 
supportive care arm. Note that neither Odom and colleagues56 nor Amgen report the absolute 
EQ-5D utility value for the best supportive care arm or the panitumumab plus best supportive 
care arm, only the mean difference between them (0.22).
Safety data: panitumumab
Amgen reports the number of patients experiencing adverse events from the Van Cutsem 
study,7 in which KRAS status was unknown, and from the retrospective analysis by Amado 
and colleagues,32 in which KRAS status was available for 92% of patients. In total, 100% of 
panitumumab patients in Amado and colleagues32 with KRAS WT status developed an adverse 
event and 90% of best supportive care patients developed an adverse event. Table 39 is taken from 
Amgen’s report detailing the percentages of patients with KRAS WT status and KRAS mutant 
status receiving panitumumab who experienced grade 3 or 4 adverse events or who withdrew 
because of adverse events.
Liver resection: panitumumab
Amgen reports on a Delphi consultation of 15 clinical specialists in the UK on the expected rates 
of liver resection in patients with metastatic colorectal cancer after first-line therapy. It suggests 
that 5–9% of these patients could be expected to undergo liver resection. Amgen summarises 
the results of the Delphi consultation, which include that ‘a majority of the clinical experts 
agreed that treating chemorefractory patients with panitumumab as a single agent may lead 
to downsizing of liver metastases’ (p. 43, Amgen's submission71) and ‘mean survival following 
successful liver resection in a chemorefractory patient on panitumumab was three years; 
estimates of five years and 10 years were expected in 20–24% and 10–14% of patients respectively’ 
(p. 43, Amgen's submission71).
TABLE 39 Adverse events experienced by patients with KRAS WT status receiving panitumumab in Amado et al.32
Adverse event
% developing adverse event
KRAS WT KRAS mutant
Grade 3/4 44 28
Treatment related (grade 3) 25 12
Withdrawal because of adverse event: non-specified 7 5
Withdrawal because of adverse event: panitumumab related 2 1
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Overall summary of industry submissions
The base-case ICERs reported by Merck Serono (£47,000 per QALY gained for cetuximab 
plus best supportive care compared with best supportive care and £44,000 per QALY gained 
for cetuximab plus irinotecan compared with best supportive care) are highly likely to be 
underestimates given the concerns that we have over the estimate of treatment duration and the 
costs assumed for best supportive care, drug administration and KRAS testing. An alternative 
ICER using Merck Serono’s model of £82,000 per QALY gained for cetuximab plus best 
supportive care compared with best supportive care is more likely.
The very basic cost calculations submitted by Roche for bevacizumab plus FOLFIRI compared 
with cetuximab plus FOLFIRI are reasonably robust to alternative drug acquisition, drug 
administration and KRAS test cost estimates, but offer very little information for the 
decision-making process.
Amgen makes no claims for the cost-effectiveness of panitumumab, but its analysis of the 
crossover in the study by Amado and colleagues32 is reasonable, suggesting an overall survival 
advantage of 2.74 or 3.13 months (depending on the method used) for panitumumab plus best 
supportive care compared with best supportive care.
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Chapter 6 
The Peninsula Technology Assessment 
Group’s cost-effectiveness analysis
Independent economic assessment
Scope of the economic evaluation
Our economic evaluation is restricted to patients with KRAS WT status on third-line or further 
lines of treatment for metastatic colorectal cancer for reasons described below. We estimate the 
cost-effectiveness of cetuximab plus best supportive care compared with best supportive care, 
panitumumab plus best supportive care compared with best supportive care and cetuximab plus 
irinotecan compared with best supportive care. We are not able to model cost-effectiveness as 
a function of the line of treatment because we do not have access to the required underlying 
individual patient data from the clinical trials.
The scope of our analysis is reduced relative to the original NICE scope in two respects. First, 
although the NICE scope refers to second-line treatment, we do not model the cost-effectiveness 
of any drugs for second-line treatment because of the lack of relevant clinical data. There is only 
one RCT of any of the assessed drugs for second-line use, the RCT of cetuximab plus irinotecan 
compared with irinotecan (EPIC trial);74 however, the clinical results are not stratified according 
to KRAS status. In addition, we note that Merck Serono does not model the cost-effectiveness 
of cetuximab plus best supportive care or cetuximab plus irinotecan for second-line treatment 
and that there appears to be little clinical demand for second-line use. Second, because of the 
lack of clinical evidence, we did not model treatment with bevacizumab in combination with 
chemotherapy not containing oxaliplatin for those on second or subsequent lines of treatment. 
Both of these issues were agreed with NICE during the preparation of this report.
The following section describes the structure of our cost-effectiveness model. Subsequent 
sections describe the parameterisation of the model and a comparison of the results of our model 
with those of other relevant models, including that submitted by Merck Serono, the manufacturer 
of cetuximab.
Model structure
The cost-effectiveness model, implemented in Microsoft Excel 2007, simulates a cohort of 
people with KRAS WT metastatic colorectal cancer on third or subsequent lines of treatment. 
The structure of the model was informed by a review of the literature and expert opinion. The 
basic design of the model is simple and has been used previously to simulate the progression of 
metastatic cancers, for example for metastatic renal cell carcinoma.85 There are three health states: 
progression-free survival, progressive disease and death (Figure 5).
In Figure 5, arrows represent the possible transitions between health states. Circular arrows 
denote that patients can remain in a state at the end of each model cycle. During each cycle, a 
patient is assumed to be in one of the states. Patients are assumed to move between states once at 
the end of each cycle.
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Although our model closely resembles a Markov state-transition approach, it differs in that an 
‘area under the curve’/‘cohort partition’ method is used to determine state populations at each 
cycle of the model (rather than using transition probabilities). In this method, the number of 
people in each health state at each successive model cycle is determined by using survival curve 
data to apportion the overall cohort between the states. This approach has been used in previous 
HTAs.85 Using this method, there is no requirement to calculate the probabilities of transition 
between health states (depicted by the arrows in Figure 5) as estimates of populations for each 
health state are derived directly from the survival curves.
Differences in clinical effectiveness between treatments are represented by the differences 
between progression-free survival and overall survival curves (and hence the respective 
populations of each disease state at each successive cycle of the model). Estimates of cost and 
utility per cycle are assigned to the progression-free survival and progressive disease states, and 
these provide an aggregated output over the modelled time horizon for the total costs and utility 
per person for each treatment. The main economic outcome presented is the incremental cost per 
QALY gained.
The model cycle length is 1 month and the model time horizon is 10 years, after which time 
virtually all people in all cohorts have died. A model half-cycle correction is applied.
Future costs and benefits are discounted at 3.5% per annum and the perspective is that of the 
NHS and PSS in accordance with the NICE reference case.72
After treatment with any of the comparator drugs, in common with Merck Serono, we assume no 
further lines of drug treatment.
Sensitivity of the Kirsten rat sarcoma test
We assume that everyone tested as KRAS WT is indeed WT, that is, the sensitivity of the 
KRAS test (to test for KRAS mutant status) in routine clinical practice is 100%. However, if the 
sensitivity of the test used in routine clinical practice is < 100%, some people may be incorrectly 
diagnosed with KRAS WT status. These people will then receive panitumumab plus best 
supportive care or cetuximab plus best supportive care even though they will not benefit from 
these drugs. Therefore, these drugs compared with best supportive care will actually have higher 
costs per QALY than the figures produced from our model. To be more precise, we should 
consider the relative sensitivities of the tests for patients with KRAS mutant status as used in the 
RCTs of panitumumab plus best supportive care and cetuximab plus best supportive care and 
the sensitivity of the test used in the routine testing of patients. If the sensitivities are equal, the 
cost-effectiveness of these drugs will be the same as calculated in our model. If the sensitivities of 
Death
Progression-free Progressive
FIGURE 5 Structure of the PenTAG cost-effectiveness model.
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the tests used in the RCTs are greater than the sensitivity of the test used in routine practice, the 
cost-effectiveness of these drugs will actually be worse than predicted by our model. In this case, 
we should model the clinical effectiveness for those who are assessed as KRAS mutant status from 
the RCTs in addition to that for people assessed as KRAS WT status.
We asked Merck Serono and Amgen for the sensitivity of KRAS tests used in routine practice. 
Amgen replied that the probability of a patient with KRAS mutant status being incorrectly 
diagnosed as KRAS WT ‘using the standard KRAS test assured by appropriate external quality 
assurance’ is 14 in every 10,000 tests, that is, 0.14%.71 In summary, Merck Serono does not 
quantify the probability of incorrectly diagnosing a patient as KRAS WT but instead claims that 
it is ‘slim’. If insufficient tumour sample is available for testing then the test result is reported as 
not available.
Progression-free survival and overall survival
The distribution of progression-free survival and overall survival times across those in:
 ■ the best supportive care treatment group is taken directly from the RCT of cetuximab plus 
best supportive care compared with best supportive care47
 ■ the cetuximab plus best supportive care treatment group is also taken directly from the RCT 
of cetuximab plus best supportive care compared with best supportive care47
 ■ the panitumumab plus best supportive care treatment group is taken from the RCT of 
panitumumab plus best supportive care compared with best supportive care,32 adjusted for 
the indirect comparison with best supportive care and cetuximab plus best supportive care
 ■ the cetuximab plus irinotecan treatment group is taken from a variety of sources and is 
adjusted for the indirect comparison with best supportive care and cetuximab plus best 
supportive care.
Details are given in Evidence to inform model parameters, Overall survival, progression-free 
survival and treatment duration.
Time on treatment
The mean duration of drug treatment is a key determinant of the mean drug acquisition costs 
and therefore of cost-effectiveness. Ideally, we would model the mean duration of drug treatment 
as experienced in the RCTs. This is reported as a mean of 10 treatment cycles for patients with 
KRAS WT status on panitumumab plus best supportive care,32 but is not reported for patients 
with KRAS WT status on cetuximab plus best supportive care or for cetuximab plus irinotecan. 
However, in the pivotal trials of cetuximab plus best supportive care compared with best 
supportive care, panitumumab plus best supportive care compared with best supportive care and 
cetuximab plus irinotecan compared with cetuximab (BOND), all drugs were taken until disease 
progression, the occurrence of intolerable adverse events or death. In the RCT of cetuximab 
plus best supportive care compared with best supportive care,37 treatment with cetuximab was 
additionally stopped because of ‘worsening symptoms of the cancer, or request by the patient’. 
Therefore, we modelled treatment duration by treatment group (Table 40). We have good 
corroborating evidence that it is reasonable to assume that KRAS WT patients randomised to 
cetuximab took the drug until disease progression (see Time on cetuximab treatment).
Details are given in Evidence to inform model parameters, Overall survival, progression-free 
survival and treatment duration.
Postprogression survival
Postprogression survival is calculated as overall survival minus progression-free survival.
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Severe adverse events
We do not model disutilities due to adverse events associated with drug treatment directly. 
Instead, as Merck Serono, we allow for disutilities indirectly in that we use utilities specific to 
each treatment.
We base our estimates of the costs of treating adverse events on those calculated by Merck 
Serono; see Costs of treating adverse events for details.
Evidence to inform model parameters
Overall survival, progression-free survival and treatment duration
Given that there is no single RCT with all treatment groups, it was necessary to perform an 
indirect comparison between some pairs of treatments. For progression-free survival, overall 
survival and time on drug treatment, we chose the baseline treatment for the indirect comparison 
to be best supportive care taken from the RCT of cetuximab plus best supportive care compared 
with best supportive care.47 The clinical effectiveness for those on best supportive care is also 
available from the RCT of panitumumab plus best supportive care compared with best supportive 
care.32 However, this was not considered an appropriate estimate for the baseline treatment 
for best supportive care because the effectiveness in this treatment group was confounded by 
substantial crossover (76% of patients).
Best supportive care
Progression-free survival for best supportive care We have based our estimate of progression-free 
survival for best supportive care on the analysis of the individual patient data by Merck Serono. 
In particular, we have assumed the same mean time in progression-free survival as Merck 
Serono, namely 2.72 months. This is the most important summary statistic of progression-free 
survival given that cost-effectiveness is a function of mean values. We did not use precisely the 
same progression-free survival curve as Merck Serono, because this function is commercial-in-
confidence. We specified that progression-free survival follows a Weibull distribution, as this 
is a flexible function, widely used in cancer survival analysis. We read off the progression-free 
survival probabilities at monthly intervals from the published Kaplan–Meier graphs for patients 
with KRAS WT status.47 We then fitted a Weibull curve to these data by minimising the sums of 
squares of differences between actual and fitted probabilities. We estimated the shape parameter, 
γ, of the Weibull from this fit to the Kaplan–Meier curve. However, note that the shape is not 
important, because cost-effectiveness is almost completely insensitive to it. Instead, it is the mean 
progression-free survival that is critical, which we fix to be the same as that reported by Merck 
Serono. Finally, given that we have specified the mean, this then specifies the scale parameter, λ, 
of the Weibull, given that the mean of the Weibull is:
TABLE 40 Treatment duration: panitumumab plus best supportive care, cetuximab plus best supportive care and 
cetuximab plus irinotecan
Drug Treatment duration modelled Source/rationale
PAN + BSC Mean of 20 weeks (one dose every 
2 weeks; mean of 10 doses)
As reported in Amado et al.32 for patients with KRAS WT status
CET + BSC Until disease progression Assume main reason for stopping treatment is disease progression
Based on median treatment duration in Jonker et al.37 trial being very similar to median 
progression-free survival in this trial (8.1 weeks vs 8.2 weeks) and clinical opinion
CET + IRIN Until disease progression Based on median treatment duration in BOND being very similar to median progression-
free survival (7 weeks vs 6.5 weeks)49
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PAN, panitumumab.
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We estimated the uncertainty in progression-free survival for the probabilistic sensitivity analysis 
purely by modelling the uncertainty in the mean progression-free survival. This is valid given 
that it is the mean progression-free survival that drives cost-effectiveness. First, for simplicity, 
we fixed the shape value, γ, of the Weibull. Next, we specified that the mean progression-free 
survival follows a gamma distribution with a mean of 2.72 months, as above. We then estimated 
the standard error of the mean progression-free survival by making two simplifying assumptions. 
The first was that progression-free survival approximately follows an exponential distribution. 
We can then say that the standard deviation of progression-free survival across patients 
approximately equals the mean progression-free survival, as this is a property of the exponential 
distribution. The second simplifying assumption was that no patients in the best supportive care 
arm in the RCT of cetuximab plus best supportive care compared with best supportive care were 
censored, which is probably approximately true, given that progression occurs quickly. In this 
case, the standard error of the mean progression-free survival equals:
≈ = =
standard deviation of PFS for BSC
no. of patients on BSC in CET + BSC vs BSC RCT
mean PFS for BSC
no. of patients on BSC in CET + BSC vs BSC RCT
2.72
105
0.27 months
≈ = =
standard deviation of PFS for BSC
no. of patients on BSC in CET + BSC vs BSC RCT
mean PFS for BSC
no. of patients on BSC in CET + BSC vs BSC RCT
2.72
105
0.27 months
≈ = =
standard deviation of PFS for BSC
no. of patients on BSC in CET + BSC vs BSC RCT
mean PFS for BSC
no. of patients on BSC in CET + BSC vs BSC RCT
2.72
105
0.27 months  [Equation 2]
Finally, the scale parameter, λ, of the Weibull is back-calculated from the fixed gamma and 
variable mean, using the formula of the mean of the Weibull described above.
Overall survival for best supportive care As for progression-free survival for best supportive care, 
we based our estimate of overall survival for best supportive care on the analysis of the individual 
patient data by Merck Serono. In particular, we assume the same mean overall survival as that 
calculated by Merck Serono of 6.2 months. Next, we again specified that overall survival for best 
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FIGURE 6 Peninsula Technology Assessment Group and Merck Serono progression-free survival for patients with 
KRAS WT status in the best supportive care group.
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supportive care follows a Weibull function, and we read off the overall survival probabilities at 
monthly intervals from the published Kaplan–Meier graphs for patients with KRAS WT status.47 
We then fitted a Weibull curve to these data by minimising the sums of squares of differences 
between actual and fitted probabilities. We estimated the shape parameter, γ, of the Weibull from 
the shape parameter of this fit to the Kaplan–Meier curve. Finally, given that we have specified 
the mean, this then specifies the scale parameter, λ, of the Weibull (Figure 7).
We estimated the uncertainty in overall survival for the probabilistic sensitivity analysis in 
exactly the same way as for the uncertainty in progression-free survival on best supportive care, 
as explained in the last section. Our estimation of the standard error of mean overall survival 
assumes that no patients were censored in the best supportive care arm of the cetuximab plus best 
supportive care compared with best supportive care RCT. This assumption is less likely to hold 
for overall survival than for progression-free survival, but given the lack of further data, and the 
need for simplicity, this was again our assumption.
It is impossible to know the correlation between overall survival and progression-free survival 
for best supportive care without access to the underlying individual patient data from the RCT 
of cetuximab plus best supportive care compared with best supportive care. Nonetheless, it 
seems intuitive that these quantities will be highly correlated. Therefore, given the lack of further 
evidence, we assumed that overall survival and progression-free survival are perfectly correlated. 
This was implemented in the model by using the same random number to draw values for mean 
progression-free survival and overall survival.
Cetuximab monotherapy
We modelled the time on cetuximab treatment, progression-free survival and overall survival 
for the cetuximab plus best supportive care group directly from the RCT of cetuximab plus best 
supportive care compared with best supportive care.47
Progression-free survival for cetuximab plus best supportive care As in the best supportive care 
group, given that Merck Serono have the underlying individual patient data from this trial, we 
have based our estimate of progression-free survival for cetuximab plus best supportive care on 
the analysis of the individual patient data by Merck. In particular, we assume the same mean 
progression-free survival for cetuximab plus best supportive care as that calculated by Merck 
(4.78 months or 0.40 years). Next, we again specified that progression-free survival for cetuximab 
Time (months)
Merck OS BSC
PenTAG OS BSC
Kaplan–Meier
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 2 4 6 8 10 12 14
O
S
 B
S
C
FIGURE 7 Peninsula Technology Assessment Group and Merck Serono overall survival for patients with KRAS WT 
status in the best supportive care group.
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plus best supportive care follows a Weibull function, and again we read off the progression-
free survival probabilities at monthly intervals from the published Kaplan–Meier graphs for 
patients with KRAS WT status.47 We then fitted a Weibull curve to these data by minimising the 
sums of squares of differences between actual and fitted probabilities. We estimated the shape 
parameter, γ, of the Weibull from the shape parameter of this fit to the Kaplan–Meier curve. 
Finally, given that we have specified the mean, this then specifies the scale parameter, λ, of the 
Weibull (Figure 8).
We estimated the uncertainty in progression-free survival for the probabilistic sensitivity 
analysis in exactly the same way as we estimated the uncertainty in progression-free survival 
on best supportive care, as described above. Again, we modelled the uncertainty in the mean 
progression-free survival by specifying that the mean progression-free survival follows a gamma 
distribution with a mean of 4.78 months, as above. In this case, the standard error of the mean 
progression-free survival equals:
≈ = =
mean PFS for cetuximab
number of patients taking cetuximab in CET + BSC vs BSC RCT
4.78
110
0.46 months
≈ = =
mean PFS for cetuximab
number of patients taking cetuximab in CET + BSC vs BSC RCT
4.78
110
0.46 months  [Equation 3]
Time on cetuximab treatment Time on cetuximab treatment is an extremely important quantity 
because it affects the total mean cost of cetuximab acquisition and administration per person, 
and the former in particular is a critical driver of the cost-effectiveness of cetuximab compared 
with best supportive care.
Ideally, we would model the mean total dose of cetuximab per patient with KRAS WT status, 
allowing for wastage of cetuximab. However, these data are not published. Alternatively, we 
would model the dose intensity of cetuximab and the mean number of doses of cetuximab per 
patient with KRAS WT status (as for panitumumab; see Time on panitumumab treatment). 
Unfortunately, this information is also not published and could not be made available on request. 
We have therefore assumed that those in the cetuximab plus best supportive care compared 
with best supportive care RCT received cetuximab for the entire duration of progression-free 
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FIGURE 8 Peninsula Technology Assessment Group and Merck Serono progression-free survival for patients with 
KRAS WT status in the cetuximab plus best supportive care group.
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survival. This is mainly informed by the finding that the median time on cetuximab treatment 
for patients with KRAS WT and KRAS mutant status combined was 8.1 weeks in the RCT of 
cetuximab plus best supportive care compared with best supportive care, which is virtually 
identical to the median progression-free survival for all patients (i.e. KRAS WT and KRAS 
mutant status combined) of 8.2 weeks.37 Both our model and Merck Serono’s model predict that 
patients with KRAS WT status are progression free for a median of approximately 16 weeks. 
Therefore, we predict that patients with KRAS WT status also took cetuximab for the entire 
duration of progression-free survival, for a median of 16 weeks and a mean of 21 weeks. We have 
corroborating evidence that it is indeed reasonable to assume that WT patients took cetuximab 
until disease progression. Dr Nicole Mittman, who coauthored a paper on the cost-effectiveness 
of cetuximab compared with best supportive care42 with some of the authors of the publications 
describing the cetuximab compared with best supportive care RCT,37,47 informed us that the 
duration of cetuximab treatment for KRAS WT patients, for those who had at least one dose of 
cetuximab, was approximately 19 weeks. Given that almost all patients randomised to cetuximab 
had at least one dose of cetuximab, the mean duration of cetuximab treatment for all patients was 
approximately 19 weeks. This is very close to the mean duration of progression-free survival, at 
21 weeks.
In the RCT of cetuximab plus best supportive care compared with best supportive care, patients 
took cetuximab until death, the occurrence of serious adverse events, progression, worsening 
symptoms of the cancer or request by the patient, with or without the withdrawal of consent for 
continued follow-up.37 Although our assumption that patients took cetuximab until progression 
allows for only the ‘death’ and ‘progression’ causes for cetuximab cessation, cetuximab treatment 
was rarely discontinued because of serious adverse events, given that Merck Serono notes that 
‘In the CO.17 study 11 patients discontinued cetuximab therapy among the 287 treated subjects, 
and only 3 patients amongst the 117 KRAS WT patients taking cetuximab stopped the therapy 
due to adverse events.’69 We have no data on cetuximab cessation because of worsening symptoms 
of the cancer or request by the patient, with or without the withdrawal of consent for continued 
follow-up; therefore, it is impossible to quantify cessation resulting from these factors.
For the probabilistic sensitivity analysis, the mean time on cetuximab treatment was assumed to 
equal the mean time in progression-free survival, which we varied stochastically as explained in 
Cetuximab monotherapy, Progression-free survival for cetuximab plus best supportive care.
Overall survival for cetuximab plus best supportive care As for progression-free survival for 
cetuximab plus best supportive care (see Cetuximab monotherapy, Progression-free survival for 
cetuximab plus best supportive care), we have based our estimate of overall survival for cetuximab 
plus best supportive care on the analysis of the individual patient data by Merck Serono. In 
particular, we assume the same mean overall survival for cetuximab plus best supportive 
care as that calculated by Merck Serono (10.0 months). Next, we again specified that overall 
survival for cetuximab plus best supportive care follows a Weibull function, and we read off the 
overall survival probabilities at monthly intervals from the published Kaplan–Meier graphs for 
patients with KRAS WT status.47 We then fitted a Weibull curve to these data by minimising the 
sums of squares of differences between actual and fitted probabilities. We estimated the shape 
parameter, γ, of the Weibull from the shape parameter of this fit to the Kaplan–Meier curve. 
Finally, given that we have specified the mean, this then specifies the scale parameter, λ, of the 
Weibull (Figure 9).
We estimated the uncertainty in overall survival for the probabilistic sensitivity analysis in 
exactly the same way as for the uncertainty in progression-free survival on cetuximab plus 
best supportive care, as explained above (see Cetuximab monotherapy, Progression-free survival 
for cetuximab plus best supportive care). Our estimation of the standard error of mean overall 
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survival assumes that few patients were censored in the cetuximab plus best supportive care 
arm of the cetuximab plus best supportive care compared with best supportive care RCT. This 
assumption is less likely to hold for overall survival than for progression-free survival, but given 
the lack of further data, and the need for simplicity, this was again assumed.
Given the lack of further evidence we set overall survival and progression-free survival for 
cetuximab plus best supportive care to be perfectly correlated, just as we did for overall survival 
and progression-free survival for best supportive care.
Panitumumab plus best supportive care
As explained earlier (see Evidence to inform model parameters, Overall survival, progression-free 
survival and treatment duration), for the purposes of the indirect comparison, we chose the 
best supportive care treatment group from the cetuximab plus best supportive care compared 
with best supportive care RCT to represent the clinical effectiveness of the best supportive care 
treatment group. Therefore, in modelling the clinical effectiveness of panitumumab plus best 
supportive care (time on treatment, progression-free survival and overall survival), it is necessary 
to adjust the clinical effectiveness of panitumumab plus best supportive care as reported in the 
RCT of panitumumab plus best supportive care compared with best supportive care32 in the 
manner of the Bucher indirect comparison.34 The implicit assumption is that the baseline patient 
characteristics in the two RCTs are reasonably similar, and indeed this is true (see Table 10).
Progression-free survival for panitumumab In this section we estimate progression-free survival 
for panitumumab plus best supportive care for the indirect comparison. First, we estimated 
the mean progression-free survival for the best supportive care group as 2.2 months from the 
panitumumab plus best supportive care compared with best supportive care RCT, by calculating 
the area under the best supportive care progression-free survival Kaplan–Meier curve, using 
probabilities at 4-weekly intervals. Next, we estimated the mean progression-free survival for 
the panitumumab plus best supportive care group as 4.0 months from the panitumumab plus 
best supportive care compared with best supportive care RCT, by calculating the area under the 
panitumumab plus best supportive care progression-free survival Kaplan–Meier curve, using 
probabilities at 4-weekly intervals. Adjusting progression-free survival for panitumumab plus 
best supportive care for the indirect comparison using the Bucher method34 yields a mean of:
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FIGURE 9 Peninsula Technology Assessment Group and Merck Serono overall survival for patients with KRAS WT 
status in the cetuximab plus best supportive care group.
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(mean progression-free survival for panitumumab  
+ best supportive care from the panitumumab  
+ best supportive care vs best supportive care RCT)  
× (mean progression-free survival for best supportive care from the cetuximab  
+ best supportive care vs best supportive care RCT) 
/(mean progression-free survival for best supportive care from the panitumumab  
+ best supportive care vs best supportive care RCT)  
= 4.00 × 2.72/2.15 = 5.06 months [Equation 4]
This is our estimate of the mean progression-free survival for the panitumumab plus best 
supportive care group if panitumumab plus best supportive care had been included as a third 
treatment group in the cetuximab plus best supportive care compared with best supportive 
care RCT.
Next, we specified that progression-free survival for panitumumab plus best supportive care 
follows a Weibull distribution. We then estimated the shape parameter, γ, of the Weibull by fitting 
a Weibull curve to the Kaplan–Meier panitumumab plus best supportive care progression-free 
survival curve at 4-weekly intervals, by minimising the sums of squares of differences between 
actual and expected progression-free survival.
Finally, given that we have specified the mean progression-free survival for panitumumab plus 
best supportive care and the shape parameter, γ, this then specifies the scale parameter, λ, of the 
Weibull, given the formula for the mean of the Weibull.
We estimated the uncertainty in progression-free survival on panitumumab plus best supportive 
care for the probabilistic sensitivity analysis in exactly the same way as for best supportive care 
and cetuximab plus best supportive care (see Progression-free survival for best supportive care 
and Progression-free survival for cetuximab and best supportive care). Again, we modelled the 
uncertainty in the mean progression-free survival by specifying that the mean progression-free 
survival follows a gamma distribution, given that this appropriately models positive random 
variables, with a mean of 5.1 months. In this case, the estimated standard error of the mean 
panitumumab plus best supportive care progression-free survival equals:
≈ = =
mean PFS for PAN + BSC
number of patients taking PAN in PAN + BSC vs BSC RCT
5.1
124
0.45 months
≈ = =
mean PFS for PAN + BSC
number of patients taking PAN in PAN + BSC vs BSC RCT
5.1
124
0.45 months  [Equation 5]
Time on panitumumab treatment The mean time on panitumumab is a very important parameter 
in the estimation of the cost-effectiveness of panitumumab plus best supportive care compared 
with best supportive care. The RCT of panitumumab compared with best supportive care reports 
a mean of 10 doses of panitumumab per patient for those with KRAS WT status.32 However, 
for the indirect comparison, we require the estimated number of doses of panitumumab if 
panitumumab plus best supportive care had been a treatment group in the cetuximab compared 
with best supportive care RCT. This is estimated by the Bucher indirect comparison method34 as:
(number of doses of panitumumab in the panitumumab  
+ best supportive care vs best supportive care RCT)  
× (estimated mean progression-free survival for panitumumab  
+ best supportive care for the indirect comparison 
/mean progression-free survival for panitumumab in the panitumumab  
+ best supportive care vs best supportive care RCT) [Equation 6]
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For the deterministic analysis, this quantity equals 10 × (5.06/4.0) = 12.7 doses.
Given that panitumumab is taken every 2 weeks, this corresponds to a treatment duration 
of 5.8 months or 0.49 years. Discounting has only a very small impact on the total drug 
acquisition costs given that progression-free survival is of such a short duration. Nonetheless, 
we approximated for discounting in the cost of panitumumab acquisition by assuming that all 
panitumumab doses were taken at the mean time in progression-free survival. We also used 
the adjusted number of panitumumab doses of 12.7 to estimate the total per person mean 
administration cost of panitumumab, as described below.
To estimate the mean number of doses of panitumumab for the probabilistic sensitivity analysis, 
we needed two further assumptions. First, we modelled the mean number of doses from the 
RCT of panitumumab plus best supportive care compared with best supportive care as a normal 
distribution, which is appropriate given the relatively small coefficient of variation, with a mean 
of 10 doses and a standard error of 10% of the mean, given that the standard error of mean 
progression-free survival for panitumumab plus best supportive care is approximately 10% of 
the mean progression-free survival. Second, we modelled the mean progression-free survival 
from the panitumumab plus best supportive care compared with best supportive care RCT as 
a normal distribution, with a mean of 4.0 months and a standard error of 0.36, with standard 
error estimated with two simplifying assumptions. The first was that progression-free survival 
for panitumumab plus best supportive care from the panitumumab plus best supportive care 
compared with best supportive care RCT approximately follows an exponential distribution. 
Indeed, we find this to be approximately true (gamma of Weibull = 1.2). We can then say that the 
standard deviation of progression-free survival across patients equals the mean progression-free 
survival, as this is a property of the exponential distribution. The second simplifying assumption 
is that no patients who started treatment with panitumumab plus best supportive care in the RCT 
of panitumumab plus best supportive care compared with best supportive care were censored. 
Indeed, this is also approximately true: only 7% of patients were censored.32 In this case, the 
standard error of mean panitumumab plus best supportive care progression-free survival equals:
≈ = =
standard deviation of PFS
no. of patients taking panitumumab in RCT
mean PFS
no. of patients taking panitumumab in RCT
4.0
124
0.36 months
≈ = =
standard deviation of PFS
no. of patients taking panitumumab in RCT
mean PFS
no. of patients taking panitumumab in RCT
4.0
124
0.36 months  [Equation 7]
The estimated number of doses of panitumumab if panitumumab plus best supportive care had 
been a treatment group in the cetuximab plus best supportive care compared with best supportive 
care RCT for the probabilistic sensitivity analysis is then calculated as described above for the 
deterministic case.
Overall survival for panitumumab plus best supportive care In this section we estimate overall 
survival for panitumumab plus best supportive care for the indirect comparison using a similar 
method as for the estimation of progression-free survival for panitumumab plus best supportive 
care for the indirect comparison. First, we fitted a Weibull curve to the overall survival for the 
panitumumab plus best supportive care group from the panitumumab plus best supportive 
care compared with best supportive care RCT, by minimising the sums of squares of differences 
between the actual and estimated survival probabilities, using survival probabilities at 4-weekly 
intervals. This gives a mean overall survival of 9.9 months. Next, we estimated the mean overall 
survival as 9.4 months for best supportive care from the panitumumab plus best supportive care 
compared with best supportive care RCT,32 again by fitting a Weibull curve and by minimising 
the sums of squares of differences between the actual and estimated survival probabilities, using 
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survival probabilities at 4-weekly intervals. This is the mean overall survival for best supportive 
care without adjustment for the substantial crossover of patients from the best supportive care 
group to the panitumumab plus best supportive care group. Amgen’s analysis of the individual 
patient data suggested that, after adjusting for crossover, the mean overall survival in the best 
supportive care group is 2.7 months less than for the panitumumab plus best supportive care 
group. This is discussed in detail in our critique of Amgen’s submission (see Chapter 5, Industry 
submission critique 3: Amgen, panitumumab) and assumes that we can model overall survival 
for best supportive care patients with KRAS mutant status (including some people who cross 
over) as an approximation for overall survival for best supportive care patients with KRAS WT 
status. We therefore estimate the mean overall survival for the best supportive care group as the 
mean overall survival for the panitumumab plus best supportive care group minus 2.7 months: 
9.9 – 2.7 = 7.2 months.
Adjusting mean overall survival for panitumumab plus best supportive care for the indirect 
comparison using the Bucher method yields:34
(mean overall survival for panitumumab + best supportive care from the panitumumab 
+ best supportive care vs best supportive care RCT) 
× (mean overall survival for best supportive care in the cetuximab 
+ best supportive care vs best supportive care RCT)
/(mean overall survival for best supportive care in the panitumumab 
+ best supportive care vs best supportive care RCT) 
= 9.9 × 6.2/7.2 = 8.5 months [Equation 8]
This is our estimate of the mean overall survival for the panitumumab plus best supportive care 
group if panitumumab plus best supportive care had been included as a treatment group in the 
cetuximab plus best supportive care compared with best supportive care RCT.47
Next, we specify that overall survival for panitumumab plus best supportive care follows a 
Weibull distribution. We then use the shape parameter, γ, of the Weibull from our fit to the 
Kaplan–Meier panitumumab overall survival curve, described above. Finally, given that we 
have specified the overall survival mean and the shape parameter, γ, this then specifies the scale 
parameter, λ, of the Weibull.
We estimated the uncertainty in overall survival for panitumumab plus best supportive care 
for the probabilistic sensitivity analysis in exactly the same way as for the uncertainty in 
progression-free survival on panitumumab plus best supportive care (see Progression-free 
survival for panitumumab). Our estimate of the standard error of mean overall survival assumes 
that few patients were censored in the panitumumab plus best supportive care arm of the 
panitumumab plus best supportive care compared with best supportive care RCT: 14% of patients 
were censored.32
Given the lack of further evidence, we set overall survival and progression-free survival for 
panitumumab plus best supportive care to be perfectly correlated, just as we did for overall 
survival and progression-free survival for best supportive care and for cetuximab plus best 
supportive care.
Cetuximab plus irinotecan
The pivotal BOND trial49 and supportive MABEL trial used to confirm the clinical efficacy of 
cetuximab in combination with irinotecan in the pretreated metastatic colorectal cancer setting 
did not have KRAS status as a prerequisite for recruitment, and no retrospective KRAS analysis 
has been systematically undertaken. Given that we do not have direct randomised evidence for 
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progression-free survival, time on treatment and overall survival for patients with KRAS WT 
status on cetuximab plus irinotecan, some assumptions to estimate these quantities have to be 
made. These complex assumptions are critical to an understanding of the estimation of the cost-
effectiveness of cetuximab plus irinotecan, and the associated uncertainty. Details of the methods 
used are given in Appendix 14 (progression-free survival) and Appendix 15 (overall survival).
Progression-free survival for cetuximab plus irinotecan Progression-free survival is estimated in 
three stages:
 ■ first, we estimate the median progression-free survival for patients with KRAS WT status on 
cetuximab plus irinotecan in the BOND RCT of cetuximab plus irinotecan compared with 
cetuximab plus best supportive care (as this is not reported)
 ■ next, we adjust this to estimate the median progression-free survival for patients with KRAS 
WT status on cetuximab plus irinotecan for our model
 ■ finally, we assume that progression-free survival follows a Weibull distribution (as for 
cetuximab plus best supportive care) with the same shape parameter as for cetuximab plus 
best supportive care.
A detailed description of these three stages and the assumptions made is given in Appendix 14. 
We estimate a mean progression-free survival of 8.8 months for patients receiving cetuximab plus 
irinotecan. This is similar to Merck Serono’s estimated mean of 7.8 months (Figure 10).
We note briefly that Merck Serono estimates progression-free survival for patients with KRAS 
WT status on cetuximab plus irinotecan by applying the hazard ratio of 0.47 between cetuximab 
plus irinotecan (patients with KRAS WT status) and cetuximab monotherapy (patients with 
KRAS WT status) from De Roock and colleagues48 to its curve fit to progression-free survival for 
cetuximab monotherapy (patients with KRAS WT status) (which it estimated from the cetuximab 
plus best supportive care compared with best supportive care RCT) (p. 104, Merck Serono’s 
submission69). Merck Serono states that it estimated the hazard ratio by reading off survival data 
from the progression-free survival curves published in De Roock and colleagues;48 however, it 
is difficult to verify the hazard ratio because it is not published in this study. Furthermore, the 
method used by Merck Serono introduces a good deal of uncertainty because it relies on data on 
cetuximab monotherapy (patients with KRAS WT status) for which there are only 18 people.
Uncertainty in progression-free survival for cetuximab plus irinotecan We estimated the uncertainty 
in progression-free survival on cetuximab plus irinotecan for the probabilistic sensitivity analysis 
in a similar but slightly different way to that used for uncertainty in progression-free survival for 
cetuximab plus best supportive care and panitumumab plus best supportive care. In this case, we 
modelled the uncertainty in the median progression-free survival, not the mean progression-free 
survival, given that our estimation of progression-free survival for cetuximab plus irinotecan 
is based on the median. First, for simplicity, we fixed the shape value gamma of the Weibull for 
progression-free survival. Next, we specified that the median (not the mean) progression-free 
survival follows a gamma distribution, which is appropriate for positive random variables, 
with a mean of 7.1 months (see stage 2, Appendix 14). We then estimated the standard error 
of the median progression-free survival as simply equal to 20% of the mean: 1.4 months. This 
method was chosen as being the most pragmatic, given the lack of evidence on this quantity. 
Note that the ratio of the standard error to the mean of the median, at 20%, is greater than the 
corresponding ratio for the mean progression-free survival for best supportive care, cetuximab 
and panitumumab (all approximately 10%), to reflect the extra uncertainty in progression-
free survival for cetuximab plus irinotecan. Finally, the scale parameter, λ, of the Weibull for 
progression-free survival is back-calculated from the fixed gamma and variable median, using the 
following formula for the median t* of the Weibull: 0.5 = exp(–λt*γ).
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Time on cetuximab plus irinotecan treatment The time on cetuximab plus irinotecan treatment 
is an extremely important quantity because it affects the total mean cost of cetuximab plus 
irinotecan acquisition per person, which is a critical driver of the cost-effectiveness of cetuximab 
plus irinotecan compared with best supportive care.
Unfortunately, the mean duration of cetuximab plus irinotecan treatment for patients with 
KRAS WT status in the BOND RCT is not reported. In the absence of this crucial information, 
we assume that all patients take cetuximab plus irinotecan treatment for the entire duration of 
progression-free survival. This gives a median duration of cetuximab plus irinotecan treatment of 
31 weeks, and a mean duration of 38 weeks.
Given the importance and uncertainty of the mean duration of cetuximab plus irinotecan 
treatment, we vary the mean duration of irinotecan treatment and the mean duration of 
cetuximab treatment in our sensitivity analyses.
There is some support for our base-case assumption that patients in the cetuximab plus best 
supportive care and cetuximab plus irinotecan treatment groups in the BOND RCT took 
cetuximab until progression. The median progression-free survival for all patients (KRAS WT 
and KRAS mutant status combined) in the cetuximab plus best supportive care treatment group 
was 1.5 months (6.5 weeks), and the median number of cetuximab doses in the cetuximab plus 
best supportive care treatment group was seven.49 Given that cetuximab was given once per 
week in the BOND RCT, this suggests that it was taken until disease progression. Similarly, the 
median progression-free survival for all patients (KRAS WT and KRAS mutant status combined) 
in the cetuximab plus irinotecan treatment group was 4.1 months (17.8 weeks), and the median 
number of cetuximab doses in the cetuximab plus irinotecan treatment group was virtually 
identical, at 18.49
As for treatment with cetuximab (see Cetuximab monotherapy), Merck Serono forced the mean 
time on cetuximab plus irinotecan treatment in its model to equal its estimate of the mean time 
on cetuximab plus irinotecan treatment for patients with KRAS WT status in the BOND RCT 
of cetuximab plus irinotecan compared with cetuximab plus best supportive care (see table 59, 
Merck Serono’s submission69). However, we believe that it was a very serious limitation that 
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FIGURE 10 Peninsula Technology Assessment Group and Merck Serono progression-free survival for patients with 
KRAS WT status in the cetuximab plus irinotecan group.
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Merck Serono did not state this, their derivation of the mean time on cetuximab plus irinotecan 
treatment of 19 weeks (4.4 months) (although this was stated in the model), and also a very 
serious omission that it did not explain the derivation of this figure in its report. We questioned 
Merck Serono on the derivation of the 19 weeks and received the following reply: ‘The BOND 
study compared cetuximab plus irinotecan compared with cetuximab monotherapy, but was 
undertaken before KRAS status was identified as a marker for response; hence, the mean number 
of infusions is not available for the KRAS WT population. For the ITT analysis, the mean 
number of infusions was 18 for those on cetuximab plus irinotecan and 7 for those on cetuximab 
monotherapy (Cunningham et al. 2004) . . . The mean number of cetuximab and irinotecan 
combination therapy infusions within the model for the KRAS WT population was not increased 
proportionately as per cetuximab monotherapy. The increasing side effects with combination 
therapy are likely to limit the treatment duration.’
We strongly disagree with Merck Serono’s derivation of the mean duration of cetuximab plus 
irinotecan treatment for three important reasons. First, it seems highly unlikely that patients 
with KRAS WT status would take cetuximab plus irinotecan for the same time as those patients 
with KRAS mutant status. It is far more likely that the duration of treatment would be longer for 
patients with KRAS WT status than for those with KRAS mutant status, and therefore longer 
for patients with KRAS WT status than for all patients combined. This is because cetuximab 
is known to improve progression-free survival for patients with KRAS WT status but not for 
those with KRAS mutant status. Furthermore, in BOND, drug treatment was given until disease 
progression or the occurrence of adverse events, and three sources cite a substantially longer 
progression-free survival time for cetuximab plus irinotecan treatment for patients with KRAS 
WT status than for those with KRAS mutant status: 7.8 months compared with 2.8 months,48 
7.4 months compared with 2.1 months86 and 5.5 months compared with 2.8 months.83 Second, 
Merck Serono has equated means with medians: it sets the mean duration of cetuximab plus 
irinotecan treatment for patients with KRAS WT status equal to the median duration of 
cetuximab plus irinotecan treatment for all patients. Given that the mean is usually greater than 
the median, for example by a factor of 1.44 for the exponential distribution, Merck Serono’s 
estimate for the mean treatment duration of cetuximab plus irinotecan for all patients in BOND 
is probably an underestimate. Third, Merck Serono has made no attempt to adjust the treatment 
duration from BOND for the indirect comparison with best supportive care.
For the probabilistic sensitivity analysis, the mean time on cetuximab plus irinotecan treatment 
was assumed to equal the mean time in progression-free survival, which we varied stochastically 
as explained in the previous section.
Overall survival for cetuximab plus irinotecan Here, we estimate overall survival for cetuximab 
plus irinotecan for patients with KRAS WT status for the purposes of the indirect comparison. 
We first note that both our estimate and Merck Serono’s estimate of overall survival are highly 
uncertain given the lack of randomised evidence, and that we have both had to make substantial 
assumptions. Furthermore, we believe that the uncertainty in overall survival for cetuximab plus 
irinotecan is considerably greater than that for progression-free survival.
Our method to estimate overall survival proceeds in two stages:
 ■ first, we estimate the median overall survival for patients with KRAS WT status on cetuximab 
plus irinotecan for our model
 ■ next, we assume that overall survival follows a Weibull distribution (as for cetuximab) with 
the same shape parameter as for cetuximab plus best supportive care.
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A detailed description of these two stages and the assumptions made is given in Appendix 15. We 
estimate a mean overall survival of 16.6 months for patients receiving cetuximab plus irinotecan. 
This is similar to Merck Serono’s estimated mean of 16.3 months (Figure 11).
Both our estimate and Merck Serono’s estimate of overall survival for patients with KRAS WT 
status on cetuximab plus irinotecan are highly uncertain given that we have both had to make 
substantial assumptions. Therefore, we also present sensitivity analyses in which we use different 
methods of estimating overall survival (see Appendix 15).
Uncertainty in overall survival for cetuximab plus irinotecan We estimated the uncertainty in 
overall survival for the probabilistic sensitivity analysis in exactly the same way as for the 
uncertainty in progression-free survival on cetuximab plus irinotecan, namely by modelling the 
uncertainty in median overall survival. We estimated the standard error of the median overall 
survival as simply equal to 20% of the mean of the median, to reflect the substantial uncertainty 
in overall survival.
Given the lack of further evidence, we set overall survival and progression-free survival for 
cetuximab plus irinotecan to be perfectly correlated, just as we did for best supportive care, 
panitumumab plus best supportive care and cetuximab plus best supportive care.
Utilities
Health-related quality of life literature
Au and colleagues44 describe the HRQoL information collected using the EORTC QLQ-C30 
during the cetuximab plus best supportive care compared with best supportive care RCT.
Compliance was high at baseline (> 90%) but declined over time, particularly for best supportive 
care. The authors believe that this selective non-compliance may make QoL for cetuximab plus 
best supportive care conservative because more people on best supportive care than on cetuximab 
plus best supportive care who were in poor health stopped completing the questionnaire. 
Conversely, given that the RCT was not blinded, people’s judgement of their QoL could have 
been biased downwards for people on best supportive care, and biased upwards for those on 
cetuximab (because of a potential placebo effect). Also, given that those people who complete the 
questionnaire are likely to be healthier, on average, than those who do not, all utilities from Au 
and colleagues44 are likely to be overestimates.
Merck OS
cetuximab + irinotecan
PenTAG OS
cetuximab + irinotecan
Time (months)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40
O
S
 c
et
ux
im
ab
 +
 ir
in
ot
ec
an
FIGURE 11 Peninsula Technology Assessment Group and Merck Serono overall survival for patients with KRAS WT 
status in the cetuximab plus irinotecan group.
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For patients with KRAS WT status, treatment with cetuximab plus best supportive care 
resulted in less physical function deterioration over time than best supportive care. Treatment 
with cetuximab plus best supportive care resulted in improved global health status at 8 weeks 
compared with baseline, whereas the global health status of patients on best supportive care 
worsened. At 16 weeks, the global health status of patients on cetuximab plus best supportive care 
was approximately unchanged from baseline, whereas the global health status of patients on best 
supportive care was much reduced from baseline.
The cost-effectiveness study of Mittmann and colleagues42 reports that the HUI3 was also used in 
the RCT of cetuximab plus best supportive care compared with best supportive care. Although 
the NICE reference case72 states a preference for the EQ-5D, Mittmann and colleagues present the 
only utility data from the RCT of which we are aware. Health was assessed at baseline and at 4, 
8, 16 and 24 weeks after randomisation (Table 41). Merck Serono claims that these values relate 
to patients with KRAS WT status only; however, this is difficult to believe given that there were 
more patients in the utility data set than there were patients with KRAS WT status in the RCT.
At each follow-up time, mean utility scores for cetuximab plus best supportive care were higher 
than those for best supportive care. For the cetuximab plus best supportive care arm, utilities 
remained largely unchanged over time. By contrast, utilities in the best supportive care arm 
generally declined over time, with the exception of the last time point, which may have been 
unrepresentative because of the relatively small sample size.
Merck Serono assumed the utilities from the RCT of cetuximab plus best supportive care 
compared with best supportive care in its economic model (given in Table 42). These utilities 
were calculated from the HUI3 index, although Merck Serono provides very little detail of the 
calculations. We agree with Merck Serono’s claim that the QoL data reflect both the positive 
aspects of a response to treatment with cetuximab plus best supportive care and the negative 
aspects of treatment such as adverse events.
However, we are concerned that, although both Mittmann and colleagues42 and Merck Serono 
both report utilities estimated by the HUI3, the values reported by Merck do not always tally with 
the values quoted in Mittmann and colleagues. For example, the Mittmann values would suggest 
that the utility for progression-free survival for cetuximab plus best supportive care should be 
about 0.73, whereas Merck Serono reports 0.81.
Merck Serono’s estimated utilities for progressive disease are also a limitation of the approach. 
First, because of high dropout rates, there are far fewer utility observations for patients in 
progressive disease than for those in progression-free survival. Second, at the point of data cut-
off, a large proportion of patients were still alive in both treatment arms.37 This means that the 
utilities for progressive disease do not include many time points when patients are close to death. 
Therefore, we suspect that the true mean utilities for progressive disease for best supportive care 
and cetuximab plus best supportive care, averaged over the total time in progressive disease, may 
be lower than the values used by Merck Serono.
In the economic evaluation of bevacizumab for first-line treatment and cetuximab plus irinotecan 
for second-line and further treatment of metastatic colorectal cancer, Tappenden and colleagues10 
assumed a utility of 0.80 in progression-free survival and 0.60 in progressive disease, independent 
of treatment. The progression-free survival value of 0.80 was taken from HUI3 responses from 
a small study of 173 people with colorectal cancer of various stages taken from the US SEER 
database. The progressive disease value of 0.60 appears to have been a ‘best guess’ given the 
dearth of relevant literature.
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Odom and colleagues56 assessed the HRQoL of patients in the RCT of panitumumab plus best 
supportive care compared with best supportive care. QoL was assessed using the EQ-5D, NICE’s 
preferred instrument,72 using the VAS, and the NCCN FCSI. Data were available for 208 patients 
with KRAS WT status (112 panitumumab plus best supportive care arm, 96 best supportive 
care arm). Only outcomes before disease progression up to week 17 of the study were used 
because of small sample sizes after this time. The QoL of patients with KRAS WT status taking 
panitumumab plus best supportive care was better than the QoL of those on best supportive 
care, with a significant difference of 0.22 in the EQ-5D utility (95% CI 0.12 to 0.32).56 Similar 
to the QoL study in the cetuximab plus best supportive care compared with best supportive 
care RCT, there were many missing data, particularly in the later weeks, although patients 
receiving panitumumab plus best supportive care had a higher percentage of available data 
for each post-baseline week than those receiving best supportive care. This could bias against 
panitumumab, and this is confirmed by analysis in Odom and colleagues.56 Also, similar to the 
cetuximab plus best supportive care compared with best supportive care RCT, the panitumumab 
plus best supportive care compared with best supportive care RCT was not blinded. Therefore, 
patients’ judgement of QoL could have been biased downwards for those on best supportive care 
and upwards for those on panitumumab plus best supportive care. Also, given that those people 
who complete the questionnaire are likely to be healthier, on average, than those who do not, all 
utilities from Odom and colleagues are likely to be overestimates.
Utilities in the Peninsula Technology Assessment Group’s model
Our choice of utilities is given in Table 43 and is based on those supplied by Merck Serono. 
This seems appropriate because the utilities were collected in the RCT of cetuximab plus best 
supportive care compared with best supportive care, the same source as for our baseline efficacy 
estimates. These utilities are probably overestimates because people who complete HRQoL 
TABLE 41 Health utilities from the RCT of cetuximab plus best supportive care compared with best supportive care 
reported by Mittmann and colleagues42 
Time of 
assessment
CET + BSC,  
mean ± SD (n)
BSC,  
mean ± SD (n)
Baseline 0.72 ± 0.23 (263) 0.71 ± 0.24 (260)
Week 4 0.73 ± 0.26 (220) 0.68 ± 0.26 (184)
Week 8 0.73 ± 0.24 (190) 0.66 ± 0.28 (149)
Week 16 0.73 ± 0.24 (119) 0.63 ± 0.30 (72)
Week 24 0.77 ± 0.22 (82) 0.70 ± 0.24 (36)
BSC, best supportive care; CET, cetuximab; SD, standard deviation
TABLE 42 Utilities used by Merck Serono in its economic model 
CET +BSC BSC
Progression-free survival
No. of patients 294 170
Mean utility (SE) 0.809 (0.011) 0.746 (0.017)
Progressive disease
No. of patients 83 85
Mean utility (SE) 0.789 (0.025) 0.693 (0.027)
BSC, best supportive care; CET, cetuximab.
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questionnaires are likely to be healthier, on average, than those who do not. In addition, given 
that both RCTs7,37 were not blinded, people’s judgement of their QoL could have been biased 
upwards for those on cetuximab plus best supportive care and panitumumab plus best supportive 
care, because of the placebo effect. However, without further information, it is not possible to 
quantify the bias in either case.
For best supportive care we use the mean utilities quoted by Merck Serono – 0.75 in progression-
free survival and 0.69 in progressive disease – taken from the RCT of cetuximab plus best 
supportive care compared with best supportive care.47 For cetuximab monotherapy, as Merck 
Serono did, we used the mean utility of 0.81, also taken from the RCT of cetuximab plus best 
supportive care compared with best supportive care. Our clinical advisor believes that it is indeed 
plausible that people taking cetuximab plus best supportive care in progression-free survival 
have a higher HRQoL than people in progression-free survival in the best supportive care group, 
as follows. First, HRQoL for cancer patients is broadly affected by two factors: tumour bulk and 
the degree of drug toxicity. Given that cetuximab is not particularly toxic (e.g., compared with 
chemotherapy drugs such as irinotecan), the HRQoL of people in progression-free survival 
on cetuximab plus best supportive care would be similar to that for people in progression-free 
survival on best supportive care. Second, tumour bulk will, on average, be lower in progression-
free survival for patients taking cetuximab, because some patients respond to cetuximab, that is, 
their tumour shrinks.
However, the mean utility of 0.79 for patients in the cetuximab plus best supportive care 
treatment group in progressive disease seems too high. This value is only marginally lower 
than the 0.81 for patients in the cetuximab plus best supportive care group in progression-free 
survival, and is substantially higher than the utility of 0.69 for patients in the best supportive care 
group in progressive disease. This may result from differential time spent in progressive disease 
by those treated with best supportive care and cetuximab plus best supportive care, leading to 
questionnaires being completed by patients who had been in progressive disease for a longer 
time, on average, in the best supportive care group than in the cetuximab plus best supportive 
care group. This is due to the fairly short data cut-off time and the fact that patients in the best 
supportive care group progressed faster than those in the cetuximab plus best supportive care 
group. We sought clarification from Merck Serono on this point. Merck Serono did not deny 
this assertion, but replied: ‘The assumption in the model simplifies the detailed observations 
by assuming one utility weight per disease state. There may be biases caused by the fact that the 
model assumes the same utility in PFS [progression-free survival] and from progression until 
death, but it is not likely to affect the cost effectiveness.’
TABLE 43 Utilities used in the PenTAG model 
Progression-free survival Progressive disease
Mean (SE) Correlation Source Mean (SE) Correlation Source
BSC 0.75 (0.08) Baseline MS submission 0.69 (0.07) Correlated with BSC 
progression-free survival
MS submission
CET + BSC 0.81 (0.08) Correlated with BSC 
progression-free survival
MS submission 0.69 (0.07) Set equal to BSC 
progressive disease
Adjusted from 
MS submission
PAN + BSC 0.87 (0.09) Correlated with BSC 
progression-free survival
Based on Odom 
et al.56 See also 
calculations in 
Appendix 11 
0.69 (0.07) Set equal to BSC 
progressive disease
MS submission
CET + IRIN 0.75 (0.08) Set equal to BSC 
progression-free survival
MS submission 0.69 (0.07) Set equal to BSC 
progressive disease
Adjusted from 
MS submission
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A mean utility of 0.69 for patients in the cetuximab plus best supportive care treatment group 
in progressive disease, the same as for patients in the best supportive care group in progressive 
disease, seems more appropriate. Indeed, we set the mean utility for patients in all groups in 
progressive disease equal, at 0.69, and for the probabilistic sensitivity analysis we set the utility for 
all patients in all groups in progressive disease equal within each simulation. Our justification is 
as follows: all patients in progressive disease, regardless of treatment group, are, by definition, off 
active drug treatment and as such there is no drug toxicity. Second, tumour bulk will be similar 
for all patients, regardless of treatment group in progressive disease, given that tumour bulk is a 
major criterion for disease progression.
The value of 0.69 for all patients in progressive disease is probably an overestimate because it 
is likely that many patients were alive for several months after their last HRQoL questionnaire, 
because of the limited data cut-off time. However, it is impossible to quantify the magnitude of 
any such bias without access to the detailed individual patient data.
Next, we used the utilities measured in the RCT of panitumumab plus best supportive care 
compared with best supportive care, published in Odom and colleagues,56 to estimate that the 
mean utility in progression-free survival for patients taking panitumumab plus best supportive 
care is 0.12 higher than for patients in progression-free survival on best supportive care. Similar 
to the assertion that the utility of patients receiving cetuximab plus best supportive care is higher 
than for patients in progression-free survival in the best supportive care group, our clinical 
expert is satisfied with the analogous finding for patients receiving panitumumab plus best 
supportive care. Odom and colleagues do not provide absolute utilities, only difference from 
baseline. Detailed calculations are given in Appendix 11, but, broadly, we calculate the increment 
in utility by weighting the progression-free survival curve for panitumumab by the decrease in 
utility from baseline for panitumumab plus best supportive care over time, and weighting the 
progression-free survival curve for best supportive care by the decrease in utility from baseline 
for best supportive care over time. We then estimate the mean utility for patients in progression-
free survival on panitumumab plus best supportive care in the manner of an indirect comparison 
as the utility for patients on best supportive care from the cetuximab plus best supportive care 
compared with best supportive care RCT plus the difference in utility between panitumumab 
plus best supportive care and best supportive care from the panitumumab plus best supportive 
care compared with best supportive care RCT, which equals 0.75 + 0.12 = 0.87. Although this 
value is evidence based, we caution that it is high compared with that corresponding to the UK 
general population.
Finally, we assume that the mean utility for patients in progression-free survival taking cetuximab 
plus irinotecan is equal to 0.75, which is the utility for patients in progression-free survival in 
the best supportive care group. Furthermore, in the probabilistic sensitivity analysis, we assume 
that the progression-free survival utilities for patients in the best supportive care and cetuximab 
plus irinotecan groups are equal within each simulation. Conversely, Merck Serono chose a mean 
utility of 0.81 for patients in progression-free survival taking cetuximab plus irinotecan, the 
same as for patients in progression-free survival taking cetuximab plus best supportive care. As 
stated above, HRQoL is influenced by both tumour mass and drug toxicity. On the one hand, we 
might expect the HRQoL for patients in progression-free survival on cetuximab plus irinotecan 
to be higher than for patients in progression-free survival in the best supportive care group 
because the tumour mass for patients in progression-free survival on cetuximab plus irinotecan 
is, on average, smaller than that for patients in progression-free survival on best supportive 
care. On the other hand, one might expect the HRQoL for people in progression-free survival 
on cetuximab plus irinotecan to be lower than for patients in the best supportive care group 
because irinotecan is a toxic chemotherapy. On balance, our clinical advisor suggests that the 
mean utility for patients taking cetuximab plus irinotecan is probably lower than for patients in 
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progression-free survival in the best supportive care treatment group. It is difficult to estimate the 
net effect, but note that Starling and colleagues61 report that, in the MABEL single-arm study of 
cetuximab plus irinotecan, the mean utility, as assessed by the EQ-5D, was 0.746, which is similar 
to our estimate of 0.75.
For the probabilistic sensitivity analysis, we modelled all utilities as beta distributions. We 
could have taken the standard errors of the utilities for cetuximab plus best supportive care 
and best supportive care from the RCT of cetuximab plus best supportive care compared with 
best supportive care; however, this would capture only uncertainty within the RCT. Instead, 
we attempted to capture broader uncertainty, for example to allow for the fact that utilities in 
progressive disease were not collected throughout the progressive disease of all patients, and to 
allow for extra uncertainty given that not all people completed the HRQoL questionnaires. This 
broader uncertainty was achieved by setting the standard errors of all utilities equal to 10% of the 
mean of each utility. Indeed, this is similar to Merck Serono’s approach of setting the standard 
error equal to 20% of the mean for variables for which data on uncertainty are not available. We 
chose the standard error as 10% because this gave a plausible range of simulated utilities, given 
our experience of the utilities in other disease areas. Although the standard errors are clearly 
approximate, our method seems to be reasonably pragmatic.
It is impossible to accurately model the correlation between the utilities. Therefore, we took 
the pragmatic view of assuming correlation between all utilities, as shown in Table 43. This 
then captures various commonsense ideas, for example that the utility in progressive disease 
should always be less than the utilities in progression-free survival, and that if the utility for 
best supportive care progression-free survival is higher than expected, then so too should be the 
utility for all the other treatments in progression-free survival.
We did not model additional utility decrements associated with adverse events in the base case, 
as our utilities reflect the experiences of people on treatment and therefore include treatment-
related adverse events that did not result in treatment discontinuation.
Costs
We model the following costs: KRAS testing, drug acquisition, drug administration, consultant 
outpatient visits, computerised tomography scans, best supportive care in progressive disease and 
treatment for adverse events. All costs are inflated to 2011–12 values where appropriate.
In addition to the cost of drug acquisition, mean drug costs per person allow for treatment 
duration (see Overall survival, progression-free survival and treatment duration) and dose intensity 
(see Dose intensities).
Costs of epidermal growth factor receptor and Kirsten rat 
sarcoma testing
Across the UK as a whole, to test the suitability of a patient for cetuximab or panitumumab, 
most patients are tested only for KRAS, not for EGFR status (Dr Ian Chandler, Consultant 
Histopathologist, Royal Devon & Exeter Hospital, Exeter, personal communication, 18 March 
2011). Therefore, we model the cost of the KRAS test only. There are no testing costs for people 
on best supportive care.
When we model the mean cost of testing per EGFR-expressing metastatic colorectal cancer 
patient with KRAS WT status, we need to cost for all patients who take the KRAS test, not just 
those who are KRAS WT. This is because, although people who test negative will not receive the 
drug treatment, they will nonetheless incur the testing costs. The total cost of the KRAS test per 
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person in the model is then taken as the cost of a test divided by the proportion of people who 
are KRAS WT. In common with Merck Serono, we assume a cost per KRAS test of £160.80
We set the proportion of people with KRAS WT disease as 54%. This is taken from Merck 
Serono’s submission: ‘Global clinical trial data indicates that . . . approximately 30–50% have 
KRAS WT disease (Erbitux Summary of Product Characteristics, November 2010). A more 
accurate estimate for the proportion of patients with KRAS WT disease is available from 
local KRAS testing facilities in Wales. The figure of 54% with KRAS WT disease from the 
local laboratories has consequently been used throughout the submission’ (p. 16, Merck 
Serono’s submission69).
Combining this information, we assume a cost for KRAS testing per person tested as 
£160/54% = £296 for all treatments apart from best supportive care, for which the cost was set 
at zero. This cost is very low compared with other costs, such as for drug acquisition. For the 
probabilistic sensitivity analysis we modelled the cost of a KRAS test as a gamma distribution, 
independent of all other model parameters. It is very difficult to select an appropriate standard 
error; therefore, we chose the pragmatic solution of setting the standard error equal to 20% of 
the mean.
Drug prices
Table 44 presents the drug prices, which for panitumumab and irinotecan have been taken from 
BNF 61.76 The price of cetuximab was provided by Merck Serono, and NICE have instructed us to 
use this value.
In common with Merck Serono, we assumed a dosage of irinotecan of 180 mg/m2 every 
2 weeks. Indeed, members of Merck Serono’s advisory board (see appendix 1, Merck Serono’s 
submission69) agreed that most clinicians in the UK follow this regime. In common with 
Merck Serono, we assumed the generic price for irinotecan, although this is not an important 
assumption because the price of the branded version of irinotecan, Campto (Pfizer), is 
very similar.
All drugs are given intravenously in fixed vial sizes. Any unused drug left in the vials after 
administration is discarded, partly to avoid contamination; this is thought to be common practice 
across the UK (Kate Copland, personal communication). Therefore, in our base case, we assumed 
total wastage of all drugs that remain in vials at the end of the infusion for each patient. Also in 
common with Merck Serono, we assumed the smallest vial sizes for all drugs to minimise the 
drug costs per patient, after allowing for wastage of drugs.
The doses of cetuximab and irinotecan are given in proportion to body surface area. Merck 
Serono assumed a body surface area of 1.79 m2, representing the mean value from Sacco 
and colleagues.87 In this study, the authors calculated the body surface area of 3613 patients 
receiving chemotherapy for various cancers in the UK in 2005 from the height and weight, 
using the Dubois and Dubois method88 (also quoted by Merck Serono): body surface area 
(m2) = 0.007184 × weight (kg)0.425 × height (cm)0.725. Merck Serono’s value of 1.79 m2 is the mean 
over several cancers and over men and women.
As is standard practice in HTA, Merck Serono then assumed that the body surface areas of all 
patients is the same, 1.79 m2. However, in reality, weights, heights and surface areas vary and, 
as such, the amount of drug wastage will also vary. As suggested by Sacco and colleagues, we 
captured this by modelling the distribution of body surface areas in a population of people 
receiving palliative chemotherapy for colorectal cancer, with 66% men and 34% women, and 
assumed the typical sex mix in the RCTs for metastatic colorectal cancer. We then calculated the 
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total drug used, including wastage, for each patient in this range, and then took the average of 
these dosages. The details are given in Appendix 12.
The mean body surface area of 1.79 m2 cited by Merck Serono refers to people with a range of 
cancers. To be more precise, the mean is 1.85 m2 for people receiving palliative chemotherapy for 
colon cancer (66% men, 34% women). If we assume that all patients have the same body surface 
area of 1.85 m2, the dose per administration of cetuximab for all patients, allowing for wastage, 
is 500 mg (after the first dose). However, using our methodology of assuming a distribution for 
doses across patients, the mean dose per patient per administration, allowing for wastage, is 
511 mg. Similarly, the corresponding figures for irinotecan are 360 mg and 352 mg. In these cases, 
the effect of assuming a distribution for dosages has little effect on the mean dose per patient 
and hence on cost-effectiveness. However, this is coincidental; Sacco and colleagues found that 
cost-effectiveness can change substantially.
The dose of panitumumab is proportional to weight, not body surface area. Merck Serono 
assumed that the weights of all patients are the same, at 64 kg. Again, we modelled the 
distribution of body weights in a population receiving palliative chemotherapy for colorectal 
cancer, with 66% men and 34% women. The details are given in Appendix 12 and we calculate the 
mean weight as 74.9 kg. If we assume that all patients have the same mean weight of 74.9 kg, the 
dose per administration of panitumumab, allowing for wastage, is 500 mg. However, assuming a 
distribution for the doses across patients, the mean dose per patient per administration, allowing 
for wastage, is 499 mg. Again, assuming a distribution for dosages has little effect on the mean 
dose per person and hence on cost-effectiveness.
We assume no drug costs for patients in the best supportive care treatment arm. This reflects the 
experience of the cetuximab compared with best supportive care RCT, that is, that only a very 
small proportion of patients in the best supportive care arm took expensive drug treatments (e.g. 
2.5% of patients took irinotecan before progression) (see p. 164, Merck Serono’s submission69).
Dose intensities
For consistency between the costs of the drugs and the clinical outcomes, it is necessary to model 
the amounts of the drugs actually taken in the relevant clinical trials. The dose intensity of a drug 
is defined as the amount of drug administered in a trial as a proportion of the amount that would 
have been administered if there had been no dose reductions or dose interruptions. This does not 
TABLE 44 Drug prices used in the PenTAG model
Dose and frequency Price
Cost per month model cycle
No vial wastage With vial wastage
Cetuximab (Erbitux)
Initially 400 mg/m2 body area, 
followed by weekly 250 mg/m2
£136.50 per 20-ml (100-mg) vial, 
£682.50 per 100-ml (500-mg) viala
£3108 first month, £2730 
subsequently
£3421 first month, £3026 
subsequently
Panitumumab (Vectibix)
6 mg/kg every 2 weeks 20 mg/ml, net price: £379.29 per 
5-ml vial, £1517.16 per 20-ml vial
£3693 £4104
Irinotecan (generic)
180 mg/m2 every 2 weeks £49.03 per 2-ml vial, 20 mg/ml £882 £935
a The price of cetuximab is given by Merck. The price quoted in BNF 6176 is higher, at £178.10 per 20-ml (100-mg) vial and £890.50 per 100-
ml (500-mg) vial.
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include people who withdraw from treatment because of adverse events. Mean dose intensities 
per person used in our model are given in Table 45. We assume a dose intensity for panitumumab 
plus best supportive care of 100%.
For the probabilistic sensitivity analysis we modelled the dose intensities as beta distributions, 
in which we assumed that the dose intensity for any one patient lies between 0% and 100%. The 
standard error for cetuximab plus best supportive care was calculated as:
N
(mean dose intensity)(100%-mean dose intensity)
 [Equation 9]
where n = 287, the number of people taking cetuximab in the RCT of cetuximab plus best 
supportive care compared with best supportive care.
The standard error for cetuximab in combination with irinotecan was calculated in the same way, 
but with n = 218 from the BOND RCT49 of cetuximab plus irinotecan compared with irinotecan. 
Given that we assumed a mean dose intensity for panitumumab plus best supportive care of 100% 
and that we specify that the dose intensity per person lies between 0% and 100%, this forces the 
standard error of the dose intensity for panitumumab plus best supportive care to be 0%. Clearly, 
there should be no correlation between the dose intensities across drugs.
Drug costs per month, drug costs adjusted for dose intensity, and drug administration costs (see 
the following section) are shown in Figure 12.
Drug administration costs
According to the Summary of Product Characteristics the administration of drugs should be 
as follows:
 ■ cetuximab: the first dose is administered as a 120-minute intravenous infusion and all 
subsequent doses are administered as 60-minute infusions28
 ■ panitumumab is administered as a 60-minute intravenous infusion29
 ■ irinotecan for use in combination therapy is administered as an intravenous infusion over 
30–90 minutes followed by infusion with 5-FU/FA.89
Merck Serono assumes that cetuximab and panitumumab cost £180 per infusion, corresponding 
to the HRG ‘Deliver simple parenteral chemotherapy at first attendance’, ‘Daycase and regular 
day/night’ from the NHS reference costs 2008–2009.77 Merck Serono also assumes that an infusion 
of cetuximab and irinotecan, when given together, costs £213, corresponding to the HRG ‘Deliver 
more complex chemotherapy at first attendance’, ‘Daycase and regular day/night’, also from the 
NHS reference costs 2008–2009.77
TABLE 45 Dose intensities used in the PenTAG model
Drug Treatment arm
Mean dose 
intensity
Standard 
error Source
CET CET + BSC 98% 0.8% Merck Serono submission, p. 11069
CET CET + IRIN 94% 1.6% Merck Serono submission, p. 11069
IRIN CET + IRIN 90% 2.0% Merck Serono submission, p. 11069
PAN PAN + BSC 100% 0.0% Amgen’s response to PenTAG’s questions (see Appendix 13)
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PAN, panitumumab.
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By contrast, Roche assumes a cost of £218 for the administration of bevacizumab, cetuximab 
and cetuximab plus irinotecan, corresponding to the HRG ‘Deliver subsequent elements of a 
chemotherapy cycle’, ‘Outpatients’, also from the NHS reference costs 2008–2009,77 although we 
note that the database lists this as £227, not £218.
In common with Roche, and unlike Merck Serono, we assume the cost of £227 in 2008–9 prices 
for the intravenous administration of cetuximab monotherapy and panitumumab, corresponding 
to the HRG SB15Z ‘Deliver subsequent elements of a chemotherapy cycle’, ‘Outpatients’ from the 
NHS reference costs 2008–2009.77 We calculate that non-drug NHS costs have typically increased 
at approximately 4% per annum over the last 5 years, using the Hospital & Community Health 
Services Pay & Prices Index.79 Inflating the administration costs over 3 years at 4% per annum, 
from 2008–9 to 2011–12, the date of this appraisal, gives £255 per administration.
For patients in the cetuximab plus irinotecan group, when irinotecan is administered (every 
2 weeks) it is given during the same visit to the hospital as for cetuximab (every week). We 
assumed a cost of £255 for the administration of cetuximab and half this amount, £128, for the 
subsequent administration of irinotecan. We did not assume the same cost for the administration 
of irinotecan because, according to our clinical advisor, the patient will already be mostly set up 
to receive the second drug, irinotecan, after the first drug, cetuximab. At the other extreme, we 
do not assume £0 for the administration of irinotecan because there will still be some nursing 
functions to perform. In the absence of further information, we assume the average of these costs, 
that is, £128.
When we estimated the total acquisition cost per patient of cetuximab and cetuximab plus 
irinotecan, we assumed that patients took these drugs while in progression-free survival. Also, 
we estimated the total acquisition cost per patient of panitumumab based on the mean of 10 
doses reported in the panitumumab plus best supportive care compared with best supportive 
care RCT.32 For the purpose of calculating the total administration cost per patient of all these 
treatments, we assumed the same mean number of administrations as we did in our calculation 
of the total acquisition cost per patient. Figure 12 displays one important component of this 
calculation, the mean administration cost per person per month by treatment.
Pharmacy drug preparation costs
All drugs require preparation by a hospital pharmacist. We costed for the time of drug 
preparation as follows. The preparation times per infusion of bevacizumab, irinotecan and 
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cetuximab according to the task (e.g. clinical check of prescription, drug reconstitution and 
labelling of product) were determined to be equal (Kate Copland, personal communication; see 
Appendix 12). We assume that the same schedule applies to panitumumab. Using the information 
in Appendix 12, we calculate the total cost of the preparation of one infusion as £15 for all drugs.
Probabilistic sensitivity analysis: drug administration and pharmacy preparation For the 
probabilistic sensitivity analysis, we modelled the cost of a single drug administration (including 
pharmacy preparation) as a gamma distribution. We tried to capture the broader uncertainty of 
this variable given that there may be alternative sources for this cost in addition to the source that 
we chose, namely, the NHS reference costs 2008–2009. This was achieved by setting the standard 
error equal to 20% of the mean cost. This is the same approach as that used by Merck Serono, that 
is, setting the standard error equal to 20% of the mean for variables for which data on uncertainty 
are not available. We assumed perfect correlation between cetuximab plus best supportive care 
and panitumumab plus best supportive care by setting the administration costs equal for each 
simulation. The cost of administration of cetuximab plus irinotecan was also set to correlate 
perfectly with the other drug administration costs, and for each simulation we set it equal to the 
cost for the other drugs multiplied by the ratio of the mean cost for cetuximab plus irinotecan to 
the mean cost for the other drugs.
Medical management costs
Our clinical expert advised us on the nature and frequency of medical management (Table 46).
In common with Merck Serono, we took our estimate of the cost of medical management for 
all treatment groups in progressive disease from a study of UK patients with breast cancer, 
reported by Remak and Brazil.78 Once patients are off active drug treatment, and at the end stage 
of metastatic cancer, resources to alleviate pain and other symptoms are similar across cancer 
types and therefore the data from the breast cancer study are appropriate. Table 5 from Remak 
and Brazil reports the monthly cost in progressive disease as £675 per patient in year 2000 prices. 
This represents mostly medication, hospitalisations, hospice stays, outpatient visits, scans and 
laboratory tests. Inflating the cost at 4% per annum over 11 years, from 2000 to 2011, gives £1039 
per month. This is noticeably higher than the £785 used by Merck Serono, even though it also 
used Remak and Brazil to estimate this cost. We believe that this difference arises because Merck 
Serono incorrectly inflated the cost over a shorter time period.
Our clinical expert believes that blood tests would be performed once every 2 weeks for people 
taking cetuximab plus irinotecan and once per month for people on all other active drug 
treatments. Patients in the best supportive care group would have no blood tests. We have not 
modelled the cost of blood tests because the cost per test is negligible, at about £3.28 [£2.92 from 
NHS reference costs 2008–2009, speciality code DAP823, Haematology (excluding anticoagulant 
services),77 inflated by 4% per annum over 3 years].
Unlike Merck Serono, we assumed no magnetic resonance imaging scans. Our clinical advisor 
suggests that scans would be performed only for patients for whom tumour resection is an 
option. There would be very few such patients in this patient population because they are taking 
late-line drugs.
Merck Serono states that some patients in the RCT of cetuximab plus best supportive care 
compared with best supportive care received radiotherapy for palliation of symptoms in 
progressive disease in both treatment groups (see p. 203, Merck Serono’s submission69). It 
calculates the total cost of radiotherapy per patient as £34 for patients in the cetuximab plus 
best supportive care group and £46 for patients in the best supportive care group; however, 
given that these figures are dwarfed by other costs in the model, we do not cost for radiotherapy 
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received in progressive disease. Similarly, Merck Serono states that some patients in the RCT of 
cetuximab plus best supportive care compared with best supportive care received chemotherapy 
for palliation of symptoms (see p. 204, Merck Serono’s submission69). It calculates the total cost of 
chemotherapy per patient as £359 for patients in progression-free survival in the best supportive 
care group, £624 in progressive disease in the cetuximab plus best supportive care group and 
£827 in progressive disease in the best supportive care group. We do not cost for palliative 
chemotherapy: first, because use of palliative chemotherapy in clinical practice may differ from 
that in the RCT; second, because the costs are very small compared with other costs; and, third, 
because the progressive disease chemotherapy costs for the two treatment arms nearly cancel 
each other out.
For the probabilistic sensitivity analysis, we modelled each medical management cost as a gamma 
distribution. We tried to capture the broader uncertainty of these variables given that there may 
be alternative sources for these costs in addition to the sources that we chose. This was achieved 
by setting the standard errors of all costs equal to 20% of the mean costs, which reflects much 
uncertainty and because this gives a plausible range of simulated costs. Also, we assumed that all 
medical management costs are independent of all other model parameters.
Costs of treating adverse events
As explained in Severe adverse events, in our base case we base our estimates of the mean costs 
of treating adverse events on those calculated by Merck Serono. The mean costs per person 
assumed by Merck Serono are £2760 for best supportive care, £3671 for cetuximab plus best 
supportive care, £880 for panitumumab plus best supportive care and £3671 for cetuximab plus 
irinotecan; however, we use only Merck Serono’s values for best supportive care, cetuximab plus 
best supportive care and cetuximab plus irinotecan. This approach seems reasonable given that 
(1) Merck Serono has performed an extensive analysis of these costs from its RCT of cetuximab 
compared with best supportive care,47 (2) we have found no logical flaws in its calculations (see 
TABLE 46 Medical management costs in the PenTAG model
Health state Population Frequency
Mean 
cost
Mean cost 
per 1-month 
model cycle Source
Consultant outpatient visits
Progression-
free survival
During all active 
drug treatmenta
1 visit per 
2 weeks
£136 
per 
visit
£295 £121 per visit (n = 106), NHS reference costs 2008–2009 
– NHS Trusts and PCTs combined Consultant Led: Follow up 
Attendance Non-Admitted Face to Face Service Code 370: 
Medical oncology;77 £136 inflated to 2011/12 at 4% per 
annum79
BSC group Never £0
Computerised tomography scans
Progression-
free survival
During all active 
drug treatmenta
Every 
3 months
£112 
per 
scan
£37 £100 (interquartile range £75–109, n =162), NHS reference 
costs 2008–2009 – NHS Trusts and PCTs combined Diagnostic 
Imaging: Outpatient Computerised Tomography Scan, one area, 
no contrast. Currency code RA08Z;77 £112 inflated to 2011/12 
at 4% per annum79
BSC group Never £0
Medication, hospitalisations, hospice stays, outpatient visits, scans and laboratory tests
Progressive 
disease
All treatment 
groups
N/A £1039 Remak and Brazil78 inflated by 4% per annum from 2000 to 
2011
BSC, best supportive care; N/A, not applicable; PCT, primary care trusts.
a Cetuximab, cetuximab + irinotecan, bevacizumab or panitumumab.
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Chapter 5) and (3) the costs estimated by Merck Serono are very small compared with other 
costs, for example drug costs.
We have not used Merck Serono’s cost of £880 for treating adverse events for panitumumab 
plus best supportive care because its justification for this figure seems invalid (see Chapter 5). 
In particular, it seems unreasonable that the cost for panitumumab plus best supportive care 
should be less than that for best supportive care given that the incidence of grade 3 and 4 adverse 
events is greater for panitumumab plus best supportive care than for best supportive care for 
virtually every adverse event category.7 Instead, we set the mean cost of treating adverse events 
for panitumumab plus best supportive care equal to that for best supportive care, at £2760 per 
person. The true value for panitumumab plus best supportive care may be somewhat higher than 
that for best supportive care and we explore this in a sensitivity analysis.
For the probabilistic sensitivity analysis, we model all costs of treating adverse events as gamma 
distributions. Given the lack of an obvious choice for the standard errors, we chose the pragmatic 
solution of setting all standard errors equal to 20% of each mean. It is also very difficult to 
parameterise the correlations between these costs across treatments. For simplicity, we set the 
cost for panitumumab plus best supportive care equal to that for best supportive care for each 
simulation, and these costs were independent of the cost for cetuximab plus best supportive care, 
which itself was independent of the cost for cetuximab plus irinotecan.
Deterministic one-way sensitivity analysis
We performed several one-way sensitivity analyses for the cost-effectiveness of cetuximab 
compared with best supportive care, panitumumab compared with best supportive care and 
cetuximab plus irinotecan compared with best supportive care.
Probabilistic sensitivity analysis
We performed probabilistic sensitivity analysis to incorporate parameter uncertainty in the 
cost-effectiveness analysis. Values for each stochastic parameter in each of 1000 simulations 
of the cost-effectiveness model were drawn at random from a specified distribution. The 
distributions, standard errors and correlations for all parameters are given in Evidence to inform 
model parameters. The results are plotted on cost-effectiveness planes and cost-effectiveness 
acceptability curves, which show the probability that a treatment is the most cost-effective given a 
particular willingness-to-pay threshold.
The Peninsula Technology Assessment Group’s 
cost-effectiveness results
We present our cost-effectiveness results in this section. We present and discuss first the base-
case results and then the results of the sensitivity analyses.
Table 47 presents the aggregated totals for the base-case results for the four treatments 
and Table 48 displays the incremental results compared with best supportive care and the 
corresponding cost-effectiveness ratios.
Survival results
The relative proportions of patients in each health state for each treatment throughout the time 
horizon of the model are displayed in Figure 13. The mean duration in each health state for each 
treatment (as reported in Table 47) is represented in these graphs by the area under each curve. 
Accordingly, mean progression-free survival is represented by the area under the dotted line, 
and the area between the dotted line and the solid overall survival curve represents the mean 
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progressive disease time. As expected, virtually all patients are predicted to have died 3 years 
from the start of treatment.
We predict that average progression-free survival is least for people under best supportive care 
(0.23 years = 2.7 months), greater for cetuximab plus best supportive care and panitumumab plus 
best supportive care [0.40 and 0.42 years respectively (approximately 5 months)] and greatest 
for cetuximab plus irinotecan (0.73 years = 8.8 months) (see Table 47 and Figure 13). Given that 
drugs are taken largely until progression, cetuximab plus best supportive care and panitumumab 
plus best supportive care are taken for similar times (0.40 and 0.49 years respectively) and 
cetuximab plus irinotecan is taken for longer (0.73 years).
Next, we predict that people spend a similar time in progressive disease on best supportive care 
and panitumumab plus best supportive care (0.29 years = 3.4 months), longer in progressive 
disease on cetuximab (0.44 years = 5.2 months) and longer still in progressive disease on 
cetuximab plus irinotecan (0.65 years = 7.8 months). Note that the time in progressive disease 
on panitumumab plus best supportive care is uncertain because it is calculated from overall 
survival for best supportive care in the panitumumab plus best supportive care compared with 
best supportive care RCT, which is confounded because of crossover of people from the best 
supportive care to the panitumumab plus best supportive care arm. The time in progressive 
disease on cetuximab plus irinotecan is even more uncertain because it is calculated from 
overall survival for cetuximab plus irinotecan, which is highly uncertain (see Overall survival, 
progression-free survival and treatment duration, Cetuximab plus irinotecan). Average overall 
TABLE 47 Peninsula Technology Assessment Group base-case results: patients with KRAS WT status
CET PAN CET + IRIN BSC
Life-years (mean, undiscounted)
Time on drug treatment 0.40 0.49 0.73a N/A
Progression free 0.40 0.42 0.73 0.23
Post progression 0.44 0.29 0.65b 0.29
Total (mean) 0.84 0.71 1.38b 0.51
Total (median) 0.75 0.60 1.25b 0.40
QALYs (mean, discounted) 
Progression free 0.32 0.36 0.54 0.17
Post progression 0.29 0.19 0.43b 0.19
Total 0.61 0.56 0.97b 0.36
Costs (£) (mean, discounted)
KRAS test 296 296 296 0
Drug costs 14,408 23,643 32,022a 0
Drug administration 5546 3374 12,714a 0
Consultant monitoring appointment 1397 1479 2533 0
Computerised tomography scans 178 188 322 0
BSC in progressive disease 5304 3473 7790b 3496
Adverse events 3671 2760 3671 2760
Total 30,800 35,213 59,348 6256
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; N/A, not applicable; PAN, panitumumab.
a Uncertain because time on cetuximab + irinotecan treatment not reported.
b Highly uncertain because of uncertainty in overall survival (see Overall survival for cetuximab plus irinotecan).
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TABLE 48 Peninsula Technology Assessment Group base-case incremental results vs best supportive care for patients 
with KRAS WT status
CET vs BSC PAN vs BSC CET + IRIN vs BSC
Life-years (mean, undiscounted)
Progression free 0.17 0.20 0.50
Post progression 0.15 0.00 0.37a
Total (mean) 0.32 0.19 0.87a
Total (median) 0.35 0.20 0.85a
QALYs (mean, discounted) 
Progression free 0.15 0.19 0.37
Post progression 0.10 0.00 0.24a
Total 0.25 0.19 0.60a
Costs (£) (mean, discounted)
KRAS test 300 300 300
Drug costs 14,400 23,600 32,000b
Drug administration 5500 3400 12,700b
Consultant monitoring appointment 1400 1500 2500
Computerised tomography scans 200 200 300
BSC in progressive disease 1800 0 4300a
Adverse events 900 0 900
Total 24,500 29,000 53,100
Cost per life-year gained 78,000 145,000 64,000c
Cost per QALY 98,000 150,000 88,000c
BSC, best supportive care; CET, cetuximab; PAN, panitumumab; IRIN, irinotecan.
a Highly uncertain because of uncertainty in overall survival (see Overall survival for cetuximab plus irinotecan).
b Uncertain because time on cetuximab + irinotecan treatment not reported.
c Highly uncertain because of uncertainty in overall survival and because time on cetuximab + irinotecan treatment not reported.
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survival, the sum of progression-free survival and progressive disease, is least for best supportive 
care (0.51 years = 6.2 months), greater for cetuximab plus best supportive care and panitumumab 
plus best supportive care (0.84 and 0.71 years or 10.0 and 8.5 months respectively) and greatest 
for cetuximab plus irinotecan (1.38 years = 16.6 months), which we repeat is very uncertain.
The relative QALYs in progression-free survival and progressive disease are similar to the 
relative life-years in progression-free survival and progressive disease. To be more precise the 
relative mean QALYs in progression-free survival for cetuximab plus best supportive care and 
panitumumab plus best supportive care compared with best supportive care (e.g. QALYs in 
progression-free survival for cetuximab compared with QALYs in progression-free survival for 
best supportive care) are greater than the relative mean life-years (e.g. progression-free survival 
for cetuximab compared with progression-free survival for best supportive care) because we 
assume that the QoL of people on these drugs is better than the QoL on best supportive care. 
This is not the case for cetuximab plus irinotecan because we assume that the QoL of people on 
this treatment is the same as the QoL for best supportive care. This is also not the case for QALYs 
and life-years in progressive disease because we assume that the QoL of all people is equal in 
progressive disease.
Cost results
We now turn to the expected costs per person. The expected drug acquisition costs are by far the 
largest single cost item (see Table 47) and account for the largest incremental costs compared 
with best supportive care (Figure 14). The acquisition costs are least for cetuximab plus best 
supportive care (about £14,000 per person), greater for panitumumab plus best supportive care 
(about £24,000 per person) and greatest for cetuximab plus irinotecan (£32,000 per person), 
although the last figure is particularly uncertain given that the mean duration of cetuximab plus 
irinotecan treatment is not reported. The expected drug acquisition costs are calculated as the 
product of the mean drug acquisition cost per person per unit time and the discounted mean 
duration of drug treatment. Figure 12 suggests that the mean drug acquisition cost per person 
per unit time, allowing for dose intensity, is lowest for cetuximab monotherapy (£3000 per 
month), greater for cetuximab plus irinotecan (£3700 per month) and greatest for panitumumab 
plus best supportive care (£4100 per month). From Table 47, cetuximab plus best supportive 
care and panitumumab plus best supportive care are taken for similar times (0.40 and 0.49 years 
respectively) and cetuximab plus irinotecan is taken for much longer (0.73 years). Combining 
these two pieces of information, the expected drug acquisition cost is least for cetuximab plus 
best supportive care because it is both the cheapest per person per unit time and is taken for the 
least time. The expected drug acquisition cost is greatest for cetuximab plus irinotecan because 
the acquisition cost per unit time is nearly as great as for panitumumab plus best supportive care 
and because we predict that it is taken for far longer than the other two treatments.
The expected drug administration costs and expected costs in progressive disease are the next 
largest single cost items (see Table 47); however, the cost-effectiveness of the drugs compared 
with best supportive care is influenced more by expected drug administration costs because these 
account for larger incremental costs compared with best supportive care (see Figure 14). Similar 
to the total per person drug acquisition costs, these are calculated as the product of the mean 
drug administration cost per person per unit time and the discounted mean duration of drug 
treatment. From Figure 12, the mean drug administration cost per person per unit time is lowest 
for panitumumab (£600 per month) because it is given relatively infrequently (every 2 weeks), 
greater for cetuximab plus best supportive care (£1200 per month) because it is given relatively 
frequently (once per week) and greatest for cetuximab plus irinotecan (£1500 per month) because 
cetuximab plus best supportive care is given every week and there are two drugs to administer 
every second week. From Table 47, cetuximab plus best supportive care and panitumumab plus 
best supportive care are taken for similar times (0.40 and 0.49 years respectively) and cetuximab 
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plus irinotecan is taken for much longer (0.73 years). Combining this information, the expected 
total drug administration cost is least for panitumumab plus best supportive care because it is 
easily the least expensive per person per unit time and is taken for much less time than cetuximab 
plus irinotecan and for a similar time as cetuximab plus best supportive care. The expected total 
drug administration cost for cetuximab plus irinotecan is by far the greatest because it has the 
greatest administration cost per unit time and because we predict that it is taken for far longer 
than the other two treatments.
Absolute costs for best supportive care in progressive disease are fairly large for all treatments 
(between £3500 and £7800), but the incremental costs compared with best supportive care 
are small, with the exception of the cetuximab plus irinotecan group, because the mean times 
spent in progressive disease are fairly similar between treatments, again with the exception of 
cetuximab plus irinotecan (see Table 47).
All other costs (KRAS testing, consultant monitoring appointments, computerised tomography 
scans and treatment of serious adverse events) are much smaller and therefore have very little 
impact on cost-effectiveness.
Cost-effectiveness results
Combining all of the information on expected costs and QALYs per person, we estimate the 
following ICERs:
 ■ cetuximab plus best supportive care compared with best supportive care: £98,000 per QALY
 ■ panitumumab plus best supportive care compared with best supportive care: £150,000 
per QALY
 ■ cetuximab plus irinotecan compared with best supportive care: £88,000 per QALY.
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Our estimate of the ICER for cetuximab plus best supportive care compared with best supportive 
care is based on the relevant clinical effectiveness evidence from a high-quality RCT,37 
although we caution that, although we have some evidence for the mean treatment duration 
of cetuximab, the precise information is not published. The ICER for panitumumab plus best 
supportive care compared with best supportive care is based on relevant clinical effectiveness 
evidence from another high-quality RCT;7 however, there remains some uncertainty because 
we rely on an adjustment for the crossing over of many people from the best supportive care 
to the panitumumab plus best supportive care treatment group, and there is uncertainty about 
the accuracy of the adjustment. The ICER for cetuximab plus irinotecan compared with best 
supportive care is the most uncertain because there is much uncertainty about progression-free 
survival on cetuximab plus irinotecan, and hence treatment duration, and even more uncertainty 
about overall survival (see Overall survival, progression-free survival and treatment duration, 
Cetuximab plus irinotecan).
The incremental costs and QALYs for cetuximab plus best supportive care and panitumumab 
plus best supportive care compared with best supportive care are similar, whereas these quantities 
are far greater for cetuximab plus irinotecan (Figure 15 and see Table 48).
End-of-life criteria
In Tables 49–51 we assess the treatments against all of NICE’s EoL criteria except that concerning 
the patient population size for indications that are outside the scope of this appraisal. Merck 
Serono considers that both cetuximab plus best supportive care and cetuximab plus irinotecan 
qualify for EoL criteria.
Deterministic sensitivity analyses
Cetuximab plus best supportive care compared with best 
supportive care
One-way deterministic sensitivity analyses for cetuximab plus best supportive care compared 
with best supportive care are reported in Table 52 and Figure 16, which show the impact on 
the deterministic ICER of various alterations in model parameters. The sensitivity analyses 
were chosen on the basis of general interest (e.g. assuming no discounting), plausibility (e.g. 
varying mean progression-free survival and overall survival by two standard errors) or Merck 
Serono’s assumptions. None of these sensitivity analyses brings the ICER within usually accepted 
willingness-to-pay thresholds.
The ICER remains above £70,000 per QALY in all cases. The ICER is most sensitive to overall 
survival for best supportive care and cetuximab plus best supportive care, noting that we have 
varied these quantities to the most extreme values (two standard errors from the mean) that are 
consistent with the RCT of cetuximab plus best supportive care compared with best supportive 
care.47 The ICER is reasonably sensitive to mean progression-free survival for cetuximab plus 
best supportive care because this is proportional to the mean duration of cetuximab plus best 
supportive care treatment and hence the cost of cetuximab acquisition, which strongly influences 
the ICER. The ICER is less sensitive to mean progression-free survival for best supportive care 
because this is not associated with any drug costs.
The ICER is fairly sensitive to the administration cost of cetuximab when this is varied within a 
plausible range, because cetuximab is given regularly (once per week). The ICER falls moderately 
when we use Merck Serono’s utilities, although we disagree with these values. The ICER increases 
moderately when we assume that the HRQoL of people in progression-free survival is the same 
for those on cetuximab plus best supportive care and those on best supportive care, but we have 
good evidence that the QoL is higher for people on cetuximab plus best supportive care. The 
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FIGURE 15 PenTAG base-case cost-effectiveness results. BSC, best supportive care; WTP, willingness to pay.
TABLE 49 Assessment of cetuximab plus best supportive care treatment for metastatic colorectal cancer against 
NICE’s EoL criteria
EoL criteria CET + BSC for mCRC
Meets 
criteria Justification
Life expectancy on current standard care 
< 24 months
6.2 months Yes Clear
Treatment provides extension to life 
expectancy compared with current 
standard care of > 3 months
Mean extension to life expectancy of 
3.9 months. Probability life extension 
> 3 months = 0.78
Yes Clear
No alternative treatment with comparable 
benefits is available through the NHS
True Yes Clear
The treatment is licensed or otherwise 
indicated for small patient populations
Merck Serono estimates 260−390 
people per year eligible for CET 
for mCRC (p. 149, Merck Serono’s 
submission69)
Unsure Population is small for mCRC but we do not 
assess use of CET for other indications
The estimates of the extension to life are 
robusta
True Yes Probability extension to life > 3 months = 0.78 
estimated directly from high-quality RCT. No 
adjustment for crossover needed
Overall assessment Unsure We do not assess the size of the patient 
population for other indications, but all other 
EoL criteria are met
BSC, best supportive care; CET, cetuximab; mCRC, metastatic colorectal cancer.
a And can be shown or reasonably inferred from either progression-free survival or overall survival (taking account of trials in which crossover 
has occurred and been accounted for in the effectiveness review).
ICER is insensitive to all other parameters when they are varied within plausible ranges. For 
example, it is insensitive to the discount rate for costs and benefits because patients typically 
have a short life expectancy. Also, for the calculation of the mean cost of cetuximab acquisition, 
the ICER is insensitive to whether we assume that all people have the same body surface area or 
whether we more realistically assume a range of surface areas; however, as already stated, this 
is purely coincidental in this case and we recommend that the distribution should be routinely 
modelled whenever drugs are administered in patient-related doses.
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TABLE 50 Assessment of cetuximab plus irinotecan treatment for metastatic colorectal cancer against NICE’s 
EoL criteria
EoL criteria CET + IRIN for mCRC
Meets 
criteria Justification
Life expectancy on current 
standard care < 24 months
6.2 months Yes Clear
Treatment provides extension 
to life expectancy compared 
with current standard care of 
> 3 months
Mean extension to life expectancy of 10.4 months. 
Probability life extension > 3 months = 0.99
Yes Clear
No alternative treatment 
with comparable benefits is 
available through the NHS
True Yes Clear
The treatment is licensed or 
otherwise indicated for small 
patient populations
Merck Serono estimates 260−390 people per 
year eligible for CET for mCRC (p. 149, Merck 
Serono’s submission69)
Unsure Population is small for mCRC but we do not 
assess use of cetuximab for other indications
The estimates of the 
extension to life are robusta
Estimate of extension to life expectancy relies on 
two important assumptions concerning splitting 
of overall survival data for KRAS WT and KRAS 
mutant patients and use of non-RCT data
Unsure If ‘robust’ means that we have high confidence 
in our mean estimate of overall survival then 
evidence is not ‘robust’. If ‘robust’ means that we 
have high confidence that treatment increases 
overall survival by at least 3 months then 
evidence is ‘robust’
Overall assessment Unsure We are not sure whether or not all criteria passed
CET, cetuximab; IRIN, irinotecan; mCRC, metastatic colorectal cancer.
a And can be shown or reasonably inferred from either progression-free survival or overall survival (taking account of trials in which crossover 
has occurred and been accounted for in the effectiveness review).
TABLE 51 Assessment of panitumumab plus best supportive care treatment for metastatic colorectal cancer against 
NICE’s EoL criteria
EoL criteria PAN + BSC for mCRC
Meets 
criteria Justification
Life expectancy on current 
standard care < 24 months
6.2 months Yes Clear
Treatment provides 
extension to life expectancy 
compared with current 
standard care of > 3 months
Indirect comparison: Mean extension to life 
expectancy of 2.3 months. Probability life 
extension > 3 months = 0.25
Direct comparison: Mean extension to life 
expectancy of 2.7 months. Probability life 
extension > 3 months = 0.39
No Probability that panitumumab provides extension 
to life expectancy compared with current standard 
care of > 3 months is low
No alternative treatment 
with comparable benefits is 
available through the NHS
True Yes Clear
The treatment is licensed 
or otherwise indicated for 
small patient populations
Merck Serono estimates 260−390 people per 
year eligible for CET for mCRC (p. 149, Merck 
Serono’s submission69) and we estimate a similar 
number will be eligible for panitumumab
Yes Population small
The estimates of the 
extension to life are robusta
False Unsure Although extension to life expectancy comes 
from high-quality RCT, adjustment for crossover 
introduces much uncertainty
Overall assessment No Not all EoL criteria passed
BSC, best supportive care; CET, cetuximab; mCRC, metastatic colorectal cancer; PAN, panitumumab.
a And can be shown or reasonably inferred from either progression-free survival or overall survival (taking account of trials in which crossover 
has occurred and been accounted for in the effectiveness review).
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TABLE 52 Sensitivity analyses: cetuximab plus best supportive care vs best supportive care 
Parameter Base case Sensitivity analysis ICER (£)
Base case N/A N/A 98,000
General
Discounting costs and benefits 3.5% per annum 0% per annum 97,000
Effectiveness
Mean PFS CET + BSC 0.40 years 0.47 years (increased by 2 SE) 107,000
0.32 years (decreased by 2 SE) 89,000
Mean PFS BSC 0.23 years 0.27 years (increased by 2 SE) 101,000
0.18 years (decreased by 2 SE) 95,000
Mean OS CET+BSC 0.84 years 1.00 years (increased by 2 SE) 74,000
0.68 years (decreased by 2 SE) 158,000
Mean OS BSC 0.51 years 0.61 years (increased by 2 SE) 127,000
0.41 years (decreased by 2 SE) 81,000
Costs
Dose intensity CET 98% 85% 91,000
Mean mg CET per person 511 mg CET (allowing for distribution of 
body surface area)
500 mg CET (assumed all same body 
surface area)
97,000
KRAS test cost £160 per test Halve cost: £80 98,000
Double cost: £320 99,000
CET administration £270 per administration Halve cost: £135 87,000
Double cost: £540 120,000
Merck Serono assumption: £180 91,000
Medical management costs 
(consultant visit, computerised 
tomography scans, BSC in PD) 
Halve all unit costs or frequencies 91,000
Double all unit costs or frequencies 112,000
Adverse event costs CET + BSC = £3671,
BSC = £2760
CET + BSC and BSC equal 95,000
CET + BSC and BSC doubled 102,000
Utilities
PFS and PD CET + BSC PFS = 0.81, PD = 0.69 ; 
BSC PFS = 0.75, PD = 0.69
Merck Serono values: CET + BSC 
PFS = 0.81, PD = 0.79; BSC PFS = 0.75, 
PD = 0.69
84,000
PFS CET + BSC PFS = 0.81; BSC PFS = 0.75 CET + BSC PFS = BSC PFS = 0.75 108,000
BSC, best supportive care; CET, cetuximab; N/A, not applicable; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
Panitumumab plus best supportive care compared with best 
supportive care
One-way deterministic sensitivity analyses for panitumumab plus best supportive care compared 
with best supportive care are reported in Table 53 and Figure 17. None of these sensitivity 
analyses brings the ICER below usually accepted willingness-to-pay thresholds.
The ICER remains very high, > £110,000 per QALY in all cases. As for the comparison of 
cetuximab plus best supportive care compared with best supportive care, the ICER is most 
sensitive to overall survival for best supportive care and panitumumab plus best supportive 
care. As for cetuximab plus best supportive care compared with best supportive care, the ICER 
is reasonably sensitive to mean progression-free survival for panitumumab plus best supportive 
care, because this is proportional to the mean cost of panitumumab acquisition. The ICER is less 
sensitive to mean progression-free survival for best supportive care because this is not associated 
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with any drug costs. Further, concerning the clinical effectiveness, we addressed the confounding 
due to substantial crossover of people from the best supportive care to panitumumab plus best 
supportive care arms in the RCT as follows. We performed a sensitivity analysis in which we 
varied overall survival for panitumumab plus best supportive care so that the time in progressive 
disease is equal for the panitumumab plus best supportive care and best supportive care arms. 
This models the plausible scenario in which mortality is affected only while patients are on 
panitumumab. Once they are off panitumumab, in progressive disease, the mortality rate is equal 
to that in progressive disease in the best supportive care arm. This analysis was performed by 
adjusting overall survival for panitumumab plus best supportive care only very slightly, from a 
mean of 0.708 years to 0.709 years. Not surprisingly, the ICER changed only incrementally. In 
the base case we took the clinical effectiveness for the best supportive care arm from the RCT 
of cetuximab plus best supportive care compared with best supportive care, not the RCT of 
panitumumab compared with best supportive care. When we use the RCT of panitumumab plus 
best supportive care compared with best supportive care, that is, we perform a direct comparison 
of panitumumab plus best supportive care compared with best supportive care using data only 
from the panitumumab plus best supportive care compared with best supportive care RCT, the 
ICER decreases only slightly.
FIGURE 16 Sensitivity analyses: cetuximab plus best supportive care vs best supportive care. Admin., administration; 
AE, adverse event; BSC, best supportive care; decr., decreased by; incr., increased by; med. manage., medical 
management; OS, overall survival; PFS, progression-free survival; SE, standard error.
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In our base case we assume that panitumumab is typically taken for slightly longer (0.49 years) 
than patients are in progression-free survival for (0.42 years). Indeed, we have good evidence for 
the treatment duration of panitumumab for patients with KRAS WT status, as this is reported 
directly from the RCT. However, in cost-effectiveness analyses of drugs for terminal cancers, 
it is normal to assume that drugs are taken until disease progression. Under this assumption, 
the ICER decreases moderately. The ICER is less sensitive to the drug administration cost than 
the ICER for cetuximab plus best supportive care compared with best supportive care because 
panitumumab is taken less frequently than cetuximab (once every 2 weeks compared with once 
a week respectively). The ICER increases substantially when we assume that the QoL of people 
in progression-free survival is equal for those on panitumumab plus best supportive care and 
those on best supportive care, but we have good evidence that the QoL is higher for people on 
TABLE 53 Sensitivity analyses: panitumumab plus best supportive care vs best supportive care 
Parameter Base case Sensitivity analysis ICER (£)
Base case N/A N/A 150,000
General
Discounting costs and benefits 3.5% per annum 0% per annum 149,000
Effectiveness
Mean PFS PAN + BSC 0.42 years 0.50 years (increased by 2 SE) 161,000
0.35 years (decreased by 2 SE) 138,000
Mean PFS BSC 0.23 years 0.27 years (increased by 2 SE) 155,000
0.18 years (decreased by 2 SE) 145,000
Mean OS PAN + BSC 0.708 years 0.86 years (increased by 2 SE) 110,000
0.58 years (decreased by 2 SE) 254,000
0.709 years, so that PD PAN = PD BSC 150,000
Mean OS BSC 0.51 years 0.61 years (increased by 2 SE) 221,000
0.41 years (decreased by 2 SE) 116,000
PAN + BSC and BSC effectiveness BSC from CET + BSC vs BSC RCT, 
PAN from PAN + BSC vs BSC RCT, 
adjusted for indirect comparison
All from PAN + BSC vs BSC RCT only 
(direct comparison)
142,000
Costs
Dose intensity PAN 100% 85% 132,000
Mean mg PAN per person 499 mg (allowing for distribution of 
weights)
500 mg (all people assumed same 
weight)
150,000
Mean duration PAN therapy 0.49 years Same as mean PFS: 0.42 years 132,000
KRAS test cost £160 per test Halve cost: £80 150,000
Double cost: £320 152,000
PAN administration £270 per administration Halve cost: £135 142,000
Double cost: £540 168,000
Merck Serono assumption: £180 144,000
Medical management costs 
(consultant visit, computerised 
tomography scans, BSC in PD) 
Halve all unit costs or frequencies 146,000
Double all unit costs or frequencies 159,000
Adverse events costs PAN + BSC = BSC = £2760 PAN + BSC same as 
CET + BSC = £3671, BSC = £2760
155,000
Utilities PAN + BSC PFS = 0.87; 
BSC PFS = 0.75
PAN + BSC PFS = BSC PFS = 0.75 203,000
BSC, best supportive care; CET, cetuximab; N/A, not applicable; OS, overall survival; PAN, panitumumab; PD, progressive disease;  
PFS, progression-free survival.
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panitumumab plus best supportive care. The ICER is insensitive to all other parameters when 
they are varied within plausible ranges. For example, for the calculation of the mean cost of 
panitumumab acquisition, the ICER is insensitive to whether we assume that all people are the 
same weight or whether we more realistically assume a distribution of weights.
Cetuximab plus irinotecan compared with best supportive care
One-way deterministic sensitivity analyses for cetuximab plus irinotecan compared with best 
supportive care are reported in Table 54 and Figure 18.
The ICER remains very high, > £55,000 per QALY in all cases. The ICER is most sensitive to 
overall survival for cetuximab plus irinotecan. In particular, it is more sensitive to overall survival 
for cetuximab plus irinotecan than to overall survival for best supportive care because we have 
imposed a higher coefficient of variation (ratio of standard error to mean) for overall survival for 
cetuximab plus irinotecan to reflect its greater uncertainty. The alternative method of estimating 
overall survival for cetuximab plus irinotecan, that is, in which we do not adjust for crossover in 
the BOND RCT, yields a substantially higher ICER (see Appendix 15, Method A). However, we do 
not favour this approach because we should make some adjustment for treatment crossover. The 
ICER changes moderately when we use two other alternative methods to estimate overall survival 
for cetuximab plus irinotecan, that is, when we use information on progression-free survival 
and when we simply set our estimate of the median overall survival for patients with KRAS WT 
FIGURE 17 Sensitivity analyses: panitumumab plus best supportive care vs best supportive care. Admin., 
administration; AE, adverse event; BSC, best supportive care; decr., decreased by; incr., increased by; med. manage., 
medical management; OS, overall survival; PD, progressive disease; PFS, progression-free survival; SE, standard error.
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status on cetuximab plus irinotecan for our model equal to that from the BOND RCT without 
adjustment for indirect comparison (see Appendix 15, Methods C and D).
The ICER increases substantially when we adjust overall survival for cetuximab plus irinotecan 
so that the mean time in progressive disease for cetuximab plus irinotecan equals the mean time 
in progressive disease for best supportive care. As explained in the last section, this models the 
plausible scenario in which mortality is affected only whilst people are on active treatment, in 
this case cetuximab plus irinotecan. We believe that this is a useful sensitivity analysis given the 
substantial uncertainty in overall survival for cetuximab plus irinotecan.
The ICER is sensitive to mean progression-free survival for cetuximab plus irinotecan because 
this is proportional to the mean cost of cetuximab plus irinotecan acquisition and because it is 
very uncertain. The ICER is less sensitive to mean progression-free survival for best supportive 
care because this is not associated with any drug costs and because it is more certain. The ICER 
increases substantially when we model progression-free survival for cetuximab plus irinotecan 
using the cetuximab plus best supportive care compared with best supportive care RCT (see 
Appendix 14, Method A). The ICER is largely unchanged when we model progression-free 
survival for cetuximab plus irinotecan using alternative methods (see Appendix 14, Methods 
B–D), that is, using only additional information from De Roock and colleagues,48 Lievre and 
colleagues86 or De Roock and colleagues83 respectively.
In our base case, we predict that people take both irinotecan and cetuximab for a mean of 
0.73 years, that is, nearly 9 months. We understand that irinotecan may typically be tolerated 
by patients for rather less than this period, given its toxicity. Therefore, we also modelled the 
scenario in which irinotecan is taken for substantially less time (0.42 years or 5 months), but 
the treatment duration of cetuximab is unchanged at 0.73 years. In this case the ICER decreases 
only marginally because irinotecan is substantially less expensive than cetuximab. In a different 
sensitivity analysis we modelled the time on treatment for both irinotecan and cetuximab as 
0.42 years, that is, 5 months. This corresponds approximately to the mean progression-free 
survival time for all patients (KRAS WT and KRAS mutant status combined) on cetuximab plus 
irinotecan in the BOND RCT, in which the median progression-free survival time is 4.1 months. 
However, we do not suggest that this treatment duration of 0.42 years for cetuximab plus 
irinotecan is realistic. Instead, it should be seen as being lower than the true value because the 
0.42 years represents the treatment duration for all patients (KRAS WT and KRAS mutant status 
combined) whereas we are modelling patients with KRAS WT status only, and progression-free 
survival and hence treatment duration for patients with KRAS WT status is longer than for 
those with KRAS mutant status. This correlates with other sources of evidence, for example the 
cetuximab plus best supportive care compared with best supportive care RCT47 and De Roock 
and colleagues,48 De Roock and colleagues83 and Lievre and colleagues.86
We considered the following further sensitivity analysis on the duration of cetuximab and 
irinotecan treatment. In this analysis we assumed that the duration of treatment is a function of 
response time and that the mean response time for patients taking the combination therapy is 
the same as that for cetuximab monotherapy. We also assumed that the difference between the 
mean time on the combination therapy and the mean time on the monotherapy was due entirely 
to the difference in the proportions of patients responding between the combination therapy and 
the monotherapy. The mean duration of cetuximab plus irinotecan therapy was then estimated as 
equal to the mean duration of cetuximab monotherapy multiplied by the estimated response rate 
for KRAS WT patients in the cetuximab plus irinotecan arm of the BOND RCT divided by the 
measured response rate for KRAS WT patients in the cetuximab arm of the cetuximab compared 
with best supportive care RCT. The response rate for KRAS WT patients in the cetuximab arm 
of the cetuximab compared with best supportive care RCT is 12.8%.47 Also, the response rate for 
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TABLE 54 Sensitivity analyses: cetuximab plus irinotecan vs best supportive care 
Parameter Base case Sensitivity analysis ICER (£)
Base case N/A N/A 88,000
General
Discounting costs and 
benefits
3.5% per annum 0% per annum 86,000
Effectiveness
Median PFS CET + IRIN 0.59 years 0.82 years (increased by 2 SE) 109,000
0.36 years (decreased by 2 SE) 65,000
0.88 years, using CET vs BSC RCT (see Appendix 14, Method A) 114,000
0.61 years, using De Roock et al.48 (see Appendix 14, Method B) 90,000
0.59 years, using Lievre et al.86 (see Appendix 14, Method C) 87,000
0.57 years, using De Roock et al.83 (see Appendix 14, Method D) 86,000
Mean PFS BSC 0.23 years 0.27 years (increased by 2 SE) 89,000
0.18 years (decreased by 2 SE) 86,000
Median OS CET + IRIN 1.25 years 1.75 years (increased by 2 SE) 62,000
0.75 years (decreased by 2 SE) 191,000
0.91 years, so that PD CET + IRIN = PD BSC 134,000
0.94 years (see Appendix 15, Method A) 129,000
1.48 years (see Appendix 15, Method C) 73,000
1.12 years (see Appendix 15, Method D) 101,000
Mean OS BSC 0.51 years 0.61 years (increased by 2 SE) 96,000
0.41 years (decreased by 2 SE) 80,000
Costs
Dose intensity 94% CET, 90% IRIN 100% CET, 100% IRIN 92,000
85% CET, 85% IRIN 83,000
Mean mg CET + IRIN per 
person
511 mg CET, 352 mg IRIN 
(allowing for distribution of 
body surface area)
500 mg CET, 360 mg IRIN (all people assumed same body 
surface area)
87,000
Mean duration therapies 0.73 years CET, 0.73 years 
IRIN
0.73 years CET, 0.42 years IRIN 81,000
0.42 years CET + IRIN (same as all people in BOND)49 56,000
Dosing schedule IRIN 180 mg/m2 once every 
2 weeks
350 mg/m2 every 3 weeks 90,000
125 mg/m2 for each of 4 weeks with 2 weeks’ rest 88,000
KRAS test cost £160 per test Halve cost: £80 88,000
Double cost: £320 88,000
CET + IRIN administration £270 per administration CET, 
£143 per administration IRIN
Halve both costs 77,000
Double both costs 109,000
IRIN: £0 83,000
Merck Serono assumption total: £196 79,000
Medical management 
costs (consultant visit, 
computerised tomography 
scans, BSC in PD) 
Halve all unit costs or frequencies 82,000
Double all unit costs or frequencies 100,000
Adverse events costs CET = £3671, BSC = £2760 CET and BSC equal 86,000
CET double BSC 89,000
Utilities CET + IRIN PFS = 0.75, 
PD = 0.69 ; BSC PFS = 0.75, 
PD = 0.69
Merck Serono values: CET + IRIN PFS = 0.81, PD = 0.79; 
BSC PFS = 0.75, PD = 0.69
75,000
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
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FIGURE 18 Sensitivity analyses: cetuximab plus irinotecan vs best supportive care. Admin., administration; AE, 
adverse event; BSC, best supportive care; CET, cetuximab; decr., decreased by; incr., increased by; IRIN, irinotecan; 
med. manage., medical management; OS, overall survival; PD, progressive disease; PFS, progression-free survival; SE, 
standard error.
all patients in the cetuximab plus irinotecan arm of the BOND RCT is 22.9%.49 We then estimate 
the response rate for KRAS WT patients in the cetuximab plus irinotecan arm of the BOND RCT 
as the response rate for all patients (22.9%) multiplied by the response rate for the cetuximab 
arm for all patients in the cetuximab compared with best supportive care RCT (8%)47 divided 
by the response rate for the cetuximab arm for all patients in the BOND RCT (10.8%).49 This 
gives the estimated response rate for KRAS WT patients in the cetuximab plus irinotecan arm 
of the BOND RCT of 22.9% × 8%/10.8% = 17.0%. Then, the estimated mean time on cetuximab 
plus irinotecan = 17.0%/12.8% × 0.40 years = 0.53 years, where 0.40 years is the mean time on 
cetuximab monotherapy for KRAS WT patients. Assuming a mean duration of the combination 
therapy of 0.53 years yields an ICER of £66,000 per QALY.
The ICER is fairly sensitive to the drug administration cost. In addition, the ICER falls 
moderately when we use Merck Serono’s utility assumptions, but we disagree with its values for 
cetuximab plus irinotecan. The ICER is insensitive to all other parameters when they are varied 
within plausible ranges. For example, the ICER is insensitive to the dosing regimen of irinotecan, 
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partly because irinotecan is much less expensive than cetuximab, and partly because the dose of 
irinotecan per unit time is similar for all regimes.
Probabilistic sensitivity analysis
The scatterplots shown in Figures 19–21 depict the results of the 1000 simulations of the 
probabilistic sensitivity analysis in terms of the incremental cost–utility of cetuximab plus 
best supportive care, panitumumab plus best supportive care and cetuximab plus irinotecan 
compared with best supportive care. In all simulations, all treatments generated more QALYs 
and more costs than best supportive care. There is clearly more uncertainty in the incremental 
costs and QALYs of cetuximab plus irinotecan compared with best supportive care than in those 
of cetuximab plus best supportive care compared with best supportive care or panitumumab 
plus best supportive care compared with best supportive care. This is because we have assumed 
more uncertainty in the mean progression-free survival and overall survival of cetuximab plus 
irinotecan than in the mean progression-free survival and overall survival of cetuximab plus 
best supportive care and panitumumab plus best supportive care, to reflect the fact that we 
were forced to make assumptions about the effectiveness of cetuximab plus irinotecan whereas 
the effectiveness of the other two treatments was taken directly from RCTs. In all cases the 
incremental costs and QALYs are correlated. This is because we have assumed correlations 
between progression-free survival and overall survival for all treatments. So, for example, the 
longer that patients are in progression-free survival, and hence the higher the total drug cost (as 
this is proportional to the time in progression-free survival), the longer the overall survival, and 
hence the higher the total QALYs.
Figure 22 gives the cost-effectiveness acceptability curves for the four treatments, showing 
the probability that each provides best value for money given a range of willingness-to-pay 
thresholds. We predict that panitumumab plus best supportive care is never the most cost-
effective option, and cetuximab monotherapy is unlikely to be the most cost-effective option 
regardless of the willingness-to-pay threshold. For willingness-to-pay values < £90,000 per QALY, 
best supportive care is likely to be the most cost-effective treatment, and for values > £90,000 
per QALY, cetuximab plus irinotecan is likely to be most cost-effective. For willingness-to-pay 
values of ≤ £60,000 per QALY, we predict that the probability that best supportive care is the most 
cost-effective treatment is approximately 100%.
Comparison of the results of the Peninsula Technology 
Assessment Group, Merck Serono and Mittmann and colleagues42
In the preceding sections we described our cost-effectiveness analyses and those of Merck 
Serono, the manufacturer of cetuximab, and Mittmann and colleagues.42 In this section we 
compare the results of these analyses and discuss the reasons for the different predictions of 
cost-effectiveness from the PenTAG model and the Mittmann evaluation of cetuximab plus best 
supportive care compared with best supportive care relative to Merck Serono’s model; and from 
the PenTAG model of cetuximab plus irinotecan compared with best supportive care relative to 
Merck Serono’s model.
No comparisons of the cost-effectiveness of panitumumab plus best supportive care compared 
with best supportive care for patients with KRAS WT status are possible because Amgen, the 
manufacturer of panitumumab, did not submit a cost-effectiveness analysis to NICE and we are 
not aware of any other relevant fully published models.
We have adjusted the results of Mittmann and colleagues’ evaluation in three ways so that it is as 
comparable as possible with our model and Merck Serono’s model. First, Mittman and colleagues 
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FIGURE 19 Probabilistic sensitivity analysis results: incremental cost–utility per person of cetuximab plus best 
supportive care compared with best supportive care. BSC, best supportive care.
FIGURE 20 Probabilistic sensitivity analysis results: incremental cost–utility per person of panitumumab plus best 
supportive care compared with best supportive care. BSC, best supportive care.
FIGURE 21 Probabilistic sensitivity analysis results: incremental cost–utility per person of cetuximab plus irinotecan 
compared with best supportive care. BSC, best supportive care.
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report the estimated mean acquisition and administration costs of cetuximab combined. We 
separated out these two values. We did this by assuming the same ratio of mean drug acquisition 
cost to administration cost as in our model. Second, and most importantly, we used the same 
cost per mg of cetuximab in our model as Merck Serono used in its model, which is relevant to 
the UK at today’s date. Mittmann and colleagues assumed a cost of C$3.24 per mg, which equals 
£2.05 per mg assuming an exchange rate of £1 = C$1.58 (as at 6 May 2011), whereas we use a cost 
of £1.37 per mg as does Merck Serono. Third, we inflated all non-drug costs at 4% per annum 
over 4 years because all costs reported by Mittmann and colleagues are given at 2007 prices.
Cetuximab plus best supportive care compared with best supportive care
A summary of the cost-effectiveness results for cetuximab plus best supportive care compared 
with best supportive care is given in Tables 55–58. We believe that Mittmann and colleagues’ 
results are worthy of close scrutiny because they focus on the relevant KRAS WT population and 
the trial-based economic evaluation appears to have been conducted to a high standard.
Importantly, the ICER for cetuximab plus best supportive care compared with best supportive 
care from our analysis (£98,000 per QALY) is similar to that from the adjusted results from the 
Mittmann analysis (£101,000 per QALY) but very different to that from Merck Serono’s analysis 
(£48,000 per QALY).
First, note that there are very many similarities between our model and Merck Serono’s model, 
for example we assume the same:
 ■ clinical effectiveness for cetuximab plus best supportive care and best supportive care
 ■ health states of progression-free survival and progressive disease
 ■ cost per mg of cetuximab
 ■ dose intensity for cetuximab of 98% 
 ■ costs of treating adverse events.
In addition, we used similar utilities, the only difference being that we assume a lower utility than 
Merck Serono for cetuximab plus best supportive care in progressive disease.
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FIGURE 22 Probabilistic sensitivity analysis results: cost-effectiveness acceptability curves.
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The difference between Merck Serono’s assessment of cost-effectiveness and our assessment 
of cost-effectiveness is almost entirely caused by the large difference in total mean cost of 
acquisition and administration of cetuximab: for drug acquisition we estimate £14,400 whereas 
Merck Serono estimates £8200, and for drug administration we estimate £5600 whereas Merck 
Serono estimates £2000 (see Table 55). This itself is mostly due to the fact that we estimate a 
far higher mean time on cetuximab treatment than Merck Serono: 0.40 years (4.8 months) 
compared with 0.22 years (2.6 months) (see Overall survival, progression-free survival and 
treatment duration, Cetuximab plus irinotecan for justification of this input). We both assume 
that cetuximab is taken while patients are in progression-free survival, and we assume the same 
mean time in progression-free survival; however, Merck Serono additionally imposes an artificial 
maximum time on cetuximab treatment. When we use Merck Serono’s model and lift its cap on 
the time on treatment, its estimate of the mean time on cetuximab treatment increases from 0.22 
to 0.40 years, equal to our estimate, and the ICER increases from £48,000 per QALY to £75,000 
per QALY. As well as assuming a shorter mean time on treatment, Merck Serono also assumes a 
lower cost per administration than us, £180 compared with £270.
Mittmann and colleagues42 estimate the mean total acquisition cost per person of cetuximab as 
£8900 (see final column in Table 55) using the 2011 UK cost per mg of cetuximab and assuming 
the same proportionate split of costs between cetuximab acquisition and administration as 
in our model. This value is similar to that of Merck but far lower than our value of £14,400. 
Unfortunately, Mittmann and colleagues42 do not give their estimated mean duration of 
cetuximab treatment for patients with KRAS WT status; instead, they mention only that the 
TABLE 55 Comparison of the deterministic results per patient with KRAS WT status of PenTAG, Merck Serono and 
Mittmann and colleagues42
CET + BSC
PenTAG Merck Serono Mittmann unadjusteda Mittmann adjusteda
Life-years (mean, undiscounted)
Time on CET 0.40 0.22 NR
Progression free 0.40 0.40 N/Ab
Post progression 0.44 0.44 N/Ab
Total (mean) 0.84 0.84 0.79
QALYs (mean, discounted)
Progression free 0.32 0.32 N/Ab
Post progression 0.29 0.34 N/Ab
Total (mean) 0.61 0.66 0.51
Costs (£) (mean, discounted)
KRAS testing 300 200 c
Drug costs 14,400 8200 18,500 8900
Drug administration 5500 2000 6000
Medical management in PFS 1600 3700 5100 6000
BSC in PD 5300 4100
Adverse events 3700 3700
Total 30,800 21,800 23,600 20,900
BSC, best supportive care; CET, cetuximab, N/A, not applicable; NR, not reported; PD, progressive disease; PFS, progression-free survival.
a Assuming an exchange rate of £1 = C$1.58 (as at 6 May 2011); all values undiscounted in Mittmann et al.42
b Mittmann et al.’s analysis42 does not split into PFS/PD.
c Not included because it cancels out as Mittmann et al.42 assume testing in both treatment groups.
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median duration of cetuximab treatment in the RCT was 8.1 weeks for the whole population 
(i.e. those with KRAS WT and KRAS mutant status combined). The mean total acquisition cost 
of cetuximab of £8900, given a cost of cetuximab of £1.37 per mg, equates to a mean time on 
cetuximab of approximately 0.23 years, which is similar to that assumed by Merck and far lower 
than that assumed by us.
TABLE 56 Comparison between the PenTAG and Merck Serono models and the trial-based analysis by Mittmann 
and colleagues42
PenTAG Merck Serono Mittmann et al.42
Cost data Modelled Modelled Directly measured
Discounting costs and 
benefits
3.5% per annum 3.5% per annum None
Perspective UK payer UK payer Canadian payer
Duration Lifetime Lifetime 18–19 months
Utilities PFS and PD from Merck Serono 
(CO.17 trial47)
PFS and PD from CO.17 
trial47
Baseline and follow-up from CO.17 trial47
Effectiveness estimates Same mean PFS and OS assumed for CET + BSC vs BSC No extrapolation of OS beyond end of CO.17 trial
BSC, best supportive care; CET, cetuximab; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
TABLE 57 Comparison of the deterministic results for the KRAS WT population of PenTAG, Merck Serono and 
Mittmann and colleagues42 for best supportive care (for comparison with cetuximab)
BSC
PenTAG Merck Serono Mittmann unadjusteda Mittmann adjusteda
Life-years (mean, undiscounted)
Progression free 0.23 0.23b N/Ac
Post progression 0.29 0.29 N/Ac
Total (mean) 0.51 0.51b 0.51
QALYs (mean, discounted)
Progression free 0.17 0.17b N/Ac
Post progression 0.19 0.20 N/Ac
Total (mean) 0.36 0.37b 0.33
Costs (£) (mean, discounted)
KRAS testing 0 0 d
Drug costs 0 0 0
Drug administration 0 0 0
Medical management in PFS 0 2100 2300 2700
BSC in PD 3500 2700
Adverse events 2800 2800
Total 6300 7600 2300 2700
BSC, best supportive care; N/A, not applicable; PD, progressive disease; PFS, progression-free survival.
a Assuming an exchange rate of £1 = C$1.58 (as at 6 May 2011); all values undiscounted in Mittmann et al.42 
b After PenTAG corrected for error in calculation of proportion in PFS at week 0.
c Mittmann et al.’s analysis42 does not split into PFS/PD.
d Not included because it cancels out as Mittmann et al.42 assume testing in both treatment groups.
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There are several further differences between Mittmann and colleagues’ evaluation and Merck 
Serono’s model and our model (see Table 56). Mittmann and colleagues consider costs and 
consequences over 18–19 months, the duration of the cetuximab plus best supportive care 
compared with best supportive care RCT. At the end of the study 77% of patients on cetuximab 
plus best supportive care and 82% on best supportive care had died. However, we believe that 
Mittman and colleagues should have extrapolated overall survival. Mittmann and colleagues 
speculate that if they had extrapolated overall survival their estimated ICER would have fallen. 
The final major difference is that Mittmann and colleagues used different utilities even though 
they also took utilities from the cetuximab plus best supportive care compared with best 
supportive care RCT.
None of the differences in assessed cost-effectiveness between our model and Merck Serono’s 
model is due to differences in effectiveness assumptions; we both assume the same mean 
progression-free survival and overall survival for cetuximab plus best supportive care and best 
supportive care (see Tables 55 and 56 and the survival curves shown in Figures 6–9). Given that 
Mittmann and colleagues42 do not separate the progression-free survival and progressive disease 
health states, we can compare only their estimates of mean overall survival. Their estimated 
overall survival of 0.79 years for cetuximab plus best supportive care is slightly less than, but 
very similar to, the 0.84 years used in both our model and that presented in the Merck Serono 
submission (see Table 55). Mittmann and colleagues’ value is probably lower because they did not 
extrapolate overall survival beyond the trial follow-up period. Their estimated overall survival of 
0.51 years for best supportive care is exactly the same as the value used in both our model and 
Merck Serono’s model.
TABLE 58 Comparison of the deterministic results of PenTAG, Merck Serono and Mittmann and colleagues42 for 
cetuximab plus best supportive care 
CET + BSC
PenTAG Merck Serono Mittmann unadjusteda Mittmann adjusteda
Life-years (mean, undiscounted)
Progression free 0.17 0.17 N/Ab
Post progression 0.15 0.15 N/Ab
Total (mean) 0.32 0.32 0.28
QALYs (mean, discounted)
Progression free 0.15 0.15 N/Ab
Post progression 0.10 0.14 N/Ab
Total (mean) 0.25 0.30 0.18
Costs (£) (mean, discounted)
KRAS testing 300 200 0
Drug costs 14,400 8200 18,500 8900
Drug administration 5500 2000 6000
Medical management in PFS 1600 1600 2800 3300
BSC in PD 1800 1400
Adverse events 900 900
Total 24,500 14,300 21,300 18,200
ICER (incremental cost per QALY) 98,000 48,000c 118,000 101,000
BSC, best supportive care; N/A, not applicable; PD, progressive disease; PFS, progression-free survival.
a Assuming an exchange rate of £1 = C$1.58 (as at 6 May 2011); all values undiscounted in Mittmann et al.42
b Mittmann et al.’s analysis42 does not split into PFS/PD.
c After PenTAG corrected for Merck Serono’s error in calculation of proportion in PFS at week 0.
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Merck Serono’s estimate of total discounted QALYs for cetuximab plus best supportive care, 
at 0.66, is slightly higher than our estimate of 0.61; this is because Merck Serono assumes a 
slightly higher utility for those in progressive disease. Mittmann and colleagues’ estimate of 0.51 
is slightly lower than our value because they assume slightly lower mean overall survival and 
they use slightly different utilities to those used in our model and Merck Serono’s model. Our 
estimate of 0.36 for total QALYs for best supportive care is virtually the same as Merck Serono’s 
value of 0.37 because we use the same mean overall survival and utilities for best supportive care. 
Mittmann and colleagues’ estimate of 0.33 is similar but not the same as our value because they 
have used different utilities.
Merck Serono’s estimate of £3700 for the total mean cost of medical management in progression-
free survival for cetuximab is substantially higher than our estimate of £1600. However, as 
we state in Chapter 5, we believe that Merck Serono’s estimated cost per unit time for those in 
progression-free survival is logically flawed. It has based its estimate on a value from Remak 
and Brazil;78 however, this refers specifically to the treatment of breast cancer, not colorectal 
cancer. Similarly, Merck Serono’s flawed estimate of £2100 for the total mean cost of medical 
management in progression-free survival for best supportive care is substantially higher than our 
estimate of £0. However, coincidentally, we estimate the same mean incremental costs for medical 
management in progression-free survival for cetuximab compared with best supportive care 
(£1600) (see Table 58).
Our estimates for the mean costs of best supportive care in progressive disease for both 
treatments are slightly higher than those of Merck Serono because we have inflated the cost of 
best supportive care in progressive disease per unit time, quoted in Remak and Brazil,78 over a 
greater period of time than Merck Serono.
Cetuximab plus irinotecan compared with best supportive care
A summary of the results from our model and Merck Serono’s model is given in Tables 59–61.
The ICER for cetuximab plus irinotecan compared with best supportive care from our analysis, 
£88,000 per QALY, is much higher than Merck Serono’s ICER of £44,000 per QALY.
As for the comparison of cetuximab plus best supportive care compared with best supportive 
care, first note that there are many similarities between our model and Merck Serono’s model, for 
example we assume:
 ■ similar progression-free survival and overall survival for best supportive care and for 
cetuximab plus irinotecan
 ■ the same health states of progression-free survival and progressive disease
 ■ the same cost per mg for cetuximab and irinotecan
 ■ the same dose intensities of 94% for cetuximab and 90% for irinotecan
 ■ the same costs of treating adverse events
 ■ the same utilities for best supportive care, although we assume lower utilities for cetuximab 
plus irinotecan in progression-free survival and in progressive disease.
As for the comparison of cetuximab plus best supportive care compared with best supportive 
care, the difference between Merck Serono’s and our assessment of cost-effectiveness is almost 
entirely due to the large difference in total mean costs of acquisition and administration of 
cetuximab plus irinotecan: for drug acquisition we estimate £32,000 whereas Merck Serono 
estimates £17,400, and for administration we estimate £12,700 whereas Merck Serono 
estimates £3800.
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Hoyle et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced 
for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated 
with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha 
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
127 Health Technology Assessment 2013; Vol. 17: No. 14DOI: 10.3310/hta17140
Very little of the difference in estimated cost-effectiveness between our model and the Merck 
Serono model is due to differences in effectiveness assumptions because we assume very similar 
mean progression-free survival and overall survival for best supportive care, and similar 
progression-free survival and overall survival for cetuximab plus irinotecan (even though our 
method of estimating the effectiveness for cetuximab plus irinotecan is rather different to Merck 
Serono’s method) (see Tables 59–61 and the survival curves for cetuximab plus irinotecan in 
Figures 10 and 11). Instead, the substantial differences in mean costs of drug acquisition and 
administration are mostly due to the fact that we estimate a far longer mean time on cetuximab 
plus irinotecan treatment than Merck Serono: 0.73 years (8.8 months) compared with Merck 
Serono’s estimate of 0.37 years (4.4 months). As we explained in Overall survival, progression-free 
survival and treatment duration, Cetuximab plus irinotecan, we strongly disagree with Merck 
Serono’s derivation of mean time on cetuximab plus irinotecan treatment. We both assume 
that cetuximab is taken while patients are in progression-free survival; however, Merck Serono 
additionally imposes an artificial maximum time on cetuximab plus irinotecan treatment. When 
we use Merck Serono’s model and lift its cap on the time on treatment, its estimate of the mean 
time on cetuximab plus irinotecan treatment increases from 0.37 to 0.65 years (equal to mean 
progression-free survival), slightly below our estimate of 0.73 years, and its ICER increases 
from £44,000 to £67,000 per QALY. Notice also that, if we use Merck Serono’s estimated mean 
progression-free survival for cetuximab plus irinotecan of 0.65 years, our ICER decreases slightly, 
from £88,000 to £82,000 per QALY. Merck Serono’s estimate of the mean total administration 
cost per person of cetuximab plus irinotecan is lower than our estimate mostly because it assumes 
a far shorter mean time on treatment, but also because it assumes a lower cost per administration 
per month than us: £840 compared with £1480.
TABLE 59 Comparison of the deterministic results of the PenTAG and Merck Serono models for cetuximab plus 
irinotecan for the KRAS WT population
CET + IRIN
PenTAG Merck Serono
Life-years (mean, undiscounted)
Time on CET + IRIN 0.73 0.37
Progression free 0.73 0.65
Post progression 0.65 0.70
Total (mean) 1.38 1.36
QALYs (mean, discounted)
Progression free 0.54 0.53
Post progression 0.43 0.53
Total (mean) 0.97 1.06
Costs (£) (mean, discounted)
KRAS testing 300 160
Drug costs 32,000 17,400
Drug administration 12,700 3800a
Medical management in PFS 2900 6100
BSC in PD 7800 6400
Adverse events 3700 3700
Total 59,300 37,600a
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PD, progressive disease; PFS, progression-free survival.
a After correcting for Merck Serono’s error in which model cell referred to CET + BSC administration, not CET + IRIN administration.
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TABLE 60 Comparison of the deterministic results of the PenTAG and Merck Serono models for best supportive care 
(for comparison with cetuximab plus irinotecan) for the KRAS WT population
BSC
PenTAG Merck Serono
Life-years (mean, undiscounted)
Progression free 0.23 0.24
Post progression 0.29 0.31
Total (mean) 0.51 0.55
QALYs (mean, undiscounted) 
Progression free 0.17 0.18
Post progression 0.19 0.21
Total (mean) 0.36 0.39
Costs (£) (mean, undiscounted)
KRAS testing 0 0
Drug costs 0 0
Drug administration 0 0
Medical management in PFS 0 2200
BSC in PD 3500 2900
Adverse events 2800 2800
Total 6300 7900
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PD, progressive disease; PFS, progression-free survival.
TABLE 61 Comparison of the deterministic results of the PenTAG and Merck Serono models for cetuximab plus 
irinotecan vs best supportive care for the KRAS WT population
CET + IRIN vs BSC
PenTAG Merck Serono
Life-years (mean, undiscounted)
Progression free 0.50 0.42
Post progression 0.37 0.39
Total (mean) 0.87 0.81
QALYs (mean, undiscounted) 
Progression free 0.37 0.35
Post progression 0.24 0.32
Total (mean) 0.60 0.67
Costs (£) (mean, undiscounted)
KRAS testing 300 200
Drug costs 32,000 17,400
Drug administration 12,700 3800
Medical management in PFS 2900 3900
BSC in PD 4300 3500
Adverse events 900 900
Total 53,100 29,600
ICER (incremental cost per QALY) 88,000 44,000
BSC, best supportive care; CET, cetuximab; IRIN, irinotecan; PD, progressive disease; PFS, progression-free survival.
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Although we estimate slightly longer overall survival on cetuximab plus irinotecan than Merck 
Serono (1.38 years compared with 1.36 years), we estimate slightly lower total QALYs than Merck 
Serono (0.97 compared with 1.06). This is because we estimate lower utilities for cetuximab plus 
irinotecan in progression-free survival and progressive disease than Merck Serono. Our estimate 
of 0.36 for total QALYs for best supportive care is very similar to Merck’s value of 0.39 because we 
use very similar mean overall survival and the same utilities for best supportive care.
Merck Serono’s estimate of £6100 for the mean total cost of medical management in progression-
free survival for cetuximab plus irinotecan is substantially higher than our estimate of £2900. 
However, we believe that Merck Serono’s estimated cost per unit time for people on cetuximab 
plus irinotecan while in progression-free survival is logically flawed. Similarly, Merck Serono’s 
flawed estimate of £2200 for the mean total cost of medical management in progression-free 
survival for best supportive care is substantially higher than our estimate of £0. However, 
coincidentally, we estimate similar mean total incremental costs for medical management in 
progression-free survival for cetuximab plus irinotecan compared with best supportive care.
Our estimates for the mean costs of best supportive care in progressive disease for both 
treatments are slightly higher than those of Merck Serono because we inflate the cost per unit 
time of best supportive care in progressive disease, quoted in Remak and Brazil,78 over a longer 
period of time than Merck Serono.
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Chapter 7 
Discussion
Aim
The question addressed was, ‘What is the clinical effectiveness and cost-effectiveness of 
cetuximab (monotherapy or combination chemotherapy), bevacizumab (combination with 
non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic 
colorectal cancer after first-line chemotherapy’.
The populations of interest were limited to those with KRAS WT metastatic colorectal cancer in 
the cases of cetuximab and panitumumab.
The aim was addressed through a HTA comprising a systematic review of clinical effectiveness 
and cost-effectiveness studies, a review and critique of manufacturer submissions and a de novo 
economic analysis.
Strengths and limitations of the systematic review 
of effectiveness
The strengths of this systematic review are that it was conducted by an independent research 
team using the latest evidence in line with a prespecified protocol. The main limitation was the 
lack of evidence on bevacizumab, cetuximab and cetuximab plus irinotecan used second line in 
the populations of interest and lack of evidence on bevacizumab and cetuximab plus irinotecan 
used third line.
Strengths and limitations of the systematic review of 
economic evaluations
Again, the strengths of this systematic review are that it was conducted by an independent 
research team using the latest evidence in line with a prespecified protocol. The main limitation 
was the incomplete reporting of the reviews of the cost-effectiveness of panitumumab and the 
absence of cost-effectiveness estimates for bevacizumab.
Strengths and limitations of the critique of the manufacturers’ 
submissions
This was conducted by an independent research team using a number of established frameworks 
to identify strengths and weaknesses. The scope of the submissions on bevacizumab and 
panitumumab, which did not directly estimate cost-effectiveness, was the main limitation.
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Strengths and limitations of the Peninsula Technology 
Assessment Group’s model
Strengths
Our assessment of the cost-effectiveness of drugs for metastatic colorectal cancer is independent. 
Our analysis is the second independent fully published cost-effectiveness analysis of cetuximab 
compared with best supportive care for KRAS WT patients, the first being that of Mittmann and 
colleagues.42 Our analysis is the first independent fully published cost-effectiveness analysis of 
panitumumab plus best supportive care compared with best supportive care for patients with 
KRAS WT status and of cetuximab plus irinotecan compared with best supportive care for 
patients with KRAS WT status. We have carefully compared our model and the results of our 
analysis with those of Mittmann and colleagues42 and Merck Serono and in so doing we have 
highlighted areas in common and those where there is disagreement.
Our model adheres to the NICE reference case72 and has been extensively checked. In addition 
to our base-case analysis we also present numerous one-way sensitivity analyses, which we have 
chosen carefully to reflect the key areas of uncertainty and disagreements between ourselves and 
Merck Serono. We also present probabilistic analyses in which we vary the key parameters within 
plausible ranges.
Our certainty about the accuracy of our analyses for cetuximab plus best supportive care 
compared with best supportive care and panitumumab plus best supportive care compared 
with best supportive care is increased given that the effectiveness evidence that underpins 
these analyses is taken from high-quality RCTs whose data are mature. There is much greater 
uncertainty concerning the analysis of cetuximab plus irinotecan compared with best supportive 
care given the lack of effectiveness evidence, particularly for patients with KRAS WT status.
We have confidence in the accuracy of our utility estimates for the best supportive care, 
panitumumab and cetuximab treatment arms. Indeed, their accuracy is greater than is typically 
available for cost-effectiveness analysis, with the data being derived from direct observation of 
patients in trials. This is not true for the utilities for cetuximab plus irinotecan.
Limitations
There are some factors that limit the accuracy of our analysis. For example, the mean duration 
of drug treatment for the KRAS WT population, a vital parameter, is available in published form 
only for panitumumab. Indeed, the mean durations of cetuximab and cetuximab plus irinotecan 
treatment are not published for patients with KRAS WT status, although the mean duration 
of cetuximab treatment was provided to us by personal communication. These are important 
limitations of our analysis given that cost-effectiveness is very sensitive to these parameters.
The external validity of the results is uncertain given that we use efficacy data from RCTs in 
which patients are relatively young (median age approximately 63 years) and fit (an ECOG 
performance status of 0–2) in comparison with patients in actual clinical practice, who are 
typically older and less fit (some with an ECOG performance status of 3–4).
Progression-free survival and overall survival for cetuximab plus irinotecan are available only 
for the whole population (KRAS WT and KRAS mutant combined). Like Merck Serono we have 
therefore been forced to adjust these estimates using other data sources to obtain estimates of 
progression-free survival and overall survival in the KRAS WT population. However, we have 
provided several possible methods of adjustment and the ICER for cetuximab plus irinotecan 
compared with best supportive care remains high regardless of which estimates for progression-
free survival and overall survival are used.
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In common with Merck Serono we do not stratify our analysis according to the line of treatment 
as the necessary individual patient data were not available.
We estimate the cost of medical management in progressive disease for all treatment groups 
based on a study of medical management in progressive disease for women with breast cancer.78 
Like Merck Serono we believe that this is methodologically acceptable given the absence of 
suitable alternatives but do caution that the data from this publication are now rather old, relating 
to practices from the year 2000.
Main findings in the light of limitations
Effectiveness review
There is consensus about the evidence on the effectiveness of cetuximab and panitumumab for 
patients with KRAS WT status. Based on RCTs, both cetuximab and panitumumab are effective 
used third line, particularly with respect to progression-free survival. For cetuximab, median 
progression-free survival increases from approximately 2 months to approximately 4 months 
(hazard ratio 0.40, 95% CI 0.30 to 0.54). For panitumumab, median progression-free survival 
increases from approximately 1.8 months to approximately 3 months (hazard ratio 0.45, 95% CI 
0.34 to 0.59).
We broadly agree with Merck Serono’s estimate of the effectiveness of cetuximab plus irinotecan 
for KRAS WT people even though it has not been directly measured in a RCT.
There is an absence of RCT evidence for bevacizumab combined with non-oxaliplatin 
chemotherapy in second-line and further lines of therapy.
Economic evaluations
Cost-effectiveness of cetuximab compared with best 
supportive care
There are many similarities between Merck Serono’s model for cetuximab compared with best 
supportive care and the PenTAG de novo model. Importantly, we assume the same mean times 
as Merck Serono for progression-free survival and overall survival for cetuximab and for best 
supportive care. Nonetheless, Merck Serono estimates a far lower ICER for cetuximab compared 
with best supportive care than us: £47,000 compared with £98,000 per QALY gained. This is 
explained almost entirely by Merck Serono’s estimates of the total mean costs of cetuximab 
acquisition and administration, which are far lower than our estimates. These differences are due 
almost entirely to Merck Serono’s far lower estimate of the mean time on cetuximab treatment: 
2.6 months compared with our estimate of 4.8 months. Merck Serono’s derivation of its estimate 
is based on its imposition of an artificial maximum time on cetuximab treatment. When we use 
Merck Serono’s model and lift the cap on the time on cetuximab treatment, the ICER increases 
from £47,000 to £75,000 per QALY gained.
We are aware of only one other fully published cost-effectiveness analysis of any of the treatments 
in this appraisal for KRAS WT people, that of Mittmann and colleagues.42 They perform a trial-
based economic analysis to consider cost-effectiveness from the health-care payer perspective in 
Canada. After we adjust their result for the cost per mg of cetuximab appropriate in the UK in 
2011, and other costs for inflation to the year 2011, we estimate that their ICER is approximately 
equivalent to £101,000 per QALY gained. This is very close to our estimate of £98,000 per QALY 
gained and much higher than Merck Serono’s £48,000 per QALY gained.
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Cost-effectiveness of cetuximab plus irinotecan compared with best 
supportive care
Again, there are many similarities between Merck Serono’s model for cetuximab plus irinotecan 
compared with best supportive care and the PenTAG de novo model. Importantly, we assume 
similar mean times as Merck Serono for progression-free survival and overall survival for 
cetuximab plus irinotecan and for best supportive care. Merck Serono estimates a far lower ICER 
for cetuximab plus irinotecan compared with best supportive care: £44,000 per QALY compared 
with our estimate of £88,000 per QALY. Similar to the case of cetuximab compared with best 
supportive care, this is explained almost entirely by Merck Serono’s estimates of the total mean 
costs of cetuximab plus irinotecan acquisition and administration, which are far lower than our 
estimates. These differences, in turn, are due almost entirely to Merck Serono’s far lower estimate 
of the mean time on cetuximab plus irinotecan treatment: 4.4 compared with our estimate of 
8.8 months. Merck Serono’s derivation of its estimate is based on its imposition of an artificial 
maximum time on cetuximab plus irinotecan treatment. When we use Merck Serono’s model and 
lift the cap on the time on treatment the ICER increases from £44,000 to £67,000 per QALY.
Cost-effectiveness of panitumumab compared with best 
supportive care
The estimate of cost-effectiveness from the PenTAG de novo model is £150,000 per QALY gained, 
with no alternative estimate being offered by the manufacturer.
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Chapter 8 
Conclusions
Implications
On balance we conclude that, used as third- and subsequent-line treatment relative to best 
supportive care, cetuximab plus best supportive care, cetuximab plus irinotecan plus best 
supportive care and panitumumab plus best supportive care are not cost-effective if decision 
thresholds of £20,000 per QALY or £30,000 per QALY are used.
There is no additional evidence on the effectiveness and cost-effectiveness of cetuximab used in 
second-line treatment to that informing the guidance on second-line use provided by TA118.16
In common with the manufacturer we were not able to estimate the cost-effectiveness of 
bevacizumab in combination with non-oxaliplatin chemotherapy second line or beyond because 
of the absence of RCT evidence.
Suggested research priorities
 ■ Given the lack of clinical data for patients with KRAS WT status taking cetuximab plus 
irinotecan, it would be useful to conduct a RCT for these patients comparing cetuximab plus 
irinotecan with cetuximab plus best supportive care or panitumumab plus best supportive 
care. It would be helpful to collect HRQoL data in such a trial.
 ■ There is a need to have data documenting the proportions of patients on the various 
pathways of disease once metastatic colorectal cancer has occurred to better inform the 
clinical costs and overall costs.
 ■ We cannot model the cost-effectiveness of bevacizumab in combination with non-oxaliplatin 
chemotherapy because of the absence of relevant clinical evidence. Ideally, a RCT should 
be conducted if this is thought to be a potentially important use of the agent by the wider 
clinical community.
 ■ Given that the mean duration of cetuximab plus irinotecan treatment strongly influences 
cost-effectiveness, and that it is not known with certainty, further data on this parameter 
from the BOND RCT of cetuximab plus irinotecan compared with cetuximab would 
be helpful.
 ■ Given that the medical management cost data come from a study of women with breast 
cancer carried out over 10 years ago, collecting data on the medical management of 
metastatic colorectal cancer would be useful.
Ongoing trials identified in the course of this appraisal indicate that some of the gaps in 
knowledge may already be being addressed.
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Appendix 1 
Literature search strategies
Database searching was conducted on 17 November 2010 with the database results being uploaded first into EndNote X4 for conversion into RIS format and second into EPPI 
Reviewer (version 4) for deduplication and screening. 
Tappenden and colleagues’ 2007 search strategy10 was employed as the initial basis for syntax 
development. Early includable studies/trials from testing the search syntax were used to 
benchmark the development of the strategy and the final result was checked again on this basis. 
The final strategy was quality controlled by our clinical expert, Dr Mark Napier. 
No study design filters were added to the searches in order to retrieve a range of study designs 
and to locate results of mixed methodological focus, including RCTs, clinically controlled trials 
and systematic reviews, in addition to economic evaluations and any adverse event literature 
relating to the interventions.
Significant duplication between the resources was anticipated, giving a reasonable n 
for screening. 
MEDLINE 
Host: Ovid
Resource parameters: 1950 to November Week 1 2010 – current
Date searched: 17 November 2010
Date limits applied: 2005 – current
Searcher: C Cooper
Hits: 1472
1. (Cetuximab or IMC C225 or MAb C225 or C225 or Erbitux).mp.
2. (Bevacizumab or Avastin or nsc 704865 or nsc704865).mp.
3. (Panitumumab or ABX-EGF* or Vectibix).mp.
4. or/1-3
5. Neoplasms/
6. Carcinoma/
7. Adenocarcinoma/
8. Or/5-7
9. Colonic Diseases/ 
10. Rectal Diseases/
11. Exp Colon/
12. Exp rectum/
13. Or/9-12
14. 8 AND 13
15. exp Colorectal Neoplasms/
16. (neoplasm$ or neoplasia adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab. 
17. (carcinoma adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
18. (adenocarcinoma adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
19. (cancer$ or CRC adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
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20. (tumour$ or tumor$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
21. (malignan$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
22. (metasta$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
23. ((First line or second line or first-line or second-line or 1st line or 2nd line) and (chemo$) 
adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
24. (Epidermal Growth Factor Receptor or EGFR or KRAS or VEGF adj3 (colorectal or colon$ 
or rect$ or intestin$ or bowel)).ti,ab.
25. or/15-24 
26. 14 or 25
27. 4 AND 26
28. limit 27 to yr=”2005 -Current” 
EMBASE
Host: Ovid
Resource parameters: 1980 to 2010 Week 45
Date searched: 17 November 2010
Date limits applied: 2005 – current
Searcher: C Cooper
Hits: 3417
1. (Cetuximab or IMC C225 or MAb C225 or C225 or Erbitux).mp. or cetuximab/
2. (Bevacizumab or Avastin or nsc 704865 or nsc704865).mp. or Bevacizumab/
3. (Panitumumab or ABX-EGF* or Vectibix).mp. or Panitumumab/
4. Or/1-3
5. *neoplasm/
6. *Carcinoma/
7. *Adenocarcinoma/
8. Or/5-7
9. exp colon disease/
10. exp rectum disease/
11. Exp Colon/
12. Exp rectum/
13. Or/9-12
14. 8 AND 13
15. exp colorectal tumor/
16. (neoplasm$ or neoplasia adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab. 
17. (carcinoma adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
18. (adenocarcinoma adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
19. (cancer$ or CRC adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
20. (tumour$ or tumor$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
21. (malignan$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
22. (metasta$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
23. ((first line or second line or first-line or second-line or 1st line or 2nd line) and (chemo$) 
adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).ti,ab.
24. (Epidermal Growth Factor Receptor or EGFR or KRAS or VEGF adj3 (colorectal or colon$ 
or rect$ or intestin$ or bowel)).ti,ab.
25. or/15-24
26. 14 or 25
27. 4 AND 26
28. limit 27 to yr=“2005 -Current”
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The Cochrane Library
Host: http://onlinelibrary.wiley.com/o/cochrane/cochrane_search_fs.html?newSearch=true
Resource parameters: Issue 11 of 12, November 2010
Date searched: 17 November 2010
Date limits applied: 2005 – current
Searcher: C Cooper
Hits: 269
1. (“Cetuximab” or “IMC C225” or “MAb C225” or “C225” or “Erbitux”) 
2. (“Bevacizumab” or “Avastin” or “nsc 704865” or “nsc704865”)
3. (“Panitumumab” or “ABX-EGF*” or “Vectibix”)
4. #1 or #2 or #3
5. MeSH descriptor Neoplasms, this term only
6. MeSH descriptor Carcinoma, this term only
7. MeSH descriptor Adenocarcinoma, this term only
8. #5 or #6 or #7
9. MeSH descriptor Colonic Diseases, this term only
10. MeSH descriptor Rectal Diseases, this term only
11. MeSH descriptor Colon explode all trees
12. MeSH descriptor Rectum explode all trees
13. #9 or #10 or #11 or #12
14. #8 AND #13
15. MeSH descriptor Colorectal Neoplasms explode all trees
16. (neoplasm* or neoplasia near/3 (colorectal or colon* or rect* or intestine* or bowel)) 
17. (carcinoma near/3 (colorectal or colon* or rect* or intestine* or bowel))
18. (adenocarcinoma near/3 (colorectal or colon* or rect* or intestine* or bowel))
19. (cancer* or CRC near/3 (colorectal or colon* or rect* or intestine* or bowel))
20. (tumour* or tumor near/3 (colorectal or colon* or rect* or intestine* or bowel))
21. (malignan* near/3 (colorectal or colon* or rect* or intestine* or bowel))
22. (metasta* near/3 (colorectal or colon* or rect* or intestine* or bowel))
23. ((First line or second line or first-line or second-line or 1st line or 2nd line) and (chemo*) 
near/3 (colorectal or colon* or rect* or intestine* or bowel))
24. (Epidermal Growth Factor Receptor or EGFR or KRAS or VEGF near/3 (colorectal or colon* 
or rect* or intestine* or bowel))
25. (#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
26. (#14 OR #25)
27. (#4 AND #26), from 2005 to 2010
Web of Science
Host: ISI
Resource parameters: 1900 – current
Date searched: 17 November 2010
Date limits applied: 2005 – current
Searcher: C Cooper
Hits: 2481
1. TS=((Cetuximab or Erbitux OR Bevacizumab or Avastin OR Panitumumab or Vectibix))
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2. TS=((colorectal) SAME (neoplasm* or neoplasia or carcinoma or adenocarcionoma or 
cancer* or tumour* or tumor* or malignan* or metastasi*))
3. TS=((bowel) SAME (neoplasm* or neoplasia or carcinoma or adenocarcionoma or cancer* 
or tumour* or tumor* or malignan* or metastasi*))
4. TS=((colon*) SAME (neoplasm* or neoplasia or carcinoma or adenocarcionoma or cancer* 
or tumour* or tumor* or malignan* or metastasi*))
5. TS=((animal* or mice or rat or rats or dog* or cat* or rabbit* or pig))
6. #2 OR #3 OR #4
7. #1 AND #6
8. #6 NOT #5
9. Timespan=2005-2010
EconLit
Host: EBSCOhost
Resource parameters: (1969 – current)
Date searched: 17 November 2010
Date limits applied: 2005 – current
Searcher: C Cooper
Hits: 0
 (Cetuximab OR Erbitux OR Bevacizumab OR Avastin OR Panitumumab OR Vectibix)
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Appendix 2  
Protocol
Technology Assessment Report commissioned by the NETSCC HTA Programme on behalf of 
the National Institute for Health and Clinical Excellence
HTA 10/11/01
FINAL PROTOCOL
November 2010
Title of the project
Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-
oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic 
colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and 
part-review of technology appraisal No. 118).
Name of TAR team and project ‘lead’
PenTAG, Peninsula College of Medicine and Dentistry, University of Exeter
Name: Chris Hyde
Post held: Prof of Public Health & Clinical Epidemiology
Official address: PenTAG, Peninsula Medical School, Vesey Building, Salmon Pool Lane, Exeter, 
EX2 4SG
Telephone number: 01392 726051
E-mail address: christopher.hyde@pcmd.ac.uk
Plain English Summary
This project will review and update the evidence presented to the National Institute of Health and 
Clinical Excellence (NICE) in 2007 on how good a number of drugs (cetuximab, bevacizumab 
and panitumumab) are for treating metastatic colorectal cancer (cancer that has spread beyond 
the bowel and stopped responding to initial chemotherapy). The assessment will also assess 
whether the reviewed drugs are likely to be considered good value for money for the NHS. 
Decision problem
Purpose 
Colorectal cancer is a malignant neoplasm arising from the lining of the large intestine (colon 
and rectum). Approximately 34,000 new cases of colorectal cancer were diagnosed in England 
and Wales in 2007, and approximately 14,000 deaths registered in 2008. The median age of 
patients at diagnosis is over 70 years. 
NIHR Journals Library
150 Appendix 2 
In metastatic colorectal cancer the tumour has spread beyond the confines of the locoregional 
lymph nodes to other parts of the body. This is described as stage IV of the American Joint 
Committee on Cancer (AJCC) tumour node metastases (TNM) system or stage D of Dukes’ 
classification. Between 20% and 55% of people first diagnosed with colorectal cancer have 
metastatic disease. In addition, approximately 50% to 60% of patients who have undergone 
surgery for early stage colorectal cancer with apparently complete excision will eventually 
develop advanced disease and distant metastases (typically presenting within two years of initial 
diagnosis). The five-year survival rate for metastatic colorectal disease is 12%. 
The management of metastatic colorectal cancer is mainly palliative and involves a combination 
of specialist treatments (such as palliative surgery, chemotherapy and radiation), symptom 
control and psychosocial support. NICE have examined several chemotherapy agents used 
at various points in the care of metastatic colorectal cancer (see Section 4.3). This appraisal 
continues this examination. 
Interventions
This technology assessment report (TAR) will consider three pharmaceutical interventions:
 – Cetuximab monotherapy and in combination with chemotherapy
 – Bevacizumab in combination with non-oxaliplatin based chemotherapy
 – Panitumumab monotherapy.
Cetuximab (Erbitux, Merck Serono) is a recombinant monoclonal antibody that blocks the 
human epidermal growth factor receptor (EGFR), inhibiting the growth of tumours expressing 
EGFR. Cetuximab has a UK marketing authorisation for the treatment of patients with 
EGFR-expressing, KRAS wild-type metastatic colorectal cancer either in combination with 
chemotherapy or as a single agent in patients who have failed oxaliplatin- and irinotecan-based 
therapy and who are intolerant to irinotecan.
Bevacizumab (Avastin, Roche Products) is a recombinant monoclonal antibody that acts 
as an angiogenesis inhibitor by targeting the biologic activity of human vascular endothelial 
growth factor (VEGF), which stimulates new blood vessel formation in the tumour. It has a UK 
marketing authorisation in combination with fluoropyrimidine-based chemotherapy for the 
treatment of patients with metastatic carcinoma of the colon or rectum.
Panitumumab (Vectibix, Amgen) is a recombinant monoclonal antibody that blocks the 
EGFR, inhibiting the growth of tumours expressing EGFR. It has a UK marketing authorisation 
as monotherapy for the treatment of EGFR expressing metastatic colorectal cancer with 
non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-
containing chemotherapy regimens.
Place of the interventions in the treatment pathway
NICE currently recommends oxaliplatin in combination with infusional 5-fluorouracil plus 
folinic acid (FOLFOX) and irinotecan in combination with infusional 5-fluorouracil plus folinic 
acid (FOLFIRI) as first-line treatment options for advanced colorectal cancer. FOLFOX or 
irinotecan alone are recommended as subsequent therapy options (technology appraisal No. 93).1 
The oral analogues of 5-fluorouracil, capecitabine and tegafur, in combination with uracil (and 
folinic acid) are also recommended as first-line treatment options for metastatic colorectal cancer 
(technology appraisal No. 61).2 
Cetuximab in combination with FOLFOX, or in combination with FOLFIRI, is recommended as 
an option for the first-line treatment of metastatic colorectal cancer where the metastatic disease 
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is confined to the liver and the aim of treatment is to make the metastases resectable (technology 
appraisal No. 176).3 
In technology appraisal No. 118, bevacizumab in combination with 5-fluorouracil plus folinic 
acid, with or without irinotecan, as a first-line treatment and cetuximab in combination with 
irinotecan, as a second and subsequent line treatment were not recommended for metastatic 
colorectal cancer.4 
In technology appraisal No. 150, NICE was unable to recommend the use of cetuximab for 
the treatment of colorectal cancer following failure of oxaliplatin-containing chemotherapy 
because no evidence submission was received from the manufacturer of the technology 
(terminated appraisal).5
There is also an ongoing STA on bevacizumab in combination with oxaliplatin and either 5FU or 
capecitabine for the treatment of metastatic colorectal cancer.
Relevant comparators
The main comparators of interest are:
 ■ Irinotecan- or oxaliplatin-based chemotherapy regimens
 ■ The interventions will be compared with each other (where appropriate)
 ■ Best supportive care: pain control, antiemetics, appetite stimulants (steroids) and, in some 
cases, radiotherapy.
Population and relevant sub-groups
This will depend on the particular drug under consideration:
 ■ People with EGFR-expressing and KRAS wild-type metastatic colorectal cancer that has 
progressed after first-line chemotherapy (cetuximab and panitumumab population).
 ■ People with metastatic colorectal cancer that has progressed after first-line chemotherapy 
(bevacizumab population).
Subgroup: Variation in outcome depending on whether tumour response has occurred 
will be assessed if evidence is available. This will help inform any deliberations concerning 
continuation rules.
Outcomes to be addressed 
The following outcomes will be measured:
 ■ Overall survival (OS)
 ■ Progression-free survival (PFS)
 ■ Response rate 
 ■ Adverse effects of treatment
 ■ Health-related quality of life (HRQL)
 ■ Liver resection rates will also be considered if evidence is available.
Methods for synthesis of evidence of clinical effectiveness
The assessment report will include a systematic review of the evidence for clinical effectiveness of 
cetuximab monotherapy and in combination with chemotherapy; bevacizumab in combination 
with non-oxaliplatin based chemotherapy; and panitumumab monotherapy. The review will 
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be undertaken following the general principles published by the NHS Centre for Reviews and 
Dissemination.6 The components of the review question will be:
Population: Adults with metastatic colorectal cancer – this will be further restricted to EGFR-
expressing and KRAS wild-type metastatic colorectal cancer for cetuximab and panitumumab in 
line with the marketing authorisations for these treatments. Adults will in addition have had to 
fail first-line chemotherapy.
Interventions: This technology assessment report (TAR) will consider three 
pharmaceutical interventions:
 ■ Bevacizumab in combination with non-oxaliplatin based chemotherapy
 ■ Cetuximab monotherapy and in combination with chemotherapy
 ■ Panitumumab monotherapy.
Each should be being used in accordance with the marketing authorisation and in the 
populations indicated in the previous paragraph.
Comparators: Any clinically relevant alternative treatment for the population in question, but 
particularly including:
 ■ Irinotecan- or oxaliplatin-based chemotherapy regimens.
 ■ One of the other interventions under consideration.
 ■ Best supportive care: pain control, anti-emetics, appetite stimulants (steroids); and, in some 
cases, radiotherapy.
Outcomes: The following kinds of outcomes will be measured in a variety of scales reflecting the 
included studies:
 ■ Overall survival
 ■ Progression-free survival
 ■ Response rate
 ■ Adverse effects of treatment
 ■ Health-related quality of life
 ■ Liver resection rates (if available).
Search strategy 
The search strategy will comprise the following main elements:
 ■ Searching of electronic databases
 ■ Contact with experts in the field
 ■ Scrutiny of bibliographies of retrieved papers and manufacturer submissions
 ■ Follow-up on mentions of potentially relevant ongoing trials noted in NICE guidance on 
colorectal cancer.
The main electronic databases of interest will be:
MEDLINE (Ovid); PubMed; EMBASE; The Cochrane Library including the Cochrane Systematic 
Reviews Database, Cochrane Controlled Trials Register, DARE, NHS EED and HTA databases; 
NRR (National Research Register); Web of Science Proceedings; Current Controlled Trials; 
Clinical Trials.gov; FDA website; EMEA website. These will be searched from search end-date of 
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the last MTA7 on this topic April 2005. Although panitumumab was not covered in this report, 
we believe that relevant interventional research is highly unlikely to have been published on this 
drug prior to this date.
The searches will be developed and implemented by a trained information specialist using the 
search strategy detailed in the MTA by Tappenden et al as the starting point.7
Inclusion criteria 
For the review of clinical effectiveness, in the first instance, only systematic reviews of 
randomised controlled trials (RCTs) and RCTs will be considered. However, if key outcomes 
of interest are not measured at all in the included RCTs we will discuss whether extending the 
range of included study designs i.e. to controlled clinical trials could be of value and feasible in 
the time available with NICE. The systematic reviews will be used as a source for finding further 
included studies and to compare with our systematic review. Systematic reviews provided as part 
of manufacturer’s submissions will be treated in a similar manner. These criteria may be relaxed 
for consideration of adverse events, for which observational studies may be included.
Titles and abstracts will be examined for inclusion by two reviewers independently. Disagreement 
will be resolved by consensus. 
Exclusion criteria 
Studies will be excluded if they do not match the inclusion criteria, particularly:
 ■ Non-randomised studies (except if agreed, in the absence of RCTs)
 ■ Animal models
 ■ Preclinical and biological studies
 ■ Narrative reviews, editorials, opinions
 ■ Non-English-language papers
 ■ Reports published as meeting abstracts only, where insufficient methodological details are 
reported to allow critical appraisal of study quality.
Data extraction strategy
Data will be extracted independently by one reviewer using a standardised data extraction form 
and checked by another. Discrepancies will be resolved by discussion, with involvement of a third 
reviewer if necessary.
Quality assessment strategy
Consideration of study quality will be based on the guidelines set out by the NHS Centre for 
Reviews and Dissemination6 and include the following factors for RCTs:
 ■ Timing, duration and location of the study
 ■ Method of randomisation
 ■ Allocation concealment
 ■ Blinding
 ■ Numbers of participants randomized, excluded and lost to follow up
 ■ Whether intent to treat analysis is performed
 ■ Methods for handling missing data
 ■ Appropriateness of statistical analysis.
This framework will be adapted should other study designs subsequently be included.
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Methods of analysis/synthesis
Data will be tabulated and discussed in a narrative review. Where appropriate, meta-analysis will 
be employed to estimate a summary measure of effect on relevant outcomes based on intention to 
treat analyses. 
Meta-analysis will be carried out using fixed and random effects models, using RevMAN 
supplemented with STATA or equivalent software as required. Heterogeneity will be explored 
through consideration of the study populations, methods and interventions, by visualisation of 
results and, in statistical terms, by the χ2 test for homogeneity and the I2 statistic.
Sub-group analyses by completeness of tumour response will be undertaken if appropriate data 
are available. 
Methods for synthesising evidence of cost-effectiveness
Review question
For the interventions and populations indicated above, the existing evidence on cost-effectiveness 
will be systematically reviewed.
Search strategy
The searches will again be developed and implemented by a trained information specialist using 
the search strategy detailed in the MTA by Tappenden et al.7 as the starting point.7 The range of 
sources searched will include those for clinical effectiveness and extend to include NHS EED and 
EconLit. April 2005 will again be the starting point.
Study selection criteria and procedures
The inclusion and exclusion criteria for the systematic review of economic evaluations will be 
identical to those for the systematic review of clinical effectiveness, except:
Non-randomised studies will be included (e.g. decision model based analyses, or analyses of 
patient-level cost and effectiveness data alongside observational studies). 
Full cost-effectiveness analyses, cost–utility analyses, cost–benefit analyses and cost consequence 
analyses will be included. (Economic evaluations which only report average cost-effectiveness 
ratios will only be included if the incremental ratios can be easily calculated from the 
published data.) 
Stand alone cost analyses based in the UK NHS will also be sought and appraised.
Based on the above inclusion/exclusion criteria, study selection will be made by one reviewer. 
Study quality assessment 
The methodological quality of the economic evaluations will be assessed by one reviewer 
according to internationally accepted criteria such as the Consensus on Health Economic 
Checklist (CHEC) questions developed by Evers et al.8 Any studies based on decision models 
will also be assessed against the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) guidelines for good practice in decision analytic modelling.9 
Data extraction strategy
Data will be extracted by one researcher into two summary tables: one to describe the study 
design of each economic evaluation and the other to describe the main results. 
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In study design table: author and year; model type or trial based; study design (e.g. cost-
effectiveness analysis [CEA], cost utility analysis [CUA] or cost-analysis); service setting/country; 
study population; comparators; research question; perspective, time horizon, and discounting; 
main costs included; main outcomes included; sensitivity analyses conducted; and other notable 
design features.
For modelling-based economic evaluations a supplementary Study Design table will record 
further descriptions of: model structure (and note its consistency with the study perspective), and 
knowledge of disease/treatment processes; sources of transition and chance node probabilities; 
sources of utility values; sources of resource use and unit costs; handling of heterogeneity in 
populations; evidence of validation (e.g. debugging, calibration against external data, comparison 
with other models).
In the results table for each comparator we will show; incremental cost; incremental effectiveness/
utility and incremental cost-effectiveness ratio(s). Excluded comparators on the basis of 
dominance or extended dominance will also be noted. The original authors’ conclusions will 
be noted, and also any issues they raise concerning the generalisability of results. Finally the 
reviewers’ comments on study quality and generalisability (in relation to the TAR scope) of their 
results will be recorded.
Synthesis of extracted evidence
Narrative synthesis, supported by the data extraction tables, will be used to summarise the 
evidence base. 
Economic modelling 
The general approach will be consistent with the NICE reference standard.10 A new cost-
effectiveness analysis will be carried out from the perspective of the UK NHS and Personal Social 
Services (PSS) using a decision analytic model. This will build on the modelling approach used in 
the original MTA7 and be informed by modelling approaches used in subsequent NICE appraisals 
and published cost-effectiveness literature reviewed (see Section 6). 
Model structure will be determined on the basis of available research evidence and clinical 
expert opinion.
The sources of parameter values that determine the effectiveness of the interventions being 
compared will be obtained from our own systematic review of clinical effectiveness or other 
relevant research literature. Where required parameters are not available from good quality 
published studies in the relevant patient group we may use data from manufacturer submissions 
to NICE. 
Cost data will be identified from NHS and PSS reference costs or, where these are not relevant, 
will be extracted from published work and/or sponsor submissions to NICE. If insufficient data 
are retrieved from published sources, costs may be derived from individual NHS Trusts or groups 
of Trusts. 
To reflect health related quality of life, utility values will be sought either directly from relevant 
research literature or indirectly from quality of life studies. 
Analysis of uncertainty will focus on costs and utilities, assuming cost per QALY can be 
estimated. Uncertainty will be explored through one way sensitivity analysis and, if the data 
NIHR Journals Library
156 Appendix 2 
and modelling approach permit, probabilistic sensitivity analysis. The outputs of probabilistic 
sensitivity analysis will be presented using plots on the cost-effectiveness plane and cost-
effectiveness acceptability curves.
A life-time time horizon will be taken for our analysis and both cost and outcomes (QALYs) will 
be discounted at 3.5%.10 
We will collate the available relevant material necessary to inform an assessment of the 
applicability of the End of Life Criteria.
The TAR team cannot guarantee to consider any data or information relating to the technologies 
if received after 21 February 2011.
Handling the company submissions
All data submitted by the manufacturers will be considered if received by the TAR team no later 
than 21 February 2011. Data arriving after this date will not be considered.
If the data meet the inclusion criteria for the review they will be extracted and quality assessed in 
accordance with the procedures outlined in this protocol. Any economic evaluations included in 
the company submission will be assessed against NICE’s guidance on the Methods of Technology 
Appraisal2 and will also be assessed for clinical validity, reasonableness of assumptions and 
appropriateness of the data used. Where the TAR team have undertaken further analyses, using 
models submitted by manufacturers or via de novo modelling and cost effectiveness analysis, a 
comparison will be made of the alternative models used for the analysis.
Any ‘commercial in confidence’ data taken from a company submission will be underlined and 
highlighted in the assessment. 
Expertise in this TAR team
Name Institution Expertise
Louise Crathorne PenTAG, Peninsula Medical School, University of Exeter Systematic reviewing and project management
Tracey Jones-Hughes PenTAG, Peninsula Medical School, University of Exeter Systematic reviewing 
Martin Hoyle PenTAG, Peninsula Medical School, University of Exeter Health economics and economic modelling (lead)
Paul Tappenden ScHARR, University of Sheffield Economic modelling (liaison with previous MTA)
Jaime Peters PenTAG, Peninsula Medical School, University of Exeter Economic modelling
Chris Cooper PenTAG, Peninsula Medical School, University of Exeter Information science
Mark Napier Royal Devon and Exeter Foundation Trust Clinical expert
Chris Hyde PenTAG, Peninsula Medical School, University of Exeter Systematic reviewing and economic evaluation. Project 
guarantor
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Timetable/milestones
Event Expected due date
Draft scope 29/07/10
Team to comment on draft scope 26/08/10
Early sight of final scope 20/09/10
Final scope 25/10/10
Final protocol due 01/11/10
Consultee information meeting (CIM) (if applicable) 13/12/10
Manufacturers’ submission 21/02/11
ERG Appraisal Report due 02/06/11
1st Appraisal Committee meeting 04/08/11
2nd Appraisal Committee meeting 05/10/11
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Appendix 3 
Clinical effectiveness: data extraction forms
Au et al.44
Design Participants Arms Outcomes
Study design: 
Supplementary study 
to parallel open-label 
RCT
Country: Australia and 
Canada
No. of centres: 
Unknown
Funding: Amgen, 
Bristol-Myers Squibb, 
Merck Serono
Notes: This is a 
supplementary paper 
to Jonker et al.37
Number randomised: 572
Inclusion criteria: Advanced, pretreated, 
EFGR-detectable, histologically proven 
metastatic colorectal cancer for which no other 
standard anticancer therapies were available. 
All had prior chemotherapy and all experienced 
treatment failure or were considered unsuitable 
for treatment with both irinotecan and 
oxaliplatin
Therapy common to all participants: Best 
supportive care
Sample attrition/dropout: Compliance 
with HRQoL questionnaire – cetuximab 
(93.7–60.8%), BSC (94.4–35.4%)
Arm no. 1
Name: Cetuximab plus 
best supportive care
n: 287
Drug: Cetuximab
Starting daily dose: 
400 mg/m2 intravenously 
over 2 hours
Dosage details: 
250 mg/m2 intravenously 
weekly
Arm no. 2
Name: best supportive 
care
n: 285
Drug: not applicable
Starting daily dose: not 
applicable
Dosage details: not 
applicable
Primary outcome measure: Overall 
survival
Secondary outcome measure(s): 
Progression-free survival, response rate, 
safety, HRQoL
Method of assessment: Participants 
attended clinic visits scheduled at 
baseline and weeks 4, 8, 16 and 24 and 
completed the self-administered EORTC 
QLQ-C30
Scoring was completed according to 
the EORTC QLQ-C30 manual and linear 
transformation was used to standardise 
raw scores to range between 0 and 100
Higher scores correspond to better 
HRQoL in functional scales and global 
health status and to worse HRQoL in 
symptom scores
Missing items in a scale were handled 
using the methods outlined in the 
scoring manual
Baseline characteristics
CET + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Refers to Jonker et al.37 for full characteristics; stated as balanced between arms
Age (years), median 63
BSC, best supportive care; CET, cetuximab.
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Results
CET + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Study medication: duration of 
treatment
Until disease progression or toxicity
Compliance with HRQoL assessments
Received at baseline 287 93.7% 285 94.4%
Received at 4 weeks 266 86.5% 270 68.5%
Received at 8 weeks 239 81.2% 238 63.9%
Received at 16 weeks 197 67% 172 46.5%
Received at 24 weeks 158 60.8% 113 35.4%
EORTC QLQ-C30 scale by assessment time (mean change scores)
Week 8 physical function
Overall 185 –3.9 (SD 15.6) 147 –8.6 (SD 20.4) 0.046
KRAS WT 90 –0.69 (SD 13.59) 62 –7.15 (SD 20.26) 0.11
KRAS mutant 48 –6.53 (SD 16.30) 46 –12.9 (SD 21.56) 0.14
Week 8 global health status
Overall 185 –0.5 (SD 20.4) 149 –7.1 (SD 22.4) 0.008
KRAS WT 88 3.22 (SD 19.63) 63 –7.67 (SD 21.34) 0.0016
KRAS mutant 48 –4.69 (SD 20.48) 47 –9.57 (SD 24.63) 0.53
Week 16 physical function
Overall 125 –5.9 (SD 17.7) 76 –12.5 (SD 21.6) 0.027
KRAS WT 69 –3.43 (SD 17.93) 36 –13.8 (SD 21.47) 0.0078
KRAS mutant 27 –9.51 (SD 19.45) 22 –9.47 (SD 22.85) 0.72
Week 16 global health status
Overall 128 –3.6 (SD 22.6) 75 –15.2 (SD 25.8) < 0.001
KRAS WT 70 –0.24 (SD 21.19) 36 –18.1 (SD 27.64) < 0.001
KRAS mutant 28 –9.52 (SD 19.60) 21 –13.9 (SD 26.79) 0.62
Week 8 global health status, 
≥ 10-point decrease
23.2% 38.3% 0.004
Week 16 global health status, 
≥ 10-point decrease
31.3% 49.3% 0.069
Week 8 physical function, 
≥ 10-point decrease
24.9% 34.7% 0.051
Week 16 physical function, 
≥ 10-point decrease
30.4% 43.4% 0.069
Week 8 physical function, ≥ 10-point decrease
KRAS WT 17.8%
KRAS mutant 31.3% 0.09
Week 16 physical function, ≥ 10-point decrease
KRAS WT 21.7%
KRAS mutant 40.7% 0.08
Median time (months) for physical 
function to decrease by 10 points 
5.4 3.7 0.022
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CET + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Median time (months) for global 
health scale to decrease by 10 
points
5.4 3.7 0.062
Mean change scores of other scales and domains
8 weeks
Role function –5 –12.7 0.02
Fatigue 8.2 1.2 0.002
Nausea 6.2 0.7 0.007
Pain 8.4 –0.9 < 0.001
Dyspnoea 7.8 0.7 0.005
Sleep 4.3 –1.6 0.03
Financial impact 2.0 –4.5 < 0.001
16 weeks
Role function –7.5 –23.8 < 0.001
Social function –3.9 –11.3 0.04
Fatigue 15.8 2.3 < 0.001
Nausea 11.3 0.9 < 0.001
Pain 13.6 1.1 0.007
Dyspnoea 23.0 1.6 < 0.001
Appetite 13.3 –1.8 < 0.001
Constipation 11.4 0.5 0.02
Overall HRQoL response (improvements at least one time point)
Pain 47% 27% 0.001
Fatigue 41% 31% 0.04
Nausea 22% 16% 0.01
Dyspnoea 22% 13% 0.04
Financial impact 23% 14% 0.003
Global health scale
KRAS WT 40%
KRAS mutant 19% 0.01
Sleep
KRAS WT 36%
KRAS mutant 23% 0.03
BSC, best supportive care; CET, cetuximab; SD, standard deviation.
Methodological issues
Randomisation and allocation
Eligible patients were randomly assigned on a 1 : 1 basis to receive cetuximab plus best supportive 
care or best supportive care alone.
Data analysis
Primary HRQoL analysis was defined prospectively as a comparison of the change of scores from 
baseline to 8 or 16 weeks for the physical function and global health status scales respectively 
(Wilcoxon’s test).
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Secondary HRQoL analyses, defined prospectively, included comparisons of the proportions of 
patients with worsened physical function and global health status at 8 and 16 weeks using Fisher’s 
exact test and the time to deterioration in physical function and global health status scales using 
the log-rank test.
HRQoL – improved (increase in 10 units), worsened (decrease in 10 units) or remained stable 
(change < 10 units). The chi-squared test was used to compare the distributions of HRQoL 
response categories between arms.
HRQoL outcomes were analysed by KRAS status. Correlation between HRQoL response and 
objective tumour response was also sought.
Power calculation
Not reported; see Jonker and colleagues.37
Conflicts of interest
Lead author and seven colleagues declare consultancy fees. 
Quality appraisal
1. Was the assignment to the treatment groups really random? Not reported
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Reported – yes
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Unclear; however, the KRAS 
analysis was blinded
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Adequate
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Adequate
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Jonker et al.37
Design Participants Arms Outcomes
Study design: 
Parallel, open-label 
RCT
Country: Australia 
and Canada
No. of centres: 
Unknown
Funding: Not 
reported
Length of follow-
up: 14.6 months
Number randomised: 572
Inclusion criteria: Advanced colorectal 
cancer expressing EGFR that was 
detectable by immunohistochemical 
methods in a central reference laboratory. 
The patients had either been treated with a 
fluoropyrimidine, irinotecan and oxaliplatin 
with no response to treatment (as defined 
by unacceptable adverse events or 
progression of the tumour within 6 months 
of completion of treatment) or had 
contraindications to treatment with these 
drugs. The patients had disease that could 
be measured or otherwise evaluated; an 
ECOG performance status of 0–2; adequate 
bone marrow, kidney and liver function; and 
no serious concurrent illness
Exclusion criteria: Patients were ineligible 
if they had received any agent that targets 
the EGFR pathway or treatment with a 
murine monoclonal antibody. Previous 
bevacizumab treatment was permitted but 
not required
Therapy common to all participants: 
Best supportive care
Arm no. 1
Name: Cetuximab plus 
best supportive care
n: 287
Drug: Cetuximab
Starting daily dose: 
Intravenously as an initial 
dose of 400 mg/m2 of body 
surface area, administered 
over 120 minutes
Dosage details: Weekly 
maintenance infusion of 
250 mg/m2, administered 
over 60 minutes
Arm no. 2
Name: Best supportive 
care
n: 285
Drug: N/A
Starting daily dose: N/A
Dosage details: Measures 
designed to provide 
palliation of symptoms and 
improve quality of life
Primary outcome measure: Overall 
survival, defined as time from randmisation 
until death from any cause
Secondary outcome measure(s): 
Progression-free survival, defined as time 
from randomisation until the first objective 
observation of disease progression or death 
from any cause
Response rates, defined according to the 
modified RECIST
QoL, assessed by mean changes in scores 
of physical function and global health status 
at 8 and 16 weeks
Method of assessment: All patients 
were assessed every 4 weeks. Telephone 
monitoring was conducted until death for 
patients unable to attend the clinic. Chest 
radiographs and cross-sectional imaging 
were performed at baseline and every 
8 weeks in both study groups until tumour 
progression occurred
Quality of life was assessed using the EORTC 
QLQ-C30 at baseline and at 4, 8, 16 and 
24 weeks after randomisation
Baseline characteristics
Demographics
CET + BSC BSC
p-valuen Estimate % n Estimate %
Age (years) 287 63a 28.6–88.1b 285 63.6a 28.7–85.9b
Sex (n male) 287 186 64.8 285 182 63.9
ECOG status
0 287 72 25.1 285 64 22.5
1 287 148 51.6 285 154 54.0
2 287 67 23.3 285 67 23.5
Site of primary cancer
Colon only 287 171 59.6 285 161 56.5
Rectum only 287 63 22.0 285 70 24.6
Colon and rectum 287 53 18.5 285 54 18.9
Any previous radiotherapy 287 103 35.9 285 99 34.7
Previous chemotherapy
Adjuvant therapy 287 108 37.6 285 103 36.1
No. of regimens
1 or 2 287 50 17.4 285 54 18.9
3 287 109 38.0 285 108 37.9
4 287 87 30.3 285 72 25.3
≥ 5 287 41 14.3 285 51 17.9
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Demographics
CET + BSC BSC
p-valuen Estimate % n Estimate %
Thymidylate synthase inhibitor 287 287 100 285 285 100
Irinotecan 287 277 96.5 285 273 95.8
Oxaliplatin 287 281 97.9 285 278 97.5
Sites of disease
Liver 287 230 80.1 285 233 81.8
Lung 287 188 65.5 285 180 63.2
Lymph nodes 287 130 45.3 285 117 41.1
Peritoneal cavity 287 45 15.7 285 41 14.4
No. of sites of disease
1 287 40 13.9 285 53 18.6
2 287 84 29.3 285 69 24.2
3 287 84 29.3 285 89 31.2
≥ 4 287 79 27.5 285 74 26.0
BSC, best supportive care; CET, cetuximab.
a Median.
b Range.
Results
CET + BSC BSC
p-valuen Estimate % n Estimate %
ITT population
Study medication: duration of 
treatment
8 weeks
Overall survival 287 0.77a 0.005
ECOG performance status of 0 or 1 0.72b
ECOG performance status of 2 0.89c
< 65 years 0.77d
> 65 years 0.75e
Female 0.69f
Male 0.80g
Median survival (months) 287 6.1 285 4.6
No rash 2.6
Grade 1 rash 4.8
Grade 2 rash 8.4 0.001h
Progression-free survival 0.68i
Response rate
Partial response 287 23 8.0 285 0 0 < 0.001
Stable disease 287 90 31.4 285 31 10.9 < 0.001
Proportion of patients alive at 
6 months
287 50 285 33
Proportion of patients alive at 
12 months
287 21 285 16
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CET + BSC BSC
p-valuen Estimate % n Estimate %
Deterioration in physical function 
at 8 weeks
287 –3.9 285 –8.6 < 0.05
Deterioration in physical function at 
16 weeks
287 –5.9 285 –12.5 0.03
Deterioration in global health scale 
at 8 weeks
287 –0.5 285 –7.1 0.008
Deterioration in global health scale 
at 16 weeks
287 –3.6 285 –15.2 < 0.001
Safety population
Any adverse event 288 226 78.5 274 162 59.1
Oedema 288 15 5 274 16 5.8
Fatigue 288 95 33.0 274 71 25.9
Anorexia 288 24 8.3 274 16 5.8
Constipation 288 10 3.5 274 16 5.8
Nausea 288 16 5.6 274 15 5.5
Vomiting 288 16 5.6 274 15 5.5
Non-neutropenic infection 288 37 12.8 274 15 5.5
Confusion 288 16 5.6 274 6 2.2
Abdominal pain 288 38 13.2 274 43 15.7
Other pain 288 43 14.9 274 20 7.3
Dyspnoea 288 47 16.3 274 34 12.4
Rash 288 34 11.8 274 1 0.4
Infusion reaction – grade 1 288 30 10.4 274 0 0
Infusion reaction – grade 2 288 16 5.6 274 0 0
Infusion reaction – grade 3 288 8 2.8 274 0 0
Infusion reaction – grade 4 288 5 1.7 274 0 0
Rash – grade 1 288 114 39.6 274 32 11.7
Rash – grade 2 288 107 37.2 274 11 4.0
Rash – grade 3 288 34 11.8 274 1 0.4
Rash – grade 4 288 0 0 274 0 0
Hypomagnesaemia – grade 1j 288 95 36.7 274 29 14.6
Hypomagnesaemia – grade 2j 288 28 10.8 274 1 0.4
Hypomagnesaemia – grade 3j 288 7 2.7 274 0 0
Hypomagnesaemia – grade 4j 288 8 3.1 274 0 0
BSC, best supportive care; CET, cetuximab.
a Hazard ratio for disease progression (95% CI 0.64 to 0.92).
b Hazard ratio for disease progression (95% CI 0.58 to 0.89).
c Hazard ratio for disease progression (95% CI 0.62 to 1.27).
d Hazard ratio for disease progression (95% CI 0.61 to 0.98).
e Hazard ratio for disease progression (95% CI 0.56 to 1.0).
f Hazard ratio for disease progression (95% CI 0.50 to 0.94).
g Hazard ratio for disease progression (95% CI 0.63 to 1.01).
h p-value for rashes.
i Hazard ratio for disease progression (95% CI 0.57 to 0.80).
j The results for hypomagnesemia are based on 259 patients in the cetuximab group and 198 patients in the supportive-care group.
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Methodological issues
Randomisation and allocation
Eligible patients were stratified according to centre and ECOG performance status and randomly 
assigned in a 1 : 1 ratio. Randomisation was peformed by the National Cancer Institute of Canada 
Clinical Trials Group central office with the use of a minimisation method that dynamically 
balanced patients according to stratification factors.
Data analysis
Time-to-event variables were summarised with the use of Kaplan–Meier plots.
Primary comparisons of the treatment groups were made with the use of the stratified log-rank 
test. Hazard ratios with 95% CIs were calculated from stratified Cox regression models with 
treatment group as the single factor. Deterioration in QoL score was defined a priori as a decline 
of ≥ 10 points from baseline.
All p-values were two-sided.
Power calculation
It was estimated a priori that 445 deaths would provide a statistaical power of 90% and a two-
sided alpha of 5% to detect an absolute increase of 9.6% in the 1-year overall survival from the 
predicted 1-year overall survival of 14.1% in the group assigned to supportive care alone (hazard 
ratio 0.74).
Conflicts of interest
Two authors are employees of the National Cancer Institute of Canada Clinical Trials Group and 
received funding from Bristol-Myers Squibb and Amgen. Two authors received research grants 
from Bristol-Myers Squibb and one author received consulting fees from Amgen. One author is 
an employee of and owns equity in Bristol-Myers Squibb.
Quality appraisal
1. Was the assignment to the treatment groups really random? Reported – yes
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Reported – yes
4. Were the eligibility criteria specified? Reported – yes
5. Were outcome assessors blinded to the treatment allocation? No
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Adequate
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Reported – yes
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Karapetis et al.45
Design Participants Arms Outcomes
Study design: Retrospective 
KRAS analysis of parallel, 
open-label RCT
Country: Australia and 
Canada
No. of centres: Unknown
Funding: National Cancer 
Institute of Canada, ImClone 
Systems and Bristol-Myers 
Squibb
Length of follow-up: Not 
reported
Notes: Cetuximab therapy 
was continued until the 
disease progressed or until 
the patient could not tolerate 
the toxic effects
Number randomised: 572
Inclusion criteria: Not fully 
reported in this paper, only 
states that no patients had 
received previous therapy 
directed against EGFR. Refer 
to Jonker et al.37 for main 
trial
Exclusion criteria: Not 
reported
Therapy common to all 
participants: Best supportive 
care
Arm no. 1
Name: Cetuximab plus best 
supportive care
n: 287
Drug: Cetuximab
Starting daily dose: Intravenously 
as an initial dose of 400 mg/m2 of 
body surface area, administered over 
120 minutes
Dosage details: Weekly maintenance 
infusion of 250 mg/m2, administered 
over 60 minutes
Arm no. 2
Name: Best supportive care
n: 285
Drug: N/A
Starting daily dose: N/A
Dosage details: Measures designed 
to provide palliation of symptoms and 
improve quality of life
Primary outcome measure: Overall 
survival, defined as time from 
randomisation until death from any 
cause
Secondary outcome measure(s): 
Progression-free survival, defined 
as time from randomisation until the 
first objective observation of disease 
progression or death from any cause
Response rates, defined according to 
the modified RECIST
QoL, assessed by mean changes in 
scores of physical function and global 
health status at 8 and 16 weeks
Method of assessment: Patients 
were evaluated for tumour response 
or progression every 8 weeks by 
radiological imaging
Assays of tissue samples for KRAS 
mutations were performed in a blinded 
fashion
N/A, not applicable.
Baseline characteristics
Demographics
All KRAS mutant KRAS WT
p-valuen Estimate % n Estimate % n Estimate %
Age 572 63.2a 164 62.0b 230 63.5c 0.57
< 65 years 572 335 58.6 164 99 60.4 230 133 57.8
≥ 65 years 572 237 41.4 164 65 39.6 230 97 42.2
Sex 0.20
Female 572 204 35.7 164 63 38.4 230 74 32.2
Male 572 368 64.3 164 101 61.6 230 156 67.8
ECOG performance status
0 572 136 23.8 164 34 20.7 230 56 24.3 0.70
1 572 302 52.8 164 94 57.3 230 127 55.2
2 572 134 23.4 164 36 22.0 230 47 20.4
Site of primary cancer
Colon only 572 332 58.0 164 108 65.9 230 137 59.6 0.41
Rectum only 572 133 23.3 164 32 19.5 230 50 21.7
Colon and rectum 572 107 18.7 164 24 14.6 230 43 18.7
Any previous 
radiotherapy
572 202 35.3 164 50 30.5 230 77 33.5 0.53
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Demographics
All KRAS mutant KRAS WT
p-valuen Estimate % n Estimate % n Estimate %
Previous chemotherapy
Adjuvant therapy 572 211 36.9 164 57 34.8 230 83 36.1 0.79
No. of regimens
1 or 2 572 104 18.2 164 27 16.5 230 46 20.0 0.70
3 572 217 37.9 164 69 42.1 230 86 37.4
4 572 159 27.8 164 46 28.0 230 63 27.4
≥ 5 572 92 16.1 164 22 13.4 230 35 15.2
Thymidylate 
synthase inhibitor
572 572 100 164 164 100 230 230 100
Irinotecan 572 550 96.2 164 161 98.2 230 219 95.2 0.12
Oxaliplatin 572 559 97.7 164 163 99.4 230 222 96.5 0.06
Sites of disease
Liver 572 463 80.9 164 129 78.7 230 189 82.2 0.38
Lung 572 368 64.3 164 98 59.8 230 144 62.6 0.57
Lymph nodes 572 247 43.2 164 64 39.0 230 103 44.8 0.25
Peritoneal cavity 572 86 15.0 164 23 14.0 230 38 16.5 0.50
No. of sites of disease
1 572 93 16.3 164 27 16.5 230 40 17.4 0.27
2 572 153 26.7 164 45 27.4 230 63 27.4
3 572 173 30.2 164 42 25.6 230 75 32.6
≥ 4 572 153 26.7 164 50 30.5 230 52 22.6
Treatment
Cetuximab plus 
BSC
572 287 50.2 164 81 49.4 230 117 50.9 0.77
BSC 572 285 49.8 164 83 50.6 230 113 49.1
BSC, best supportive care.
a Median (range 28.6–88.1 years).
b Median (range 37.4–88.1 years).
c Median (range 28.6–85.9 years).
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Results
CET + BSC BSC
p-valuen Estimate % n Estimate %
ITT population
Study medication: duration of treatment
KRAS assessed 287 198 69.0 285 196 68.8
Overall survival
KRAS mutant 198 0.98a 196
KRAS WT 198 0.55b 196
1-year survival rate – mutant 198 196 13.2
1-year survival rate – WT 198 196 20.1
Median overall survival (months)
KRAS mutant 198 4.5 196 4.6
KRAS WT 198 9.5 196 4.8
Progression-free survival
KRAS mutant 198 0.99c
KRAS WT 198 0.4d
KRAS mutant, median PFS (months) 198 1.8 196 1.8
KRAS WT, median PFS (months) 198 3.7 196 1.9
Response rate
KRAS mutant 198 196 0
KRAS WT 198 196 0
Global health scale at 8 weeks, mean change
KRAS mutant 198 –4.7 196 –9.6
KRAS WT 198 3.2 196 –7.7
Difference WT 198 10.9e 0.002
Global health scale at 16 weeks, mean change
KRAS mutant 198 –9.5 196 –13.9
KRAS WT 198 –0.2 196 –18.1
Difference WT 198 17.9f < 0.001
Safety population No safety 
data 
presented; 
refer to 
Jonker et 
al.37
BSC, best supportive care; CET, cetuximab; PFS, progression-free survival.
a Hazard ratio for disease progression (95% CI 0.70 to 1.37).
b Hazard ratio for disease progression (95% CI 0.41 to 0.74).
c Hazard ratio for disease progression (95% CI 0.73 to 1.35).
d Hazard ratio for disease progression (95% CI 0.30 to 0.54).
e 95% CI 4.2 to 17.6.
f 95% CI 7.6 to 28.2.
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Methodological issues
Randomisation and allocation
Not applicable as a retrospective study; see Jonker and colleagues37 for main study.
Data analysis
All randomly assigned patients for whom data on KRAS mutation status were available were 
included in the analysis.
Survival was summarised with the use of Kaplan–Meier curves and the difference in survival 
between treatment groups compared with the use of the log-rank test, with hazard ratios and 95% 
CIs calculated from a Cox regression model with a single covariate.
To assess whether or not KRAS was an independant prognostic factor for patients receiving 
supportive care, a multivariate Cox regression model was fitted to data for patients receiving 
supportive care alone. The Cox regression model, with treatment, KRAS mutation status and their 
interaction as covariates, was used to assess the interaction between treatment and KRAS status.
All reported p-values are two-sided and were not adjusted for multiple testing.
For QoL, Wilcoxon’s tests were used to compare the treatment arms with respect to the mean 
change from baseline in scores on the global QoL scale. A difference of more than 10 points was 
considered to indicate clinical significance.
Power calculation
Not reported.
Conflicts of interest
Two authors received consulting fees from Merck Serono, two authors received consulting 
fees from Bristol-Myers Squibb, two authors were employed by the National Cancer Institute 
of Canada Clinical Trials Group and funded by Bristol-Myers Squibb and Amgen, one author 
received consulting fees from ImClone and two authors received research grants from Amgen, 
Merck Serono, Bristol-Myers Squibb and Alphapharm.
Quality appraisal
1. Was the assignment to the treatment groups really random? Not applicable
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Reported – yes
4. Were the eligibility criteria specified? Reported – yes
5. Were outcome assessors blinded to the treatment allocation? Partial
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Adequate
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Reported – yes
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Peeters et al.52
Design Participants Arms Outcomes
Study design: 
Supplementary study to 
open-label, Phase III RCT. 
See Van Cutsem et al.7
Country: Not reported
No. of centres: Unknown
Funding: Not reported
Length of follow-up: 
Median follow-up time 
for all patients was 
29 months (range 
24–38 months) and for 
39 surviving patients it 
was 28 months (range 
24–26 months)
Number randomised: 463
Inclusion criteria: Pathological 
diagnosis of metastatic colorectal 
adenocarcinoma, ECOG performance 
status of 0–2, radiological 
documentation of disease progression 
during or within 6 months after the 
last administration of fluoropyrimidine, 
irinotecan and oxaliplatin, two or three 
prior chemotherapy regimens, EGFR 
membrane staining on ≥ 1% tumour 
cells by immunohistochemistry 
at a central laboratory, adequate 
haematological, renal and hepatic 
function and no symptomatic brain 
metastases
Exclusion criteria: Not reported
Therapy common to all 
participants: Best supportive care
Arm no. 1
Name: Panitumumab 
plus best supportive 
care
n: 231
Drug: Panitumumab
Dosage details: 
Panitumumab 6.0 mg/
kg twice a week plus 
BSC
Arm no. 2
Name: Best supportive 
care
n: 232
Drug: N/A
Starting daily dose: 
N/A
Dosage details: N/A
Primary outcome measure: Progression-free 
survival, defined as the time from randomisation 
to the earliest radiological disease progression 
per modified RECIST by blinded central review or 
death, with censoring at the last complete tumour 
assessment
Secondary outcome measure(s): Overall 
survival time and best overall objective response 
by central radiology, safety (including skin toxicity 
severity), patient-reported skin toxicity, disease-
related symptoms and HRQoL
Method of assessment: Blinded central 
radiological tumour assessment using modified 
RECIST at specified time points from weeks 8 to 
48 and every 3 months thereafter until disease 
progression. Responses were confirmed no less 
than 4 weeks after the response criteria were 
first met. At the discretion of the investigator, 
patients could be evaluated for radiographic 
tumour assessment after developing symptoms 
consistent with disease progression
Patient-reported outcome assessments were 
obtained at baseline and every 2 weeks or 
monthly during the treatment phase of the study 
and at the 30-day safety follow-up visit. Patient-
reported skin toxicity was measured using the 
modified Dermatology Life Quality Index (mDLQI); 
colorectal cancer symptoms were measured 
using the NCCN FCSI; HRQoL was measured 
using the EQ-5D and the EORTC QLQ-C30 global 
health status/QOL scale
N/A, not applicable.
Baseline characteristics
No characteristics reported; see main paper by Van Cutsem and colleagues.7
Results
PAN + BSC BSC
p-valuen Estimate % n Estimate %
Number of completed questionnaires
mDLQI week 4 208 189 184 128
mDLQI week 8 208 112 184 47
mDLQI week 12 208 91 184 12
mDLQI week 16 208 66 184 6
EQ-5D week 4 208 189 184 129
EQ-5D week 8 208 112 184 46
EQ-5D week 12 208 92 184 13
EQ-5D week 16 208 66 184 7
FCSI subscale week 4 208 190 184 130
FCSI subscale week 8 208 113 184 47
FCSI subscale week 12 208 91 184 13
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PAN + BSC BSC
p-valuen Estimate % n Estimate %
FCSI subscale week 16 208 66 184 7
Progression-free survival
Onset of grade 2 or above 
skin toxicity
363 0.71 0.0230
Onset of grade 2 or above 
skin toxicity in 2 months, 
all patients
363 0.63 0.0126
Skin toxicity grades 2–4 vs 
grade 1
182 0.63a 0.0063
Skin toxicity grades 2–4 
WT
110 0.75b
Grade 2-onset skin toxicity, 
any time, all patients
182 0.71c 0.0230
Grade 2-onset skin toxicity, 
0–1 months, all patients
182 0.27d 0.0476
Grade 2-onset skin toxicity, 
1–2 months, all patients,
182 0.69e 0.0575
Grade 2-onset skin toxicity, 
2–3 months, all patients
182 0.69f 0.4205
Grade 2-onset skin toxicity, 
> 3 months, all patients
110 1.02g 0.9628
Grade 2-onset skin toxicity, 
any time, WT
110 0.75h 0.2021
Grade 2-onset skin toxicity, 
0–2 months, WT
110 0.55i 0.0453
Grade 2-onset skin toxicity, 
>2 months, WT
110 1.12j 0.7589
Grade 2-onset skin toxicity, 
any time, mutant
72 0.83k 0.4635
Grade 2-onset skin toxicity, 
0–2 months, mutant
72 0.84l 0.5049
Grade 2-onset skin toxicity, 
> 2 months, mutant
72 0.79m 0.7111
Overall survival
Skin toxicity grades 2–4 vs 
grade 1
182 0.6n 0.0033
Skin toxicity grade 2 or 
above, all patients
182 0.63o 0.0034
Grade 2 onset skin toxicity, 
0–2 months, all patients
182 0.45p 0.0480
Grade 2 onset skin toxicity, 
2–4 months, all patients,
182 0.42q 0.0139
Grade 2 onset skin toxicity, 
4–6 months, all patients
182 0.97r 0.9276
Grade 2 onset skin toxicity, 
6 months, all patients
182 0.71s 0.1394
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PAN + BSC BSC
p-valuen Estimate % n Estimate %
Grade 2 onset skin toxicity, 
0–4 months, all patients
182 0.43t 0.0017
Grade 2 onset skin toxicity, 
> 4 months, all patients
182 0.77u 0.1965
Grade 2 onset skin toxicity, 
any time, WT
110 0.58v 0.0252
Grade 2 onset skin toxicity, 
0–4 months, WT
110 0.45w 0.0569
Grade 2 onset skin toxicity, 
> 4 months, WT
110 0.66x 0.1628
Grade 2 onset skin toxicity, 
any time, mutant
72 0.85y 0.5318
Grade 2 onset skin toxicity, 
0–4 months, mutant
72 0.44z 0.0406
Grade 2 onset skin toxicity, 
> 4 months, mutant
72 1.3aa 0.4349
Safety population
Skin toxicity grade 1 and 
above
229 209 91
Skin toxicity grades 2–4 229 158 69
Skin toxicity grade 1 288 51 17.7
BSC, best supportive care; CET, cetuximab.
a Hazard ratio for disease progression (95% CI 0.45 to 0.88).
b Hazard ratio for disease progression (95% CI 0.49 to 1.17).
c Hazard ratio for disease progression (95% CI 0.53 to 0.95).
d Hazard ratio for disease progression (95% CI 0.08 to 0.99).
e Hazard ratio for disease progression (95% CI 0.47 to 1.01).
f Hazard ratio for disease progression (95% CI 0.28 to 1.71).
g Hazard ratio for disease progression (95% CI 0.53 to 1.95).
h Hazard ratio for disease progression (95% CI 0.49 to 1.17).
i Hazard ratio for disease progression (95% CI 0.31 to 0.99).
j Hazard ratio for disease progression (95% CI 0.55 to 2.25).
k Hazard ratio for disease progression (95% CI 0.51 to 1.36).
l Hazard ratio for disease progression (95% CI 0.50 to 1.40).
m Hazard ratio for disease progression (95% CI 0.22 to 2.78).
n Hazard ratio for disease progression (95% CI 0.43 to 0.85).
o Hazard ratio for disease progression (95% CI 0.46 to 0.86).
p Hazard ratio for disease progression (95% CI 0.21 to 0.99).
q Hazard ratio for disease progression (95% CI 0.21 to 0.84).
r Hazard ratio for disease progression (95% CI 0.45 to 2.08).
s Hazard ratio for disease progression (95% CI 0.45 to 1.12).
t Hazard ratio for disease progression (95% CI 0.26 to 0.73).
u Hazard ratio for disease progression (95% CI 0.52 to 1.14).
v Hazard ratio for disease progression (95% CI 0.36 to 0.94).
w Hazard ratio for disease progression (95% CI 0.20 to 1.02).
x Hazard ratio for disease progression (95% CI 0.37 to 1.18).
y Hazard ratio for disease progression (95% CI 0.52 to 1.41).
z Hazard ratio for disease progression (95% CI 0.20 to 0.97).
aa Hazard ratio for disease progression (95% CI 0.68 to 2.49).
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Methodological issues
Randomisation and allocation
Not reported.
Data analysis
Patients were stratified by ECOG score (0–1 vs 2) and geographical region (Western Europe vs 
Central and Eastern Europe vs the rest of the world).
The primary analysis of patient-reported outcomes used analysis of covariance to estimate 95% 
CIs for the least squares adjusted means within and between the panitumumab and BSC groups 
for the time-adjusted area under the curve for the mDLQI, FCSI and EQ-5D scales.
To account for lead-time bias and under-reporting of skin toxicity because of early treatment 
discontinuation, a landmark approach was used that limited the analysis to patients having at 
least grade 1 skin toxicity with a progression-free survival time of at least 28 days.
Patients were excluded if they had no post-baseline assessments.
For progression-free survival and overall survival analyses, a Cox proportional hazards model 
was used to examine the relationship between severity of skin toxicity and time to event.
Pearson correlation coefficients were used to examine the association between patient-reported 
skin toxicity and median post-baseline patient-reported outcomes. Kruskal–Wallis and Terpstra–
Jonckheere tests were used to examine general and ordered associations between severity of skin 
toxicity and the minimum post-baseline mDLQI score.
Time to onset of the first grade 2 or higher skin toxicity was modelled as a time-dependent 
covariate in separate Cox models for progression-free survival and overall survival among 
all randomised patients, with indicators for their randomisation factors. Time to onset was 
examined at any time and in 1- to 2-month increments with a piecewise model. Months were 
calculated by multiplying the number of days by 12 and dividing by 364.25.
All p-values were two-sided.
Power calculation
Not reported.
Conflicts of interest
One author has financial interests in Amgen and Merck Serono, one author receives research 
funding from Amgen, one author is on the advisory board of Amgen and three authors are 
employed by and own stock in Amgen.
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Quality appraisal
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Reported  – yes
5. Were outcome assessors blinded to the treatment allocation? Partial
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Reported – yes
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Adequate
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Siena et al.53
Design Participants Arms Outcomes
Study design: 
Supplementary study to 
parallel, open-label RCT
Country: Unknown
No. of centres: 
Unknown
Funding: Amgen
Length of follow-up: 
Median follow-up 
time for survival for all 
patients was 72 weeks 
(range 52–113 weeks)
Notes: This is a 
supplementary paper to 
Van Cutsem et al.7
Number randomised: 463
Inclusion criteria: Inclusion 
criteria were pathological 
diagnosis of metastatic 
colorectal adenocarcinoma, 
radiological documentation of 
disease progression during 
or within 6 months following 
the last administration of 
fluoropyrimidine, irinotecan and 
oxaliplatin, prior exposure of 
prespecified doses of irinotecan 
and oxaliplatin and two or three 
prior chemotherapy regimens
Exclusion criteria: Not 
reported
Therapy common to all 
participants: Best supportive 
care
Arm no. 1
Name: Panitumumab 
plus best supportive care
n: 231
Drug: Panitumumab
Starting daily dose: Not 
reported
Dosage details: Not 
reported
Arm no. 2
Name: Best supportive 
care
n: 232
Drug: N/A
Starting daily dose: N/A
Dosage details: N/A
Primary outcome measure: Progression-free survival
Secondary outcome measure(s): Best objective 
response, overall survival and patient-reported 
outcomes
Method of assessment: Objective tumour response 
was assessed by blinded central radiology review using 
modified RECIST criteria at specified time points from 
week 8 to week 48 and every 3 months thereafter until 
disease progression. Responses were confirmed no less 
than 4 weeks after response criteria were first met
Tumour response, including stable disease, was 
evaluated at the first scheduled assessment (week 8)
Patient-reported outcome assessments were taken 
at baseline and every 2 weeks or monthly during the 
treatment phase of the study and at the 30-day safety 
follow-up visit. Colorectal cancer symptomatology 
was measured using the NCCN FCSI and HRQoL was 
measured using the EQ-5D, the EQ-5D VAS and two 
global health items from the EORTC QLQ-C30 (range 
between 0 and 100)
Missing items in a scale were handled by the methods 
outlined in the scoring manual
N/A, not reported.
Baseline characteristics
PAN + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Not reported; refers to Van Cutsem et al.7 for full characteristics
BSC, best supportive care; PAN, panitumumab.
Results
PAN + BSC BSC
p-valuen Estimate % n Estimate %
Completion of PRO
PRO all enrolled analysis set 231 207 232 184
PRO all enrolled analysis set and alive 
at week 8, EQ-5D
231 179 232 164
Patients completing EQ-5D
Week 4 231 189 232 129
Week 8 231 111 232 47
Week 12 231 91 232 14
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PAN + BSC BSC
p-valuen Estimate % n Estimate %
Week 16 231 62 232 7
PRO all enrolled analysis set and alive 
at week 8, FCSI
231 181 232 166
Patients completing FCSI
Week 4 231 190 232 130
Week 8 231 112 232 48
Week 12 231 90 232 14
Week 16 231 62 232 7
Progression-free survival
PAN vs BSC 463 0.63a < 0.001
Response rate
Partial response 231 22 10 232 0 0
Stable disease 231 62 27 232 23 10
Time to death (months)
Overall, median 231 7.6
With PD at week 8, median 231 3.6
Alive at week 8 without PD, median 231 8.6
Alive at week 8 with PD, median 231 4.3
Safety population
No data reported
BSC, best supportive care; PAN, panitumumab; PD, progressive disease; PRO, patient-reported outcome.
a Hazard ratio for disease progression (95% CI 0.52 to 0.77).
Methodological issues
Randomisation and allocation
Not reported.
Data analysis
To assess whether or not the treatment differences in progression-free survival were due to 
patients with an objective response, a post hoc sensitivity analysis of progression-free survival 
that removed responding patients in the panitumumab group was conducted to evaluate 
the contribution of non-responding patients to the treatment effect with panitumumab. The 
objective was to evaluate the association between progression-free survival and colorectal cancer 
symptoms, HRQoL and overall survival.
The t-tests and least squares estimates were calculated for differences in patient-reported outcome 
measures, controlling for baseline score by progression status as of week 8.
For overall survival within each treatment group, survival was examined among patients 
surviving to at least week 8. A Cox regression model was used to examine the correlation 
between time to radiological progression and time to death.
Patients who died without radiological progression were censored at their last radiological 
assessment of time to progression.
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Power calculation
Not reported; see Van Cutsem and colleagues.7
Conflicts of interest
Not reported.
Quality appraisal
1. Was the assignment to the treatment groups really random? Not reported
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Unclear
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Reported – yes
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Adequate
9. Did the analyses include an ITT analysis? Unclear
10. Were withdrawals and dropouts completely described? Reported – yes
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Van Cutsem et al.7
Design Participants Arms Outcomes
Study design: Parallel, 
open-label RCT
Country: Unknown
No. of centres: Unknown
Funding: Amgen
Length of follow-up: All 
patients were followed up 
for survival approximately 
every 3 months for up 
to 2 years after random 
assignment. The median 
follow-up time after 
crossover from best 
supportive care was 
61 weeks (range 18 to 
103 weeks)
Number randomised: 463
Inclusion criteria: Pathological 
diagnosis of metastatic colorectal 
adenocarcinoma and radiological 
documentation of disease progression 
during or within 6 months 
following the last administration 
of fluoropyrimidine, irinotecan 
and oxaliplatin; dose intensity of 
irinotecan ≥ 65 mg/m2 per week 
and of oxaliplatin ≥ 30 mg/m2 per 
week were required; > 18 years; 
ECOG status 0–2; two or three 
prior chemotherapy regimens for 
metastatic colorectal cancer; and 1% 
EGFR-positive membrane staining in 
primary or metastaic tumour cells by 
immunohistochemistry prospectively 
read centrally (after amendment – 
10% in original protocol)
Exclusion criteria: Symptomatic 
brain metastases, interstitial 
pneumonitis or pulmonary fibrosis, 
systematic chemotherapy or 
radiotherapy within 30 days before 
random assignment and prior anti-
EFGR agents
Therapy common to all 
participants: Best supportive care
Arm no. 1
Name: Panitumumab 
plus best supportive care
n: 231
Drug: Panitumumab
Dosage details: 
Panitumumab was 
administered using a 
60-minute intravenous 
infusion at 6 mg/kg once 
every 2 weeks until 
patients progressed or 
unacceptable toxicity 
developed. Premedication 
was not required
Arm no. 2
Name: Best supportive 
care
n: 232
Drug: N/A
Starting daily dose: N/A
Dosage details: N/A
Primary outcome measure: Progression-
free survival by blinded central radiology 
assessment, calculated from day of random 
assignment until radiological progression or 
death
Secondary outcome measure(s): Objective 
response, overall survival and safety. Best 
objective response by blinded central review 
and overall survival time. Overall survival 
was calculated from the day of random 
assignment until death, censoring patients 
at the last day known to be alive. All patients 
were followed up for survival every 3 months 
for up to 2 years after random assignment. 
Best supportive care patients determined by 
the investigator to have disease progression 
were eligible to receive panitumumab under 
a separate study. The crossover evidence 
was based on prior evidence of activity with 
panitumumab and cetuximab
Method of assessment: Objective tumour 
response was evaluated by central radiology 
review using modified RECIST at weeks 8, 12, 
16, 24, 32, 40 and 48 and every 3 months 
thereafter until disease progression, and 
confirmed no less than 4 weeks after the 
criteria for response were first met. At the 
discretion of the investigator, patients could be 
evaluated for radiographic tumour assessment 
after developing symptoms consistent with 
disease progression
N/A,not applicable.
NIHR Journals Library
180 Appendix 3
Baseline characteristics
Demographics
PAN + BSC BSC
n Estimate % n Estimate %
Sex
Male 231 146 63 232 148 64
Female 231 85 37 232 84 36
Race/ethnicity
White 231 229 99 232 228 98
Other 231 2 1 232 4 2
Age (years)
Median 62 63
Minimum 27 27
Maximum 82 83
Primary diagnosis
Colon cancer 231 153 66 232 157 68
Rectal cancer 231 78 34 232 75 32
ECOG performance status
0 231 107 46 232 80 34
1 231 94 41 232 115 50
2 231 29 13 232 35 15
3 231 1 0 232 2 1
Cells with EGFR membrane staining
1% to < 10% 231 57 25 232 57 25
10–100% 231 172 74 232 174 75
Intensity of EGFR staining
3+ (strong) 231 47 20 232 41 18
2+ (moderate) 231 122 53 232 113 49
1+ (weak) 231 60 26 232 78 34
0 231 0 0 232 0 0
Previous adjuvant chemotherapy 231 86 37 232 78 34
Previous lines of chemotherapy
2 231 230 100 232 232 100
3 231 84 36 232 88 38
BSC, best supportive care; PAN, panitumumab.
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Hoyle et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced 
for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated 
with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha 
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
181 Health Technology Assessment 2013; Vol. 17: No. 14DOI: 10.3310/hta17140
Results
PAN + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Duration of treatment Until disease progression or toxicity
Progression-free survival
PAN vs BSC 463 0.54a < 0.0001
Male 294 0.57b
Female 169 0.51c
Age < 65 years 276 0.51d
Age 65+ years 187 0.60e
Primary cancer: colon 310 0.55f
Primary cancer: rectal 153 0.53g
ECOG performance status 0–1 396 0.56h
ECOG performance status 2–3 67 0.46i
Previous regimens: 2 290 0.63j
Previous regimens: 3 149 0.39k
Metastasis sites: 1–2 322 0.49l
Metastasis sites: 3–5 139 0.67m
Intensity of EGFR staining: 1+ 138 0.62n
Intensity of EGFR staining: 2+ 235 0.51o
Intensity of EGFR staining: 3+ 88 0.58p
Cells with EGFR staining: 1 to < 10% 114 0.47q
Cells with EGFR staining: 10–100% 346 0.57r
Time (weeks), median 231 8s 232 7.3t
Time (weeks), mean 231 13.08u 232 8.5v
Associated with skin toxicity, grades 2–4 vs grade 1 231 0.62w
Overall survival
PAN vs BSC 436 1x
Deaths 231 186 232 194
Associated with skin toxicity, grades 2–4 vs grade 1 231 0.59y
Objective response 231 22 232 0
Median time to response (weeks) 231 7.9z
Median duration of response (weeks) 231 17aa
Safety population
All grades
Patients with at least one adverse event 229 229 234 202
Erythema 229 146 234 2
Dermatitis acneiform 229 142 234 2
Pruritis 229 130 234 5
Skin exfoliation 229 56 234 0
Fatigue 229 55 234 34
Paronychia 229 55 234 0
Abdominal pain 229 53 234 39
Anorexia 229 50 234 43
Nausea 229 50 234 36
Diarrhoea 229 48 234 26
Rash 229 46 234 2
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PAN + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Skin fissures 229 45 234 1
Constipation 229 44 234 21
Vomiting 229 42 234 28
Dyspnoea 229 33 234 31
Pyrexia 229 33 234 29
Asthenia 229 33 234 27
Cough 229 31 234 17
Back pain 229 24 234 16
Oedema 229 24 234 13
General physical health deterioration 229 23 234 8
Grade 3
Patients with at least one adverse event 229 75 234 41
Erythema 229 12 234 0
Dermatitis acneiform 229 17 234 0
Pruritis 229 5 234 0
Skin exfoliation 229 5 234 0
Fatigue 229 10 234 7
Paronychia 229 3 234 0
Abdominal pain 229 17 234 8
Anorexia 229 7 234 5
Nausea 229 2 234 1
Diarrhoea 229 3 234 0
Rash 229 2 234 0
Skin fissures 229 2 234 0
Constipation 229 6 234 2
Vomiting 229 5 234 2
Dyspnoea 229 9 234 8
Pyrexia 229 0 234 4
Asthenia 229 6 234 5
Cough 229 1 234 0
Back pain 229 4 234 0
Oedema 229 2 234 1
General physical health deterioration 229 11 234 2
Grade 4
Patients with at least one adverse event 229 4 234 2
Erythema 229 0 234 0
Dermatitis acneiform 229 0 234 0
Pruritis 229 0 234 0
Skin exfoliation 229 0 234 0
Fatigue 229 0 234 0
Paronychia 229 0 234 0
Abdominal pain 229 0 234 1
Anorexia 229 1 234 0
Nausea 229 0 234 0
Diarrhoea 229 0 234 0
Rash 229 0 234 0
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PAN + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Skin fissures 229 0 234 0
Constipation 229 0 234 0
Vomiting 229 0 234 0
Dyspnoea 229 2 234 0
Pyrexia 229 0 234 0
Asthenia 229 1 234 0
Cough 229 0 234 0
Back pain 229 0 234 0
Oedema 229 0 234 0
General physical health deterioration 229 5 234 1
BSC, best supportive care; PAN, panitumumab; SD, standard deviation.
a Hazard ratio for disease progression (95% CI 0.44 to 0.66).
b Hazard ratio for disease progression (95% CI 0.44 to 0.73).
c Hazard ratio for disease progression (95% CI 0.36 to 0.71).
d Hazard ratio for disease progression (95% CI 0.40 to 0.67).
e Hazard ratio for disease progression (95% CI 0.43 to 0.83).
f Hazard ratio for disease progression (95% CI 0.43 to 0.70).
g Hazard ratio for disease progression (95% CI 0.37 to 0.75).
h Hazard ratio for disease progression (95% CI 0.45 to 0.69).
i Hazard ratio for disease progression (95% CI 0.27 to 0.81).
j Hazard ratio for disease progression (95% CI 0.49 to 0.81).
k Hazard ratio for disease progression (95% CI 0.26 to 0.57).
l Hazard ratio for disease progression (95% CI 0.38 to 0.63).
m Hazard ratio for disease progression (95% CI 0.47 to 0.95).
n Hazard ratio for disease progression (95% CI 0.42 to 0.91).
o Hazard ratio for disease progression (95% CI 0.39 to 0.67).
p Hazard ratio for disease progression (95% CI 0.37 to 0.90).
q Hazard ratio for disease progression (95% CI 0.31 to 0.71).
r Hazard ratio for disease progression (95% CI 0.46 to 0.72).
s 95% CI 7.9 to 8.4.
t 95% CI 7.1 to 7.7.
u SD 0.8.
v SD 0.5.
w Hazard ratio for disease progression (95% CI 0.46 to 0.72).
x Hazard ratio for disease progression (95% CI 0.82 to 1.22).
y Hazard ratio for disease progression (95% CI 0.42 to 0.85).
z Hazard ratio for disease progression (95% CI 6.7 to 15.6).
aa Hazard ratio for disease progression (95% CI 7.9 to 76.7).
Methodological issues
Randomisation and allocation
Patients were randomly assigned in a 1 : 1 ratio to receive panitumumab plus best supportive care 
or best supportive care alone. Randomisation was stratified by ECOG performance status (0 or 1 
vs 2) and region (Western Europe vs Central and Eastern Europe vs the rest of the world).
Data analysis
The primary analysis included all patients randomly assigned. Progression-free survival 
was analysed at the 5% significance level using a log-rank test stratified by baseline ECOG 
performance status and region. A 1% test of objective response at the primary analysis and 4% 
test of overall survival were prespecified conditional on a significant progression-free survival 
difference. The primary analysis of overall survival and an update of objective response rates and 
duration of response were conducted after a minimum of 12 months’ follow-up. Kaplan–Meier 
methodology was used to estimate progression-free survival, overall survival and time to and 
duration of response, including 95% CIs for event-free rates and difference in rates. The 65% 
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CIs for time-to-event quartiles were calculated according to Brookmeye and Crowley.90 Hazard 
ratios for progression-free survival and overall survival were estimated using a Cox proportional 
hazards regression model adjusted for the randomisation factors.
Power calculation
The study had 90% power for a two-sided 1% significance level test given a hazard ratio 
(panitumumab relative to best supportive care) of 0.67. The sample size goal was 430 patients, 
with an event goal of 362 patients with progressive disease by central review or death.
Conflicts of interest
Two authors were employed by Amgen, two authors were consultants for Amgen, Merck and 
Roche and two authors received research funding from Amgen and GlaxoSmithKline.
Quality appraisal
1. Was the assignment to the treatment groups really random? Unclear – not reported whether 
or not randomisation was performed centrally
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Adequate
4. Were the eligibility criteria specified? Reported – yes
5. Were outcome assessors blinded to the treatment allocation? Reported – yes
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Reported – yes
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Partial
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Van Cutsem et al.38
Design Participants Arms Outcomes
Study design: Open-
label single-arm study 
– supplementary to main 
trial reported by Van Cutsem 
et al.7
Country: Unknown
No. of centres: Unknown
Funding: Amgen
Length of follow-up: 
Patients who discontinued 
the extension study were to 
complete a safety follow-
up visit 4 weeks after the 
last panitumumab infusion. 
Patients were followed for 
survival approximately every 
3 months for up to 2 years 
from the randomisation 
phase of the Phase III study
Number randomised: N/A
Inclusion criteria: Patients who had 
radiographically documented disease 
progression while receiving best 
supportive care in the Phase III study
Patients were required to complete 
the last assessement in the Phase III 
study not more than 3 months before 
enrolment in the extension study 
and in the interim could not have 
received systemic chemotherapy, 
radiotherapy, investigational agents 
or antitumour therapies including 
approved antitumour small molecules 
and biologics
Patients were required to have 
adequate renal and hepatic function 
and an ECOG performance status of 
0, 1 or 2 at entry into the extension 
study. EGFR membrane expression 
in ≥ 1% of tumour cells was an 
eligibility criterion for the Phase III 
study
Exclusion criteria: During this 
interval patients could not have had 
a myocardial infarction, interstitial 
pneumonitis or pulmonary fibrosis. 
Brain metastases, if present, were to 
be controlled and asymptomatic
Therapy common to all 
participants: Best supportive care
Arm no: 1
Name: Panitumumab plus 
best supportive care
n: 231
Drug: Panitumumab
Dosage details: 
Panitumumab was 
administered using a 
60-minute intravenous 
infusion of 6 mg/kg once 
every 2 weeks until patients 
progressed or unacceptable 
toxicity developed. 
Premedication was not 
required
Primary outcome measure: Safety, 
including incidence of grade 3/4 adverse 
and treatment-related events, skin-related 
events and antibody formation
Secondary outcome measure(s): 
Although no secondary end points were 
prespecified in the protocol, the efficacy of 
panitumumab monotherapy was explored 
by assessing progression-free survival, 
ORR, time to and duration of response, 
duration of stable disease and survival 
using the local investigators’ assessment of 
radiographic images
Method of assessment:
Primary – Safety assessments were carried 
out every 2 weeks and at the safety follow-
up visit 4 weeks after the last panitumumab 
infusion. Adverse events were graded 
using the NCI-CTC version 2.0 with the 
exception of selected dermatological toxic 
effects (erythema, rash, desquamation and 
ulceration), which were graded using the 
NCI-CTC version 3.0 with modifications
Secondary – Patients were evaluated for 
tumour response every 8 weeks from the 
first dose of panitumumab and at the time 
of suspected disease progression according 
to a modified version of RECIST. Stable 
disease was first evaluated at the first 
scheduled assessment (week 8). Disease 
control rate was defined as the sum of 
the objective response and stable disease 
rates. Tumour responses were confirmed 
no less than 4 weeks after the criteria for 
response were first met. Patients with no 
response confirmation were considered 
non-responders
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Baseline characteristics
Demographics
PAN + BSC
n Estimate %
Sex
Male 176 111 63
Race
White or Caucasian 176 175 99
Japanese 176 1 1
Age (years)
Median 176 62a
≥ 65 years 176 67 38
Primary diagnosis
Colon cancer 176 113 64
Rectal cancer 176 63 36
Number of prior chemotherapy regimens
Median 176 2b
Number of prior chemotherapy lines
1–2 176 114 65
≥ 3 176 62 35
Duration of BSC in the Phase III study (weeks)
0–2 176 16 9
3–6 176 45 26
7–10 176 89 51
11–20 176 21 12
20–47 176 5 3
Percentage of tumour cells with membrane EGFR staining
< 1% 176 1 1
1–9% 176 45 26
10–20% 176 53 30
21–35% 176 19 11
> 35% 176 58 33
ECOG performance status
0 176 53 30
1 176 85 48
2 176 38 22
BSC, best supportive care; PAN, panitumumab; ORR, overall response rate.
a Range 32–83 years.
b Range 2–6 years.
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Results
PAN + BSC
n Estimate %
Duration of treatment Until disease progression or toxicity
Best objective response
Complete response 176 1 0.6
Partial response 176 19 11
Stable disease 176 58 33
Disease progression 176 65 37
Unevaluablea 176 4 2
No radiological scan available 176 29 16
Disease control 176 78 44
Time to response (weeks)
Median (range) 176 8 7–25
Duration of response (weeks)b
Median (range) 176 16 8–35
Duration of stable disease (weeks)
Median (range) 176 16 7–63
Progression-free survival time (weeks)c
Median (95% CI) 176 9.4 8.0 to 13.4
Overall survival time (months)d
Median (95% CI) 176 6.3 5.1 to 6.8
Safety 
All grades
Patients with at least one adverse 
evente
176 162 92
Erythema 176 112 64
Acne 176 104 59
Pruritus 176 101 57
Rash 176 93 53
Other skin manifestations 176 65 37
Paronychia and other nail 
disorders
176 50 28
Skin exfoliation 176 22 13
Diarrhoea 176 15 9
Conjunctivitis 176 10 6
Nausea 176 8 5
Grade 3
Patients with at least one adverse 
event
176 29 16
Erythema 176 8 5
Acne 176 11 6
Pruritus 176 2 1
Rash 176 8 5
Other skin manifestations 176 4 2
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PAN + BSC
n Estimate %
Paronychia and other nail 
disorders
176 3 2
Skin exfoliation 176 1 1
Diarrhoea 176 1 1
Conjunctivitis 176 1 1
Nausea 176 0 0
Grade 4
Patients with at least one adverse 
event
176 3 2
Erythema 176 1 1
Acne 176 0 0
Pruritus 176 0 0
Rash 176 0 0
Other skin manifestations 176 0 0
Paronychia and other nail 
disorders
176 0 0
Skin exfoliation 176 0 0
Diarrhoea 176 0 0
Conjunctivitis 176 0 0
Nausea 176 0 0
BSC, best supportive care; PAN, panitumumab.
a Patients who had only one assessment.
b For the 20 responders.
c At the time of study completion, 158 (90%) patients had disease progression or had died of any cause.
d 145 (82%) patients died.
e There were no grade 5 treatment-related adverse events.
Methodological issues
Randomisation and allocation
Not applicable as this was a single-arm study.
Data analysis
The primary analyses of safety and efficacy outcomes included all enrolled patients who received 
at least one dose of panitumumab.
Time to response was calculated as the period from enrolment date to the first objective response. 
Duration of response was calculated only for the responders as the period from the first objective 
response to the first observation of disease progression or death due to disease progression.
Duration of stable disease was calculated as the period from enrolment date to the first 
observation of disease progression or death due to disease progression; only patients who had at 
least one scan of stable disease as their best response were included.
Progression-free survival time was calculated as the period from enrolment date to the first 
observation of disease progression or death.
Overall survival time was calculated as the period from enrolment to death.
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Descriptive statistics were calculated for the incidence of objective response (with two-sided 
95% CIs), adverse events, laboratory values, changes in vital signs and antibody measurements. 
Time-to-event outcomes were analysed using Kaplan–Meier methods. For the analyses on overall 
survival, a minimum of 12 months of follow-up was included.
Among patients with skin toxicity, the relationship between severity of skin toxicity and overall 
survival was evaluated using a Cox regression model adjusted for the Phase III randomisation 
factors, ECOG score and geographical region. Patients were included in the analysis if they were 
progression free for at least 28 days to allow the worst severity of skin toxicity to manifest.
Power calculation
The sample size was limited to the patients enrolled in the best supportive care arm of the Phase 
III study who met the eligibility criteria (planned n = 200). Assuming a true event rate of 1%, the 
probability of at least one patient experiencing a given adverse event was 87% for a sample size 
of 200.
Conflicts of interest
None reported.
Quality appraisal
1. Was the assignment to the treatment groups really random? Not applicable – single-arm 
extension study
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Not applicable
4. Were the eligibility criteria specified? Reported – yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Adequate
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Reported – yes
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Amado et al.32
Design Participants Arms Outcomes
Study design: 
Supplementary study 
to parallel, open-label 
RCT
Country: Unknown
No. of centres: 
Unknown
Funding: Amgen
Length of follow-up: 
Median follow-up 
time for remaining 
36 patients was 
14.1 months
Number randomised: 463
Inclusion criteria: Patients with 
metastatic colorectal cancer 
with EGFR expression in ≥ 1% 
of tumour cells (assessed by 
immunohistochemistry) and 
documented evidence of disease 
progression after failure of 
fluoropyrimidines and prespecified 
exposure to oxaliplatin and 
irinotecan
Exclusion criteria: Not reported
Therapy common to all 
participants: Best supportive care
Arm no. 1
Name: Panitumumab 
plus best supportive care
n: 208
Drug: Panitumumab
Dosage details: 
Panitumumab was 
administered using a 
60-minute intravenous 
infusion at 6 mg/kg once 
every 2 weeks
Arm no. 2
Name: Best supportive 
care
n: 219
Drug: N/A
Starting daily dose: 
N/A
Dosage details: N/A
Primary outcome measure: Progression-free 
survival, defined as the interval from random 
assignment to radiological progression or death
Secondary outcome measure(s): Objective 
response rate, overall survival and safety
Method of assessment: Tumour status was 
assessed radiographically every 4–8 weeks from 
week 8 until disease progression assessed by blinded 
central review using the RECIST
A best response of stable disease was determined at 
or after week 8 after random assignment
Mutant KRAS status was detected using a validated 
kit that identifies seven mutations in codons 12 and 
13 using allele-specific real-time polymerase chain 
reaction. KRAS analysis was performed blinded. A 
central laboratory validated the assay for analytical 
and diagnostic performance, established acceptance 
criteria and included appropriate quality controls for 
each assay
N/A, not applicable.
Baseline characteristics
Demographics
PAN + BSC BSC
p-valuen Estimate % n Estimate %
Mutant
Sex
Male 84 47 56 100 64 64
Race/ethnicity
White 84 84 100 100 97 97
Age (years)
Median 62 62
Minimum 27 27
Maximum 79 83
Primary diagnosis
Colon cancer 84 53 63 100 65 65
Rectal cancer 84 31 37 100 35 35
ECOG performance status
0 84 43 51 100 37 37
1 84 28 33 100 47 47
≥ 2 84 13 15 100 16 16
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Demographics
PAN + BSC BSC
p-valuen Estimate % n Estimate %
Cells with EGFR membrane staining
1% to <10% 84 20 24 100 23 23
10–100% 84 63 75 100 77 77
Intensity of EGFR staining
3+ (strong) 84 17 20 100 17 17
2+ (moderate) 84 42 50 100 51 51
1+ (weak) 84 24 29 100 32 32
0 84 1 1 100 0 0
Prior adjuvant chemotherapy 84 27 32 100 40 40
Prior lines of chemotherapy
2 84 54 64 100 74 74
3 84 23 27 100 24 24
WT
Sex
Male 124 83 67 119 76 64
Race/ethnicity
White 124 122 98 119 118 99
Age (years)
Median 62.5 63.0
Minimum 29 32
Maximum 82 81
Primary diagnosis
Colon cancer 124 86 69 119 82 69
Rectal cancer 124 38 31 119 37 31
ECOG performance status
0 124 53 43 119 40 34
1 124 56 45 119 62 52
≥ 2 124 15 12 119 17 14
Cells with EGFR membrane staining
1% to < 10% 124 31 25 119 29 24
10–100% 124 93 75 119 89 75
Intensity of EGFR staining
3+ (strong) 124 25 20 119 22 18
2+ (moderate) 124 69 56 119 58 49
1+ (weak) 124 30 24 119 39 33
0 124 0 0 119 0 0
Prior adjuvant chemotherapy 124 50 40 119 32 27
Prior lines of chemotherapy
2 124 79 64 119 63 53
3 124 41 33 119 49 41
BSC, best supportive care; PAN, panitumumab.
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Results
PAN + BSC BSC
p-valuen Estimate Mean n Estimate Mean
Duration of treatment Until disease progression or toxicity
Progression-free survival (weeks)
KRAS assessable, median 208 0.59a 8 219 7.3
WT, median 124 0.45b 12.3 119 7.3
Mutant, median 84 0.99c 7.4 100 7.3
Crossover, WT, median 90 0.32d 16.4
Crossover, mutant, median 77 7.9
WT progression-free survival (subset analysis)
PAN vs BSC 243 0.45e
Male 159 0.42f
Female 84 0.46g
Age < 65 years 141 0.42h
Age 65+ years 102 0.47i
Primary diagnosis: colon cancer 168 0.47j
Primary diagnosis: rectal cancer 75 0.36k
ECOG performance status: 0–1 211 0.47l
ECOG performance status: 2–3 32 0.35m
Prior regimens: 2 142 0.54n
Prior regimens: 3 90 0.28o
Prior regimens: 3+ 100 0.27p
Metastasis sites: 1–2 172 0.42q
Metastasis sites: 3–5 69 0.52r
EGFR staining intensity: 1+ 69 0.30s
EGFR staining intensity: 2+ 127 0.49t
EGFR staining intensity: 3+ 47 0.34u
Cells with EGFR staining: 1 to < 10% 60 0.33v
Cells with EGFR staining: 10–35% 101 0.41w
Cells with EGFR staining: > 35% 81 0.37x
Overall survival
KRAS assessable, deaths 208 186 219 205
WT, median (months) 124 107 8.1 119 110 7.6
Mutant, median (months) 84 79 4.9 100 95 4.4
Response rate
KRAS assessable
Stable disease, (%) 208 25 219 10
Disease progression (%) 208 50 219 68
Response rate 219 0
Crossover
Response rate 167 20
Stable disease 167 55
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PAN + BSC BSC
p-valuen Estimate Mean n Estimate Mean
WT
Partial response 124 17
Stable disease 124 42 119 14
Response rate
Median time to response (weeks) 124 7.9y
Median duration of response (weeks) 124 19.7z
Mutant
Stable disease 84 10 100 8
Safety population
Combined arm
KRAS assessable, treatment-related grade 3 
adverse events
427 20
WT integument-related events 243 25
Mutant integument-related events 184 13
WT grade 4 integument-related events 243 0
Mutant grade 4 integument-related events 184 1
Separate arm
Adverse event, mutant 84 100 100 84
Adverse event, WT 124 100 119 90
Diarrhoea, all grades, WT 124 24
Diarrhoea, all grades, mutant 84 19
Diarrhoea, grade 3, WT 124 2
Diarrhoea, grade 3, mutant 84 1
BSC, best supportive care; PAN, panitumumab.
a Hazard ratio for disease progression (95% CI 0.48 to 0.72).
b Hazard ratio for disease progression (95% CI 0.34 to 0.59).
c Hazard ratio for disease progression (95% CI 0.73 to 1.36).
d Hazard ratio for disease progression (95% CI 0.22 to 0.45).
e Hazard ratio for disease progression (95% CI 0.34 to 0.59).
f Hazard ratio for disease progression (95% CI 0.30 to 0.59).
g Hazard ratio for disease progression (95% CI 0.29 to 0.73).
h Hazard ratio for disease progression (95% CI 0.29 to 0.60).
i Hazard ratio for disease progression (95% CI 0.31 to 0.73).
j Hazard ratio for disease progression (95% CI 0.34 to 0.65).
k Hazard ratio for disease progression (95% CI 0.21 to 0.61).
l Hazard ratio for disease progression (95% CI 0.35 to 0.62).
m Hazard ratio for disease progression (95% CI 0.15 to 0.82).
n Hazard ratio for disease progression (95% CI 0.38 to 0.76).
o Hazard ratio for disease progression (95% CI 0.17 to 0.47).
p Hazard ratio for disease progression (95% CI 0.17 to 0.44).
q Hazard ratio for disease progression (95% CI 0.30 to 0.59).
r Hazard ratio for disease progression (95% CI 0.30 to 0.89).
s Hazard ratio for disease progression (95% CI 0.16 to 0.56).
t Hazard ratio for disease progression (95% CI 0.31 to 0.75).
u Hazard ratio for disease progression (95% CI 0.20 to 0.58).
v Hazard ratio for disease progression (95% CI 0.18 to 0.63).
w Hazard ratio for disease progression (95% CI 0.28 to 0.60).
x Hazard ratio for disease progression (95% CI 0.18 to 0.75).
y Range 7.0–15.6 weeks.
z Range 7.9–88.7 weeks.
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Methodological issues
Randomisation and allocation
Refer to Van Cutsem et al.7
Data analysis
All analyses were prespecified in a statistical analysis plan before KRAS mutation assessment.
A quantitative interaction test at a two-sided 5% level was used to compare the progression-free 
survival log-hazard ratio (hazard ratio panitumumab relative to best supportive care) from a Cox 
model with covariates for the randomisation factors between the WT and mutant KRAS groups.
Kaplan–Meier methods were used to estimate progression-free survival and overall survival. 
Conditional on a significant interaction test, sequential testing at a 5% level of progression-free 
survival, followed by overall survival and overall response rate, were planned within the WT 
group between panitumumab and BSC.
A log-rank test was used for progression-free survival, a Wilcoxon’s test for overall survival 
and a generalised Cochran–Mantel–Haenszel test for response rate, each stratified by the 
randomisation factors.
Power calculation
Based on an assessable sample size of 380 patients and assuming 60% WT prevalence, power was 
estimated at > 99% if the hazard ratio was 1.0 in the mutant group and at 87% if the hazard ratio 
was 0.8 in the mutant group, assuming an overall hazard ratio of 0.54 among all patients.
Conflicts of interest
The majority of authors are employed by Amgen and have stock ownership.
Quality appraisal
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Adequate
4. Were the eligibility criteria specified? Partial
5. Were outcome assessors blinded to the treatment allocation? Reported – yes
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Reported – yes
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Reported – yes
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Asmis et al.43
Design Participants Arms Outcomes
Study design: 
Supplementary 
study to parallel 
open label RCT
Country: 
Unknown
No. of centres: 
Unknown
Funding: 
Unknown
Length of 
follow-up: Not 
reported
Number randomised: 572
Inclusion criteria: 
Patients with metastatic 
colorectal cancer with EGFR 
immunohistochemically 
detectable
Exclusion criteria: Not 
reported
Therapy common to 
all participants: Best 
supportive care
Arm no. 1
Name: Cetuximab plus best 
supportive care
n: 287
Drug: Cetuximab
Starting dose: 400 mg/m2
Dosage details: Weekly 
dose of 250 mg/m2
Arm no. 2
Name: Best supportive care
n: 285
Drug: N/A
Starting daily dose: N/A
Dosage details: N/A
Primary outcome measure: Main trial – overall survival, 
defined as time from randomisation until death from any 
cause
Secondary outcome measure(s): Main trial – progression-
free survival, defined as time from randomisation until the first 
objective observation of disease progression or death from 
any cause; response rates, defined according to the modified 
RECIST; QoL, assessed by mean changes in scores of 
physical function and global health status at 8 and 16 weeks. 
This study – relationship between age, comorbidity and 
performance status in predicting outcome
Method of assessment: A CCI score was determined for 
each patient by two physician reviewers. After co-operative 
scoring of an initial cohort of 20 patient charts to establish 
internal consistency, the remainder of the patient charts were 
scored independently with scoring discrepancies resolved by 
consensus. Previous diagnosis of venous thromboembolism 
was also specifically recorded by reviewers
N/A, not applicable.
Baseline characteristics
Demographics
Age < 65 years Age ≥ 65 years
p-valuean Estimate % n Estimate %
Sex
Male 335 203 60.6 237 72 30.4 0.03
Female 335 132 39.4 237 165 69.6
ECOG performance status
0 335 79 23.6 237 57 24.1 0.84
1 335 180 53.7 237 122 51.5
2 335 76 22.7 237 58 24.5
Body mass index (kg/m2) 0.29
Median (range) 335 26.1 15.6–42.5 237 25.3 15.6–45.0
Low (< 20) 335 33 9.9 237 25 10.5
Normal (20–25) 335 101 30.1 237 85 35.9
High (> 25) 335 201 60.0 237 127 53.6
Site of primary disease 0.15
Colon only 335 189 56.4 237 143 60.3
Rectum only 335 83 24.8 237 50 21.1
Colon and rectum 335 63 18.8 237 44 18.6
Time from initial diagnosis to randomisation (years) 0.07
Median (range) 335 2.2 0.5–15.7 237 2.5 0–14.7
≥ 2 335 181 54.0 237 146 61.6
< 2 335 154 46 237 91 38.4
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Age < 65 years Age ≥ 65 years
p-valuean Estimate % n Estimate %
Lactate dehydrogenase 0.37
≤ upper normal limit 335 83 24.8 237 51 21.5
> upper normal limit 335 235 70.1 237 175 73.8
Alkaline phosphate 0.93
≤ upper normal limit 335 93 27.8 237 66 27.8
> upper normal limit 335 241 71.9 237 168 70.9
Haemoglobin 0.07
CTC grade 0 335 122 36.4 237 69 29.1
CTC grade ≥ 1 335 213 63.6 237 168 70.9
Serum creatinine 0.06
CTC grade 0 335 309 92.2 237 208 87.8
CTC grade ≥ 1 335 25 7.5 237 29 12.2
Number of previous chemotherapy drug classes 0.005
≤ 2 335 9 2.7 237 19 8.0
> 2 335 326 97.3 237 218 92.0
Comorbidity score 0.002
0 335 268 80.0 237 162 68.4
≥ 1 335 67 20.0 237 75 31.6
Venous thromboembolism 0.95
No 335 303 90.4 237 214 90.3
Yes 335 32 9.6 237 23 9.7
KRAS status 0.68
WT 335 133 39.7 237 97 40.9
Mutant 335 99 29.6 237 65 27.4
Treatment 0.15
BSC only 335 158 47.2 237 127 53.6
Cetuximab plus 
BSC
335 177 52.8 237 110 46.4
Duration of treatment (weeks) 0.47
Median (range) 335 8 1–46.3 237 8.1 1–60
Cumulative dose (mg/m2) 0.47
Median (range) 335 2155 390.8–
10,331
237 2202 395.8–
15,216
BSC, best supportive care; CTC, common toxicity criteria.
a From Fisher's exact test.
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Demographics
Comorbidity score 0 Comorbidity score ≥ 1
p-valuean Estimate % n Estimate %
Sex 0.06
Male 430 267 62.1 142 41 28.9
Female 430 163 37.9 142 101 71.1
ECOG performance status 0.80
0 430 105 24.4 142 31 21.8
1 430 224 52.1 142 78 54.9
2 430 101 23.5 142 33 23.2
Body mass index (kg/m2) 0.21
Median (range) 430 25.4 15.6–42.0 142 26.2 16.4–45.0
Low (< 20) 430 41 9.5 142 17 12.0
Normal (20–25) 430 148 34.4 142 38 26.8
High (> 25) 430 241 56.0 142 87 61.3
Site of primary disease 0.46
Colon only 430 244 56.7 142 88 62.0
Rectum only 430 101 23.5 142 32 22.5
Colon and rectum 430 85 19.8 142 22 15.5
Time from initial diagnosis to randomisation (years) 1.0
Median (range) 430 2.3 0.5–15.7 142 2.2 0–10.9
≥ 2 430 246 57.2 142 81 57.0
< 2 430 184 42.8 142 61 43.0
Lactate dehydrogenase 0.91
≤ upper normal limit 430 100 23.3 142 34 23.9
> upper normal limit 430 308 71.6 142 102 71.8
Alkaline phosphate 0.59
≤ upper normal limit 430 117 27.2 142 42 29.6
> upper normal limit 430 310 72.1 142 99 69.7
Haemoglobin 0.22
CTC grade 0 430 150 34.9 142 41 28.9
CTC grade ≥ 1 430 280 65.1 142 101 71.1
Serum creatinine 0.41
CTC grade 0 430 391 90.9 142 126 88.7
CTC grade ≥ 1 430 38 8.8 142 16 11.3
Number of previous chemotherapy drug classes 1.0
≤ 2 430 21 4.9 142 7 4.9
> 2 430 409 95.1 142 135 95.1
Age (years) 0.002
Median (range) 430 62.0 28.6–88.1 142 65.8 35.5–85.2
< 65 430 268 62.3 142 67 47.2
≥ 65 430 162 37.7 142 75 52.8
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Comorbidity score 0 Comorbidity score ≥ 1
p-valuean Estimate % n Estimate %
Venous thromboembolism 0.44
No 430 391 90.9 142 126 88.7
Yes 430 39 9.1 142 16 11.3
KRAS status 0.29
WT 430 168 39.1 142 62 43.7
Mutant 430 128 29.8 142 36 25.4
Missing 430 134 31.2 142 44 31.0
Treatment 0.12
BSC only 430 206 47.9 142 79 55.6
Cetuximab plus BSC 430 224 52.1 142 63 44.4
Duration of treatment (weeks) 0.06
Median (range) 430 8 1–60 142 16 1–55.9
Cumulative dose (mg/m2) 0.06
Median (range) 430 2152 391–15,216 142 3508 396–12,650
BSC, best supportive care.
a From Fisher’s exact test.
Results
CET + BSC
p-valuen Estimate 95% CI
Duration of treatment Until disease progression or toxicity
Overall survival (hazard ratio)
Age ≥ 65 vs < 65 years, all patients 1.05 0.87 to 1.27 0.60
CCI score ≥ 1 vs 0, all patients 0.80 0.65 to 1.00 0.047
CCI score ≥1 versus 0 0.66 0.47 to 0.92 0.02
Presence of venous thromboembolism, all 
patients
1.49 1.10 to 2.02 0.009
Performance status 2 vs 0 1.92 1.34 to 2.74 < 0.0001
Median duration of treatment (weeks), CCI ≥ 1 15.6 0.006
Median duration of treatment (weeks), CCI = 0 8
CET vs BSC, < 65 years 0.77 0.61 to 0.98
CET vs BSC, ≥ 65 years 0.75 0.56 to 1.00
CET vs BSC, comorbidity 0 0.80 0.65 to 0.99 0.21
CET vs BSC, comorbidity ≥ 1 0.61 0.42 to 0.90
Age (years)
< 65 1 0.60
≥ 65 1.05 0.87 to 1.27
Comorbidity score
0 1 0.047
≥ 1 0.80 0.65 to 1.00
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CET + BSC
p-valuen Estimate 95% CI
Venous thromboembolism
No 1 0.009
Yes 1.49 1.10 to 2.02
Gender
Female 1 0.107
Male 0.85 0.70 to 1.04
ECOG performance status
0 1 < 0.0001
1 1.15 0.92 to 1.45
2 2.51 1.93 to 3.27
Body mass index (kg/m2) < 0.0001
Low (< 20) 1
Normal (20–25) 0.77 0.56 to 1.05
High (> 25) 0.54 0.40 to 0.72
Site of primary disease 0.068
Colon only 1
Rectum only 0.83 0.66 to 1.05
Colon and rectum 0.82 0.64 to 1.05
Time from initial diagnosis to randomisation (years) < 0.0001
≥ 2 1
< 2 1.57 1.31 to 1.90
Lactate dehydrogenase < 0.0001
≤ upper normal limit 1
> upper normal limit 1.99 1.56 to 2.53
Alkaline phosphate
≤ upper normal limit 1
> upper normal limit 2.16 1.73 to 2.70 < 0.001
Haemoglobin
CTC grade 0 1
CTC grade ≥ 1 2.02 1.64 to 2.48
Serum creatinine 0.839
CTC grade 0 1
CTC grade ≥ 1 1.03 0.75 to 1.42
Number of previous chemotherapy drug classes 0.192
≤ 2 1
> 2 1.35 0.86 to 2.11
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CET + BSC
p-valuen Estimate 95% CI
KRAS status 0.007
WT 1
Mutant 1.36 1.09 to 1.70
Treatment 0.004
BSC only 1
CET + BSC 0.76 0.63 to 0.92
Safety
Grade 3 or worse by age group
Age < 65 years
Any 178 140 1.00
Oedema 178 9 1.00
Fatigue 178 53 0.157
Anorexia 178 14 0.827
Constipation 178 8 0.327
Nausea 178 11 0.609
Vomiting 178 14 0.034
Non-neutropaenic infection 178 25 0.589
Confusion 178 6 0.061
Abdominal pain 178 29 0.051
Other pain 178 31 0.173
Dyspnoea 178 20 0.005
Rash 178 20 0.711
Age > 65 years
Any 110 86
Oedema 110 6
Fatigue 110 42
Anorexia 110 10
Constipation 110 2
Nausea 110 5
Vomiting 110 2
Non-neutropaenic infection 110 12
Confusion 110 10
Abdominal pain 110 9
Other pain 110 12
Dyspnoea 110 27
Rash 110 14
Grade 3 or worse by comorbidity score
Comorbidity score 0
Any 225 176 1.000
Oedema 225 11 0.748
Fatigue 225 73 0.762
Anorexia 225 18 0.796
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CET + BSC
p-valuen Estimate 95% CI
Constipation 225 9 0.696
Nausea 225 14 0.536
Vomiting 225 16 0.002
Non-neutropaenic infection 225 22 0.005
Confusion 225 12 0.758
Abdominal pain 225 32 0.404
Other pain 225 35 0.691
Dyspnoea 225 33 0.177
Rash 225 28 0.661
Constipation 225 9 0.696
Comorbidity score ≥ 1
Any 63 50
Oedema 63 4
Fatigue 63 22
Anorexia 63 6
Constipation 63 1
Nausea 63 2
Vomiting 63 0
Non-neutropaenic infection 63 15
Confusion 63 4
Abdominal pain 63 6
Other pain 63 8
Dyspnoea 63 14
Rash 63 6
BSC, best supportive care; CET, cetuximab.
Methodological issues
Randomisation and allocation
Not reported.
Data analysis
Variables of patient age and CCI score were dichotomised – age < 65 compared with ≥ 65 years 
and CCI score 0 compared with ≥ 1 – with higher scores indicating greater comorbidity. The chi-
squared test was used to perform univariate analyses for the association between age group and 
baseline patient, disease and treatment characteristics. Logistic regression modeling was used to 
perform multivariate analyses to identify independant characteristics correlated with age. Similar 
analyses were carried out for the association between comorbidity group and baseline patient, 
disease and treatment characteristics and to identify characteristics associated with comorbidity. 
Univariate and multivariate analyses of overall survival and progression-free survival by age 
and comorbidity were carried out using log-rank tests and Cox regression models respectively. 
Univariate and multivariate analyses of response by age and comorbidity were carried out using 
Fisher’s exact test and a logistical regression model respectively.
Power calculation
Not reported.
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Conflicts of interest
Two authors have acted on advisory boards for Bristol-Myers Squibb, two authors have acted 
on advisory boards for Merck Serono and one author is employed by and owns stock in 
Bristol-Myers Squibb. 
Quality appraisal
1. Was the assignment to the treatment groups really random? Not reported
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Adequate
4. Were the eligibility criteria specified? Partial
5. Were outcome assessors blinded to the treatment allocation? Unclear
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Reported – yes
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Partial
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Odom et al.56
Design Participants Arms Outcomes
Study design: 
Supplementary study 
to parallel, open-
label RCT
Country: Western 
Europe, Central 
Europe, Eastern 
Europe, Canada, 
Australia and New 
Zealand
No. of centres: 
Unknown
Funding: Amgen
Length of follow-
up: Minimum of 
12 months
Number randomised: 463
Inclusion criteria: Patients 
with EGFR-detectable 
metastatic colorectal cancer 
and documented evidence 
of disease progression after 
failure of fluoropyrimidines 
and prespecified exposure to 
oxaliplatin and irinotecan
Exclusion criteria: Not 
reported
Therapy common to all 
participants: Best supportive 
care
Arm no. 1
Name: Panitumumab plus best 
supportive care
n:
Drug: Panitumumab
Dosage details: Panitumumab 
was administered using a 
60-minute intravenous infusion at 
6 mg/kg once every 2 weeks
Arm no. 2
Name: Best supportive care
n:
Drug: N/A
Starting daily dose: N/A
Dosage details: N/A
Primary outcome measure: Overall survival, 
defined as time from randomisation until death 
from any cause
Secondary outcome measure(s): HRQoL
Method of assessment: Progression assessed 
by central radiological review at specified time 
points from weeks 8 to 48, then every 3 months 
thereafter. KRAS tumour status was evaluated in a 
blinded fashion
Colorectal cancer symptoms were assessed using 
the NCCN FCSI. Patients responded to each item 
of this questionnaire using a 5-point scale ranging 
from 0 to 4. The minimal clinically important 
difference was defined as a change in score of 
≥ 3 points
Overall HRQoL was measured at baseline and 
monthly until disease progression using the EQ-5D 
index. The minimal clinically important difference 
for the EQ-5D index has been estimated as a 
change in score of ≥ 0.08 points
N/A, not applicable.
Baseline characteristics
Demographics
PAN + BSC BSC
p-valuen Estimate % n Estimate %
All patients
Sex
Men 188 123 65 175 113 65
Women 188 65 35 175 62 35
Race/ethnicity
White 188 187 99 175 171 98
Other 188 1 1 175 4 2
Age (years), mean (SD) 188 61 10 175 62 10
Primary diagnosis
Colon cancer 188 126 67 175 117 67
Rectal cancer 188 62 33 175 58 33
ECOG performance status
0 188 91 48 175 62 35
1 188 76 40 175 91 52
2 188 21 11 175 22 13
Time since primary diagnosis (months), 
mean (SD)
188 31 22 175 32 21
Time since metastatic disease (months), 
mean (SD)
188 21 10 175 22 11
Baseline EQ-5D index, mean (SD) 188 0.72 0.24 175 0.68 0.25
Baseline FSCI score, mean (SD) 188 72.7 13.69 175 71.84 14.28
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PAN + BSC BSC
p-valuen Estimate % n Estimate %
WT
Sex
Men 112 79 701 96 62 645
Women 112 33 29 96 34 35
Race/ethnicity
White 112 111 99 96 95 99
Other 112 1 1 96 1 1
Age (years), mean (SD) 112 62 10 96 62 10
Primary diagnosis
Colon cancer 112 78 70 96 68 71
Rectal cancer 112 34 30 96 28 29
ECOG performance status
0 112 52 46 96 35 36
1 112 50 45 96 51 53
2 112 10 9 96 10 10
Time since primary diagnosis (months), 
mean (SD)
112 33 25 96 31 20
Time since metastatic disease (months), 
mean (SD)
112 22 10 96 24 13
Baseline EQ-5D index, mean (SD) 112 0.73 0.24 96 0.68 0.23
Baseline FSCI score, mean (SD) 112 73.21 13.05 96 71.78 13.48
Mutant
Sex
Men 76 44 58 79 51 65
Women 76 32 42 79 28 35
Race/ethnicity
White 76 76 100 79 76 96
Other 76 0 0 79 3 4
Age (years), mean (SD) 76 60 11 79 61 11
Primary diagnosis
Colon cancer 76 48 63 79 49 62
Rectal cancer 76 28 37 79 30 38
ECOG performance status
0 76 39 51 79 27 34
1 76 26 34 79 40 51
2 76 11 14 79 12 15
Time since primary diagnosis (months), 
mean (SD)
76 27 17 79 34 21
Time since metastatic disease (months), 
mean (SD)
76 20 10 79 19 8
Baseline EQ-5D index, mean (SD) 76 0.71 0.25 79 0.68 0.26
Baseline FSCI score, mean (SD) 76 70.94 14.55 79 71.91 15.28
BSC, best supportive care; PAN, panitumumab; SD, standard deviation.
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Results
PAN + BSC vs BSC
n Estimate 95% CI
ITT populationa
EQ-5D index, early dropoutb
All patients 164 –0.08 –0.21 to 0.05
WT –0.19 –0.38 to 0.01
Mutant –0.02 –0.19 to 0.15
EQ-5D index, late dropout
All patients 152 0.26 0.16 to 0.37
WT 0.32 0.18 to 0.45
Mutant 0.13 –0.03 to 0.29
FCSI score, early dropoutb
All patients 184 0.53 –3.15 to 4.20
WT –2.21 –7.16 to 2.75
Mutant 4.27 –1.33 to 9.88
EQ-5D score, late dropout
All patients 150 3.63 –0.05 to 7.31
WT 5.75 1.45 to 10.04
Mutant –0.66 –7.27 to 5.95
a Least squares mean difference.
b Data up to week 9.
Methodological issues
Randomisation and allocation
Not reported.
Data analysis
The analysis set was defined as all patients in the ITT population who had at least one post-
baseline FCSI score or EQ-5D index assessment and an assessed KRAS status. Change in score 
from baseline was analysed over time using linear mixed models for repeated measures. The 
models included explanatory variables for study treatment arm, study week and the interaction 
between treatment arm and study week.
Treatment-specific estimates of the average change in each outcome score from baseline along 
with 95% CIs were calculated for the overall cohort and for each KRAS subgroup using least-
squares mean difference.
To evaluate the effect of study attrition on the estimates of treatment differences, a sensitivity 
analysis was performed using pattern-mixture models that incorporate information about 
missing data.
Dropout status was incorporated into pattern-mixture models of change in score from baseline 
for each outcome. These models included fixed effects for treatment arm, study week, dropout 
pattern group and interactions between these effects. The model included random effects.
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Power calculation
Not reported.
Conflicts of interest
Four authors are employees and stockholders of Amgen, one author is an advisory board member 
for Amgen, Eli Lilly and Company, Merck, Novartis, Roche and Sanofi-Aventis and three authors 
received funding from Amgen.
Quality appraisal
1. Was the assignment to the treatment groups really random? Not reported
2. Was the treatment allocation concealed? No
3. Were the groups similar at baseline in terms of prognostic factors? Adequate
4. Were the eligibility criteria specified? Partial
5. Were outcome assessors blinded to the treatment allocation? No
6. Was the care provider blinded? No
7. Was the patient blinded? No
8. Were the point estimates and measure of variability presented for the primary outcome 
measure? Reported – yes
9. Did the analyses include an ITT analysis? Reported – yes
10. Were withdrawals and dropouts completely described? Reported – yes
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Appendix 4 
Method of indirect comparison
To calculate the indirect comparison for cetuximab plus best supportive care compared with panitumumab plus best supportive care, the formulae reported in the appendix of the paper 
by Bucher and colleagues34 were used (see below).
Let HR(CvB) be the hazard ratio for the direct comparison between cetuximab plus best supportive 
care and best supportive care (from Karapetis and colleagues45), and let HR(PvB) be the hazard ratio 
for the direct comparison between panitumumab plus best supportive care and best supportive 
care (from Amado and colleagues32). Then the hazard ratio for the indirect comparison between 
cetuximab plus best supportive care and panitumumab plus best supportive care, HR(CvP), can be 
calculated by:
 ln(HR(CvP)) = ln(HR(CvB)) – ln(HR(PvB)) [Equation 10]
The corresponding variance for HR(CvP) is calculated by: 
var(lnHR(CvP)) = var(lnHR(CvB)) + var(lnHR(PvB)) [Equation 11]
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Appendix 5 
Critique of manufacturer’s search strategy
Randomised controlled trials
Merck Serono
Searches by Merck Serono were performed in the following databases on 5 October 2009 and 
updated on 2 November 2010:
 ■ Ovid EMBASE
 ■ Ovid MEDLINE
 ■ Ovid MEDLINE In-Process & Other Non-Indexed Citations
 ■ The Cochrane Central Register of Controlled Trials (CENTRAL).
Hand searches were also undertaken on several internet resources to identify relevant 
conference proceedings:
 ■ American Society of Clinical Oncology (ASCO): www.asco.org
 ■ European Cancer Organisation (ECCO): www.ecco-org.eu
 ■ American Association of Cancer Research (ACCR): www.aacr.org.
Separate search strategies were provided by the manufacturer for EMBASE, MEDLINE, 
MEDLINE In-Process & Other Non-Indexed Citations and CENTRAL. Database searches in 
EMBASE, MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations were based on 
a conjunction of terms identifying the metastatic colorectal cancer population with known KRAS 
status and terms identifying cetuximab, panitumumab and bevacizumab as interventions. For 
each term a combination of thesaurus headings (where possible) and free-text search words was 
used. No outcomes were specified to limit the searches in any of these databases.
The EMBASE, MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations searches 
included a study design filter to limit results to clinical trials. No additional filters were applied in 
any databases.
Within the search strategies the combinations of terms to define the metastatic colorectal cancer 
population and/or the intervention were appropriate and were replicable. Overall, we found the 
syntax to be highly focused, which has the potential to impinge on the sensitivity of the search. 
The choice of RCT filter was good and highly sensitive. The internet searches appear vague in 
their recording of findings and limited in their depth, and the CENTRAL search was considered 
poor because of some uncertainty regarding the use of the interface. That said, we found no 
additional trials.
Amgen
Searches by Amgen were performed in the following databases on 24–29 September 2010 and 
updated in January 2011:
 ■ EMBASE
 ■ MEDLINE
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 ■ MEDLINE In-Process & Other Non-Indexed Citations
 ■ CENTRAL
 ■ Cumulative Index to Nursing and Allied Health Literature (CINAHL)
 ■ Web of Science.
Conference abstracts were also searched:
 ■ Conference Proceedings Citation Index – Science (CPCI-S)
 ■ Conference Proceedings Citation Index – Social Sciences & Humanities (CPCI-SSH).
The following websites were searched to identify recently completed trials:
 ■ National Research Register: www.nihr.ac.uk/Pages/NRRArchiveSearch
 ■ Current Controlled Trials: www.controlled-trials.com/mrct/.
A search strategy was provided only for MEDLINE by the manufacturer, which we considered 
to be an acceptable bare minimum; it would have been preferable to have records of all of the 
database searches. The search employed terms identifying the metastatic colorectal cancer 
population and terms identifying cetuximab, panitumumab and bevacizumab as interventions, 
although Chemical Abstracts Service (CAS) registry numbers were not included. Free-text 
terms and medical subject heading (MESH) terms were used in the searches. No outcomes 
were specified to limit the search; however, a study design filter was in place to limit hits to 
clinical trials.
The combinations of terms within the search strategies to define the metastatic colorectal 
cancer population and/or the intervention were appropriate and were replicable. The search was 
considered satisfactory but not particularly sensitive. We found no additional trials.
Roche
The following databases were searched in January 2011:
 ■ The Cochrane Library
 ■ MEDLINE
 ■ MEDLINE In-Process & Other Non-Indexed Citations
 ■ EMBASE
 ■ EMBASE In-Process
 ■ BIOSIS.
Searches were restricted to English-language publications. Roche reports that the search strategy 
was modified to account for differences in syntax and thesaurus headings between databases. 
Searches included terms for free text and the relevant MESH/EMTREE index terms.
Hand searches were also undertaken on the following resources:
 ■ ASCO: www.asco.org
 ■ ESMO: www.esmo.org
 ■ ESMO/ECCO joint meeting 2009 (European Cancer Organisation conference)
 ■ reference lists of previous trials and systematic reviews.
A full search strategy, with terms listed by numerical lines, was not included in the search report. 
Consequently, it is difficult to comment on the precision of retrieval.
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Non-randomised controlled trials
Merck Serono
Manufacturer searches were performed in the following databases on 2 July 2010:
 ■ Ovid EMBASE
 ■ Ovid MEDLINE
 ■ MEDLINE In-Process & Other Non-Indexed Citations.
Separate search strategies were provided by the manufacturer for EMBASE, MEDLINE and 
MEDLINE In-Process & Other Non-Indexed Citations. EMBASE, MEDLINE and MEDLINE 
In-Process & Other Non-Indexed Citations database searches were based on a conjunction 
of terms identifying the metastatic colorectal cancer population and terms identifying 
cetuximab as an intervention, although the CAS registry numbers were not included. For 
each term a combination of thesaurus headings (where possible) and free-text search words 
was used. No study filter was used and no outcomes were specified to limit the searches 
in any of these databases. The searches were limited to English-language publications and 
human-only populations.
Amgen
Non-RCTs were not searched for.
Roche
Non-RCTS were included.
Inclusion/exclusion criteria used in study selection
Merck Serono
The submission included RCTs in which the population had advanced or metastatic colorectal 
cancer after first-line treatment, without specification of outcomes. We consider that these 
inclusion and exclusion criteria are appropriate.
Amgen
The submission included RCTs in which the population had metastatic colorectal cancer 
after first-line treatment and which compared panitumumab monotherapy with placebo, best 
supportive care, cetuximab monotherapy, bevacizumab monotherapy or irinotecan/oxaliplatin-
based chemotherapy. Outcomes were specified. Studies not available in English were excluded. 
We consider these inclusion and exclusion criteria to be appropriate.
Roche
The submission included RCTs in which the population had metastatic colorectal cancer 
requiring treatment after failure of first-line therapy. All therapies other than bevacizumab with 
non-oxaliplatin therapy were excluded. We consider these inclusion and exclusion criteria to 
be appropriate.
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Details of relevant studies not included in the  
manufacturers’ submissions
Despite the variability in search strategies between manufacturers we were unable to identify any 
additional studies.
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Appendix 6 
Clinical effectiveness: excluded studies 
Study Reason for exclusion
Ades (2009) Not a relevant intervention or population
Alberts (2005) Not a relevant population
Allegra (2009) Not a relevant intervention
An Mao (2010) Results mixed for different populations
Anonymous (2006) Not a relevant intervention
Anonymous (2007) Not a clinical trial or systematic review
Cao (2009) Not a relevant intervention or population
ClinicalTrials.gov Not a RCT or controlled clinical trial
Cunningham (2004) Not a relevant population
Folprecht (2010) Not a relevant population
Frieze (2006) Not a relevant population
Galal (2008) Not a relevant intervention
Galal (2009) Not a relevant intervention
Galfrascoli (2009) Not a relevant intervention or population
Galfrascoli (2010) Not a relevant intervention or population
Gao (2009) Not in English
Giantonio (2007) Not a relevant intervention
Gibson (2006) Not a relevant population
Golfinopoulos (2007) Results mixed for different populations 
Hapani (2009) Results mixed for different populations
Hecht (2008) Not a relevant intervention
Hoy (2006) Not a relevant population
Hurwitz (2009) Not a relevant population
Liu (2010) Not a relevant population
Liu (2010) Results mixed for different populations
Lordick (2010) Not a relevant intervention
Mross (2009) Not in English
Nie (2009) Results mixed for different populations 
Pander (2010) Not a relevant population
Pfieffer (2007) Not a RCT or controlled clinical trial
Ranpura (2010) Results mixed for different populations
Saltz (2007) Not a relevant intervention
Sargent (2005) Not a relevant intervention
Simkens (2008) Not a relevant population
Sorbrero (2008) Not a relevant population
Su (2009) Results mixed for different populations
Taieb (2008) Not a relevant population
Tol (2008) Not a relevant population
Tol (2010) Results mixed for different populations 
Tol (2010) Not a relevant population
Welch (2010) Not a relevant population
Wilke (2008) Not a RCT or controlled clinical trial
Wu (2008) Not a clinical trial or systematic review
Zhu (2007) Not a relevant population
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Appendix 7 
Ongoing trials
Trial Sponsor ID Intervention
ASPECCT – a study of panitumumab efficacy and safety 
compared with cetuximab in subjects with KRAS WT 
metastatic colorectal cancer
Amgen NCT01001377 Experimental: panitumumab
Comparator: cetuximab 
Bevacizumab maintenance vs no maintenance after stop 
of first-line chemotherapy in patients with metastatic 
colorectal cancer. A randomised multicentre Phase III non-
inferiority trial
Swiss Group for 
Clinical Cancer 
Research
NCT00544700 Experimental: bevacizumab 
maintenance therapy
Comparator: no maintenance therapy
A prospective randomised open-label trial of oxaliplatin/
fluoropyrimidine vs oxaliplatin/fluoropyrimidine plus 
cetuximab pre- and postoperatively in patients with 
resectable colorectal liver metastasis requiring 
chemotherapy
Southampton 
University Hospitals 
NHS Trust
NCT00482222 Experimental: oxaliplatin/
fluoropyrimidine plus cetuximab
Comparator: oxaliplatin/fluoropyrimidine 
Phase III trial of irinotecan-based chemotherapy plus 
cetuximab (NSC-714682) with or without bevacizumab 
(NSC-704965) as second-line therapy for patients with 
metastatic colorectal cancer who have progressed on 
bevacizumab with FOLFOX, OPTIMOXa or XELOX
Southwest 
Oncology Group
NCT00499369 Experimental: irinotecan or FOLFIRI and 
cetuximab plus bevacizumab
Comparator: irinotecan or FOLFIRI plus 
cetuximab
SPIRITT – multicentre, open-label, randomised, Phase II 
clinical trial evaluating the safety and efficacy of FOLFIRI 
with either panitumumab or bevacizumab as second-line 
treatment in subjects with metastatic colorectal cancer with 
WT KRAS tumours
Amgen NCT00418938 Experimental: FOLFIRI plus 
panitumumab
Comparator: FOLFIRI plus bevacizumab
PICCOLO – a randomised clinical trial of treatment for 
fluorouracil-resistant advanced colorectal cancer comparing 
standard single-agent irinotecan with irinotecan plus 
panitumumab and irinotecan plus ciclosporin
University of Leeds 
CTAAC (UK), 
Amgen (UK)
NCT00389870 1. Irinotecan
2. Irinotecan with ciclosporin
3. Irinotecan plus panitumumab
4. Irinotecan with ciclosporin plus 
panitumumab
Study of irinotecan and cetuximab vs irinotecan as second-
line treatment in patients with metastatic, EGFR-positive 
colorectal cancer
ImClone LLC, 
Bristol-Myers 
Squibb
NCT00063141 Experimental: cetuximab plus irinotecan
Comparator: irinotecan
A study of RO5083945 in combination with FOLFIRI vs 
FOLFIRI plus cetuximab or FOLFIRI alone as second-line 
treatment in patients with metastatic colorectal cancer
Hoffmann-La 
Roche
NCT01326000 KRAS WT A: experimental: RO5083945 
plus FOLFIRI
KRAS WT B: comparator: FOLFIRI plus 
cetuximab
KRAS mutant A: experimental: 
RO5083945 plus FOLFIRI
KRAS mutant B: comparator: FOLFIRI
CTAAC, Clinical Trials Advisory and Awards Committee; NCT, National Clinical Trials.
a A stop and go approach to administering oxaliplatin therapy before the development of resistance.
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Appendix 8 
Clinical effectiveness: supplementary tables
Study Jonker et al.37 Van Cutsem et al.7 Van Cutsem et al.38
Participants Inclusion criteria: Advanced 
colorectal cancer expressing EGFR 
detectable by immunohistochemical 
methods; previous treatment with 
either fluoropyrimidine, irinotecan 
or oxaliplatin with no response 
to treatment or contraindications 
to treatment with these drugs; 
disease that could be measured 
or evaluated, ECOG performance 
status of 0–2 with adequate bone 
marrow, kidney and liver function; 
and no serious concurrent illness
Exclusion criteria: Patients were 
ineligible if they had received 
any agent that targets the EGFR 
pathway or treatment with a murine 
monoclonal antibody. Previous 
bevacizumab treatment was 
permitted but not required
Inclusion criteria: Age ≥ 18 years; 
pathological diagnosis of metastatic 
colorectal adenocarcinoma and 
radiological documentation of disease 
progression during or within 6 months 
following the last administration 
of fluoropyrimidine, irinotecan and 
oxaliplatin (dose intensity of irinotecan 
≥ 65 mg/m2 per week and oxaliplatin 
≥ 30 mg/m2 per week); ECOG 
performance status of 0–2; two or 
three prior chemotherapy regimens for 
metastatic colorectal cancer; 1% EGFR-
positive membrane staining in primary 
or metastatic tumour cells
Exclusion criteria: Symptomatic brain 
metastases, interstitial pneumonitis 
or pulmonary fibrosis; systematic 
chemotherapy or radiotherapy within 
30 days before random assignment; 
prior anti-EFGR agents
Inclusion criteria: As for Van Cutsem 
et al.7
Exclusion criteria: As for Van Cutsem 
et al.7
Interventions Cetuximab + BSC: Given 
intravenously as an initial dose of 
400 mg/m2 of body surface area, 
administered over 120 minutes, 
followed by a weekly maintenance 
infusion of 250 mg/m2, administered 
over 60 minutes
BSC: Measures designed to provide 
palliation of symptoms and improve 
quality of life
Panitumumab + BSC: Administered 
using a 60-minute intravenous infusion 
at 6 mg/kg once every 2 weeks until 
patients progressed or unacceptable 
toxicity developed. Premedication was 
not required
BSC: Defined as the best palliative care 
excluding antineoplastic agents
Panitumumab + BSC: As for Van Cutsem 
et al.7
Study objectives To demonstrate the effect of 
cetuximab on survival or QoL in 
patients with advanced colorectal 
cancer
To evaluate the effect of panitumumab 
monotherapy in patients with 
chemorefactory metastatic colorectal 
cancer
To demonstrate the efficacy and safety of 
cetuximab for survival or QoL in patients 
with advanced colorectal cancer
Outcomes Primary: Overall survival, defined as 
time from randomisation until death 
from any cause
Secondary: Progression-free 
survival, defined as time from 
randomisation until the first 
objective observation of disease 
progression or death from any 
cause
Primary: Progression-free survival by 
blinded central radiology assessment, 
calculated from day of random 
assignment until radiological progression 
or death
Secondary: Objective response, overall 
survival and safety. Best objective 
response by blinded central review and 
overall survival time. Overall survival 
was calculated from the day of random 
assignment until death, censoring 
patients at the last day known to be 
alive. All patients were followed up for 
survival every 3 months for up to 2 years 
after random assignment
Primary: Safety, including incidence of 
grade 3/4 adverse and treatment-related 
events, skin-related events and antibody 
formation
Secondary: Although no secondary end 
points were prespecified in the protocol, 
the efficacy of panitumumab monotherapy 
was explored by assessing progression-
free survival, ORR, time to and duration 
of response, duration of stable disease 
and survival using the local investigators’ 
assessment of radiographic images
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Study Jonker et al.37 Van Cutsem et al.7 Van Cutsem et al.38
Analysis All patients who underwent 
randomisation were included in the 
efficacy analyses on the basis of the 
group to which they were assigned
Time-to-event variables were 
summarised with the use of Kaplan–
Meier plots
Primary comparisons were made 
using the stratified log-rank test. 
Hazard ratios with 95% CIs were 
calculated from stratified Cox 
regression models with treatment 
group as the single factor. 
Deterioration in QoL scores was 
defined a priori as a decline of ≥ 10 
points from baseline
It was estimated a priori that 445 
deaths would provide a statistical 
power of 90% and a two-sided 
alpha of 5% to detect an absolute 
increase of 9.6% in 1-year overall 
survival from the predicted 1-year 
overall survival of 14.1% in the 
group assigned to supportive care 
alone (hazard ratio 0.74)
Safety analysis was conducted on 
an on-treatment basis, contrasting 
patients who had at least one 
dose of cetuximab (including those 
who crossed over) with patients 
assigned to supportive care alone, 
and omitting patients who withdrew 
consent before any intervention
The primary analysis included all 
patients randomly assigned
Progression-free survival was analysed 
at the 5% significance level using a 
log-rank test stratified by baseline 
ECOG performance status and region. 
A 1% test of objective response in the 
primary analysis and 4% test of overall 
survival were prespecified conditional on 
a significant progression-free survival 
difference. The analysis of overall 
survival and an update of objective 
response rates and duration of response 
were conducted after a minimum of 
12 months’ follow-up
Kaplan–Meier methodology was used 
to estimate progression-free survival, 
overall survival and time to and duration 
of the response, including 95% CIs 
for event-free rates and difference in 
rates. The 65% CIs for time-to-event 
quartiles were calculated according to 
Brookmeye and Crowley.90 Hazard ratios 
for progression-free survival and overall 
survival were estimated using a Cox 
proportional hazards regression model 
adjusted for the randomisation factors
The study had 90% power for a two-
sided test at the 1% significance level 
given a hazard ratio (panitumumab 
relative to BSC) of 0.67. The sample size 
goal was 430 patients, with an event 
goal of 362 patients with progressive 
disease by central review or death
The primary analyses of safety and 
efficacy outcomes included all enrolled 
patients who received at least one dose of 
panitumumab
Time to response was calculated as the 
period from enrolment date to the first 
objective response. Duration of response 
was calculated only for the responders 
as the period from the first objective 
response to the first observation of 
disease progression or death due to 
disease progression
Duration of stable disease was calculated 
as the period from enrolment date to the 
first observation of disease progression 
or death due to disease progression; 
only patients who had at least one scan 
of stable disease as their best response 
were included
Progression-free survival time was 
calculated as the period from enrolment 
date to the first observation of disease 
progression or death
Overall survival time was calculated as 
the time period from enrolment to death
Descriptive statistics were calculated 
for the incidence of objective response 
(with two-sided 95% CIs), adverse 
events, laboratory values, changes in 
vital signs and antibody measurements. 
Time-to-event outcomes were analysed 
using Kaplan–Meier methods. For the 
analyses on overall survival, a minimum of 
12 months of follow-up were included
Among patients with skin toxicity, the 
relationship between severity of skin 
toxicity and overall survival was evaluated 
using a Cox regression model adjusted for 
the Phase III randomisation factors, ECOG 
score and geographical region. Patients 
were included in the analysis if they were 
progression free for at least 28 days to 
allow the worst severity of skin toxicity to 
manifest
The sample size was limited to the 
patients enrolled in the BSC arm of the 
Phase III study who met the eligibility 
criteria (planned n = 200). Assuming a 
true event rate of 1%, the probability of 
at least one patient experiencing a given 
adverse event was 87% for a sample size 
of 200
BSC, best supportive care; ORR, overall response rate.
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Appendix 9 
Cost-effectiveness: quality appraisal
TABLE 62 Summary of quality assessment of Norum60 using the critical appraisal checklist from Evers and colleagues57
Item Yes/no 
1 Is the study population clearly described? Yes. Patients with metastatic colorectal cancer having received two lines of treatment
2 Are competing alternatives clearly 
described?
Yes. The comparator is no third-line therapy
3 Is a well-defined research question posed 
in answerable form?
Yes. The cost per LYG from changing policy from no third-line therapy to cetuximab plus 
irinotecan in the treatment of metastatic colorectal cancer
4 Is the economic study design appropriate 
to the stated objective?
Yes. A model-based cost-effectiveness analysis is used reporting cost per LYG
5 Is the chosen time horizon appropriate to 
include relevant costs and consequences?
Unclear. Time horizon is not reported, but Norum states that ‘All costs occurred within one 
year and were not discounted’ (p. 533)
6 Is the actual perspective chosen 
appropriate?
Yes. The cost-effectiveness analysis is conducted from a third-party payer perspective in 
Norway
7 Are all important and relevant costs for 
each alternative identified?
Yes. Total costs include drug acquisition and administration, hospitalisation, outpatient 
therapy, EGFR analysis and family (travel) costs
8 Are all costs measured appropriately in 
physical units?
Yes. All costs were calculated according to Norwegian unit costs and converted to euros
9 Are costs valued appropriately? Yes
10 Are all important and relevant outcomes 
for each alternative identified?
Yes. LYG is the outcome used
11 Are all outcomes measured appropriately? Yes. Treatment benefit is defined as LYG and is based on data in BOND49 and Saltz et al.40
12 Are outcomes valued appropriately? Yes
13 Is an incremental analysis of costs and 
outcomes of alternatives performed?
Yes, and subjected to sensitivity analyses
14 Are all future costs and outcomes 
discounted appropriately?
No. No discounting was applied
15 Are all important variables whose values 
are uncertain appropriately subjected to 
sensitivity analysis?
Yes. One-way sensitivity analyses on all health-care costs (EGFR analysis cost, cetuximab and 
irinotecan drug costs, outpatient clinic cost, drug administration cost) and treatment impact 
on overall survival. The impact of travelling costs was not assessed in sensitivity analyses
16 Do the conclusions follow from the data 
reported?
Yes. Third-line therapy with cetuximab plus irinotecan was acknowledged to be promising but 
very expensive. Lower drug costs and/or improved survival could change these findings. This 
conclusion reflects the high base-case ICERs reported and the lower ICERs from assuming 
reduced drug costs and improved survival
17 Does the study discuss the generalisability 
of the results to other settings and patient/
client groups?
To some extent. The author discusses differences in cost of cetuximab acquisition between 
countries and also the willingness-to-pay thresholds in different countries
18 Does the article indicate that there is 
no potential conflict of interest of study 
researcher(s) and funder(s)?
The author acknowledges a research grant from the Norwegian Cancer Union for this work. 
There is no indication that this would represent a conflict of interest
19 Are ethical and distributional issues 
discussed appropriately?
No
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TABLE 63 Summary of quality assessment of Starling and colleagues61 using the critical appraisal checklist from Evers 
and colleagues58
Item Yes/no 
1 Is the study population clearly described? Yes. Patients with metastatic colorectal cancer who have failed previous chemotherapy 
treatment
2 Are competing alternatives clearly described? Yes. Active/best supportive care, where active supportive care is the best care available 
and may include chemotherapy
3 Is a well-defined research question posed in 
answerable form?
Yes. To compare the cost-effectiveness of cetuximab plus irinotecan with active/best 
supportive care
4 Is the economic study design appropriate to the 
stated objective?
Yes. A trial-based cost-effectiveness analysis of Cunningham et al.49
5 Is the chosen time horizon appropriate to include 
relevant costs and consequences?
Yes. A lifetime horizon extrapolating beyond the end of follow-up in Cunningham et al.49
6 Is the actual perspective chosen appropriate? Yes. The study was calculated from a third-payer perspective: NHS
7 Are all important and relevant costs for each 
alternative identified?
Yes. Drug acquisition and administration, inpatient hospitalisation, outpatient 
consultations, laboratory tests (including EGFR testing) and imaging
8 Are all costs measured appropriately in physical 
units?
Yes
9 Are costs valued appropriately? In pounds sterling, but source provided if unit costs not reported
10 Are all important and relevant outcomes for 
each alternative identified?
Yes. The primary health outcome is LYG with a secondary outcome of QALYs using 
utility values from the MABEL study
11 Are all outcomes measured appropriately? Yes. EQ-5D utility values from the MABEL study
12 Are outcomes valued appropriately? Unclear. Although utility values are reported to have been measured directly from 
Cunningham et al.,49 the mean utility reported by MABEL ‘was applied to all patients at 
all time points in the economic model’ (p. 209)
13 Is an incremental analysis of costs and 
outcomes of alternatives performed?
Yes, and subject to sensitivity analyses
14 Are all future costs and outcomes discounted 
appropriately?
Unclear. Discounting is not reported
15 Are all important variables whose values are 
uncertain appropriately subjected to sensitivity 
analysis?
Yes. In one-way sensitivity analyses the following were assessed: proportion of active/
best supportive care patients receiving chemotherapy, overall survival, cetuximab 
acquisition costs, chemotherapy administration costs and best supportive care costs
16 Do the conclusions follow from the data 
reported?
The conclusion does not reflect on any of the results reported
17 Does the study discuss the generalisability of 
the results to other settings and patient/client 
groups?
Yes. The authors comment that use of one RCT for the basis of the cost-effectiveness 
analysis ‘may lead to a partial and limited analyses to inform decision making’ (p. 211)
18 Does the article indicate that there is 
no potential conflict of interest of study 
researcher(s) and funder(s)?
The cost-effectiveness analysis was undertaken by the authors on behalf of Merck 
KGaA, Darmstadt. One author has received research funding from Merck and 
participated in advisory boards for Merck and Pfizer
19 Are ethical and distributional issues discussed 
appropriately?
No
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TABLE 64 Summary of quality assessment of Annemans and colleagues59 using the critical appraisal checklist from 
Evers and colleagues57
Item Yes/no 
1 Is the study population clearly described? Yes. Patients from the BOND49 study and patients receiving current care. Details on 
age, gender, body surface area and the number of previous chemotherapy regimes are 
reported
2 Are competing alternatives clearly described? Yes. Current care received by patients in three major oncology centres, with 80% of 
patients receiving chemotherapy third line
3 Is a well-defined research question posed in 
answerable form?
Yes. Comparison of the cost-effectiveness in Belgium of cetuximab plus irinotecan and 
current care in EGFR-expressing metastatic colorectal cancer patients who have failed 
irinotecan-containing therapy
4 Is the economic study design appropriate to the 
stated objective?
Yes. Retrospective cost-effectiveness analysis based on BOND and a matched 
population of patients, reporting cost per LYG
5 Is the chosen time horizon appropriate to include 
relevant costs and consequences?
Unclear. Time horizon is not reported
6 Is the actual perspective chosen appropriate? Yes. From the perspective of the health-care system in Belgium
7 Are all important and relevant costs for each 
alternative identified?
Yes. Cetuximab and irinotecan acquisition costs and the cost of drugs for treating 
adverse events. Additional costs included were for laboratory tests, imaging, 
consultations, hospitalisations and any subsequent chemotherapy
8 Are all costs measured appropriately in physical 
units?
Yes. Costs are reported in euros. Resource use data were derived directly from patient 
records
9 Are costs valued appropriately? Yes. Costs were derived from Belgian unit costs
10 Are all important and relevant outcomes for each 
alternative identified?
Yes. LYG is the outcome used
11 Are all outcomes measured appropriately? Yes. Treatment benefit is defined by overall survival based on data from the BOND 
study
12 Are outcomes valued appropriately? Yes
13 Is an incremental analysis of costs and outcomes 
of alternatives performed?
Yes, with two scenarios presented as base-case analyses (6- and 12-week treatment 
continuation rule)
14 Are all future costs and outcomes discounted 
appropriately?
Unclear. Discounting is not reported
15 Are all important variables whose values are 
uncertain appropriately subjected to sensitivity 
analysis?
Yes. The impact of changing survival and cost data in the current care arm is described
16 Do the conclusions follow from the data reported? Yes. The conclusion states that cetuximab plus irinotecan is ‘rather cost-effective in 
Belgium’ (p. 424) and this reflects the ICERs reported of €17,000 and €40,000 per 
LYG, according to whether cetuximab was discontinued at 6 or 12 weeks if there was 
no tumour response at those times
17 Does the study discuss the generalisability of 
the results to other settings and patient/client 
groups?
To some extent. The authors state that current care in the major oncology centres may 
not reflect that in smaller centres
18 Does the article indicate that there is no potential 
conflict of interest of study researcher(s) and 
funder(s)?
Unclear. There are no acknowledgements to a funding source. All authors are affiliated 
with either a university or a hospital
19 Are ethical and distributional issues discussed 
appropriately?
No
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TABLE 65 Summary of quality assessment of Wong and colleagues62 using the critical appraisal checklist from Evers 
and colleagues57
Item Yes/no
1 Is the study population clearly described? Yes. Hypothetical cohort of 1000 patients with newly diagnosed metastatic colorectal 
cancer. Patients supposedly received up to three lines of treatment before supportive care 
and death
2 Are competing alternatives clearly described? Yes. In total, nine possible treatment strategies are modelled. Five of these involve 
cetuximab third line
3 Is a well-defined research question posed in 
answerable form?
Yes. To measure the cost implications of treatment with sequential regimens that include 
chemotherapy and/or monoclonal antibodies
4 Is the economic study design appropriate to the 
stated objective?
Yes. Model-based cost-effectiveness analysis reported as cost per discounted life-year
5 Is the chosen time horizon appropriate to 
include relevant costs and consequences?
Unclear. Time horizon is not reported
6 Is the actual perspective chosen appropriate? Yes. Third-party payer
7 Are all important and relevant costs for each 
alternative identified?
No. Only costs related to drug acquisition and administration were modelled. Costs 
associated with supportive care medications, toxicity management, radiographic 
assessments or physician visits were not modelled
8 Are all costs measured appropriately in physical 
units?
Yes. Drug costs measured in US$ based on average patient weight of 75 kg and body 
surface area of 1.9 m2
9 Are costs valued appropriately? Yes. Drug costs are based on average sales prices
10 Are all important and relevant outcomes for 
each alternative identified?
Yes. Drug toxicity and discounted life-years
11 Are all outcomes measured appropriately? Yes. Treatment benefit is defined by overall survival, and for cetuximab treatments it is 
based on data from Cunningham et al.49
12 Are outcomes valued appropriately? Yes
13 Is an incremental analysis of costs and 
outcomes of alternatives performed?
Yes, and with a cost-effectiveness frontier presented
14 Are all future costs and outcomes discounted 
appropriately?
Yes. Life expectancy and costs are discounted at 3% per year
15 Are all important variables, whose values are 
uncertain, appropriately subjected to sensitivity 
analysis?
Yes. One-way sensitivity analyses were performed for changes in toxicity, progression, 
drug costs, time on supportive care and cost of supportive care
16 Do the conclusions follow from the data 
reported?
Yes. The authors report that the most effective regimens came at very high incremental 
costs, reflecting the large ICERs reported
17 Does the study discuss the generalisability of 
the results to other settings and patient/client 
groups?
To some extent. The authors comment that changes in drug costs in the future will impact 
on the cost-effectiveness of these drugs
18 Does the article indicate that there is 
no potential conflict of interest of study 
researcher(s) and funder(s)?
Conflicts of interest are declared. One author has received funding from Bristol-Myers 
Squibb while the other three authors have acted as consultants and/or received honoraria 
from Amgen, Genentech, Pfizer, Sanofi-Aventis, Roche and/or Bristol-Myers Squibb
19 Are ethical and distributional issues discussed 
appropriately?
No
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Appendix 10 
Cost-effectiveness: excluded studies
Study Reason for exclusion
Amado (2008) Not a cost-effectiveness analysis
Arocho (2009) Not in English
Au (2009) Not a cost-effectiveness analysis
Barnett (2006) Not a cost-effectiveness analysis
Blank (2010) Abstract only (no additional information received)
Borovicka (2010) Not a relevant population
Carlson (2010) Abstract only (no additional information received)
Darba (2008) Not a relevant intervention
Ducournau (2008) Not a relevant intervention
Ducournau (2008) Not a relevant intervention
Eggington (2009) Not a relevant population
Ferro (2008) Not a relevant population
Foley (2009) Not a relevant population
Foley (2010) Not a relevant population
Folprecht (2009) Not a relevant population
Fortner (2007) Not a cost-effectiveness analysis
Garattini (2008) Not a cost-effectiveness analysis
Garrell (2008) Not a relevant population
Garrison (2007) Not a relevant population
Garrison (2007) Not a relevant intervention
Graham (2008) Abstract only (no additional information received)
Greenberg (2010) Background information only
Griebsch (2010) Not a relevant population
Gyldmark (2009) Not a relevant population
Hassan (2006) Not a cost-effectiveness analysis
Hay (2008) Not a cost-effectiveness analysis
Holmberg (2009) Not a relevant population
Jansman (2007) Background information only
Jonker (2007) Not a cost-effectiveness analysis
Kabbinavar (2008) Not a cost-effectiveness analysis
Kim (2009) Not a relevant intervention
Krol (2007) Background information only
Labianca (2007) Unobtainable
Lamarque (2008) Not a relevant population (non-UK)
Lewis (2008) Not a relevant intervention
NICE (2009) Background information only
Odom (2008) Not a cost-effectiveness analysis
Papagiannopoulou (2008) Not a relevant population (non-UK)
Papagiannopoulou (2008) Not a relevant population (non-UK)
Peeters (2006) Not a cost-effectiveness analysis
Rubio (2005) Not a relevant population (non-UK)
Ruhmann (2007) Unobtainable
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Study Reason for exclusion
Salazar (2008) Not a relevant intervention
Scheithauer (2007) Not a relevant population
Shah (2009) Unobtainable
Shiroiwa (2007) Not a relevant intervention
Shiroiwa (2010) Not a relevant population (non-UK)
Siena (2007) Not a cost-effectiveness analysis
Tang (2007) Not a cost-effectiveness analysis
Tappenden (2009) Background information only
Tappenden (2007) Background information only
Tappenden (2007) Background information only
Tappenden (2007) Background information only
Tebbutt (2010) Not a relevant population
Thuss-Patience (2006) Not in English
Tigue (2007) Not a cost-effectiveness analysis
Tilden (2005) Abstract only, no additional information received 
Tonon (2009) Not in English
Torrecillas (2008) Not a relevant population
Tran (2009) Not a relevant population (non-UK)
Uyl-de Groot (2005) Not a cost-effectiveness analysis
Villa (2010) Not a relevant population
Warren (2008) Background only
Wei (2010) Abstract only (no additional information received)
Wils (2007) Not a cost-effectiveness analysis
Wong (2008) Unobtainable
Wong (2009) Not a cost-effectiveness analysis
Yabroff (2009) Not a relevant intervention
Yost (2005) Not a cost-effectiveness analysis
Yunger (2009) Not a cost-effectiveness analysis
Zafar (2009) Not a cost-effectiveness analysis
Zazaa (2009) Not a relevant intervention
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Appendix 11 
Estimation of difference in utilities 
between patients taking panitumumab 
and those on best supportive care while in 
progression-free survival
Here, we use the utilities measured in the RCT of panitumumab compared with best supportive care by Odom and colleagues56 to estimate that the utility for those in 
progression-free survival taking panitumumab is 0.12 higher than for those in progression-free 
survival on best supportive care.
Define PFSpan(t) and PFSBSC(t) as the progression-free survival probabilities as a function of time 
t for panitumumab and best supportive care respectively. Also, define ∆Upan(t) and ∆UBSC(t) 
as the changes in utility from baseline over time for panitumumab and best supportive care, 
respectively, and UB as the baseline utility. Then, the total QALYs in progression-free survival for 
panitumumab and best supportive care are:
∫∫ + ∆∞∞U PFS t dt U t PFS t dt( ) ( ) ( )B pan pan pan
00
 [Equation 12]
∫∫ + ∆∞∞U PFS t dt U t PFS t dt( ) ( ) ( )B BSC BSC BSC
00
 [Equation 13]
Expressed differently, suppose that we assume time-independent utilities in progression-free 
survival of Upan and UBSC for panitumumab and best supportive care, respectively. Then, the total 
QALYs for panitumumab and best supportive care are:
∫∞U PFS t dt( )pan pan
0
 [Equation 14]
∫∞U PFS t dt( )BSC BSC
0
 [Equation 15]
Solving these two pairs of equations gives:
∫
∫
= +
∆
∞
∞
U U
U t PFS t dt
PFS t dt
( ) ( )
( )
pan B
pan pan
pan
0
0
 [Equation 16]
∫
∫
= +
∆
∞
∞
U U
U t PFS t dt
PFS t dt
( ) ( )
( )
BSC B
BSC BSC
BSC
0
0
 [Equation 17]
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and the quantity we require, the difference between the mean progression-free survival utilities 
for panitumumab and best supportive care, is:
∫
∫
∫
∫
− =
∆
−
∆
∞
∞
∞
∞
U U
U t PFS t dt
PFS t dt
U t PFS t dt
PFS t dt
( ) ( )
( )
( ) ( )
( )
pan BSC
pan pan
pan
BSC BSC
BSC
0
0
0
0
 [Equation 18]
We calculate this quantity in our model as 0.12, using discrete time intervals. By necessity we 
have assumed that, for time periods after 17 weeks, the same decrement in utility from baseline at 
time 17 weeks applies.
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Appendix 12 
Estimation of mean dosages of cetuximab, 
irinotecan and panitumumab, including 
wastage, for patients of varying body 
surface areas and weights
To calculate the cost of cetuximab plus irinotecan, we need to estimate body surface area. Sacco and colleagues87 calculated the body surface area of 3613 patients receiving 
chemotherapy for various cancers in the UK in 2005 from the height and weight, using the 
Dubois and Dubois method:89 body surface area (m2) = 0.007184 × weight (kg)0.425 × height 
(cm)0.725.
Appendix S3 of Sacco and colleagues,87 freely available online, gives the body surface areas of 291 
men receiving palliative chemotherapy for colon cancer. We calculate the mean and standard 
deviation of these as 1.93 and 0.19 respectively. Similarly, we calculate the mean and standard 
deviation of the body surface areas of 151 women receiving palliative chemotherapy for colon 
cancer as 1.68 and 0.18 respectively. Next, we follow the methodology described in the example 
calculations in Appendix S1 of Sacco and colleagues87 to calculate the mean dosage for men and 
women independently, allowing for wastage of drugs due to fixed vial sizes. The mean dose for 
all patients, assuming 66% men and 34% women, is calculated as the average of the male and 
females doses weighted by 66% and 34% respectively.
Next, to calculate the cost of panitumumab, we need to estimate weight. Appendix S3 of Sacco 
and colleagues87 does not give the weights but Sacco provided us with the weight data that were 
used to calculate body surface area. We calculate the mean and standard deviation of the weights 
of the 291 men as 79.8 kg and 15.0 kg respectively. Similarly, we calculate the mean and standard 
deviation of the weights of the 151 women receiving palliative chemotherapy for colon cancer as 
65.3 kg and 14.0 kg respectively. Next, we again follow the methodology described in the example 
calculations in Appendix S1 of Sacco and colleagues87 to calculate the mean dosage for men and 
women independently, allowing for wastage of drugs due to fixed vial sizes. The mean dose for 
all patients, assuming 66% men and 34% women, is calculated as the average of the male and 
females doses weighted by the 66% and 34% respectively.
Pharmacy drug preparation costs
All drugs require preparation by a hospital pharmacist. Kate Copland, a hospital pharmacist from 
the Royal Devon & Exeter Hospital (Exeter, Devon), cited in personal communication (2011) 
that the preparation times per infusion of bevacizumab, irinotecan and cetuximab are equal 
(Table 66). We assume that the same schedule applies to panitumumab.
NIHR Journals Library
228 Appendix 12
TABLE 66 Hospital pharmacy preparation tasks per infusion of bevacizumab, irinotecan and cetuximab
Task Time Staff grade Average annual salarya
1 Clinical check of prescription 10 minutes Band 7 £36,000
2 Producing batch sheets and labels 5 minutes Band 4 £20,000
3 Assembly of ingredients 5 minutes Band 4 £20,000
4 Checking in of batch 5 minutes Band 4–8c £38,071
5 Decontamination of ingredients 5 minutes Band 2–4 £17,333
6 Drug reconstitution and labelling of product 15 minutes Band 2–4 £17,333
7 Final check of batch 5 minutes Band 6–8c £44,400
8 Documentation control 10 minutes Band 2–4 £17,333
a Taken from NHS terms and conditions of service handbook, Annex C, table 13.91
Using the information in Table 66, the length of the average working week (37.5) and number of 
days of holiday per year (38 days), we calculate the total cost of the preparation of one infusion 
as £15.
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Appendix 13 
Requests for clarification: Amgen 
C ommercial-in-confidence information has been removed.
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Appendix 14 
Calculating progression-free survival for 
cetuximab plus irinotecan
Progression-free survival for cetuximab plus irinotecan: stage 1
We suggest four possible methods for estimating median progression-free survival for patients 
with KRAS WT status on cetuximab plus irinotecan in the BOND RCT.49 All methods split 
out the median progression-free survival of 4.1 months for all patients combined (KRAS 
WT and KRAS mutant status) on cetuximab plus irinotecan in the BOND RCT to obtain the 
corresponding figure for patients with KRAS WT status only.
Method A
We first estimate the median progression-free survival for patients in the BOND RCT with KRAS 
WT status on cetuximab plus best supportive care as:
median progression-free survival of 3.7 months for KRAS WT patients taking cetuximab 
+ best supportive care in the RCT of cetuximab + best supportive care vs best 
supportive care45 
× median progression-free survival of 1.5 months for all patients (KRAS WT and 
mutant status) taking cetuximab + best supportive care in the BOND RCT49
/median progression-free survival of 1.9 months for all patients (KRAS WT and 
mutant status) taking cetuximab + best supportive care in the RCT of cetuximab  
+ best supportive care vs best supportive care37 
= 2.9 months [Equation 19]
Next, we estimate the median progression-free survival in the BOND RCT for patients with 
KRAS WT status taking cetuximab plus irinotecan as:
median progression-free survival of 4.1 months for all patients (KRAS WT and 
mutant status) taking cetuximab + irinotecan in the BOND RCT49 
× [estimated median progression-free survival of 2.9 months for patients with KRAS WT 
 status taking cetuximab + best supportive care in the BOND RCT
/median progression-free survival of 1.5 months for all patients (KRAS WT and mutant 
 status) taking cetuximab + best supportive care in the BOND RCT]49  
= 8.0 months [Equation 20]
Method B
Alternatively, we can estimate the median progression-free survival in the BOND RCT for 
patients with KRAS WT status taking cetuximab plus irinotecan, denoted by M, as follows. First, 
we note that the median progression-free survival for patients with KRAS mutant status taking 
cetuximab plus irinotecan is approximately 12 weeks, and the median progression-free survival 
for patients with KRAS WT status taking cetuximab plus irinotecan is approximately 34 weeks 
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from the study by De Roock and colleagues.48 Then, given that 59.3% of patients were KRAS WT 
status (the rest KRAS mutant status) in De Roock and colleagues:48
+ −M M59.3% (100% 59.3%)12
34
 
= median progression-free survival of 4.1 months for all patients (KRAS WT and mutant 
status) taking cetuximab plus irinotecan in the BOND RCT.
Solving, we find M = 5.6 months, which is considerably lower than the 8.0 months estimated 
by method A.
Method C
This method is identical to method B except that we use data from Lievre and colleagues86 instead 
of data from De Roock and colleagues.48 In Lievre and colleagues86 the median progression-free 
survival for patients with KRAS mutant status taking cetuximab plus irinotecan is approximately 
9 weeks; the median progression-free survival for patients with KRAS WT status taking 
cetuximab plus irinotecan is approximately 32 weeks; and 68% of patients were KRAS WT status. 
Solving again for M, the estimated median progression-free survival in the BOND RCT for 
patients with KRAS WT status taking cetuximab plus irinotecan is 5.3 months.
Method D
This method is identical to methods B and C except that we use data from De Roock and 
colleagues.83 In this study, the median progression-free survival for patients with KRAS mutant 
status taking cetuximab plus irinotecan is approximately 12 weeks; the median progression-free 
survival for patients with KRAS WT status is approximately 24 weeks; and 58% of patients were 
KRAS WT status. Solving for M, the estimated median progression-free survival in the BOND 
RCT for patients with KRAS WT status taking cetuximab plus irinotecan is 5.2 months. One 
possible problem with the data from De Roock and colleagues83 is that patients were treated 
with cetuximab plus chemotherapy, in which the ‘chemotherapy’ is not specified. We require the 
chemotherapy to be irinotecan, but this is not clear. However, the data set has the advantage that 
it covers many patients.
It is very difficult to choose a preferred method for estimating the median progression-free 
survival in the BOND RCT for patients with KRAS WT status taking cetuximab plus irinotecan 
because all methods rely on assumptions, and all have strengths and weaknesses. Method A 
assumes that the proportionate difference in progression-free survival for patients on cetuximab 
plus irinotecan between patients with KRAS mutant and those with KRAS WT status is similar 
to the proportionate difference in progression-free survival for patients on cetuximab between 
patients with KRAS mutant and those with KRAS WT status. However, it has the advantage that 
it relies solely on randomised data. Methods B–D assume similarity in the baseline characteristics 
of the patients on cetuximab plus irinotecan between patients with KRAS mutant and those with 
KRAS WT status, given that the De Roock and colleagues,48 De Roock and colleagues83 and Lievre 
and colleagues86 studies were observational, not randomised. However, methods B–D give very 
similar estimates of the median progression-free survival (5.6, 5.3 and 5.2 months respectively), 
and these are different to the estimate of 8.0 months from method A. Given the consistency in the 
estimates using methods B–D, we take the average of these values and hence estimate the median 
progression-free survival in the BOND RCT for patients with KRAS WT status taking cetuximab 
plus irinotecan as 5.4 months.
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Progression-free survival for cetuximab plus irinotecan: stage 2
Next, we adjust our estimate of the median progression-free survival of 5.4 months in the BOND 
RCT for patients with KRAS WT status taking cetuximab plus irinotecan for the purposes of the 
indirect comparison with other treatments, as follows:
Estimated modelled median progression-free survival for patients with KRAS WT status 
taking cetuximab + irinotecan 
= estimated median progression-free survival of 5.4 months in the BOND RCT for patients 
with KRAS WT status taking cetuximab +irinotecan (calculated in stage 1) 
× modelled median progression-free survival of 3.9 months for patients with KRAS WT 
status taking cetuximab + best supportive care (estimated from lambda and gamma 
of Weibull)
/estimated median progression-free survival of 2.9 months in the BOND RCT for patients 
with KRAS WT status taking cetuximab + best supportive care (estimated in Method A) 
= 7.1 months [Equation 21]
Progression-free survival for cetuximab plus irinotecan: stage 3
Finally, given that we have specified the median progression-free survival for cetuximab plus 
irinotecan (7.1 months), and that we assume the same Weibull shape parameter, γ, for cetuximab 
plus irinotecan as for cetuximab plus best supportive care, this then specifies the scale parameter, 
λ, of the Weibull for cetuximab plus irinotecan, given that the median t* of the Weibull is given 
by 0.5 = exp(–λt*). This then gives an estimated mean progression-free survival for cetuximab 
plus irinotecan of 8.8 months, which is similar to Merck Serono’s estimated mean of 7.8 months.
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Appendix 15 
Calculating overall survival for cetuximab 
plus irinotecan
Overall survival for cetuximab plus irinotecan: stage 1
We have identified four methods to estimate overall survival for cetuximab plus irinotecan, each 
of which has strengths and weaknesses.
Method A
This method is very similar to method A for the estimation of progression-free survival in 
Appendix 14. We first estimate the median overall survival for patients with KRAS WT status on 
cetuximab monotherapy in the BOND RCT49 as:
median overall survival of 9.5 months for patients with KRAS WT status taking cetuximab 
+ best supportive care in the RCT of cetuximab + best supportive care vs best 
supportive care45 
× median overall survival of 6.9 months for all patients (KRAS WT and mutant status) 
taking cetuximab + best supportive care in the BOND RCT49
/median overall survival of 6.1 months for all patients (KRAS WT and mutant status) 
taking cetuximab + best supportive care in the RCT of cetuximab + best supportive care vs 
best supportive care37 
= 10.7 months [Equation 22]
Next, we estimate the median overall survival in the BOND RCT for patients with KRAS WT 
status taking cetuximab plus irinotecan as:
median overall survival of 8.6 months for all patients (KRAS WT and mutant status) 
taking cetuximab + irinotecan in the BOND RCT49 
× [estimated median overall survival of 10.7 months for patients with KRAS WT status 
taking cetuximab + best supportive care in the BOND RCT
/median overall survival of 6.9 months for all patients (KRAS WT and mutant status) 
taking cetuximab + best supportive care in the BOND RCT]49 
= 13.4 months [Equation 23]
Next, we adjust our estimate of the median overall survival of 13.4 months in the BOND RCT for 
patients with KRAS WT status taking cetuximab plus irinotecan for the purposes of the indirect 
comparison, as follows:
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Estimated modelled median overall survival for patients with KRAS WT status taking 
cetuximab + irinotecan 
= estimated median overall survival of 13.4 months in the BOND RCT for patients with 
KRAS WT status taking cetuximab + irinotecan 
× (modelled median overall survival of 9.0 months for KRAS WT people taking cetuximab 
+ best supportive care
/estimated median overall survival of 10.7 months in the BOND RCT for patients 
with KRAS WT status taking cetuximab + best supportive care) 
= 11.3 months [Equation 24]
However, the problem with this step in the calculation is that there was extensive crossover: 
approximately 50% of patients randomised to cetuximab plus best supportive care crossed over 
to cetuximab plus irinotecan on disease progression in the BOND RCT. This then unfairly 
dilutes the overall survival advantage of cetuximab plus irinotecan relative to cetuximab plus 
best supportive care. Therefore, 11.3 months is probably an underestimate of the median overall 
survival of patients with KRAS WT status on cetuximab plus irinotecan.
Method B
This is very similar to the method used by Merck Serono. Merck Serono estimated overall 
survival for patients with KRAS WT status on cetuximab plus irinotecan by adjusting overall 
survival for patients with KRAS WT status on cetuximab plus best supportive care (taken from 
the cetuximab plus best supportive care vs best supportive care RCT) by the hazard ratio for 
overall survival for patients with KRAS WT status between those on cetuximab plus irinotecan 
and those on cetuximab plus best supportive care taken from other sources. Alternatively, Merck 
Serono quotes a hazard ratio of 0.53 for patients with KRAS WT status between cetuximab plus 
irinotecan and cetuximab plus best supportive care from De Roock and colleagues48 (p. 72, 
Merck Serono’s submission69). The assumption when using hazard ratios from De Roock and 
colleagues48 is that very few of the patients on cetuximab plus best supportive care later received 
cetuximab plus irinotecan on disease progression. Unfortunately, such information is not 
reported, but Merck Serono states that it estimated the hazard ratio by reading off survival data 
from the overall survival curves published in De Roock and colleagues.48
In method B, we use a very similar method as Merck Serono to estimate overall survival for 
cetuximab plus irinotecan for patients with KRAS WT status for the purposes of the indirect 
comparison. We estimate the median overall survival for patients with KRAS WT status for 
cetuximab plus irinotecan as:
median overall survival for cetuximab + best supportive care from our model 
× (median overall survival for patients with KRAS WT status on cetuximab + irinotecan 
from De Roock and colleagues48
/median overall survival for patients with KRAS WT status on cetuximab + best supportive 
care from De Roock and colleagues48) 
= 9.0 × (10.3/6.2) = 15.0 months [Equation 25]
This method uses the median overall survival for patients with KRAS WT status on cetuximab 
plus best supportive care from De Roock and colleagues,48 which is uncertain because of the very 
small sample size (18 patients). Also, this method relies on similarity in baseline characteristics 
between treatments in De Roock and colleagues48 given that that the data are retrospective, not 
randomised. The method also assumes little crossover from cetuximab plus best supportive care 
to cetuximab plus irinotecan. The estimate of the median overall survival of 15.0 months for 
KRAS WT patients on cetuximab plus irinotecan is therefore very uncertain.
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Method C
Here, we estimate that the modelled median overall survival for patients with KRAS WT status 
taking cetuximab plus irinotecan:
= estimated median overall survival of 13.4 months in the BOND RCT for patients 
with KRAS WT status taking cetuximab + irinotecan (see Method A) 
× [modelled median progression-free survival of 7.1 months for patients with 
KRAS WT status taking cetuximab + irinotecan (see Appendix 14, stage 2 calculations)
/estimated median progression-free survival of 5.4 months in the BOND RCT for 
patients with KRAS WT status taking cetuximab + irinotecan (see Appendix 14,  
stage 1 calculations)] 
= 17.7 months [Equation 26]
This method has the advantage that it does not rely on the highly uncertain data from De Roock 
and colleagues;48 however, the disadvantage is that all three quantities in the calculation above are 
themselves estimates.
Method D
Here, we simply set our estimate of the median overall survival for patients with KRAS WT status 
on cetuximab plus irinotecan in our model equal to that from the BOND RCT, which we estimate 
in method A as 13.4 months. This has the advantage of simplicity, and the estimate is not affected 
by confounding due to crossover. However, it has the disadvantage that randomisation is broken, 
and no adjustment is made for the indirect comparison with other treatments.
In summary, the median overall survival for patients with KRAS WT status on cetuximab plus 
irinotecan for our model is:
 ■ > 11.3 months from method A
 ■ 15.0 months from method B
 ■ 17.7 months from method C
 ■ 13.4 months from method D.
Considering all methods we chose method B because it is closest to the average of all methods, 
and because it gives a similar mean overall survival for patients with KRAS WT status on 
cetuximab plus irinotecan (see the following section) as estimated by Merck Serono, who used a 
slightly different method.
Overall survival for cetuximab plus irinotecan: stage 2
This stage is identical to stage 3 in the estimation of progression-free survival (see Appendix 14). 
Given that we have specified the median overall survival for cetuximab plus irinotecan and we 
assume the same shape parameter, γ, for cetuximab plus irinotecan as for cetuximab plus best 
supportive care, this then specifies the scale parameter, λ, of the Weibull. This then gives the 
estimated mean overall survival for cetuximab plus irinotecan of 16.6 months, which is very 
similar to Merck Serono’s estimate of 16.3 months.
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